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Abstract
The clinical effectiveness and cost-effectiveness of
abatacept, adalimumab, etanercept and tocilizumab for
treating juvenile idiopathic arthritis: a systematic review and
economic evaluation
Jonathan Shepherd,* Keith Cooper, Petra Harris, Joanna Picot
and Micah Rose
Southampton Health Technology Assessments Centre (SHTAC), University of Southampton,
Southampton, UK
*Corresponding author jps@soton.ac.uk
Background: Juvenile idiopathic arthritis (JIA) is characterised by joint pain, swelling and a limitation of
movement caused by inflammation. Subsequent joint damage can lead to disability and growth restriction.
Treatment commonly includes disease-modifying antirheumatic drugs (DMARDs), such as methotrexate.
Clinical practice now favours newer drugs termed biologic DMARDs where indicated.
Objective: To assess the clinical effectiveness and cost-effectiveness of four biologic DMARDs [etanercept
(Enbrel®, Pfizer), abatacept (Orencia®, Bristol-Myers Squibb), adalimumab (Humira®, AbbVie) and
tocilizumab (RoActemra®, Roche) – with or without methotrexate where indicated] for the treatment of JIA
(systemic or oligoarticular JIA are excluded).
Data sources: Electronic bibliographic databases including MEDLINE, EMBASE, The Cochrane Library and
the Database of Abstracts of Reviews of Effects were searched for published studies from inception to May
2015 for English-language articles. Bibliographies of related papers, systematic reviews and company
submissions were screened and experts were contacted to identify additional evidence.
Review methods: Systematic reviews of clinical effectiveness, health-related quality of life and
cost-effectiveness were undertaken in accordance with the Preferred Reporting Items for Systematic
Reviews and Meta-Analyses statement. A cost–utility decision-analytic model was developed to compare
the estimated cost-effectiveness of biologic DMARDs versus methotrexate. The base-case time horizon was
30 years and the model took a NHS perspective, with costs and benefits discounted at 3.5%.
Results: Four placebo-controlled randomised controlled trials (RCTs) met the inclusion criteria for the
clinical effectiveness review (one RCT evaluating each biologic DMARD). Only one RCT included UK
participants. Participants had to achieve an American College of Rheumatology Pediatric (ACR Pedi)-30
response to open-label lead-in treatment in order to be randomised. An exploratory adjusted indirect
comparison suggests that the four biologic DMARDs are similar, with fewer disease flares and greater
proportions of ACR Pedi-50 and -70 responses among participants randomised to continued biologic
DMARDs. However, confidence intervals were wide, the number of trials was low and there was clinical
heterogeneity between trials. Open-label extensions of the trials showed that, generally, ACR responses
remained constant or even increased after the double-blind phase. The proportions of adverse events and
serious adverse events were generally similar between the treatment and placebo groups. Four economic
evaluations of biologic DMARDs for patients with JIA were identified but all had limitations. Two
quality-of-life studies were included, one of which informed the cost–utility model. The incremental
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cost-effectiveness ratios (ICERs) for adalimumab, etanercept and tocilizumab versus methotrexate were
£38,127, £32,526 and £38,656 per quality-adjusted life year (QALY), respectively. The ICER for abatacept
versus methotrexate as a second-line biologic was £39,536 per QALY.
Limitations: The model does not incorporate the natural history of JIA in terms of long-term disease
progression, as the current evidence is limited. There are no head-to-head trials of biologic DMARDs,
and clinical evidence for specific JIA subtypes is limited.
Conclusions: Biologic DMARDs are superior to placebo (with methotrexate where permitted) in children
with (predominantly) polyarticular course JIA who have had an insufficient response to previous treatment.
Randomised comparisons of biologic DMARDs with long-term efficacy and safety follow-up are needed to
establish comparative effectiveness. RCTs for JIA subtypes for which evidence is lacking are also required.
Study registration: This study is registered as PROSPERO CRD42015016459.
Funding: The National Institute for Health Research Health Technology Assessment programme.
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Plain English summary
The term juvenile idiopathic arthritis (JIA) encompasses all forms of arthritis of unknown cause that startbefore 16 years of age and persist for > 6 weeks. Treatment includes disease-modifying antirheumatic
drugs (DMARDs), of which methotrexate is most commonly used in the UK. Current preferred treatment
includes newer drugs termed biologic DMARDs. We identified the most up-to-date clinical effectiveness
and cost-effectiveness evidence for four biologic DMARDs, namely abatacept (Orencia®, Bristol-Myers
Squibb), adalimumab (Humira®, AbbVie), etanercept (Enbrel®, Pfizer) and tocilizumab (RoActemra®, Roche).
The evidence was assessed systematically to evaluate whether or not treatment with a biologic DMARD
(with or without methotrexate) benefits patients with JIA, taking into account treatment costs and health.
One study comparing the biologic DMARD with a (non-active) placebo treatment was identified for each
drug. With the exception of the etanercept study, the majority of patients also received methotrexate.
Patients who received biologic DMARD treatment experienced significantly fewer disease flare ups than
those patients given placebo. Biologic DMARD treatment also led to a greater level of response (e.g. better
overall well-being). No studies directly compared the drugs with each other. A statistical method used to
compare them indirectly suggested that the four biologic DMARDs are similarly effective, but these results
must be treated with caution. The proportions of adverse events were generally similar between the
biologic DMARD and placebo groups.
Costs and health benefits appear to be generally similar for the four biologic DMARDs. Biologic DMARDs
may therefore be an effective therapy, but uncertainties remain owing to the lack of evidence from direct
comparisons between biologic DMARDs.
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Scientific summary
Background
The term juvenile idiopathic arthritis (JIA) encompasses all forms of arthritis of unknown cause with onset
prior to 16 years of age and with symptoms that persist for > 6 weeks. Suggested incidence (1.6 to 23 per
100,000) and prevalence rates (3.8 to 400 per 100,000) vary widely. The disease is characterised by joint
pain, swelling and a limitation of movement which is caused by an inflammation of the synovial membrane
of the affected joints. Left untreated, this inflammation causes a progressive erosive arthritis, which may
potentially lead to disability and growth restriction. However, disease severity and long-term outcomes are
variable both between different JIA subtypes and between different individuals with the same JIA subtype.
At onset, the particular subtype of JIA will be diagnosed according to the presenting features as
oligoarthritis, polyarthritis, enthesitis-related JIA (ERA), psoriatic arthritis (PA), systemic-onset JIA or
undifferentiated arthritis. Polyarticular-course JIA applies to patients who at a particular point in time
6 months or more after the onset of disease (JIA of any onset type) have five or more active joints.
Polyarticular-course JIA can typically include rheumatoid factor-positive (RF+) and rheumatoid factor-
negative (RF–) polyarthritis, extended oligoarthritis (EO), ERA, PA and systemic JIA (providing that there
have been no active systemic symptoms during the previous 6 months).
The treatment of JIA includes non-steroidal anti-inflammatory drugs, intra-articular corticosteroids and
disease-modifying antirheumatic drugs (DMARDs), of which methotrexate is the most common
conventional (non-biologic) DMARD used in the UK. Clinical practice now favours earlier treatment with
biologic DMARDs, where indicated.
Objectives
The aim of this multiple technology appraisal is to assess the clinical effectiveness and cost-effectiveness of
the biologic DMARDs etanercept (Enbrel®, Pfizer), abatacept [Orencia®, Bristol-Myers Squibb (BMS)],
adalimumab (Humira®, AbbVie) and tocilizumab (RoActemra®, Roche), in combination with methotrexate,
where permitted, in the treatment of JIA. It updates and extends a previous National Institute for Health
and Care Excellence (NICE) technology appraisal (TA) of etanercept conducted in 2002 (NICE TA35). The
licensed indication for etanercept has broadened since 2002 and three newer biologic DMARDs have been
licensed. This appraisal includes all subtypes of JIA, with the exception of systemic JIA with active systemic
features or persistent oligoarticular JIA.
Methods
Clinical effectiveness systematic review
Electronic bibliographic resources including MEDLINE, EMBASE, The Cochrane Library and the Database
of Abstracts of Reviews of Effects were searched for published studies from inception to May 2015 for
English-language articles. Bibliographies of included articles and systematic reviews were also searched for
additional studies, as were company submissions (CSs) to NICE. An expert advisory group was contacted to
identify additional published and unpublished evidence.
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Titles and abstracts were independently screened for eligibility by two reviewers using inclusion criteria that
were defined a priori. Inclusion criteria were applied to full texts by one reviewer and checked by a second
reviewer. Inclusion criteria were as follows:
l Population: patients with JIA including polyarthritis (both RF+ve and RF–ve, and EO, both onset and
course), ERA and PA.
l Intervention: the biologic DMARDs abatacept, adalimumab, etanercept and tocilizumab (in combination
with methotrexate where permitted), evaluated within their licensed indication. Studies of biologic
DMARDs without concomitant methotrexate were permitted if patients were intolerant to it or if
treatment with methotrexate was inappropriate.
l Comparators: DMARDs such as methotrexate (best supportive care if DMARDs are not tolerated),
as well as abatacept, adalimumab, etanercept and tocilizumab compared with each other.
l Outcomes: disease activity, disease flares, physical function, joint damage, pain, corticosteroid reducing
regimens, extra-articular manifestations (such as uveitis), body weight and height, mortality, adverse
effects of treatment and health-related quality of life (HRQoL).
l Design: randomised controlled trials (RCTs). Non-randomised studies could be considered where RCT
data were not available.
Data extraction and quality assessment were undertaken by one reviewer and checked by a second
reviewer. Differences in opinion were resolved by discussion at each stage or in consultation with a third
reviewer where necessary.
Data were synthesised through narrative reviews with tabulation of the results of included studies.
An adjusted pairwise indirect comparison of the four biologic DMARDs was presented.
Economic evaluation
A systematic review of cost-effectiveness studies and a systematic review of HRQoL studies was conducted
to identify relevant evidence to inform the economic evaluation. Studies were included in the systematic
review of cost-effectiveness if they were full economic evaluations (cost-effectiveness, cost–utility,
cost–benefit or cost–consequence analyses).
A cost–utility decision-analytic model was developed to compare the cost-effectiveness estimates of
biologic DMARDs versus methotrexate. The model used a Markov approach to estimate the costs and
health benefits for patients with JIA. The model consisted of three health states: on treatment (with
biologic DMARD), off treatment and death, with a further health state of ‘clinical remission off treatment’
also included in a scenario analysis. The model cycles were 3 months in length to be consistent with timing
between outpatient appointments in clinical practice. Patients discontinued treatment owing to adverse
events (AEs), inefficacy of the treatment or remission. The model also included the cost and disutility of
disease flares. The perspective of the analysis was that of the NHS and Personal Social Services. The model
used a time horizon of 30 years and discount rates of 3.5% for costs and health benefits. The outcome of
the economic evaluation is reported as cost per quality-adjusted life-year (QALY) gained.
Results
Clinical effectiveness
From 2554 references screened on title and abstract, 56 full texts were retrieved. One further conference
abstract was identified from a pharmaceutical CS to NICE. From these, nine full papers and 12 conference
abstracts met the inclusion criteria. The included papers and abstracts collectively described four
multicentre RCTs, with one RCT each evaluating abatacept, adalimumab, etanercept and tocilizumab. Only
the tocilizumab study included UK participants. All four studies were described as being withdrawal trials
starting with an open-label lead-in phase (12–16 weeks) in which participants had to achieve an American
College of Rheumatology (ACR) Pediatric (Pedi)-30 response level to be eligible for entry to the randomised
SCIENTIFIC SUMMARY
NIHR Journals Library www.journalslibrary.nihr.ac.uk
xxiv
double-blind withdrawal phase of the study (16–32 weeks), followed by an open-label extension (OLE).
All studies used a placebo as the comparator. With the exception of the etanercept trial, the majority of
patients in the trials received methotrexate in addition to the biologic DMARD or placebo. The distribution
of patients across the subtypes of JIA was reported for only two of the trials, with polyarthritis being the
predominant subtype. The other two trials appeared to include patients with polyarticular-course JIA.
Overall, the quality of the RCTs was reasonable, with a low risk of bias for most domains, but some
aspects were rated as unclear, primarily owing to insufficient reporting.
Significantly fewer patients who continued to receive biologic DMARDs during the randomised withdrawal
phase of the studies had arthritis flares than those receiving placebo in all four trials. Time to disease flare
for participants receiving biologic DMARDs was statistically significantly longer (reported for adalimumab
and etanercept). A greater proportion of those treated with biologic DMARDs achieved ACR Pedi
responses of ≥ 30 and had inactive disease (reported for abatacept and tocilizumab only). Generally, the
individual ACR Pedi core variables (reported for abatacept, etanercept and tocilizumab) were improved by
biologic DMARDs when compared with placebo, as were joint-related outcomes (reported for etanercept
only) and pain in two out of three studies (etanercept and tocilizumab, not abatacept). Not all studies
reported a statistical comparison for each of these outcomes. Three studies (adalimumab, etanercept and
tocilizumab) reported mortality, with no treatment-related deaths. Differences in HRQoL between trial arms
reported in one study (abatacept) were not statistically significant. The proportions of AEs and serious
adverse events (SAEs) were generally similar between the treatment groups. One study (tocilizumab)
reported subgroup data, albeit without statistical comparisons between treatment groups. None of the
studies reported data for outcomes such as corticosteroid dose reduction, extra-articular manifestations
(such as uveitis), height or weight for the randomised withdrawal phase of the trials.
An adjusted indirect comparison suggests that the four biologic DMARDs appear to be similar in terms of
disease flare and ACR Pedi-50 and -70 responses, with wide confidence intervals and clinical heterogeneity
between the trials.
There were differences across the trials in the eligibility criteria for the OLE phase, and in how the results
were reported. In some studies, it was not possible to differentiate between participants treated
continuously with a biologic DMARD (i.e. from open-label lead-in and randomised withdrawal phase) and
those who received placebo before being offered a biologic DMARD at entry to the OLE. Generally,
patients’ ACR responses remained constant over time or even increased after the double-blind phase.
Limited data for adalimumab and tocilizumab reported in abstracts at week 104 appear to support the
positive effect of these drugs on growth, but the use of different outcome measures prevents a
comparison between the drugs.
In addition to the four RCTs, seven relevant ongoing trials were identified and summarised in this report
(three investigating adalimumab and four investigating etanercept).
There is limited evidence for the clinical effectiveness of biologic DMARDs in specific JIA disease subtypes.
An observational study (CLIPPER) assessing the safety and efficacy of etanercept in children and adolescents
with EO JIA, ERA and PA found variations in response to treatment between JIA disease subtypes
(commercial-in-confidence information has been removed). By week 96, similar ACR Pedi-90 (62–72%)
and ACR Pedi-100 (51–60%) responses were achieved by participants with different JIA subtypes, and
proportions of patients with inactive disease varied between 29% (ERA and PA) and 37% (EO).
Evidence from observational studies suggests that biologic DMARDs can improve uveitis symptoms, such as
intraocular inflammation, in children with JIA. Adalimumab appears to be more effective than etanercept
in improving uveitis.
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Four pharmaceutical companies made submissions in support of their drugs to NICE. Only one of these
(Pfizer, etanercept) provided a systematic review of clinical effectiveness. This was judged to be of a good
standard. None of the submissions included any relevant RCTs that were additional to those identified in
this assessment report.
Cost-effectiveness
The systematic review of published economic evaluations identified 388 potentially relevant publications.
Of these, four studies (described in five publications) met the inclusion criteria. The studies were conducted
in the UK, the Netherlands, Canada and the Russian Federation. There were two cost–utility studies, one
cost-effectiveness study and one cost–consequence study. The studies were assessed for quality and
generalisability to the UK but all contained limitations in the methodological quality or generalisability to
the UK NHS. The study conducted in the UK was the assessment report for the previous NICE appraisal for
etanercept in children with JIA (NICE TA35). The systematic review of HRQoL identified two studies
reporting health-state utility values for patients with JIA.
In terms of the CSs to NICE, Roche (the manufacturer of tocilizumab) constructed a Markov state-transition
model that compared tocilizumab with adalimumab in children with JIA. The base-case results conclude
that tocilizumab is of similar effectiveness and is less expensive than adalimumab. Two companies, BMS
(the manufacturer of abatacept) and Pfizer (the manufacturer of etanercept) assumed that the biologic
DMARDs were equivalent in clinical effectiveness. They submitted cost analyses to compare the biologic
DMARDs. BMS concluded that abatacept was the least costly treatment option and that tocilizumab was
slightly cheaper than adalimumab. Pfizer concluded that for most ages, etanercept is the biological
treatment with the lowest acquisition cost compared with tocilizumab and adalimumab. AbbVie (the
manufacturer of adalimumab) did not submit an economic analysis and cited a number of methodological
limitations to producing an economic model. Two companies, Roche (tocilizumab) and BMS (abatacept)
submitted a confidential patient access scheme discount.
The independent model developed for this assessment report modelled one line of biological treatment
for the comparison of adalimumab, etanercept and tocilizumab versus methotrexate. From this model,
the incremental cost-effectiveness ratios (ICERs) for adalimumab, etanercept and tocilizumab versus
methotrexate are estimated at £38,127, £32,526 and £38,656 per QALY gained, respectively, using the list
price drug acquisition costs. Abatacept is licensed for second-line biological therapy after discontinuation
of an antitumour necrosis factor. Abatacept was compared with methotrexate as a second-line biological
treatment, following etanercept as the first-line biologic. In this analysis, abatacept had an ICER of £39,536
per QALY gained.
The model results are most sensitive to changes in the HRQoL utility values. The changes to the clinical
effectiveness parameters, such as treatment discontinuation and disease flare had minimal effect on the
model results. The differences in cost-effectiveness of the biologic DMARDs are primarily the effect of the
differences in the drug acquisition cost.
Discussion
Biologic DMARDs (plus methotrexate where indicated) are superior to placebo (plus methotrexate where
indicated) across a number of outcome measures in children with JIA who have had an insufficient
response to previous treatment. Owing to the withdrawal trial design, results of the double-blind phase are
applicable only to patients who have already achieved an initial (low) degree of benefit from a biologic
DMARD. Long-term treatment effectiveness in terms of ACR Pedi response appears to be sustained for
all four included RCTs and the occurrence of AEs is generally similar between biologic DMARD and
placebo-treated patients. SAEs seem to be uncommon and the long-term safety profile of the biologic
DMARDs is relatively favourable. An incremental analysis and the costs and health benefits of the four
biologic DMARDs was not presented, as the DMARDs were similar in effects and costs.
SCIENTIFIC SUMMARY
NIHR Journals Library www.journalslibrary.nihr.ac.uk
xxvi
There was insufficient evidence for all input parameters to permit a cost-effectiveness subgroup analysis for
each of the respective types of JIA within the scope of the appraisal. The modelled patient population is
people with JIA, although it is primarily relevant to those with polyarticular-course JIA.
The strengths of this assessment include the use of standard methods for evidence synthesis and economic
modelling, and the transparent reporting of the scope and methods a priori in a published protocol.
Limitations include the lack of head-to-head trial comparisons of biologic DMARDs, necessitating an
indirect comparison, and the lack of available data to inform the economic evaluation, particularly HRQoL
utility estimates (which were the most influential parameters of cost-effectiveness), long-term
discontinuation rates and the long-term impact of treatment on disease progression. Assumptions have
been made where possible based on best available evidence and expert opinion.
Conclusions
Implications for service provision
Given that biologic DMARDs are currently used in the treatment of JIA, any recommendation supporting
their use is unlikely to have significant implications for service provision (e.g. in terms of changes to
infrastructure, staff training).
Suggested research priorities
Randomised head-to-head comparisons of biologic DMARDs are necessary to establish comparative
effectiveness. Trials should be sufficiently powered, with long-term follow-up of safety and efficacy, and
should include an economic evaluation to assess cost-effectiveness.
Study registration
This study is registered as PROSPERO CRD42015016459.
Funding
The National Institute for Health Research Health Technology Assessment programme.
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Chapter 1 Background
Description of the underlying health problem
Juvenile idiopathic arthritis (JIA) is an umbrella term that encompasses all forms of arthritis with onset
before the age of 16 years and symptoms that persist for > 6 weeks for which the cause is unknown.1,2
The role of infections (either bacterial or viral) in the development of JIA has been investigated but no
unequivocal evidence to either support or rule out an association has been clearly demonstrated.3 The term
JIA has been in use since 1995 and was proposed by the International League of Associations for
Rheumatology (ILAR) committee to replace the older terms ‘juvenile rheumatoid arthritis’ and ‘juvenile
chronic arthritis’, which were the commonly used in the USA and in Europe, respectively.4 JIA is
characterised by joint pain, swelling and a limitation of movement which is caused by the inflammation of
the synovial membrane of the affected joints. If untreated, this inflammation causes progressive erosive
arthritis, which can lead to disability and growth retardation.5 JIA is classified according to the Revised ILAR
criteria6 into seven subtypes: systemic arthritis, oligoarthritis (subcategories persistent and extended),
polyarthritis rheumatoid factor negative (RF–ve), polyarthritis rheumatoid factor positive (RF+ve), psoriatic
arthritis (PA), enthesitis-related arthritis (ERA) and undifferentiated arthritis (Table 1); some forms of the
disease are more likely to be associated with extra-articular features such as uveitis (inflammation of the
middle layer of the eye).
At onset, the particular subtype of JIA will be diagnosed according to the presenting features
corresponding to one of the seven ILAR categories. As JIA progresses, more joints may become affected.
For some, where JIA was classified at onset as oligoarthritis, problems with five or more joints develop after
6 months and the JIA type is then described as extended oligoarthritis (EO). Similarly, the term polyarthritis
applies to patients who at a particular point in time 6 months or more after the onset of disease (JIA of
any onset type) have five or more active joints. In this case they are said to have polyarticular-course JIA.
The concept of polyarticular-course JIA has been used for clinical trials and can typically include RF+ve and
RF–ve polyarthritis, EO, ERA, PA and undifferentiated arthritis. Systemic JIA may also be included in the
definition of polyarticular-course JIA providing that there have been no active systemic symptoms during
the previous 6 months.14
Severity of disease and long-term outcome are variable both between different JIA subtypes and between
different individuals with the same JIA subtype (Box 1). Analyses of historical cohorts of JIA patients
(comprising a mix of JIA subtypes) have shown that > 50% of patients continued to have active disease for
as long as 17 years after disease onset and such patients would require treatment into adulthood.15,16
However, it should be noted that in historical studies the patients, particularly at disease onset, were
unlikely to have been treated with methotrexate or biologic disease-modifying antirheumatic drugs
(DMARDs), which were not available. Even when biologic DMARDs became available, they may not have
been widely used. Consequently, for all types of JIA, outcomes in general are likely to have improved
owing to more widespread use of the newer treatment strategies, particularly early in the disease course.
Nevertheless, one-third or more of children will still require treatment for JIA in adult life. JIA that persists
into adulthood is distinct from adulthood rheumatoid arthritis and should not be considered similar.
A recent systematic review of the prevalence and incidence of JIA in Europe17 found that rates varied
greatly among published studies. Incidence rates ranged from 1.6 to 23 per 100,000 (33 studies) and
prevalence rates from 3.8 to 400 per 100,000 (29 studies). The estimated annual incidence of JIA in
England in the period 1989–91 was 11 per 100,000.18 Prevalence in the UK has not been estimated since
1959 when a figure of 65 per 100,000 was reported.18 The Children’s Chronic Arthritis Association
website states that annual incidence is approximately 1 per 10,000 (i.e. 10 per 100,000) and prevalence is
about 1 per 1000 (i.e. 1000 per 1,000,000).19
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TABLE 1 Juvenile idiopathic arthritis classification according to the revised ILAR criteria
JIA classification6 and features7–12 Included in NICE appraisal scope?
Oligoarthritis
l The most common type of JIA accounting for > 50% of JIA cases in the UK13
l Usually starts before 6 years of age and is more common in girls than boys
l Affects four or fewer joints in the first 6 months, most commonly one or both
knees and/or ankles, which are swollen and may be painful
l Regular checks for chronic anterior uveitis (painless eye inflammation) required
The ILAR classification recognises two subcategories:
l Persistent oligoarthritis: affecting four or fewer joints throughout the disease
course, accounts for about 48% of JIA cases in the UK13
l EO: affecting a total of more than four joints after the first 6 months of
disease, accounts for about 6% of JIA cases in the UK13
No
Yes
Polyarthritis
Polyarthritis (RF+ve): accounts for about 4% of cases in the UK13
Polyarthritis (RF–ve): accounts for about 21% of cases in the UK13
l Polyarthritis is the second most common type of JIA, affecting about one in
four children with arthritis
l Usually starts either before 7 years of age or later in childhood
l Causes painful swelling of five or more joints in multiple sites. The same joints
on both sides of the body will often be affected
l RF–ve is the most common form. The RF+ve subtype is more often seen in
teenage girls
l Associated with chronic uveitis (painless eye inflammation)
Yes (all forms of polyarthritis)
ERA
l Accounts for about 6% of JIA cases in the UK13
l Affects the entheses (sites at which tendons attach to bones) often of lower
limb and pelvic joints as well as the joints themselves (spine or
peripheral joints)
l Can affect girls and boys, although teenage-onset disease mainly affects boys
l Associated with acute uveitis (red, painful eye)
Yes
PA
l Accounts for about 7% of JIA cases in the UK13
l Joint pain associated with the skin condition psoriasis (although the typical rash
of psoriasis may not occur until many years after the onset of arthritis) or with
a family history of psoriasis. Typically affects finger and toe joints
l Usually starts around 6 years of age and is about twice as common in girls as
in boys
l Chronic anterior uveitis is fairly common
Yes
Systemic arthritis
l Accounts for about 6% of JIA cases in the UK13
l Usually starts before 5 years of age and affects boys and girls
approximately equally
l General illness with fever, tiredness, rash, loss of appetite and weight loss as
well as joint pain. May also have enlarged glands, spleen and liver and, more
rarely, pericarditis (inflammation of the sac surrounding the heart)
Not active systemic onset JIA alone.
Those who go on to have a form
of JIA that is included (e.g.
polyarthritis) do match the remit
Undifferentiated arthritis
l JIA that does not fit into any of the above categories or that has features of
more than one type. Accounts for about 4% of JIA in the UK13
Yes
EO, extended oligoarthritis; NICE, National Institute for Health and Care Excellence.
BACKGROUND
NIHR Journals Library www.journalslibrary.nihr.ac.uk
2
BOX 1 Long-term outcomes for different subtypes of JIA
Long-term outcome7–12
Persistent oligoarthritis
l Often mild and may resolve with little or no lasting damage to joints; has the best outlook of all the types of JIA.
l Approximately half of children will have symptoms for at least 10 years, one-third or more of children will
have arthritis continuing into adulthood.
l Chronic anterior uveitis may cause blindness or visual loss if not detected and treated early enough.
Extended oligoarthritis
l Causes damage to joints so early treatment to minimise this is needed.
l Can be destructive and disabling.
l Approximately half of children will have symptoms for at least 10 years, one-third or more of children will
have arthritis continuing into adulthood.
l Chronic anterior uveitis may cause blindness or visual loss if not detected and treated early enough.
Polyarthritis
l Approximately half of children will have symptoms for at least 10 years and at least one-third of children
will have arthritis continuing into adulthood (most likely to be of the RF+ve type, which is more severe and
can require more aggressive treatment).
l Joints may become damaged if inflammation is not controlled, leading to the potential need for joint
replacement or serious disability.
ERA
l May evolve to ankylosing spondylitis in the adult years (especially in those with teenage onset) and may
require long-term disease-modifying or biologic agents.
PA
l Although there are few long-term data, disease course may be similar to chronic arthritis
(either oligoarthritis or polyarthritis) and is likely to continue into adulthood.
Systemic-onset JIA
l One-third of children will have one or two episodes that settle with treatment, one-third will have relapses
and need intermittent treatment and one-third will require ongoing treatment into adulthood and are at
risk of joint damage.
Undifferentiated arthritis
l Although there are few long-term data, clinical advisors indicate that the long-term outcome is likely
to depend on the predominant features of the arthritis and whether it is persistent oligoarthritis or
polyarticular-course arthritis.
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The sources of these data are not given; however, the same data are available in the Interim Clinical
Commissioning Policy Statement for biological therapies for the treatment of JIA.20 Based on the mid-2013
population estimates for those aged ≤ 17 years in England (approximately 11.5 million) and Wales
(approximately 630,000),21 these incidence and prevalence values equate to an estimated incidence of
1150 cases a year in England and 63 cases a year in Wales, with an estimated 11,500 and 630 children
with JIA overall in England and Wales, respectively.
A 2012 conference presentation13 presented data from a multicentre long-term prospective inception
cohort study of children with newly diagnosed inflammatory arthritis (the Childhood Arthritis Prospective
Study). This provides information on JIA subtypes classified using the ILAR criteria for 1014 newly
diagnosed children [median disease duration 5.2 months; interquartile range (IQR) 2.5–10.9 months].
Among this cohort, EO and polyarticular-course JIA may be under-represented because median disease
duration is < 6 months. Nevertheless, the proportions of each JIA subtype are similar to those reported by
an older study22 for a smaller group of children (n= 521), as shown in Table 2.
Table 2 also reports the distribution of JIA subtypes from a dataset (n=346 children and young people)
drawn from the British Society for Paediatric and Adolescent Rheumatology (BSPAR) etanercept cohort and
the Biologics for Children with Rheumatic Diseases cohort.23 These data are for patients starting a first-line
biologic DMARD from 1 January 2010 to 28 August 2014, and although a smaller cohort, is more up to
date than the other two cohorts. There are some differences in the distribution of subtypes, with a lower
proportion of patients with persistent oligoarthritis and a higher proportion with EO. This may be because
the children and young people in this cohort had longer disease duration (mean disease duration 2 years)
and therefore more may have progressed from persistent to extended oligoarthritis (i.e. a total of more than
four joints affected after the first 6 months of disease). Persistent oligoarthritis may be under-represented
as it is a milder form of JIA and generally may be adequately managed without biologic DMARDs.
In addition to the immediate impacts of the joint pain, swelling and limitation of movement that
characterise JIA, there are longer-term problems and other issues that may arise over time. Progressive joint
damage can lead to permanent disability and eventually to a need for joint replacement. A retrospective
review of 154 adolescents (aged 16–21 years) found that 14% had undergone a joint operation, with
30 separate surgeries (e.g. synovectomies, reconstructive finger or toe joint operations and one hip
TABLE 2 Proportions of different subtypes of JIA
JIA classification6
Newly diagnosed children,
% (n= 1041)13
From 17 centres within
the UK, %
Children starting first-line
antibiotics, %
Oligoarthritis
Persistent oligoarthritis
EO
48.2 (502/1041)
5.5 (57/1041)
30.1 (157/521)
15.2 (79/521)
12 (40/346)
17 (59/346)
Polyarthritis
RF+ve
RF–ve
3.6 (37/1041)
20.6 (214/1041)
7.1 (37/521)
19.6 (102/521)
29 (102/346)
8 (28/346)
ERA 5.6 (58/1041) 6.5 (34/521) 6 (20/346)
PA 7.0 (73/1041) 7.1 (37/521) 6 (20/346)
Systemic arthritis 6.0 (62/1041) 14.4 (75/521) 16 (54/346)
Undifferentiated arthritis 3.7 (38/1041) NR 2 (8/346)
Not recorded N/A N/A 4 (15/346)
N/A, not applicable; NR, not reported.
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replacement) having been undertaken.24 Growth impairment affects about 10–20% of patients with JIA
(mainly those with systemic or polyarticular JIA and who require high doses of glucocorticoids),25 and
decreased bone mass, which can lead to the development of osteoporosis, is also a recognised problem.26
Juvenile idiopathic arthritis is associated with a range of extra-articular manifestations, including uveitis,
inflammatory bowel disease and psoriasis. Uveitis commonly occurs in children with oligoarthritis and is
less common in other subtypes of JIA. It is characterised by inflammation of the middle layer of the eye,
the uveal tract. In severe cases that do not respond to treatment, uveitis can be associated with
complications such as cataract, glaucoma and macular oedema, and can lead to sight impairment and
blindness. Inflammatory bowel disease (e.g. Crohn’s disease and ulcerative colitis) is typically associated
with ERA, whereas psoriasis is associated with PA.
The incidence of childhood uveitis in North America and Europe is estimated at 4.3–6 per 100,000 children
and the prevalence at 30 per 100,000 children.27 Between 20% and 25% of uveitis cases in children are
associated with JIA. The prevalence of uveitis in JIA is between 8% and 30%, but in children with
oligoarticular onset JIA it may be between 45% and 57%.28 Uveitis in patients with JIA commonly occurs
with the early onset of arthritis (mean age at onset 3–5 years). Presentation in younger children may be
delayed owing to their inability to articulate symptoms. Screening for uveitis has therefore been
implemented for children with JIA in England.28 Complications are present in between 30% and 50% of
children with JIA with uveitis at diagnosis. A total of 50–70% of children with severe uveitis will develop
visual impairment.29
A recent systematic review of qualitative studies that explored the experiences of children living with JIA
highlighted the profound effect that JIA has on children’s lives. In particular, pain was a constant reminder
of their disease and limited children’s abilities to participate in normal life, including social events and
schooling. Their physical limitations meant that they had to look for alternative activities and potential
career options which they would be able to pursue. Many children and adolescents felt misunderstood and
some kept their illness a secret from their peers and others.30
Measures of response to treatment and definition of remission
The aim of JIA treatment is to achieve clinical remission (complete absence of active disease). Aggressive
early treatment aims to control inflammation and thus symptoms (e.g. joint pain); to decrease the number
of actively affected joints in order to prevent joint damage, loss of function and disability; and to maintain
or improve quality of life (QoL). Response to treatment is assessed in clinical trials by a validated core set of
variables that were adopted by the American College of Rheumatology (ACR) in 1997. This definition of
response is now known as the ACR Pediatric (ACR Pedi) definition of improvement.31 The lowest level of
improvement is known as ACR 30 (or ACR Pedi-30). The ACR Pedi-30 core variables are:
1. physician global assessment of disease activity (PGA) using a visual analogue scale (VAS) range from
best score of 0mm to worst score of 100mm (although in some studies this was reported as 0–10 cm)
2. patient or parent global assessment of overall well-being using a VAS (range 0–100mm, where 0 is the
best score)
3. functional ability as measured by the patient or parent using the Childhood Health Assessment
Questionnaire (CHAQ) (range 0–3, where 0 is the best score)
4. number of joints with active arthritis
5. number of joints with a limited range of motion
6. laboratory marker of inflammation [erythrocyte sedimentation rate (ESR) or C-reactive protein
(CRP) level].
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A response at the ACR Pedi-30 level is defined as an improvement in three of any six of the core variables
by at least 30%, and a worsening of no more than one of the remaining variables by > 30%. In addition
to the ACR Pedi-30, higher levels of response can also be defined: the ACR Pedi-50, -70, -90 and -100 levels
of response require at least 50%, 70%, 90% or 100% improvement, respectively, in at least three
of any six of the core set variables, with no more than one of the remaining variables worsening by
> 30%.14,32 It should be noted that according to expert advice, ACR Pedi-30 is no longer accepted as a
response but is considered a non-response or inadequate response, with response levels of at least ACR
Pedi-50 or -70 sought from a drug intervention.
More recently, in 2009, the Juvenile Arthritis Disease Activity Score (JADAS) was proposed and validated.33
The JADAS is a composite score that can be quickly calculated because it is the arithmetic sum of the
scores from the following four individual component measures:
1. PGA, measured on a 10-cm VAS (range 0= no activity and 10=maximum activity)
2. parent/patient global assessment of well-being, measured on a 10-cm VAS (range 0= very well and
10= very poor)
3. count of joints with active disease
4. ESR.
The component measures are also measures used in the ACR Pedi definition of improvement.31
The count of joints with active disease in the JADAS is primarily based on a 27-reduced joint count
(JADAS-27, total score range 0–57), although scores based on a full 71-joint count (JADAS-71, total score
range 0–101) and a 10-joint count (JADAS-10, total score range 0–40) have also been validated.33 Further
studies have shown that a 3-item JADAS that does not use ESR data is also a robust measure,34,35 which
is of particular benefit for children who do not need to provide a blood sample for routine medication
monitoring. As the JADAS has become more widely used, further proposals have been made that would
define low, medium and high disease activity35,36 and define improvement.37 With these definitions in
place, the future management goal would be to achieve minimal disease activity for all children with JIA.38
Preliminary criteria to define clinical remission in oligoarticular (persistent and extended), RF+ve and RF–ve
polyarticular and systemic JIA have also been developed.39 Two levels of clinical remission have been
proposed, namely clinical remission on medication and clinical medication off medication. The criteria for
both types of clinical remission are based on achieving inactive disease, which is defined as:
l no joints with active arthritis
l no fever, rash, serositis, splenomegaly or generalised lymphadenopathy attributable to JIA
l no active uveitis
l normal ESR or CRP (or both normal if both tested)
l a PGA that indicates no disease activity.
Clinical remission on medication is then proposed to have been achieved if all the criteria for inactive
disease have been met for a minimum of 6 continuous months while the patient is on medication. Clinical
remission off medication is proposed to have been achieved if all the criteria for inactive disease
have been met for a minimum of 12 continuous months while the patient is off all antiarthritis and
antiuveitis medications.
Since the original publication of the preliminary criteria to define clinical remission,39 validation of the criteria
for defining clinical inactive disease in oligoarticular (persistent and extended), polyarticular (RF+ve and
RF–ve) and systemic JIA has been undertaken. This has led to three changes: the addition of a definition for
no active uveitis (as defined by the Standardization of Uveitis Nomenclature Working Group); clarification
that the ESR or CRP level should be within the normal limits in the laboratory where tested or, if elevated,
not attributable to JIA; and one additional criterion (duration of morning stiffness of 15 minutes or less).40
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In addition to definitions of response to treatment and clinical remission, some publications also report on
the outcome of disease flare (periods in which symptoms worsen). A preliminary definition based on the
ACR Pedi-30 core response variables was obtained from a single small study (n= 51).41 This preliminary
definition was worsening in any two of six core response variables by 40% or more without concomitant
improvement of more than one of the remaining core response variables by 30% or more. However,
other studies have used different flare definitions (e.g. a worsening of ≥ 30% in three of six ACR
Pedi-30 variables).42
Current service provision
There is currently no National Institute for Health and Care Excellence (NICE) clinical guideline on the
treatment of JIA; however, there are two pieces of NICE guidance:
1. Guidance on the Use of Etanercept for the Treatment of Juvenile Idiopathic Arthritis [NICE Technology
Appraisal (TA)35]43 (this assessment report will inform an update of this guidance)
2. Tocilizumab for the Treatment of Systemic Juvenile Idiopathic Arthritis (NICE TA238)44 (active systemic
JIA is not included within this assessment report).
There are currently two interim commissioning statements: Biologic Therapies for the Treatment of Juvenile
Idiopathic Arthritis20 and the draft NHS Clinical Commissioning Policy for severe refractory uveitis in paediatric
patients.29 The first interim clinical commissioning policy statement was published (January 2015) by NHS
England Clinical Reference Group for Paediatric Medicine20 in the absence of NICE guidance for other biologic
DMARDs and to cover more recent changes to the licensed indications to etanercept and is being consulted
on. The purpose of the interim policy statement is to provide guidance for the use of biologic DMARDs in
patients with JIA until the planned NICE guidance is published. The statement has a broader remit than the
planned NICE guidance [Arthritis (juvenile idiopathic) – abatacept, adalimumab, etanercept and tocilizumab
(including review of TA35)] as it includes all biologic DMARDs and all types of JIA (i.e. including persistent
oligoarticular JIA and systemic JIA, which are not included in the NICE scope for the planned guidance).
A summary of the key features of the drug treatment pathway is provided in Table 3.
TABLE 3 Overview of the drug treatment pathway for JIA
When/why and who What Notes
At diagnosis to induce disease
remission, all patients
Corticosteroids:
EITHER intra-articular to all affected
joints OR systemic, preferably
intravenous [owing to the side
effects (e.g. effect on growth or
increased risk of osteoporosis) of
oral corticosteroids]
In patients with mild disease limited to
fewer than five joints, intra-articular
steroids may induce remission of
> 6 months, particularly if the
long-acting corticosteroid
triamcinolone hexacetonide is used
Patients with more severe disease may
need intravenous steroids to induce
remission, although intra-articular
steroids are used in some patients as
an alternative
To maintain remission, patients with
arthritis affecting more than five joints
or arthritis severely affecting crucial
joints (e.g. spine, ankles, hips, wrists)
MTX This accounts for around half of all
children who develop JIA
Effective in reducing the amount and
severity or arthritis but only induces
complete remission in 30–50% of
patients
When JIA remains active despite
optimal MTX dosing OR when patient
is intolerant of MTX
Biologic DMARD (many given in
coadministration with MTX to
optimise their effect)
Estimated that one-third of all children
who start treatment with MTX need
to progress to a biologic DMARD
MTX, methotrexate.
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Clinical advice to the authors of this assessment report (hereafter referred to as the assessment group)
suggested that the interim statement largely reflects current practice. However, it was acknowledged that
there would still be some variability across the country owing to differences in interpretation and limitation
on access and prescribing.
According to the second interim clinical commissioning policy statement (the draft NHS Clinical
Commissioning Policy for severe refractory uveitis in paediatric patients29), patients with JIA-associated
uveitis may be managed initially with topical corticosteroids or systemic corticosteroids if required. In more
severe cases, a DMARD can be used, with methotrexate being a standard treatment. If the disease is not
controlled with DMARDs, the next line of treatment is use of a tumour necrosis factor (TNF) inhibitor
(TNF-α is shown to be implicated in the pathogenesis of uveitis). TNF inhibitors include etanercept (Enbrel®,
Pfizer), adalimumab (Humira®, AbbVie), infliximab (REMICADE®, Centocor Ortho Biotech Inc.), golimumab
(SIMPONI®, Centocor Ortho Biotech Inc.) and certolizumab (Cimzia®, UCB Pharma S.A.), although the last
two of these may not be easily available in the UK, and only etanercept and adalimumab are licensed for
the treatment of JIA in children in Europe. For severe refractory uveitis in paediatric patients, the draft NHS
Clinical Commissioning Policy states that etanercept is not suitable for use in JIA patients with uveitis or
uveitis not associated with JIA.29 Adalimumab is recommended where methotrexate does not control
symptoms, with infliximab used in patients in whom adalimumab is not tolerated or not effective.29
Description of the technology under assessment
Four biologic DMARDs are within the scope of the NICE appraisal and are therefore included in this
assessment report: abatacept [Orencia®, Bristol-Myers Squibb (BMS)], adalimumab, etanercept and
tocilizumab (RoActemra®, Roche). The licensed indication differs across these interventions (e.g. in terms of
the age range of children and young people eligible for treatment, the previous treatment that they should
have received and the subtype of JIA) as summarised in Table 4. The Interim Clinical Commissioning Policy
Statement: Biologic Therapies for the Treatment of JIA20 provides a pragmatic estimate of 950 children
with JIA in England who are currently receiving a biologic DMARD. This estimate is based on current data
from the biologics databases in the UK which indicate that in England alone 890 children are receiving a
biologic DMARD for JIA (most of which are NICE-approved biologic DMARDs). Clinical advice to the
assessment group suggested that this figure may be an underestimate. An alternative estimate of 1500
was suggested by one clinician.
As noted earlier in Current service provision, the interim clinical commissioning policy indicates that the
initial biologic DMARDs to be considered for use would be a TNF inhibitor, which for the purposes of this
assessment would be either adalimumab or etanercept (however, etanercept is not suitable for use in JIA
patients with uveitis). If a treatment switch was required, the second-line biologic DMARD would initially
be the alternative TNF inhibitor (i.e. a switch from adalimumab to etanercept or vice versa). If a further
switch was necessary, the third-line biologic would be either abatacept or tocilizumab, and the final switch
possible would be to change abatacept to tocilizumab or vice versa. However, in terms of the marketing
authorisations, the licence for abatacept indicates that there should have been a prior insufficient response
to at least one TNF inhibitor. There is no such indication in the licence for tocilizumab.
The summary of product characteristics (SPC) for each biologic DMARD should be consulted for the
specific contraindications, special warnings and precautions for use; however, there are some aspects that
are common to all biologic DMARDs, which are summarised here.45–48 These drugs block aspects of normal
immune system signalling and, consequently, it is recommended that all patients receiving a biologic
DMARD carry an alert card to indicate that they are at increased risk of developing a serious infection.
Patients are at risk not only of typical bacterial and viral infections but also of opportunistic infections
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including invasive fungal infections. Existing latent infections (e.g. latent hepatitis B, latent tuberculosis)
could potentially reactivate. Consequently, if patients have an existing infection, treatment with a biologic
DMARD is not recommended until the infection is treated. Patients should be screened for latent
infections, and childhood vaccinations should be brought up to date prior to beginning therapy with a
biologic DMARD.
The SPCs for each of the four biologic DMARDs included in the review do not explicitly specify license
upper age limits for treatment. Clinical advisors have indicated that if adolescents are responding to
treatment then this should be continued into adulthood as required. Furthermore, some JIA patients may
need to restart a biologic DMARD in adulthood and some JIA patients may require a biologic DMARD for
the first time in adulthood.
TABLE 4 Summary of licensed indications of the biologic DMARDs under consideration in this assessment
Drug (chief mode
of action)
Polyarthritis (polyarticular)a
ERA PA Systemic onsetRF+ve RF–ve EO
Abatacept
(prevents T-cell
activation)
Yes Yes Yes –b – –
With MTX. Patients ≥ 6 years of
age with insufficient response to
DMARDs including at least one
TNF inhibitor
Adalimumab
(TNF inhibitor)
Yes Yes Yes Yes – –
With MTX unless not tolerated/not
appropriate
Patients ≥ 2 years of age, with
inadequate response to 1 or more
DMARDs
Patients ≥ 6 years
of age with
inadequate
response, to or
intolerant of,
conventional
therapy
Etanercept
(TNF inhibitor)
Yes Yes Yes Yes Yes –
Children and adolescents from
2 years of age with inadequate
response to, or intolerant of, MTX
Adolescents
from 12 years
of age with
inadequate
response, or
intolerant of,
conventional
therapy
Adolescents
from 12 years
of age with
inadequate
response, or
intolerant of,
MTX
Tocilizumab
(IL-6 inhibitor)
Yes Yes Yes – – Yes
With MTX unless not appropriate.
Patients ≥ 2 years of age who
have responded inadequately to
previous treatment with MTX
With MTX unless
not appropriate.
Patients ≥ 2 years of
age with inadequate
response to NSAIDs
and systemic
corticosteroids
IL-6, interleukin 6; MTX, methotrexate; NSAIDs, non-steroidal anti-inflammatory drugs.
a Patients with active systemic onset JIA alone will not be addressed in this multiple technology appraisal. Patients with
systemic onset JIA and a form of JIA that is included in the multiple technology appraisal (such as polyarthritis) will be
addressed in this multiple technology appraisal. Where systemic onset arthritis, ERA and PA go on to have a polyarticular
course, they could be interpreted as falling within the marketing authorisations for all four of the drugs.
b Dashes indicate that the drug is not licensed for this disease subtype.
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Abatacept
Abatacept in combination with methotrexate is indicated for the treatment of moderate to severe active
polyarticular JIA in paediatric patients aged ≥ 6 years, who have had an insufficient response to other
DMARDs including at least one TNF inhibitor.45
Abatacept is a fusion protein produced by recombinant deoxyribonucleic acid (DNA) technology in Chinese
hamster ovary cells. It inhibits T-cell activation by specifically binding to cluster differentiation (CD)80
and CD86, thereby selectively inhibiting a costimulatory pathway that is required for full activation of
T lymphocytes.45,49 Through this mechanism, abatacept modulates the downstream T lymphocyte-dependent
antibody responses and inflammation that cause the symptoms of JIA.
Treatment should be initiated and supervised by specialist physicians experienced in the diagnosis and
treatment of JIA at the appropriate dosage as indicated in Table 5. Abatacept is not recommended in
combination with TNF inhibitors.45
Adalimumab
Adalimumab in combination with methotrexate is indicated for the treatment of active polyarticular JIA
in patients from the age of 2 years who have had an inadequate response to one or more DMARDs.
Adalimumab can be given as monotherapy in the case of intolerance to methotrexate, or when continued
methotrexate treatment is inappropriate. Adalimumab is also indicated for the treatment of active ERA
in patients aged ≥ 6 years, who have had an inadequate response to, or who are intolerant of,
conventional therapy.46
Adalimumab is a fully human monoclonal antibody drug initially tested as a treatment for rheumatoid
arthritis (hence the trade name Humira – HUman Monoclonal antibody In Rheumatoid Arthritis). It binds
specifically to the inflammatory cytokine TNF, thereby neutralising its biological function46 and modifying
the inflammatory disease process. The European Medicines Agency (EMA) therapeutic indication for
adalimumab was extended to the treatment of JIA in July 2008.
Treatment should be initiated and supervised by specialist physicians experienced in the diagnosis and
treatment of JIA at the appropriate dosage as indicated in Table 6.46 The concomitant administration of
adalimumab with other biologic DMARDs [e.g. anakinra (Kineret®, Swedish Orphan Biovitrum) and
abatacept] or other TNF antagonists is not recommended.46
TABLE 5 Dosing regimen for abatacept
Mode of administration and cost Dose (children aged 6–17 years) Notes
Intravenous infusion given over a
period of 30 minutes
Cost: powder for reconstitution,
net price for a 250-mg
vial= £302.40
Body weight < 75 kg 10mg/kg, repeated at
2 weeks and 4 weeks
after initial infusion,
then every 4 weeks
Review treatment if no
response within 6 months
Body weight 75–100 kg 750mg, repeated at
2 weeks and 4 weeks
after initial infusion,
then every 4 weeks
Dosing for patients
weighing ≥ 75 kg follows
the adult dosing regimen
Body weight > 100 kg 1 g, repeated at 2 weeks
and 4 weeks after initial
infusion, then every
4 weeks
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Etanercept
Etanercept (Enbrel®, Pfizer) is a fully humanised soluble TNF receptor fusion protein produced by recombinant
DNA technology in Chinese hamster ovary cells. It is a dimer with two copies of the extracellular domain
of the TNF receptor (p75) linked with the Fc component of human immunoglobulin 1, binding to TNF-α.50
The mechanism of action of etanercept is thought to be its competitive inhibition of TNF binding to cell-surface
TNF receptor, preventing TNF-mediated cellular responses by rendering TNF biologically inactive. Etanercept
may also modulate biologic responses controlled by additional downstream molecules (e.g. cytokines,
adhesion molecules or proteinases) that are induced or regulated by TNF.47 The EMA therapeutic indication for
etanercept in the treatment of JIA was extended in July 2012 to include:
l treatment of polyarthritis (RF+ve or RF–ve) and EO in children and adolescents aged ≥ 2 years who
have had an inadequate response to, or who have proved intolerant of, methotrexate
l treatment of PA in adolescents aged ≥ 12 years who have had an inadequate response to,
or who have proved intolerant of, methotrexate
l treatment of ERA in adolescents aged ≥ 12 years who have had an inadequate response to,
or who have proved intolerant of, conventional therapy.
The age for treating polyarticular disease has been reduced from 4 to 2 years of age and the upper age
limit of 17 years has been removed.
Treatment should be initiated and supervised by specialist physicians experienced in the diagnosis and
treatment of JIA at the appropriate dosage as indicated in Table 7. The combined use of etanercept and
anakinra or etanercept and abatacept is not recommended.
TABLE 6 Dosing regimen for adalimumab
Mode of administration and cost Dosage Notes
Polyarticular JIA
Subcutaneous injection given EOW
(volume for injection is selected
from a chart based on patient
height and weight)
Cost: net price for a 40-mg prefilled
pen or prefilled syringe= £352.14;
40-mg/0.8-ml vial= £352.14
Patients aged 2 to
< 4 years
24mg/m2 BSA up to a
maximum single dose of
20mg
A clinical response is usually
achieved within 12 weeks
of treatment. Continued
therapy should be carefully
reconsidered in a patient
not responding within this
time period
Contraindicated in patients
with moderate to severe
heart failure (New York
Heart Association class III/IV)
Patients aged 4–12 years 24mg/m2 BSA up to a
maximum single dose of
40mg adalimumab
Patients aged ≥ 13 years 40mg administered
EOW regardless of body
surface area
ERA
Patients ≥ 6 years of age 24mg/m2 BSA up to a
maximum single dose of
40mg
No indication for stopping
treatment is provided
BSA, body surface area; EOW, every other week.
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Tocilizumab
Tocilizumab (RoActemra®, Roche) in combination with methotrexate is indicated for the treatment of
juvenile idiopathic polyarthritis (RF+ve or RF–ve and EO) in patients ≥ 2 years of age who have responded
inadequately to previous therapy with methotrexate. When the patient is intolerant to methotrexate or
where continued treatment with methotrexate is inappropriate, tocilizumab can be given as
monotherapy.48 Tocilizumab is also indicated for the treatment of active systemic JIA but this indication is
not included within the current NICE appraisal.
Tocilizumab is a humanised, monoclonal, antihuman interleukin-6 (IL-6) receptor (IL-6R) antibody that
binds to membrane and soluble IL-6R, inhibiting IL-6-mediated signalling – a key cytokine in rheumatoid
arthritis pathogenesis.51 IL-6 is involved in causing inflammation and is found at high levels in patients with
rheumatoid arthritis, systemic JIA and polyarticular JIA. By preventing IL-6 from attaching to its receptors,
tocilizumab reduces the inflammation and other symptoms of these diseases.48 The EMA was granted a
licence for tocilizumab in the treatment of JIA in May 2011.
Treatment should be initiated by health-care professionals experienced in the diagnosis and treatment of
JIA at the appropriate dosage as indicated in Table 8.
TABLE 8 Dosing regimen for tocilizumab
Mode of administration and cost
Dose for polyarticular JIA in patients
over 2 years of age Notes
Intravenous infusion over 1 hour
Cost: net price for 4ml
(80-mg vial)= £102.40
10-ml (200-mg) vial= £256.00;
20-ml (400-mg vial)= £512.00
Body weight < 30 kg 10mg/kg once
every 4 weeks
Dose interruptions (including
discontinuation) are recommended for
liver enzyme abnormalities, low
absolute neutrophil count and low
platelet count according to the tables
provided in the SPC
Clinical improvement is expected within
12 weeks of initiation of treatment.
Continued therapy should be carefully
reconsidered in a patient exhibiting no
improvement within this time frame
Body weight ≥ 30 kg 8mg/kg once
every 4 weeks
TABLE 7 Dosing regimen for etanercept
Mode of administration and cost Dose for JIA Notes
Subcutaneous injection
Cost: net price of a 10-mg vial
(with solvent)= £35.75
25-mg vial (with solvent)= £89.38
25-mg prefilled syringe= £89.38
50-mg prefilled pen or prefilled
syringe= £178.75
0.4mg/kg (up to a maximum of 25mg
per dose) given twice weekly with an
interval of 3–4 days between doses
OR
0.8mg/kg (up to a maximum of 50mg
per dose) given once weekly
Consider discontinuation in patients
who show no response after 4 months
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Chapter 2 Definition of the decision problem
Decision problem
In line with the scope of the NICE appraisal, the clinical effectiveness and cost-effectiveness of abatacept,
adalimumab, etanercept and tocilizumab for the treatment of JIA will be assessed.
The comparators for this assessment are: DMARDs (such as methotrexate), if DMARDs can be tolerated;
best supportive care, if DMARDs are not tolerated; biologic DMARDs (etanercept, abatacept, adalimumab
and tocilizumab) compared with each other within their licensed indications where appropriate.
The relevant population are children and young people with JIA diagnosed at onset either as polyarthritis
(RF+ve and RF–ve) or EO, and those with other forms of polyarticular-course arthritis (e.g. ERA, PA or
undifferentiated arthritis). Children/young people with JIA and uveitis are also relevant. The age of the
children/young people may vary by intervention owing to differences in the licensed indications.
As specified in the NICE scope, the following clinical effectiveness outcome measures are relevant to the
decision problem: disease activity, disease flares, physical function, joint damage, pain, reduced use of
corticosteroids; occurrence of extra-articular manifestations (such as uveitis), changes in body weight and
height, mortality, adverse effects of treatment and health-related quality of life (HRQoL).
Overall aims and objectives of the assessment
The aim of this multiple technology appraisal (MTA) is to assess the clinical effectiveness and cost-
effectiveness of abatacept, adalimumab, etanercept and tocilizumab for treating JIA.
The objectives are:
l to undertake systematic reviews of the clinical effectiveness and cost-effectiveness of abatacept,
adalimumab, etanercept and tocilizumab for the treatment of JIA, and of the HRQoL of people with JIA
l to critique the company submissions (CSs) to NICE from AbbVie (adalimumab), BMS (abatacept),
Pfizer (etanercept) and Roche (tocilizumab), and to identify the strengths and weaknesses of the
respective submissions
l to conduct an economic evaluation to establish the cost-effectiveness of abatacept, adalimumab,
etanercept and tocilizumab for the treatment of JIA.
Patients with systemic onset JIA exhibiting typical systemic features, such as spiking fever and rash, are
excluded from this MTA but if those features are no longer present (no active systemic symptoms during
the previous 6 months) and the patients have gone on to have polyarticular-course JIA, they will be
included. Similarly, patients with undifferentiated arthritis, ERA and PA that has a polyarticular course will
also be included.
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Chapter 3 Methods
Note
This report contains reference to confidential information provided as part of the NICE appraisal process.
This information has been removed from the report and the results, discussions and conclusions of the
report do not include the confidential information. These sections are clearly marked in the report.
The a-priori methods for systematically reviewing the evidence of clinical effectiveness and cost-
effectiveness are described in a research protocol published on the NICE website and registered with the
PROSPERO international prospective register of systematic reviews database (registration number
CRD42015016459). The protocol was sent to our expert advisory group (see Acknowledgements) for
comment. Minor amendments were made as appropriate. None of the comments that were received
identified specific problems with the methods of the review.
Identification of studies
Sensitive search strategies were developed and refined by an experienced information specialist. Separate
searches were conducted to identify studies of clinical effectiveness, cost-effectiveness and HRQoL.
The following databases were searched for published studies and ongoing research from inception to
May 2015: The Cochrane Library, including the Cochrane Database of Systematic Reviews, the Cochrane
Central Register of Controlled Trials, Centre for Reviews and Dissemination (University of York) Database of
Abstracts of Reviews of Effects, the NHS Economic Evaluation Database and the Health Technology
Assessment (HTA) database; MEDLINE (Ovid); EMBASE (Ovid); MEDLINE In-Process & Other Non-Indexed
Citations (Ovid); Web of Science with Conference Proceedings: Science Citation Index Expanded and
Conference Proceedings Citation Index – Science (ISI Web of Knowledge); Biosis Previews (ISI Web of
Knowledge); Zetoc (Mimas); National Institute for Health Research (NIHR)-Clinical Research Network
Portfolio; Clinical Trials.gov; International Standard Randomised Clinical Trial Number; UK Clinical Trials
Gateway; and World Health Organization International Clinical Trials Research Platform. In addition,
PsycINFO (EBSCOhost) was searched for HRQoL studies. Searches were not limited to particular trial
designs and, although searches were not restricted by language, only full texts of English-language articles
were retrieved during the study selection process. Cost-effectiveness and HRQoL searches were conducted
from database inception to May 2015. References were downloaded into Reference Manager (Professional
Edition Version 12, Thomson Reuters, New York, NY, USA) and deduplicated where necessary.
Bibliographies of included articles and systematic reviews were also searched. The CSs to NICE were searched
for any additional studies that met the inclusion criteria (see Chapter 4, Review of clinical effectiveness in
company submissions to the National Institute for Health and Care Excellence and Chapter 5, Review of
cost-effectiveness in company submissions to the National Institute for Health and Care Excellence). Members
of our advisory group were asked to identify additional published and unpublished evidence. Further details,
including search dates for each database and an example search strategy, can be found in Appendix 1.
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Inclusion and exclusion criteria
The following inclusion/exclusion criteria were applied to the clinical effectiveness review:
l Interventions: etanercept, abatacept (with or without methotrexate), adalimumab (with or without
methotrexate) and tocilizumab (with or without methotrexate). Each drug was evaluated within its
licensed indication. Studies of treatment without methotrexate were permitted if patients were
intolerant to methotrexate or for patients for whom treatment with methotrexate is inappropriate.
l Comparators: DMARDs (such as methotrexate, which is the most common conventional treatment in
the UK) if DMARDs can be tolerated and best supportive care if DMARDs are not tolerated. Etanercept,
abatacept, adalimumab and tocilizumab compared with each other.
l Population: patients with JIA including:
¢ polyarthritis (RF+ve, RF–ve and EO, both onset and course)
¢ ERA
¢ PA.
Studies of patients with systemic JIA were not included, as this was the subject of a separate NICE
appraisal (NICE TA 238).44
l Outcomes: studies reporting one or more of the following outcomes were included:
¢ disease activity
¢ disease flares
¢ physical function
¢ joint damage
¢ pain
¢ corticosteroid reducing regimens
¢ extra-articular manifestations (such as uveitis)
¢ body weight and height
¢ mortality
¢ adverse effects of treatment
¢ HRQoL.
l Study design: randomised controlled trials (RCTs). Non-randomised studies could be considered where
RCT data were not available. Any relevant systematic reviews identified in the systematic review of
clinical effectiveness were used as a source of references. Studies published as abstracts or conference
presentations were only included if published from 2012 onwards and sufficient details were presented
(or available elsewhere, e.g. in a full paper reporting on the same RCT) to allow an appraisal of the
methodology and the assessment of results to be undertaken.
The inclusion/exclusion criteria for the cost-effectiveness and HRQoL studies are presented in Chapter 5,
Systematic review of cost-effectiveness evidence and Systematic review of health-related quality-of-life
studies, respectively.
METHODS
NIHR Journals Library www.journalslibrary.nihr.ac.uk
16
Data extraction strategy
Reference screening
All studies were selected for inclusion through a two-stage process. Titles and abstracts were screened
independently by two reviewers for potential eligibility, using a standardised and piloted eligibility selection
worksheet (see Appendix 2) containing the inclusion/exclusion criteria detailed above.
Full-paper screening
Full texts for potentially relevant studies were obtained and screened using a standardised and piloted
eligibility section worksheet (see Appendix 3) by one reviewer and checked by a second reviewer, and a
final decision regarding inclusion was agreed. At each stage, any disagreements were resolved by
discussion or with the involvement of a third reviewer when necessary.
Critical appraisal strategy
Clinical effectiveness studies were appraised using the Cochrane Risk of Bias criteria (e.g. selection bias,
detection bias, performance bias, attrition bias and selective reporting bias).52 Aspects of study quality,
including statistical procedures, outcome measurement and generalisability, were also assessed.
A critical appraisal of the included clinical effectiveness and cost-effectiveness studies (Chapter 5,
Systematic review of cost-effectiveness evidence) was conducted by one reviewer and checked by a second
reviewer. Any disagreements were resolved by consensus or in consultation with a third reviewer
where necessary.
Method of data synthesis
Details of the trial outcomes in the clinical effectiveness review were synthesised through narrative review
with tabulation of the results of included studies. Quantitative pooling of outcomes across clinical
effectiveness studies in a meta-analysis was not possible as the identified evidence included only one trial
per biologic DMARD, all of which used placebo as the comparator. It was not considered appropriate to
meta-analyse the four biologic DMARDs together owing to clinical heterogeneity.
An adjusted indirect comparison of the four biologic DMARDs was performed using the method described
by Bucher and colleagues.53 An indirect comparison refers to the synthesis of data from trials in which the
technologies of interest have not been compared in head-to-head trials, but have been compared indirectly
using data from a network of trials that compare the technologies with other interventions. A distinction
is often made between adjusted and naive (unadjusted) indirect comparisons. In the adjusted indirect
comparison, the comparison of the interventions of interest is adjusted by preserving the strength of
randomisation. Unadjusted indirect comparisons are considered to be observational evidence and are,
therefore, not recommended.54,55
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Chapter 4 Clinical effectiveness
Results
Quantity and quality of available research
Titles and, where available, abstracts of a total of 2651 references identified by searches (after deduplication)
were screened and full copies of 60 references were retrieved. Of these, 29 articles were excluded after
inspection of the full text as shown in Figure 1 and these are listed in Appendix 4. The most common reason
for exclusion of a reference was an irrelevant study design (e.g. systematic reviews, which were used as a
source of references, commentaries). One full text56 was of unclear relevance to the review because the type
of JIA was not stated and it was not clear whether or not participants met the licensed indication for
etanercept therapy in respect of having an inadequate response or intolerance to methotrexate. One full
paper and eight conference abstracts relating to four ongoing studies that seemed to be relevant were tagged
for inclusion in Ongoing trials (note that a further three ongoing studies were identified from a separate
search specifically undertaken for ongoing studies, which is not represented in Figure 1; therefore,
a total of seven ongoing studies are summarised in Ongoing trials).
Nine full texts and 12 conference abstracts described four RCTs (each of which was described by at least
one full paper) that met the inclusion criteria of the review (see Figure 1). As the full texts provided the
most complete data, these were the primary source of information for this review.
Total identified from searching
(after deduplication)
(n = 2651)
Titles and abstracts inspected
(n = 2651)
Excluded
(n = 2591)
Unclear
(n = 1)
Ongoing studies (n = 1 full
text for 1 study and n = 8 
abstracts for 3 further studies)
Full texts excluded
(n = 29)
• Population, n = 4
• Intervention, n = 0
• Comparator, n = 1
• Outcomes, n = 0
• Design, n = 21
• Abstract, n = 3
References for retrieval 
and screening
(n = 60)
• Abatacept, n = 1 study (3 papers,
   1 abstract)
• Adalimumab, n = 1 study (1 paper,
   3 abstracts)
• Etanercept, n = 1 study (4 papers)
• Tocilizumab, n = 1 study (1 paper,
   8 abstracts)
Studies included
 (n = 4) (described
by 9 full papers and 
12 conference abstracts)
FIGURE 1 Flow chart for the identification of studies.
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One of the RCTs evaluated abatacept57–60 [the AWAKEN (Abatacept Withdrawal study to Assess efficacy
and safety in Key Endpoints) trial], one RCT, by Lovell and colleagues, evaluated adalimumab,61–64 one RCT
evaluated etanercept (Lovell et al.42,65–67) and one RCT evaluated tocilizumab68–76 (the CHERISH trial). For the
sake of brevity, generally only the key reference for each RCT is cited in the main text of this report. All
four RCTs used placebo as the comparator; however, with the exception of the etanercept trial, the
majority of the patients in the trials received methotrexate in addition to the biologic DMARD or placebo.
The key characteristics of the trials are presented in Table 9, with the primary and secondary outcomes
measured in trials summarised in Table 10. All studies were multicentre RCTs, with the number of centres
ranging from 9 in the etanercept study42 to 58 in the tocilizumab study.68 Locations of the studies included
the USA (all four studies), Canada (one study42), Europe (three studies,57,61,68 with only the tocilizumab
study68 including UK centres), Latin America (two studies57,68), Australia (one study68) and the Russian
Federation (one study68). In each study, participants were initially treated in an open-label phase with the
TABLE 9 Summary characteristics of included studies
Characteristic Abatacept Adalimumab Etanercept Tocilizumab
Study details AWAKEN,
Ruperto et al. (2008),57
Ruperto et al. (2010),58
Ruperto et al. (2010),59
Lovell et al. (2012)60
Multicentre
withdrawal RCT at
45 centres in Europe
(not UK), Latin
America and the USA
Lovell et al. (2008),61
Lovell et al. (2012),62
Ruperto et al. (2013),63
Ruperto et al. (2014)64
Multicentre withdrawal
RCT at 31 centres in
Europe (not UK) and
the USA
Lovell et al. (2000),42
Lovell et al. (2003),65
Lovell et al. (2006),66
Lovell et al. (2008)67
Multicentre withdrawal
RCT at nine centres in
Canada and the USA
CHERISH,
Brunner et al. (2015),68
Brunner et al. (2014),69
Baildam et al. (2014),70
Brunner et al. (2013),71
De Benedetti et al. (2013),72
Baildam et al. (2013),73
De Benedetti et al. (2013),74
Brunner et al. (2012),75
Bharucha et al. (2014)76
Multicentre withdrawal RCT
at 58 centres in Australia,
Europe (including the UK),
Latin America, Russia and
the USA
Study phasesa 16-week open-label
lead-in
24-week randomised
double-blind
withdrawal
OLE
16-week randomised
open-label
32-week randomised
double-blind
withdrawal
OLE
12-week open-label
16-week
randomised
double-blind
withdrawal
OLE
16-week open-label lead-in
24-week randomised
double-blind withdrawal
OLE
Interventionb Abatacept: n= 60
Abatacept 10mg/kg at
about 28-day intervals
for 24 weeks or until
disease flare
Adalimumab: n= 38
Adalimumab 24mg/m2
of BSA (to maximum
of 40mg) EOW for
32 weeks
Etanercept: n= 25
Etanercept 0.4mg/kg
twice weekly until
disease flare or for
16 weeks
Tocilizumab: n= 82
10mg/kg < 30 kg body
weight, n= 16
8mg/kg < 30 kg body
weight, n= 11
8mg/kg ≥ 30 kg body
weight, n= 55
Comparatorb Placebo: n= 62 Placebo: n= 37
Placebo ≥ 10 mg/m2
BSA/week
Placebo: n= 26 Placebo: n= 84
10mg/kg < 30 kg body
weight, n= 15
8mg/kg < 30 kg body
weight, n= 13
8mg/kg ≥ 30 kg body
weight, n= 56
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TABLE 9 Summary characteristics of included studies (continued )
Characteristic Abatacept Adalimumab Etanercept Tocilizumab
Key inclusion
criteria
Age 6–17 years
Activec JIA (extended
oligoarticular,
polyarticular, RF+ve
or RF–ve, systemic
without systemic
manifestations)
Inadequate response
or intolerance to
≥ 1 DMARD including
biologic agents
ACR Pedi-30 for entry
to randomised
double-blind phase
Age 4–17 years
Activec polyarticular-
course JIA (any onset
type)
Inadequate response
to NSAIDs
ACR Pedi-30 at week
16 for entry to
double-blind
withdrawal phase
Age 4–17 years
Activec JIA
Inadequate response
to NSAIDs and
methotrexate at
doses of ≤ 10mg/m2
BSA/week
Age 2–17 years
Activec polyarticular-course
or extended oligoarticular
JIA (RF+ve or RF–ve) for
≥ 6 months
Inadequate responses to or
intolerant of methotrexate.
Either never treated
with biologics or use
discontinued for a specified
minimum period
BSA, body surface area; EOW, every other week; NSAIDs, non-steroidal anti-inflammatory drugs; OLE, open-label extension.
a The key phase of interest for efficacy outcomes is in bold text with lengths of phases reported in weeks for all studies for
ease of comparison.
b During randomised double-blind withdrawal phase.
c Inclusion criteria for active disease were very similar for the adalimumab, etanercept and tocilizumab studies (key aspects
were at least five swollen joints and at least three joints with a limitation of motion). The abatacept study required at
least five active joints (with swelling or limitation of motion accompanied by pain or tenderness) and active disease
(at least two active joints and two joints with a limitation of motion).
TABLE 10 Summary of outcomes measured
Parameter Abatacept Adalimumab Etanercept Tocilizumab
Primary
outcome
Time to disease flare Proportion of
participants not
receiving methotrexate
with disease flares
(weeks 16–48)
Number of patients
with disease flare
Proportion of patients in
whom a JIA flare occurred
during part 2 (up to and
including week 40)
compared with week 16
Secondary
outcomes
Proportion of patients
at end of 6-month
double-blind phase
who had disease flare
AEs Not specifically stated
(ACR core variables,
mortality and AEs
among others
reported)
JIA–ACR Pedi-30, -50, -70,
-90 responses (week 40)
Changes from baseline
in ACR core variables
Change from baseline
in ACR core response
variables (week 40)
Pain Clinically inactive disease
(week 40)
Assessment of safety
and tolerability
HRQoL
AE, adverse event.
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biologic DMARD under investigation and had to achieve at least an ACR Pedi-30 response to the biologic
DMARD to be eligible for entry to the randomised double-blind withdrawal phase, with the number of
participants randomised ranging from 51 in the etanercept study to 166 in the tocilizumab study. As each
study investigated a different biologic DMARD, study-specific details are provided below by study drug.
Abatacept
The abatacept RCT57 was funded by BMS and consisted of three phases: a 4-month open-label lead-in
phase (days 1–113); a 6-month double-blind randomised withdrawal phase (days 114–283); and an
open-label extension (OLE) phase [up to day 1681 (5.5 years) for efficacy and up to 7 years for safety].
Enrolled participants all received abatacept intravenously (10mg/kg to a maximum of 1000mg) and were
permitted to continue to take stable methotrexate during the 4-month lead-in phase. Those achieving
an ACR Pedi-30 response were then eligible to be randomised in a 1 : 1 ratio to continued abatacept
(n= 60) or placebo (n= 62). In the 6-month randomised withdrawal phase, abatacept was given at
randomisation and at about 28-day intervals (see Table 9).
Patients were eligible for the trial if they were aged 6–17 years and had EO, polyarticular (RF+ve or RF–ve)
or systemic JIA without systemic manifestations.
Participants were required to have at least five active joints (defined as swelling or, in the absence of
swelling, limited range of motion, accompanied by either pain or tenderness), active disease (defined as at
least two active joints and two joints with a limited range of motion) and an inadequate response to, or
intolerance of, at least one DMARD, which could include biologic agents (e.g. etanercept, infliximab and
adalimumab). Exclusion criteria included active uveitis, any major concurrent medical conditions and
pregnancy or lactation.
The primary outcome measure was time to disease flare during the double-blind period. Disease flare was
defined in three ways depending on the measure used: worsening of ≥ 30% in at least three of the six
ACR core-response variables for JIA, and at least 30% improvement in no more than one variable during
the double-blind period; a worsening of ≥ 20mm on the 100-mm VAS if a global assessment by either a
physician or a parent was used; worsening in two or more joints if the number of active joints or joints
with limited range of motion was used. Clinical assessments preceded drug administration at each visit.
Secondary outcomes included the proportion of patients at the end of the 6-month double-blind phase
who had disease flare, changes from baseline in each of the six ACR core variables, pain, assessment of
safety and tolerability and HRQoL.
Adalimumab
The Lovell and colleagues RCT61 was funded by a research grant from Abbott Laboratories and consisted of
three phases: a 16-week randomised open-label phase, a 32-week randomised double-blind withdrawal
phase and an OLE phase. Enrolled participants all received adalimumab subcutaneously (24mg/m2 of body
surface area, to a maximum of 40mg) every other week and methotrexate (at least 10mg/m2 of body
surface area per week) during the 4-month lead-in phase. Those achieving an ACR Pedi-30 response were
then eligible to be randomised in a 1 : 1 ratio to continued adalimumab plus methotrexate (n= 38) or
placebo plus methotrexate (n= 37) (see Table 9). The trial included two further study arms (adalimumab
only and placebo only), but because the majority of participants in these arms had never received
methotrexate, they did not meet the licensed indication and are not included in this report.
Patients were eligible for the trial if they were aged 4–17 years and had polyarticular-course JIA of any
onset type. If systemic onset, then patients had to be free of any systemic JIA manifestations for at least
3 months prior to study qualification.77 Participants were required to have active disease (defined as five or
more swollen joints and three or more joints with a limited range of motion), to have had an inadequate
response to non-steroidal anti-inflammatory drugs (NSAIDs), and to have neither previously been treated with
methotrexate nor, if previously treated with methotrexate, have had adverse events (AEs) or an inadequate
response. Exclusion criteria included clinically significant deviations in haematological, hepatic or renal indicators;
CLINICAL EFFECTIVENESS
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ongoing infection or a recent major infection that had required hospitalisation or intravenous antibiotics; and
recent receipt of live or attenuated vaccines. Patients who had previously been treated with other biologic
agents at any time or who had received recent treatment with intravenous immune globulin, cytotoxic agents,
investigational agents, DMARDs (other than methotrexate) or corticosteroids administered by intra-articular,
intramuscular or intravenous routes were also excluded from participation.
The primary outcome for the study (percentage of participants not receiving methotrexate who had a
disease flare during the double-blind period) related to the two study arms that, as noted above, do not
meet the licensed indication and are therefore not included in this report. Disease flare was reported for
the two study arms relevant to this assessment and it was defined in different ways depending on the
measure used: worsening of ≥ 30% in at least three of the six core criteria for JIA and at least 30%
improvement in no more than one of the criteria during the double-blind period; an increase of > 30% on
the 0–100mm VAS if a global assessment was used; an increase in the number of active joints to at least
two when the patient had none or only one if the number of active joints was used, with the same
approach used for defining flare using joints with loss of motion. Outcomes were assessed every 12 weeks.
The occurrence of AEs was a secondary outcome.
Etanercept
The Lovell and colleagues RCT42,65–67 was funded by the Immunex Corporation and consisted of three
phases: an open-label lead-in phase of up to 3 months; a 4-month double-blind randomised withdrawal
phase; and an OLE phase. All enrolled participants received etanercept subcutaneously (0.4 mg/kg twice
weekly) during the 4-month lead-in phase. Those who improved and achieved an ACR Pedi-30 response
were then eligible to be randomised to continue to receive etanercept (n= 25) or placebo (n= 26) during
the withdrawal phase (see Table 9).
Patients were eligible for the trial if they were aged 4–17 years and had active polyarticular JIA despite
treatment with NSAIDs and methotrexate doses of at least 10mg/m2 of body surface area per week. Active
disease was defined as at least five swollen joints and at least three joints with limited motion with pain,
tenderness or both. Exclusion criteria included any major concurrent medical conditions and pregnancy
or lactation.
The primary outcome measure was the number of patients with disease flare during the double-blind
withdrawal period. Disease flare was defined depending on the measure used: worsening of ≥ 30% in at
least three of the six ACR core-response variables for JIA, at least 30% improvement in no more than one
variable and a minimum of two active joints; a change of at least two units on a scale from 0 to 10 if a
global assessment was used. Clinical assessments during the withdrawal phase took place on day 1,
day 15 and at the end of each month. Secondary outcomes were not specifically listed.
Tocilizumab
The tocilizumab RCT68 consisted of three phases: a 16-week open-label lead-in phase; a double-blind
randomised withdrawal phase (weeks 16–40); and an OLE phase (64 weeks). Some funding for manuscript
preparation was provided by F. Hoffmann-La Roche Ltd.
Enrolled participants were permitted to receive methotrexate and all received tocilizumab intravenously
(three groups). Those with a body weight of < 30 kg were randomised to either 10mg/kg or 8mg/kg every
4 weeks. Those with a body weight of 30 kg or more received 8mg/kg every 4 weeks during the 16-week
lead-in phase. Those achieving an ACR Pedi-30 response were then eligible to be randomised in a 1 : 1
ratio to continue tocilizumab (n= 82) or placebo (n= 84), given every 4 weeks until week 40 unless they
experienced disease flare (see Table 9).
Patients were eligible for the trial if they were aged 2–17 years and had polyarticular-course or EO JIA
that was either RF+ve or RF–ve for 6 months or more. Systemic JIA or any other categories of JIA were
excluded from the trial.78 Participants were required to have at least five active joints with a limited range
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of motion in at least three active joints and have an inadequate response, or intolerance, to methotrexate.
If participants were taking methotrexate (10–20mg/m2) or low-dose oral glucocorticoids (≤ 0.2 mg/kg/day,
daily maximum 10mg), the dose had to have been stable for 8 weeks or more (for methotrexate) or
4 weeks or more (for oral glucocorticoids). Patients had to be treatment-naive for biologics or had to have
discontinued use for a specified minimum period. No other exclusion criteria were specified.
The primary outcome measure was the proportion of participants with disease flare during the
double-blind period (up to and including week 40 compared with week 16). Disease flare was defined as
worsening of ≥ 30% in at least three of the six ACR core-response variables for JIA and at least 30%
improvement in no more than one variable during the double-blind period. Outcomes were assessed every
4 weeks. Secondary outcomes included the ACR Pedi-30, -50, -70, -90 responses, the change from
baseline in JIA core response variables and clinically inactive disease (PGA indicating no disease activity plus
the absence of all the following: joints with active arthritis, uveitis and ESR of > 20mm/hour).
Overview of the participants in the withdrawal phases of the included studies
For three of the four trials (abatacept,57 adalimumab61 and etanercept42) baseline characteristics are
provided for the participants who had achieved an ACR Pedi-30 response and who were randomised to
the double-blind withdrawal phase of each trial. The tocilizumab trial publication,68 however, presented
participant baseline characteristics for participants as randomised to the initial open-label lead-in phase,
where three groups of participants all received the study drug (if body weight was < 30 kg then
participants were randomised to either 10mg/kg or 8mg/kg every 4 weeks; if body weight was ≥ 30 kg
then participants received 8mg/kg every 4 weeks). Selected baseline characteristics are presented in
Table 11, with the full set of characteristics available in the data extraction forms (see Appendix 5). The
mean age of trial participants reflected the differing entry criteria for the trials. Participants in the
abatacept trial57 (participants aged 6–17 years were eligible) had the highest mean age (12–13 years),
whereas those in the adalimumab61 and etanercept trials42 (eligible ages were 4–17 years) had a slightly
lower mean age (approximately 9–12 years) which was similar to those enrolled in the open-label phase of
the tocilizumab study68 (eligible ages 2–17 years; mean age approximately 11 years). The majority of
participants in all four studies were female (ranging from 67% in the etanercept study42 to 80% in the
adalimumab study61) and of white ethnicity (73% in the etanercept study42 to 96% in the adalimumab
study61). The proportion of patients across the subtypes of JIA were reported for only two of the trials
(abatacept57 and etanercept42). In these two trials polyarthritis was the predominant subtype. In the
abatacept trial just under 20% of patients had systemic JIA (without systemic manifestations),57 whereas in
the etanercept trial around one-third had systemic JIA (with apparent systemic manifestations: spiking fever
and rheumatoid rash).42 The proportion of participants who were RF+ve ranged from 22% in the
adalimumab study61 to 29% in the tocilizumab study,68 and the duration of JIA from just under 4 years in
the abatacept study57 to approximately 6 years in the etanercept study.42
The treatment groups in the abatacept study57 appear similar on most variables, although the placebo
group had a smaller proportion of RF+ve patients than the abatacept group (19% vs. 32%). The
adalimumab study report61 indicated that there were no significant differences in baseline characteristics
between the placebo and adalimumab groups. Groups were described as well balanced in the etanercept
study42 with the exceptions of age group (4–8 years: 52% etanercept vs. 19% placebo; p< 0.02), ethnicity
(white ethnicity: 56% etanercept vs. 88% placebo; p< 0.02) and corticosteroid use (corticosteroid use at wash
out: etanercept 24% vs. 50% placebo; p= 0.05). The tocilizumab study did not report baseline characteristics
for those participants who entered the double-blind wash-out phase of this study.
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Assessment of the risk of bias of included studies
The Cochrane risk of bias criteria52 focus on various aspects of study design, conduct and reporting which
may help to gauge the internal validity (whether or not the study answered the research question in
a manner that was free from bias) of the individual studies. The risk of bias in the included trials is
summarised in Table 12 and further details are presented in the data extraction tables (see Appendix 5).
Only the abatacept trial57 reported sufficient details of the methods for generating the random sequence
(computer generated) and allocation concealment (interactive voice-randomisation system) to establish that
there was a low risk of selection bias in this trial. In the three other trials (adalimumab,61 etanercept42 and
tocilizumab68) the risk of selection bias associated with randomisation and allocation were unclear because
either no details were reported or there was insufficient information to make a judgement. The
randomised withdrawal phases of all four trials were described as double-blind with three of the trials
providing some information to support this statement (e.g. placebo identical in appearance,57 indication of
who was unaware of treatment assignment42,61). The risk of performance bias and detection bias was
judged to be low for all four trials. Attrition bias (systematic differences in withdrawals between trial arms)
was judged to be low for all outcomes in three trials42,61,68 (either because attrition was similar between
groups or because incomplete data were addressed). In the abatacept trial,57 however, a larger proportion
of patients dropped out of the placebo group in the double-blind phase (placebo 50%, abatacept 18%),
with the main reason being a lack of efficacy.
Although this was addressed for some outcomes (e.g. analysis of ACR variables), it was not addressed for
HRQoL, where the analysis was based on available data at each time point, hence the risk of attrition bias
is high for this outcome. Selective reporting bias was judged to be low for all the trials, as all outcomes
were reported on. The only other uncertainty surrounding study biases was the risk of bias attributable to
intercentre variability, which was not discussed in the adalimumab,61 etanercept42 and tocilizumab68 trials.
In contrast, the abatacept study57 reported that training was in place for joint assessors from each centre
who had specific and standardised joint assessment training.
TABLE 12 Summary of risk-of-bias assessment
Criteria Abatacept Adalimumab61 Etanercept42 Tocilizumab68
Selection bias
Random sequence generation Yes Unclear Unclear Unclear
Allocation concealment Yes Unclear Unclear Unclear
Performance bias
Blinding of participants and personnel Yes Yes Yes Yes
Detection bias
Blinding of outcome assessment Yes Yes Yes Yes
Attrition bias
Incomplete outcome data addressed
Non-HRQoL outcomes Yes Yes Yes Yes
HRQoL outcome No N/A N/A N/A
Reporting bias
Selective reporting Yes Yes Yes Yes
Other bias
Other sources Unclear Unclear Unclear Unclear
N/A, not applicable; no, high risk of bias; unclear, uncertain risk of bias; yes, low risk of bias.
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Assessment of clinical effectiveness: biologic disease-modifying
antirheumatic drugs versus placebo (with methotrexate where permitted)
Disease flare
The primary outcome for all four trials was disease flare, although there were some differences in the ways
in which this outcome was reported. Data on disease flare from the trials contribute to the economic
model in this assessment report (see Chapter 5, Data sources). The definitions for disease flare were
broadly consistent between the studies (a worsening of at least 30% in three or more of the six core
criteria for JIA and an improvement of ≥ 30% in no more than one of the criteria), with some studies also
including flare definitions based on global assessments and the number of active joints. In all four studies,
there were statistically significantly fewer arthritis flares in patients being treated with biologic DMARDs
than in those patients receiving placebo, and in the three studies that reported time to disease flare this
was statistically significantly longer in patients being treated with biologic DMARDs than in those receiving
placebo (Table 13).
In the abatacept study,57 by the end of the RCT period, disease flare had occurred in 20% of patients
receiving the study drug compared with 53% of patients receiving placebo (p= 0.0003). Median time to
disease flare was 6 months for the placebo group and this was statistically significantly greater than in the
TABLE 13 Disease flare during the randomised withdrawal phase
Study (length: open-label, RCTa), outcome Intervention Comparator Statistical significance
Abatacept57 (4-month open-label, 6-month RCT) ABA (n = 60) PBO (n = 62) p-value
Time to flare (months), median Not reached 6 0.0002
Disease flares, n (%) 12 (20) 33 (53) 0.0003
Disease flares, hazard ratio 0.31 (95% CI 0.16 to 0.59) NR
Adalimumab61 (4-month open-label, 8-month RCT) ADA (n = 38) PBO (n = 37) p-value
Disease flares, n/N (%) 14/38 (37) 24/37 (65) 0.02
Time to onset of disease flare (weeks) > 32 ≈ 20 0.03
Etanercept42 (3-month open-label, 8-month RCT) ETA (n = 25) PBO (n = 26) p-value
Disease flare, n (%) 7 (28) 21 (81) 0.0031b
Corticosteroid use at baselinec 0.05
Yes 3/6 (50) 12/13 (92)
No 4/19 (21) 9/13 (69)
Time to flare (days), median > 116 28 < 0.001
Tocilizumab68 (4-month open-label, 6-month RCTs) TCZ (n = 82) PBO (n = 81)d
Differencee TCZ vs. PBO
(95% CI); p-value
Proportion with JIA flare, n (%) 21 (25.6) 39 (48.1) –0.21 (–0.35 to –0.08); 0.0024
ABA, abatacept; ADA, adalimumab; CI, confidence interval; ETA, etanercept; NR, not reported; PBO, placebo; TCZ, tocilizumab.
a For ease of comparison, lengths of open-label and RCT phases are presented as time in months (where originally presented
in weeks, the value has been divided by 4; where originally presented in days, the value has been divided by 28).
b p< 0.001 after adjustment for baseline characteristics in logistic regression model.
c Authors state that with the exception of corticosteroid use at baseline (p= 0.05), none of the baseline characteristics was
a significant predictor of flare rates (p> 0.15).
d Of the 84 participants who achieved at least ACR Pedi-30 and were then randomised to placebo, three discontinued
(one owing to an insufficient therapeutic response and two owing to AEs). These three did not receive any study drug
in the randomised part of the study and so were excluded from the analyses.
e Adjusted for baseline stratification factors (background use of methotrexate and oral glucocorticoids).
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abatacept group (p= 0.0002), but the authors state that insufficient events occurred in the abatacept group
for this to be assessed. The risk of disease flare in patients randomised to continued abatacept during the
RCT phase was just under one-third of that for those receiving placebo [hazard ratio 0.31, 95% confidence
interval (CI) 0.16 to 0.95; no p-value reported].
Disease flare occurred in 37% of patients receiving adalimumab61 compared with 65% of those receiving
placebo (p= 0.02) and the time to onset of disease flare was longer in the adalimumab group.
In the etanercept study, disease flare occurred in 28% of patients receiving etanercept42 compared with
81% receiving placebo (p= 0.003). The authors of the etanercept study state that after adjustment for the
effects of baseline characteristics, the rates of flare remained significantly lower in the etanercept group
(p< 0.001), with only corticosteroid use at baseline being a significant predictor of flare rates (p= 0.05).
The median time to disease flare with etanercept was > 116 days compared with 28 days for the placebo
group, with 13/25 patients still receiving etanercept at the end of the study (day 116) (p< 0.001).
In those participants receiving tocilizumab, disease flare occurred in 26% of patients compared with 48%
receiving placebo (adjusted difference in flare rate −0.21, 95% CI −0.35 to −0.08; p= 0.0024), with
authors stating that flares in the placebo group were evident as early as 28 days after randomisation.
American College of Rheumatology Pediatric responses
ACR Pedi-30, -50 and -70 responses were reported by all four studies, with all but the etanercept study42
also reporting ACR Pedi-90 responses. The abatacept and tocilizumab studies57,68 additionally report
inactive disease, which was defined similarly in the two studies (no joints with active arthritis, normal ESR
of ≤ 20mm per hour, PGA < 10 on a 100-mm VAS,57 or PGA also < 10 on a 100-mm VAS), indicating no
disease activity with the tocilizumab study,68 also including an absence of uveitis (patients with uveitis were
excluded from the abatacept study). In all groups that continued to receive biologic DMARDs during the
randomised withdrawal phase of the study, the proportion of participants with ACR Pedi responses of 30
or more were greater than in the placebo group and when a p-value was reported the differences were
statistically significant in all but two instances (Table 14).
Although more patients receiving abatacept (82%) achieved an ACR Pedi-30 response than those patients
receiving placebo (69%), the difference was not statistically significant (p= 0.1712).57 However,
a statistically significantly greater proportion of patients in the abatacept treatment group achieved an ACR
Pedi-50, -70 or -90 response than those receiving placebo (p= 0.0071, p= 0.0185 and p= 0.0062,
respectively). In addition, statistically significantly more patients treated with abatacept (30%) than those
receiving placebo (11%; p= 0.0195) were classified as having inactive disease.
A statistically significantly higher percentage of patients being treated with adalimumab achieved ACR
Pedi-30, -50 and -70 responses compared with those receiving placebo (p= 0.03, p= 0.03 and p= 0.002,
respectively).61 The percentage of patients with ACR Pedi-90 response rates was also greater for
adalimumab-treated patients than for patients receiving placebo (42 vs. 27 placebo); however, this
difference was not statistically significant (p= 0.17).
In the etanercept study, ACR Pedi-30, -50 and -70 responses were achieved by a greater proportion of
patients being treated with etanercept during the randomised withdrawal phase than those receiving
placebo. However, a statistical comparison showing that this difference was statistically significant was
reported only for ACR Pedi-30 (p< 0.01).
A statistically significantly higher proportion of tocilizumab-treated patients achieved ACR Pedi-30, -50
and -70 responses than those receiving placebo during the randomised withdrawal phase of the study
(p= 0.0084, p= 0.0050 and p= 0.0032, respectively). Although the ACR Pedi-90 response was also higher
in the tocilizumab group, no p-value was provided. The proportion of patients with inactive disease was
36.6% for the tocilizumab group compared with 17.3% for the placebo group (no p-value provided).
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American College of Rheumatology Pediatric core variables
The adalimumab study61 did not report outcomes for the ACR Pedi core variables. The three remaining
studies, however, reported data as mean (abatacept57), median (etanercept42) or an adjusted mean for
change from baseline (tocilizumab68). In addition, the etanercept study reports additional joint and pain
outcomes, whereas the abatacept and tocilizumab studies also report additional pain outcomes
(see Joint-related outcomes and Pain).
TABLE 14 American College of Rheumatology Pediatric responses relative to baseline
Study (length: OL, RCT), outcome Intervention Comparator Statistical significance
Abatacept57 (4-month OL, 6-month RCT)
ACR Pedi, n (%)a ABA (n= 60) PBO (n= 62) p-value
30 49 (82) 43 (69) 0.1712
50 46 (77) 32 (52) 0.0071
70 32 (53) 19 (31) 0.0185
90 24 (40) 10 (16) 0.0062
Inactive diseaseb 18 (30) 7 (11) 0.0195
Adalimumab61 (4-month OL, 8-month RCT)
ACR Pedi, % ADA (n= 38) PBO (n= 37) p-value
30 63 38 0.03
50 63 38 0.03
70 63 27 0.002
90 42 27 0.17
Etanercept42 (3-month OL, 4-month RCT)
ACR Pedi, n (%)c ETA (n= 25) PBO (n= 26) p-value
30 20 (80) 9 (35) p< 0.01
50 18 (72) 6 (23) NR
70 11 (44) 5 (19) NR
Tocilizumab68 (4-month OL, 6-month RCT)
ACR Pedi, n (%) TCZ (n= 82) PBO (n= 81) Differenced TCZ vs. PBO (95% CI); p-value
30 61 (74.4) 44 (54.3) 0.09 (0.05 to 0.33); 0.0084
50 60 (73.2) 42 (51.9) 0.20 (0.06 to 0.34); 0.0050
70 53 (64.6) 34 (42.0) 0.22 (0.07 to 0.37); 0.0032
90 37 (45.1) 19 (23.5) 0.21 (0.07 to 0.35); NR
Inactive disease 30 (36.6) 14 (17.3) 0.18 (0.05 to 0.32); NR
ABA, abatacept; ADA, adalimumab; ETA, etanercept; NR, not reported; OL, open label; PBO, placebo; TCZ, tocilizumab.
a Assessed after the 6-month RCT phase or at the time of flare for patients who did not complete this period.
b Defined as number of joints with active arthritis, a PGA of ≤ 10 on a 100-mm VAS and a normal ESR rate.
c If a patient had a flare they were classified as having no response (ACR Pedi < 30) from that point on, regardless of their
ACR Pedi response at that time. Missing values were also imputed as non-responses.
d Adjusted for baseline stratification factors (background use of methotrexate and oral glucocorticoids).
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Generally, the core-response variable outcomes were in favour of treatment with the biologic DMARDs
compared with placebo. However, as can be seen in Table 15, there were some exceptions. For
abatacept,57 differences in the adjusted mean percentage change (adjustment based on an analysis of
covariance model with treatment as factor and baseline value as covariate) over the double-blind period
(from day 113 to day 282) for the parent’s global assessment and ESR rates between the treatment groups
were not significantly different (p= 0.6992 and p= 0.9562, respectively). The mean scores for the CHAQ
disability index at the end of the double-blind withdrawal trial period (day 282) were the same for both
TABLE 15 American College of Rheumatology Pediatric response core variables
Study (length: OL, RCT), outcome Intervention Comparator Statistical significance
Abatacept57 (4-month OL, 6-month RCT) ABA (n = 60) PBO (n = 62) p-valuea
Core-response variables, mean (SD)b
PGA (VAS: 100mm) 14.7 (18.9) 23.2 (21.8) 0.0004
Parent’s global assessment (VAS: 100mm) 17.9 (22.2) 23.9 (21.6) 0.6992
Physical function (CHAQ disability index: 0–3, best–worst) 0.8 (0.9) 0.8 (0.7) 0.0388
Number of active joints (number assessed not stated) 4.4 (7.0) 6.0 (5.8) 0.0245
Number of joints with LOM (number assessed not stated) 8.8 (12.8) 8.6 (12.0) 0.0128
ESR (mm/hour)c 25.1 (26.4) 30.7 (30.1) 0.9562
Etanercept42 (3-month OL, 4-month RCT) ETA (n = 25) PBO (n = 26) p-value
JIA core set criteria, medianb
PGA of disease severity (0–10, best–worst) 2 5 NR
Patient/parent global assessment of overall well-being
(0–10, best–worst)
3 5 NR
CHAQ scores (0–3, best–worst) 0.8 1.2 NR
Total number of active joints (out of 73 joints) 7.0 13.0 NR
Number of joints with LOM and with pain, tenderness,
or both (out of 71 joints; 0–10, best–worst)
1.0 4.5 NR
ESR (normal ranges 1–30mm/hour for females,
1–13mm/hour for males)c
18 30 NR
Tocilizumab68 (4-month OL, 6-month RCT) TCZ (n = 82) PBO (n = 81)
Differenced TCZ vs. PBO
(95% CI); p-value
JIA: core response variables, change from baseline – adjusted meanb
PGA of disease severity (0–100, 0= inactive disease) −45.2 −35.2 –9.9 (–16.5 to –3.4); 0.0031
Patient global assessment of well-being (0–100, 0= very poor) −32.1 −24.7 –7.4 (–14.8 to 0.0); NR
CHAQ: disability index score (0–3, 0= no disability) −0.8 −0.6 –0.2 (–0.4 to 0.0); NR
Number of active joints (range 0–71) −14.3 −11.4 –2.9 (–5.7 to –0.1); 0.0435
Number of joints with LOM (range 0–67) −9.5 −7.7 –1.8 (–4.1 to 0.5); 0.1229
ESR (mm/hour) −26.3 −12.0 –14.3 (–19.6 to –9.0); NR
ABA, abatacept; ESR, Erythrocyte sedimentation rate; ETA, etanercept; LOM, limitation of motion; PBO, placebo; NR, not
reported; OL, open label; SD, standard deviation; TCZ, tocilizumab.
a Abatacept study: p-values are based on the difference in the adjusted mean percentage change from day 113 to
day 282 (start and end of the double-blind period).
b Missing values were imputed with last-observation carried forward.
c CRP values were also reported by these studies: mean (SD) ABA 0.16 (0.25) vs. PBO 0.29 (0.54); p= 0.0255.57 Median
ETA: 0.4 vs. PBO 3.0 (normal range 0–0.79mg per decilitre).42
d Adjusted for baseline stratification factors (background use of methotrexate and oral glucocorticoids).
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groups (0.8). However, when the difference in the adjusted mean percentage change values for the CHAQ
disability index from the start to the end of the double-blind period (day 113 to day 282) are compared,
a statistically significant p-value is reported in favour of the abatacept group (p= 0.0388).
For etanercept,42 all core variable outcomes appear to be in favour of the etanercept group compared with
placebo; however, no statistical comparisons between treatment groups were reported. For the tocilizumab
study,68 differences in adjusted mean changes from baseline between treatment groups for PGA of disease
and number of active joints are reported to be statistically significant in favour of tocilizumab (p-values of
0.0031 and 0.0435, respectively); no p-values for the remaining outcomes were reported.
Joint-related outcomes
None of the trials reported any radiographic outcomes. However, in addition to the ACR Pedi core variable
outcomes that capture the numbers of active joints and joints with limited range of motion, the etanercept
study42 presented data for some additional joint-related outcomes (see Table 16).
No statistical comparisons for these outcomes were reported between the etanercept and the placebo
group; however, the median number of swollen joints (4.0 vs. 11.0 placebo), number of joints with
limitation of motion (LOM) (9 vs. 22 placebo), articular severity score (38 vs. 66 placebo) and duration of
stiffness (5 vs. 38 placebo) all favoured the etanercept treatment group (Table 16).
Pain
The adalimumab study61 did not report a pain outcome. All the other studies (abatacept,57 etanercept42 and
tocilizumab68) report pain assessed on a VAS, and the data are reported differently (mean, median and
mean change from baseline, respectively) (Table 17). The difference between the abatacept57 (mean pain
15mm) and the placebo (mean pain 21mm) treatment groups was not statistically significant (p= 0.105)
and reported mean pain scores were lower for patients being treated with abatacept. The etanercept study42
did not report a statistical comparison between treatment groups; however, median pain scores for patients
being treated with etanercept (VAS 1.5 cm) were less than half of those for patients receiving placebo (VAS
3.5 cm). The tocilizumab study68 reported the adjusted mean change from baseline, which, compared with
the placebo group, was statistically in favour of the tocilizumab treatment group (p= 0.0076).
Corticosteroid-reducing regimens
None of the included RCTs reported the effectiveness of biologic DMARDs on reducing the need
for corticosteroids.
Extra-articular manifestations (such as uveitis)
None of the included RCTs reported outcomes for extra-articular manifestations. Of note, one of the trials
(abatacept) excluded patients with active uveitis.57
TABLE 16 Joint-related outcomes (other than ACR Pedi)
Study (length: OL, RCT), outcome Intervention Comparator Statistical significance
Etanercept42 (3-month OL, 4-month RCT) ETA (n = 25) PBO (n = 26) p-value
Number of swollen joints (out of 66), median 4.0 11.0 NR
Number of joints with LOM (out of 71), mediana 9 22 NR
Articular severity score (0–962, best–worst), median 38 66 NR
Duration of morning stiffness (minutes), median 5 38 NR
ETA, etanercept; LOM, limitation of motion; NR, not reported; OL, open label; PBO, placebo.
a Although ‘number of joints with LOM’ are part of the ACR Pedi core variables, authors reported results under ‘other’
rather than under the core variables in the publication.
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Height and body weight
None of the studies reported differences in height or body weight between the treatment groups for the
double-blind, randomised controlled withdrawal phase of the trial.
Mortality
No deaths occurred in the adalimumab,61 etanercept42 and tocilizumab68 studies; this outcome was not
reported in the abatacept study.57
Quality of life: Child Health Questionnaire
The outcome measures for QoL in the abatacept study were summary physical scores, summary
psychosocial scores (both measured on a 100-mm VAS) and 15 Child Health Questionnaire (CHQ) health
concepts.58 Differences between the abatacept and placebo treatment groups were not statistically
significant for either the reported summary scores (p= 0.666 and p= 0.056, respectively), although there
appears to be a positive trend for the latter (Table 18). Abatacept-treated patients (n= 52) had improved
scores for 14 of the 15 subscales, and placebo-treated patients (n= 34) for 6 of the 15 CHQ subscales
(p> 0.05 for abatacept versus placebo for all subscales; details not data extracted).
Adverse events
A summary of AEs reported during the double-blind withdrawal trial phases is provided here with complete
details for the AEs reported by each of the studies available in the data extraction forms (see Appendix 5).
AEs reported during trial OLEs are presented below (see Adverse events open-label extension).
TABLE 17 Pain
Study (length: OL, RCT), outcome Intervention Comparator Statistical significance
Abatacept57 (4-month OL, 6-month RCT) ABA (n = 60) PBO (n = 62) p-value
Pain (parent global assessment of pain,
CHAQ VAS: 100mm), mean
15a 21a 0.105
Etanercept42 (3-month OL, 4-month RCT) ETA (n = 25) PBO (n = 26) p-value
Pain (VAS: 0–10 cm, best–worst), median 1.5 3.5 NR
Tocilizumab68 (24 weeks) TCZ (n = 82) PBO (n = 81)
Differenceb TCZ vs. PBO (95% CI);
p-value
Pain (VAS: no details reported), adjusted
mean change from baseline
−32.4 −22.3 –10.2 (–17.6 to –2.7); 0.0076
ABA, abatacept; ETA, etanercept; NR, not reported; OL, open label; PBO, placebo; TCZ, tocilizumab.
a Read off from graph by reviewer. Analysis based on available data, but the number of patients at this time point
contributing data to this outcome is unclear; 49/60 in the abatacept group and 31/62 in the placebo group completed
the 6-month double-blind period.
b Adjusted for baseline stratification factors (background use of methotrexate and oral glucocorticoids).
TABLE 18 Child Health Questionnaire
Study (length: OL, RCT), outcome Intervention Comparator Statistical significance
Abatacept57 (4-month OL, 6-month RCT) ABA (n = 52)a PBO (n = 34)a p-value
CHQ: physical summary score 43.6 41b 0.666
CHQ: psychosocial summary score 51.7 47b 0.056
ABA, abatacept; OL, open label; PBO, placebo.
a Original group sizes were ABA n= 60 and placebo n= 62, but not all participants contributed data to these analyses.
b Estimated from graph by reviewer. Number of patients in the trial arms not clear.
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Abatacept57
During the 6-month double-blind withdrawal period, there were no statistically significant differences in AEs
between the abatacept and placebo treatment groups. The total number of AEs (occurring in ≥ 5% of patients
in the open-label and double-blind phase) was 62% for the abatacept and 55% for the placebo group, with
two serious adverse events (SAEs) occurring in the placebo group but none in the abatacept group (Table 19).
The most common class of AEs in both treatment groups were infections and infestations (44–45%).
TABLE 19 Adverse events
Study, outcome Intervention Comparator Statistical significance
Abatacept57 (during 6-month double-blind period) ABA (n = 60) PBO (n = 62) p-value
Total SAEs, n (%) 0 2 (3) 0.50
Total AEs, n (%)a 37 (62) 34 (55) 0.47
Adalimumab61 (during 8-month double-blind period)
ADA (n = 38;
18.3 patient-years)
PBO (n = 37;
15 patient-years)
Any AE, number of events (number of events per
patient-year)
234 (12.8) 155 (10.3)
SAEs, possibly related to study drug, n of events
(n of events per patient-year)b
0 1 (0.1)
AEs leading to the discontinuation of the drug, n 0 0
Etanercept42 (time period unclear unless stated
below) ETA (n = 25) PBO (n = 26)
Hospitalisation for SAEs, n 2 0
Injection-site reactions during the 4-month
double-blind period, n
1 1
Most common AEs: injection-site reaction, number of
events (number of events per patient-year)
57 (3.8) 73 (4.0)
Tocilizumab68 (during 6-month double-blind period) TCZ (n = 82)c PBO (n = 81)c
SAEs and AEs occurring in ≥ 5% of patients, n (%)
Duration in study (years) 32.33 27.41
Patients with ≥ 1 AE 58 (70.7) 60 (74.1)
Total number of AEsd 147 141
Rate of AEs per 100 patient-years 454.7 514.4
SAEs
Patients with ≥ 1 SAE 3 (3.7) 3 (3.7)
Rate of SAEs per 100 patient-years 9.3 10.9
Patients with ≥ 1 infectious SAE 1 (1.2) 0
Rates of infectious SAEs per 100 patient-years 3.1 0
AEs leading to study drug discontinuation 1 (1.2)e 1 (1.2)f
ABA, abatacept; ADA, adalimumab; ETA, etanercept; PBO, placebo; TCZ, tocilizumab.
a AEs that occurred in ≥ 5% of patients in the open-label and double-blind phases.
b SAEs were death or any event that was life-threatening, required hospitalisation or prolongation of existing hospitalisation,
resulted in persistent or significant disability, congenital anomaly, or spontaneous or elective abortion, or required medical
or surgical intervention to prevent another serious outcome.
c AE data on open-label TCZ escape therapy were excluded.
d Multiple occurrences of the same AE in one individual were counted.
e Increased blood bilirubin level, highest total bilirubin reading, 50 µmol/l (normal range, 3–24 µmol/l); two consecutive
readings > 51mmol/l mandated withdrawal per protocol. The event resolved without sequelae.
f Gastroenteritis occurred 46 days after the last of five doses of placebo.
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AEs were also reported under the headings of gastrointestinal disorders, general disorders and administration
site conditions, nervous system disorders and respiratory, thoracic and mediastinal disorders (see Appendix 5).
Adalimumab61
There were 234 AEs in the adalimumab group (12.8 per patient-year) and 155 AEs in the placebo group
(10.3 per patient-year) during the 8-month double-blind period. No statistical comparisons in AEs between
treatment groups were reported. Only one SAE possibly related to the study drug was reported and this
was gastroduodenitis, which occurred in one patient in the placebo group. The most common AEs were
related to injection-site reactions [adalimumab: 73 events (4.0 events per patient-year); placebo:
57 events (3.8 events per patient-year)]. Other reported AEs were contusion, nasopharyngitis, upper
respiratory tract infection, viral infection, vomiting and excoriation (see Appendix 5). No AEs led to the
discontinuation of the treatment drug (see Table 19). Sixteen per cent of patients (27/171) had at least one
positive test for antiadalimumab antibody during the open-label and double-blind phases [methotrexate:
5/85 (6%); no methotrexate: 22/86 (26%)], but this did not lead to a greater rate of discontinuation of the
study drug, nor did it increase the incidence of SAEs. The study authors state that there was no occurrence
of opportunistic infections, malignant conditions, demyelinating diseases or lupus-like reactions.
Etanercept42
Two patients who received etanercept needed hospitalisation for SAEs (one for depression and a personality
disorder and the other for gastroenteritis-flu syndrome). It is not clear at what point in the trial these
events occurred. One patient withdrew after the first dose of etanercept (presumably at the start of the
open-label period) because of urticaria. There were only two reported injection-site reactions during
the double-blind phase of the trial, one in each treatment group (see Table 19). All other AEs were reported
to be of mild-to-moderate intensity, with no significant difference in the frequency of AEs between
the treatment groups during the double-blind phase. There were no laboratory abnormalities requiring
urgent treatment in the etanercept group. No patient had persistent elevations in autoantibodies or had
signs or symptoms of another autoimmune disease. Two patients tested positive for non-neutralising
antibody to etanercept.
Tocilizumab68
The safety population consisted of all patients who received more than one dose of study medication.
During the double-blind period, the total number of patients with at least one AE was 58 in the
tocilizumab group (454.7 AEs per 100 patient-years) and 60 in the placebo group (514.4 AEs per
100 patient-years). The most frequently reported AE in both treatment groups was nasopharyngitis
(tocilizumab: 17%, placebo 11%). Other reported AEs were headache, upper respiratory infection,
cough, pharyngitis, nausea, diarrhoea, rhinitis, vomiting, abdominal pain, oropharyngeal pain and rash
(see Appendix 5). Two AEs led to drug discontinuation, one in each treatment group (tocilizumab:
increased blood bilirubin level; placebo: gastroenteritis) and 3.7% of patients in each treatment group had
more than one SAE. One patient in the tocilizumab group suffered with more than one infectious SAE.
Rates of SAEs per 100 patient-years were similar between groups (tocilizumab: 9.3; placebo: 10.9),
whereas the rate of infectious SAEs per 100 patient-years was 3.1 for the tocilizumab group. Other
reported SAEs included pneumonia, upper limb fracture, uveitis, psychosomatic disease, enterocolitis and
complicated migraine, with one case in each category and varying by treatment group (see Appendix 5).
Subgroup analyses
Only the tocilizumab study68 reported subgroup analyses, which reported on ACR Pedi-70 and ACR Pedi-90
responses at week 40 in three subgroups: patients with background treatment of methotrexate;
background treatment of glucocorticoid; and previous biologic agent use at baseline. It is unclear if these
analyses were pre-planned or post hoc. The trial authors also stated that no differences were observed in
response to tocilizumab between patients who were RF+ve and those who were not, but no data in
support of this statement were presented. No statistical comparisons between treatment groups were
reported and it is therefore unclear if differences between the subgroups were statistically significant.
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Background methotrexate
Patients receiving background methotrexate in both the tocilizumab and the placebo groups had higher
ACR Pedi-70 and -90 response rates at the end of the double-blind RCT withdrawal phase than those who
were not in receipt of background methotrexate (Table 20). However, patients receiving tocilizumab with
or without background methotrexate had better response rates than patients in the corresponding
placebo groups.
Background glucocorticoid
At the end of the double-blind RCT phase (week 40) in the tocilizumab group, a slightly higher proportion
of participants receiving background glucocorticoid achieved an ACR Pedi-70 and -90 response than those
who were not in receipt of background glucocorticoid (see Table 20). However, among participants in the
placebo group the opposite pattern was observed, with a lower proportion of those who were in receipt
of background glucocorticoid achieving ACR Pedi-70 and -90 responses (see Table 20). Response rates for
both ACR Pedi-70 and -90 were higher in subgroups of patients receiving tocilizumab than in subgroups
of patients receiving placebo, regardless of whether or not patients received background glucocorticoid.
Previous biologic agent
Patients in either the tocilizumab or placebo groups who had received previous treatment with a biologic
agent (primarily comprising antiTNF agents) had lower ACR Pedi-70 responses at the end of the
double-blind RCT phase (week 40) than patients who had not previously been treated with a biologic agent
(see Table 20). Patients receiving placebo who had not received previous treatment with a biologic agent
had better ACR Pedi-70 and -90 response rates than patients on tocilizumab who had previous biologic
agent experience (see Table 20).
Results: open-label extensions
All four studies included OLEs with some differences in which participants were eligible to enter and
how data were presented. ACR Pedi results are presented in Table 21 and with additional outcomes
presented either in the study data extraction forms (see Appendix 5) or published papers [adalimumab:
minimal disease activity; abatacept: ACR Pedi component items, analysis according to prior exposure to
biologic agents, ACR Pedi data for those in the OLE who had not taken part in the double-blind phase and
information on antiabatacept and anticytotoxic T-lymphocyte-associated antibody production; etanercept:
ACR Pedi component items, minimal disease activity; tocilizumab: ACR Pedi component items, minimal
disease activity].
TABLE 20 American College of Rheumatology Pediatric response by background medication use at baseline at the
end of the double-blind RCT phase
Concomitant therapies
and previous exposure to
biologic agent Response level
Tocilizumab68 (4-month OL, 6-month RCT)a
TCZ (n= 82), n/N (%) PBO (n= 81), n/N (%)
Yes No Yes No
Background methotrexate ACR Pedi-70 45/67 (67.2) 8/15 (53.3) 30/64 (46.9) 4/17 (23.5)
ACR Pedi-90 32/67 (47.8) 5/15 (33.3) 18/64 (28.1) 1/17 (5.9)
Background glucocorticoid ACR Pedi-70 23/33 (69.7) 30/49 (61.2) 4/38 (36.8) 20/43 (46.5)
ACR Pedi-90 16/33 (48.5) 21/49 (42.9) 5/38 (13.2) 14/43 (32.6)
Previous biologic agent ACR Pedi-70 13/27 (48.1) 40/55 (72.7) 2/23 (8.7) 32/58 (55.2)
ACR Pedi-90 5/27 (18.5) 32/55 (58.2) 2/23 (8.7) 17/58 (29.3)
ITT, intention to treat; OL, open label; PBO, placebo; TCZ, tocilizumab.
a Proportion of patients in the intention-to-treat population with ACR Pedi-70 and ACR Pedi-90 response at the end of
the double-blind phase (week 40) by background methotrexate, glucocorticoid and previous biologic agent use at
baseline. Patients who withdrew or escaped to open-label TCZ or for whom the end point could not be determined
were classified as non-responders.
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TABLE 21 American College of Rheumatology Pediatric outcomes from trial OLE periods
Study (follow-up), outcome Intervention Comparator (during RCT phase)
Abatacept59 (OLE day 589)
ACR Pedi, n/N (%) ABA (n= 51) PBO (n= 47)
30 46/51 (90) 41/47 (87)
50 45/51 (88) 39/47 (83)
70 38/51 (75) 35/47 (75)
90 29/51 (57) 19/47 (40)
100 20/51 (39) 9/47 (19)
Inactive disease 22/51 (43) 11/47 (23)
Adalimumab61 (OLE week 104)
ACR Pedi, % ADA (n= 128a)
PBO group from RCT phase not
separately reported
30 89
50 86
70 77
90 59
100 40
Etanercept67 (OLE up to 8 years)
ACR Pedi response, 8 years (LOCFb), n/N (%) ETA (n= 58c)
PBO group from RCT phase not
separately reported
30 40/48 (83)
50 36/47 (77)
70 28/46 (61)
90 19/46 (41)
100 8/45 (18)
Tocilizumab69,71,74 (104 weeks)
ACR Pedi, proportion of patients with
improvement relative to baseline, n (%)69 TCZ (n= 82) PBO (n= 73d)
70e 71/82 (86.6) NR
90e 58/82 (70.7) NR
Proportion with inactive diseasef 52/82 (63.4) NR
ABA, abatacept; ADA, adalimumab; ETA, etanercept; LOCF, last observation carried forward; NR, not reported;
PBO, placebo; TCZ, tocilizumab.
a Only 71/128 (58%) of this group received methotrexate during the open-label and double-blind phases of the study and
met the licensed indication for adalimumab.
b A LOCF analysis was necessary because data were not available for all participants who entered the eighth year of
follow-up (n= 26) and because the remaining 32/58 (55%) of participants had discontinued the OLE already.
c Total number of participants who entered the OLE. As this is greater than the total number of participants who took
part in the double-blind phase of the study (n= 51), it is presumed that some of these participants entered the OLE
directly from the initial open-label treatment phase of the study.
d n calculated by reviewer (155 completed 104 weeks; 82 TCZ group completed 104 weeks).
e Two abstracts69,74 contain a table with a footnote to indicate patients who withdrew were excluded; however, in the
third abstract71 the table footnote states that patients who withdrew owing to non-safety reasons are non-responders,
whereas patients who withdrew owing to safety are included using LOCF.
f No active joints, no active uveitis, ESR < 20mm/hour and PGA VAS ≤ 10.
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Abatacept59
The abatacept study reported ACR Pedi data separately for those who had been treated with abatacept
continuously (lead-in, double-blind and OLE phases) and those whose abatacept had been interrupted by
placebo during the double-blind-RCT phase. The OLE included 85% of the abatacept group and 76%
of the placebo group from the double-blind phase. For those receiving continuous abatacept therapy,
treatment length ranged from 31 to 52 months (participants who had entered the study earliest had been
treated longest). Those who received placebo during the double-blind phase usually received abatacept for a
shorter period (length not stated), but the ACR Pedi scores achieved were similar for ACR Pedi-30,
-50 and -70 to those whose abatacept treatment had been continuous (see Table 21). The proportions of
participants who had received placebo during the double-blind phase achieving ACR Pedi-90 and ACR
Pedi-100 and having inactive disease are lower than those whose abatacept treatment had been continuous.
Adalimumab61
Results were reported for those who entered the OLE phase as a single group of participants (n= 128). This
group included 35 of 38 (92%) participants who received adalimumab and methotrexate, and 36 of 37
(97%) participants who received placebo and methotrexate in the double-blind phase of the study. However,
also within this group of 128 are 57 (45%) participants from two further study arms (adalimumab only and
placebo only) who are not included in this report because the majority of participants in these arms had never
received methotrexate and therefore do not meet the licensed indication. Through the first 104 weeks of the
OLE phase there was no diminution of the ACR Pedi responses, such that after 104 weeks of open-label
treatment in the extension phase, 40% of participants had an ACR Pedi-100 response (see Table 21).
Etanercept42
All 69 participants who began the open-label lead-in phase of the study (51 of whom took part in the
double-blind randomised withdrawal phase) were eligible to enter the OLE phase but only 58 did so.
Of the 58 who took part in the OLE, 26 entered the eight year of follow-up; therefore a last observation
carried forward analysis was used to calculate the ACR Pedi responses reported in Table 21. These
responses appear to have remained constant over the OLE. Although last observation carried forward
analyses are commonly used in drug trials, this method can be prone to bias when used in progressive
diseases such as JIA, and results should be interpreted with caution.
Tocilizumab68
Results from the OLE of the tocilizumab study68 are reported in conference abstracts.69,71,74 Only participants
who achieved at least ACR Pedi-30 during the open-label phase and who then continued into the
double-blind RCT phase of the trial were eligible to enter the OLE, either after a JIA flare or when they
completed the double-blind RCT phase. One-hundred and sixty (96%) of the 166 participants eligible to
enter the OLE did so and 155 (97%) completed 104 weeks of follow-up (16-week open-label plus 24 weeks
double-blind RCT plus 64 weeks OLE). ACR Pedi-70, ACR Pedi-90 and proportion with inactive disease are
presented (see Table 21) only for the 82 participants who received continuous tocilizumab throughout the
study and the proportion achieving each of these measures increased since the end of the double-blind
phase (see Table 21).
Growth
Adalimumab61
Two abstracts62,63 report limited data for growth from a post hoc analysis of JIA patients who had taken
part in any arm of the double-blind phase of the RCT and entered the OLE (this includes n= 58 who were
not receiving methotrexate and who were therefore not receiving adalimumab treatment according to the
licensed indication). All patients who received more than one dose of adalimumab +/– methotrexate were
included in the analysis (n= 133). Patients were assigned by baseline weight into two groups: ≤ 33rd
percentile (41%, n= 55) and > 33rd percentile (59%, n= 59) based on the US Centres for Disease Control
and Prevention growth charts. Missing data were analysed using last observation carried forward. Those in
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the ≤ 33rd percentile baseline weight group had a higher mean percentile change from baseline in height
at week 104 than those in the > 33rd percentile group (values for mean height percentile change from
baseline estimated from graph by reviewer 5.5 and 3.3, respectively).62 Similar patterns were stated to have
been observed for weight and body mass index. At week 104 there were no statistically significant
differences between the methotrexate and the non-methotrexate groups in mean changes from baseline
in height, weight or body mass index (p> 0.26). Long-term adalimumab treatment appears to show
improvement in growth for JIA patients who were in the ≤ 33rd percentile weight group at baseline
receiving adalimumab with or without the addition of methotrexate. However, caution in the
interpretation of the results is recommended owing to the limitations in the data presented and the
absence of an appropriate control group.
Tocilizumab76
The Roche CS included data for growth and glucocorticoid treatment at week 104 based on a conference
abstract76 from the CHERISH trial.68 Most growth data came from a subset of patients (n= 123) with the
highest growth potential, represented by patients with Tanner stage < 4 at baseline. The Tanner stages are
based on a scale of physical development in children, adolescents and adults (boys: development of external
genitalia; girls: breast development; boys and girls: pubic hair), with stage 5 being the final adult/mature
stage. Growth measures included height standard deviation scores (SDSs) and height velocity. The mean
height SDS of patients with polyarticular JIA and Tanner stage < 4 was below normal at baseline {–0.68
[standard deviation (SD) 1.23]} and rose to –0.19 (SD 1.14) at week 104 (n= 103) with the difference being
statistically significant (p< 0.001 vs. baseline). Of these patients, 71.8% had an increased height SDS.
The CS states (CS page 16)78 that there was no observed difference in patients who received placebo during
the randomised phase of the trial (based on 154 patients of the growth population with height SDS data at
both time points); however, fewer than half of the patients received placebo through the entire 24 weeks
of the randomised phased of the trial, as most escaped to tocilizumab before week 40. For the entire
growth population (n= 187; i.e. not restricted to those with Tanner stage < 4), the reported mean change
in height SDS from baseline to week 104 was 0.25 (SD 0.54) (no p-value for comparison with baseline
reported). The mean daily oral glucocorticoid dose decreased from baseline [0.05mg/kg (SD 0.08mg/kg)]
to week 104 [(n= 103) (0.02mg/kg (SD 0.05 mg/kg)]. A multiple linear regression analysis for the same
103 patients indicated that height velocity at week 52 was related to baseline age (p< 0.001) and oral
glucocorticoid use at the end of week 52 (p= 0.0002). No data for week 104 were reported. Caution in the
interpretation of the growth results is recommended owing to the limitations in the data presented and
the absence of an appropriate control group.
Adverse events
This is a summary of OLE AEs presented in the published papers.
Abatacept: OLE to day 589 and year 7
In the abatacept study,57 common AEs (occurring in 10% or more of the total group, no data extracted) and
common SAEs (occurring in 1% or more of the total group) were reported separately for those who had
been in the abatacept group and those who had been in the placebo group during the double-blind period
of the trial, and those who had not entered the double-blind phase because they did not achieve an ACR
Pedi-30 response during initial open-label treatment. SAEs by day 589 (approximately 20–21 months)
occurred in 23/153 patients (Table 22); the most common SAEs were arthritis flares (n= 6), arthralgia
(n= 2), foot deformity (n= 2), pyrexia (n= 2) and vomiting (n= 2). The proportions of SAEs at day 589
were similar in the three groups. At 7-year follow-up (reported in an abstract60), 30/153 (19.6%) patients
had SAEs. Most were unrelated and were primarily musculoskeletal or infectious events. The incidence rate
(per 100 patient-years) of SAEs in the OLE at 7 years (5.6/100 patient-years) did not increase versus the
6-month double-blind rate (6.8/100 patient-years).
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Adalimumab: open-label extension ongoing
The OLE was ongoing at the time the key trial publication was published, and the time period for which
events were reported is not clear.61 SAEs possibly related to study drug occurred in seven patients during
the OLE (a table in the published paper61 suggests none was receiving methotrexate, in which case they
were not receiving adalimumab treatment according to the licensed indication). Three patients discontinued
treatment owing to AEs during the OLE.
Etanercept: year 8
In the etanercept study42 OLE, the safety analyses captured SAEs, medically important infections (MIIs) and
mortality, as well as some ‘events of interest’ (including opportunistic infections, tuberculosis, lupus,
demyelinating disorders, malignancies and lymphomas). Non-SAEs were not recorded.67 There were a total
of 39 SAEs based on 318 patient-years of etanercept exposure (n= 69), with 26 patients entering their
eighth year of etanercept treatment, equating to 0.12 events per patient-year (Table 23). There were nine
MIIs resulting in the need for intravenous antibiotic therapy or hospitalisation, equating to 0.03 events per
patient-years, with only one reported MII since 4-year follow-up (pyelonephritis).
TABLE 22 Open-label extension AEs for abatacept
Abatacept57 (OLE: day 589,59 7 years60)
SAEs
DB ABA (n= 58),
n (%)a
DB PBO (n= 59),
n (%)a
Patients with less than an ACR Pedi-30
response initially (n= 36), n (%)
Total SAEs, n/N (%) 8/58 (14) 8/59 (14) 7/36 (19)
Most common SAEs
Arthritis flaresb 3 (5.2) 3 (8.3)
Arthralgiab 1 (1.7) 1 (1.7) 1 (2.8)
Foot deformityb 1 (1.7) 1 (1.7)
Pyrexia 1 (1.7) 1 (1.7)
Vomiting 1 (1.7)
SAEs year 7, n/N (%) 30/153 (19.6)
ABA, abatacept; DB, double blind; PBO, placebo.
a Patients who had been in the randomised double-blind phase.
b All related to underlying disease.
TABLE 23 Open-label extension AEs for etanercept
Etanercept42 (OLE: up to 8 years67)
Year of etanercept treatment from RCT
(excluding gaps between RCT and OLE)
SAEa MIIb
Number
of events
Number of events/
patient-year
Number
of events
Number of events/
patient-year
1 (n= 69; 57 patient-years of drug exposure) 5 0.09 2 0.04
9 (n= 14; 4 patient-years of drug exposure) 0 0 0 0
Total for all years (n= 69; 318 patient-years
of drug exposure)
39 0.12 9 0.03
a SAEs occurring during the study or within 30 days of the last dose of etanercept. Defined as events that were fatal or
life-threatening, required hospitalisation or prolonged an existing hospitalisation, resulted in a persistent or significant
disability or incapacity, or resulted in a congenital anomaly or birth defect.
b Defined as MIIs resulting in the need for intravenous antibiotic therapy or hospitalisation.
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The most common new SAEs reported beyond 4 years of drug exposure were flares or worsening of
disease, occurring in 6/9 patients (67%).
Tocilizumab: 104 weeks
Long-term AEs rates based on a safety population of 188 patients (307 patient-years) were 406.5 per
100 patient-years over 104 weeks (approximately 2 years) in patients receiving tocilizumab, based on an
abstract only.69 The equivalent SAEs rate was 11.1 per 100 patient-years (Table 24). Infections categorised
into the most common AEs and SAEs were 151.4 and 5.2 per 100 patient-years, respectively. The study
also reports AE safety population data for elevations of alanine aminotransferase and aspartate
aminotransferase, grade 2/3/4 thrombocytopenia, grade-3 lowest neutrophil count and low-density
lipoprotein cholesterol (see data extractions in Appendix 5).
Assessment of clinical effectiveness: biologic disease-modifying
antirheumatic drugs versus each other (with methotrexate where permitted)
Background
None of the RCTs included in the systematic review of clinical effectiveness directly compared any of the
biologic DMARDs with each other. It was therefore necessary to undertake an indirect comparison of the
drugs to inform the assessment of comparative clinical effectiveness. One published indirect comparison
was identified through literature searching, by Otten and colleagues.79 This was a systematic review of
RCTs that constructed two separate evidence networks: polyarticular-course JIA and systemic JIA. For each
network, a series of pairwise indirect comparisons was conducted, with placebo as a common comparator,
using the method described by Bucher and colleagues.53
Three RCTs were included in Otten and colleagues’79 polyarticular-course JIA network,42,57,61 all of which
have been included in this assessment report. However, this network did not include tocilizumab, as at
that time no RCT evidence for that drug in polyarticular-course JIA was published. The network therefore
included only comparisons of three of the four biologic DMARDs of relevance to the scope of this
assessment (abatacept, adalimumab and etanercept). We have conducted a similar adjusted indirect
comparison to Otten and colleagues79 including the recently published tocilizumab RCT by Brunner and
colleagues (the CHERISH trial).68 Figure 2 illustrates the design of the analysis, representing what is termed
a star network.80
Otten and colleagues79 indirectly compared the drugs in relative risk (RR) of disease flare. We have similarly
included disease flare as an outcome and, in addition, have chosen ACR Pedi-50 and -70 responses as an
outcome. ACR Pedi-50 and -70 were chosen as opposed to ACR Pedi-30, as it was considered that a
higher level would be a more clinically relevant level of treatment response. Furthermore, owing to the
design of the RCTs, all patients who were randomised had achieved an ACR Pedi-30 response at the end
of the open-label lead-in phase.
TABLE 24 Open-label extension AEs for tocilizumab
Tocilizumab68 (OLE: 104 weeks69)
AEs and SAEs
Safety population= 188 patients with 307 patient-years
of tocilizumab exposure
AEs, rates/100 patient-years 406.5
SAEs, rates/100 patient-years 11.1
Most common AE: infections 151.4
Infections: SAE 5.2
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The adjusted indirect comparison should be considered to be exploratory rather than definitive owing to
limitations in the evidence base and heterogeneity between the included trials.
l There is only one trial available for each drug. Although the trials were considered to be of generally
good methodological quality and low risk of bias, evidence networks are considered weaker if
informed by small numbers of studies and small numbers of participants.81 The number of patients in
the trials was also relatively low (ranging from 51 to 163).
l There is some variation in the proportion of subtypes of JIA in the included trials. Although the network
is considered to be most applicable to polyarticular-course JIA, in one trial (etanercept42) around
one-third of patients were classified as having systemic JIA with apparent systemic manifestations
(which is outside the scope of the current appraisal). There was insufficient evidence from RCTs to
construct a network for PA, or ERA because outcome data for these subtypes of JIA were not reported
separately in trials, even though some cases with these subtypes may have been included.
l The duration of JIA ranged from just under 4 years57 to approximately 6 years across the trials.42
A study by the BSPAR etanercept cohort found that shorter disease duration was an independent
predictor of achieving an excellent response to treatment (ACR Pedi-90) at one year.82 Disease duration
has also been found to be a predictor of response to etanercept83 and to methotrexate84 among
patients from the German Biologika in der Kinderrheumatologie (BIKER) registry. Differences between
the trials in disease duration may therefore potentially confound results.
l Three of the four trials permitted patients to take methotrexate in addition to the biologic DMARD
(in proportions of patients varying from 74% to 100%), whereas the fourth trial (etanercept)83 did not
permit use of methotrexate.
l Previous therapy with biologic DMARDs had been received by approximately one-third of participants
who entered the initial open-label run-in of two trials (abatacept57 and tocilizumab68). Prior therapy
with another biologic DMARD was an exclusion criterion for the adalimumab trial61 and was not
mentioned for the earliest trial (etanercept42), presumably because no other biological therapies were
available at the time. Currently, it is unclear whether or not prior biologic DMARD treatment influences
the effectiveness of subsequent biologic treatment.
l The mean age of patients across the trials varied from around 7.5 years to 13 years. Part of this
variation may reflect the age ranges specified in the inclusion criteria of the trials and potentially the
mix of JIA subtypes in the trials, which have a different mean age at onset. Age could be an effect
modifier given the progressive nature of JIA.
l The duration of the double-blind randomised treatment phase of the trials varied from 4 months42 to
8 months.61 Treatment duration may affect outcomes that are time dependent, such as disease flare.
Direct evidence
Placebo
(all four trials)
Etanercept
(Lovell et al. 
200042)
Adalimumab
(Lovell et al. 
200861)
Abatacept
(Ruperto et al. 
200857)
Tocilizumab
(Brunner et al. 
201568)
FIGURE 2 Indirect comparison of biologic DMARDs.
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Results
Figure 3 illustrates the results of the four included RCTs comparing the biologic DMARDs with placebo
(with background methotrexate where permitted) on the outcome of disease flare (the adalimumab trial61
stratified results according to whether or not patients received methotrexate background therapy,
and we have included data only for patients who did receive methotrexate, in accordance with the
licensed indication – this applies to disease flare and to ACR Pedi-50/-70). Treatment with each of the
four DMARDs resulted in a statistically significant reduction in the RR of a disease flare, ranging from
0.38 to 0.57. (We have not presented a pooled RR given differences between the DMARDs and also
heterogeneity between the trials.)
Table 25 reports adjusted pairwise indirect comparisons for the four biologic DMARDs for the outcome
of disease flare. The point estimate for risk of flare was lower for etanercept than the other three
comparators. Abatacept had a lower risk of flare than adalimumab and tocilizumab. Tocilizumab had a
lower risk of flare than adalimumab only. Adalimumab was associated with a higher risk of disease flare
than the other three comparators. The ranking of treatments in terms of risk of flare was therefore
etanercept, abatacept, tocilizumab and adalimumab. However, none of the comparisons demonstrated a
statistically significant difference between the treatments being compared, with CIs crossing 1 in every
case. The results of our analysis match those of Otten and colleagues,79 with the exception of the
comparison with tocilizumab, which was not included in their polyarticular-course JIA trial network
(as discussed above).
TABLE 25 Indirect comparisons of biologic DMARDs: disease flare
Comparison RR (95% CI)
Etanercept vs. adalimumab 0.61 (0.27 to 1.38)
Etanercept vs. abatacept 0.92 (0.39 to 2.18)
Etanercept vs. tocilizumab 0.65 (0.30 to 1.43)
Adalimumab vs. abatacept 1.51 (0.72 to 3.15)
Adalimumab vs. tocilizumab 1.07 (0.56 to 2.04)
Abatacept vs. tocilizumab 0.71 (0.35 to 1.43)
0.05 0.20 1.00
Favours biologic DMARD Favours placebo
5.00 20.00
Study or subgroup
Abatacept57
Adalimumab61
Etanercept42
Tocilizumab68
Events Total
Experimental
Events Total
Control RR
M–H, fixed, 95% CI
12
14
7
21
60
38
25
82
33
24
21
39
62
37
26
81
0.38 (0.22 to 0.66)
0.57 (0.35 to 0.92)
0.35 (0.18 to 0.67)
0.53 (0.35 to 0.82)
RR
M–H, fixed, 95% CI
FIGURE 3 Summary forest plot of biologic DMARDs vs. placebo: disease flare. M–H, Mantel–Haenszel.
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Figure 4 illustrates the results of the four included RCTs comparing the biologic DMARDs with placebo
(with background methotrexate where permitted) on the outcome of ACR Pedi-50 response. Treatment
with each of the four DMARDs led to a statistically significant greater proportion of participants with ACR
Pedi-50 response, with the RR ranging from 1.41 to 3.12.
Table 26 reports adjusted pairwise indirect comparisons for the four biologic DMARDs for the ACR Pedi-50
response outcome. Etanercept had a higher RR for treatment response than the other three comparators.
Adalimumab had a higher RR for treatment response than abatacept and tocilizumab. Adalimumab had a
higher RR for treatment response than tocilizumab. The ranking of treatments in terms of treatment
response was therefore etanercept, adalimumab, abatacept and tocilizumab. With the exception of
etanercept compared with tocilizumab, none of the comparisons indicated a statistically significant
difference between the treatments being compared, with CIs crossing 1.
Figure 5 illustrates the results of the four included RCTs comparing the biologic DMARDs with placebo
(with background methotrexate where permitted) on the ACR Pedi-70 response outcome. Treatment with
each of the four DMARDs led to a statistically significant greater proportion of participants with ACR
Pedi-70 response, with the RR ranging from 1.54 to 2.34.
TABLE 26 Indirect comparisons of biologic DMARDs: ACR Pedi-50 response
Comparison RR (95% CI)
Etanercept vs. adalimumab 1.87 (0.77 to 4.53)
Etanercept vs. abatacept 2.10 (0.95 to 4.64)
Etanercept vs. tocilizumab 2.21 (1.01 to 4.84)
Adalimumab vs. abatacept 1.12 (0.65 to 1.96)
Adalimumab vs. tocilizumab 1.18 (0.69 to 2.02)
Abatacept vs. tocilizumab 1.05 (0.72 to 1.53)
0.05 0.20 1.00
Favours biologic DMARDFavours placebo
5.00 20.00
Study or subgroup
Abatacept57
Adalimumab61
Etanercept42
Tocilizumab68
Events Total
Experimental
Events Total
Control RR
M–H, fixed, 95% CI
46
24
18
60
60
38
25
82
32
14
6
42
62
37
26
81
1.49 (1.12 to 1.96)
1.67 (1.03 to 2.70)
3.12 (1.48 to 6.56)
1.41 (1.10 to 1.81)
RR
M–H, fixed, 95% CI
FIGURE 4 Summary forest plot of biologic DMARDs vs. placebo: ACR Pedi-50 response. M–H, Mantel–Haenszel.
0.05 0.20 1.00
Favours biologic DMARDFavours placebo
5.00 20.00
Study or subgroup
Abatacept57
Adalimumab61
Etanercept42
Tocilizumab68
Events Total
Experimental
Events Total
Control RR
M–H, fixed, 95% CI
32
24
11
53
60
38
25
82
19
10
5
34
62
37
26
81
1.74 (1.12 to 2.71)
2.34 (1.31 to 4.18)
2.29 (0.93 to 5.65)
1.54 (1.14 to 2.08)
RR
M–H, fixed, 95% CI
FIGURE 5 Summary forest plot of biologic DMARDs vs. placebo: ACR Pedi-70 response. M–H, Mantel–Haenszel.
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Table 27 reports adjusted pairwise indirect comparisons for the four biologic DMARDs for the outcome of
ACR Pedi-70 response. Etanercept had a higher RR for treatment response than abatacept and tocilizumab
but a slightly lower RR for treatment response than adalimumab. Adalimumab had a higher RR for
treatment response than abatacept and tocilizumab. Abatacept had a higher RR for treatment response
than tocilizumab. The ranking of treatments in terms of treatment response for ACR Pedi-70 (adalimumab,
etanercept, abatacept and tocilizumab) was therefore different from the ACR Pedi-50. None of the
comparisons indicated a statistically significant difference between the treatments being compared, with
CIs crossing 1.
The results of this exploratory analysis based on the limited evidence available currently (only one trial for
each of the four biologic DMARDs) supports etanercept being more effective than the other three biologic
DMARDs in terms of preventing disease flares and achieving a response to treatment based on a
composite index (ACR Pedi-50), whereas the ACR Pedi-70 exploratory analysis shows adalimumab with a
slight advantage over etanercept (although see comment below about CIs). Abatacept appeared to be
superior to tocilizumab for all outcome measures. Adalimumab appeared to be less effective than
abatacept and tocilizumab in terms of preventing disease flare but more effective in terms of ACR Pedi-50
and -70 responses. Therefore, there was no consistent ranking of treatment comparisons across these
outcome measures. The indirect comparisons were generally not statistically significant and CIs were wide,
so caution is advised in the interpretation of these results. Furthermore, the etanercept trial42 appears to
have some differences from the other trials which may confound the results, namely the absence of
methotrexate background therapy and the longer duration of JIA disease. There was also a noticeably
higher rate of flares in the placebo arm of that trial than in the other three trials (81% compared with
48–65%) which may account for the bigger treatment effect seen. Taking the above limitations into
account, an overall interpretation of the results of the indirect comparison is that, owing to the absence of
statistically significant differences between the biologic DMARDs, they currently appear to be similar in
treatment effectiveness. This accords with the conclusion reached by Otten and colleagues79 who
suggested that the short-term efficacy of the biologic DMARDs in polyarticular-course JIA seem similar.
Furthermore, the clinical advisors to the assessment group felt that these data generally reflect clinical
experience in that when used for the same indication in the same population, effectiveness was likely to
be similar. However, there was also a recognition that for individual patients, and potentially for particular
subgroups of JIA patients, differential effects of each biologic DMARD might be apparent but these
differential effects have not yet been captured by current trial data.
TABLE 27 Indirect comparisons of biologic DMARDs: ACR Pedi-70 response
Comparison RR (95% CI)
Etanercept vs. adalimumab 0.98 (0.33 to 2.87)
Etanercept vs. abatacept 1.31 (0.48 to 3.60)
Etanercept vs. tocilizumab 1.49 (0.57 to 3.85)
Adalimumab vs. abatacept 1.34 (0.65 to 2.79)
Adalimumab vs. tocilizumab 1.52 (0.79 to 2.92)
Abatacept vs. tocilizumab 1.13 (0.66 to 1.93)
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Summary of the systematic review of clinical effectiveness
l Four multicentre RCTs, one each evaluating abatacept, adalimumab, etanercept and tocilizumab, met
the inclusion criteria of this review. Only the tocilizumab RCT included UK patients. Seven additional
RCTs (three for adalimumab and four for etanercept) are described as ongoing (details summarised in
Ongoing trials, below).
l Each RCT had three phases, an open-label lead-in period, a randomised withdrawal period and an OLE.
The lengths of the lead-in and randomised phases varied between studies (open-label lead-in:
12–16 weeks; randomised double-blind withdrawal phase 16–32 weeks). In each study patients had to
achieve an ACR Pedi-XX response during the initial open-label phase in order to be eligible for entry
to the randomised double-blind withdrawal phase. Therefore, results are applicable only to patients
who have already achieved an initial (low) degree of benefit from a biologic DMARD.
l The quality of the included RCTs was reasonable overall, with a low risk of bias judged for most items,
although some aspects were rated as unclear, mainly owing to a lack of reporting.
l Disease flare: this was the primary outcome in all four RCTs, with definitions broadly consistent
between the studies. Patients who continued to receive biologic DMARDs during the randomised
withdrawal phase of the studies had statistically significantly fewer arthritis flares than those receiving
placebo in all four studies, whereas time to disease flare reported in three studies (abatacept, adalimumab
and etanercept) was statistically significantly longer in those treated with biologic DMARDs.
l ACR Pedi: a greater proportion of patients receiving biologic DMARDs during the randomised
withdrawal phase of the studies achieved ACR Pedi responses of ≥ 30 than placebo-treated patients,
with differences statistically significant in all but two instances where p-values were reported. The
proportion of biologic DMARD-treated patients with inactive disease was more than twice that of
placebo-treated patients in the two studies (abatacept and tocilizumab) reporting this outcome.
l ACR Pedi core variables: in the three studies reporting this outcome (abatacept, etanercept and
tocilizumab) results were generally in favour of treatment with biologic DMARDs when compared
with placebo.
l Joint-related outcomes: one study (etanercept) reported additional joint outcomes without statistical
comparisons. All outcomes favoured etanercept over placebo.
l Pain: three studies reported pain (abatacept, etanercept and tocilizumab). A statistically significant
difference in the mean change from baseline favoured the tocilizumab group. Although pain scores
were lower for those receiving biologic DMARDs in the remaining two studies, differences between
treatment groups were not statistically significant in the abatacept study and no statistical comparison
reported in the etanercept study.
l Mortality: no treatment-related deaths were reported in the three studies reporting this outcome
(adalimumab, etanercept and tocilizumab).
l Outcomes not reported by the included RCTs for the randomised withdrawal phase of the trials were
corticosteroid-reducing regimens, extra-articular manifestations (such as uveitis), height and weight.
l HRQoL: reported by the abatacept study only, with differences between treatment groups for the
physical and psychosocial summary scores not statistically significant. Those treated with abatacept had
improved scores for 14 of the 15 CHQ subscales compared with 6 out of 15 for placebo-treated patients.
l AEs: during the randomised withdrawal phase of the trials, the proportions of AEs and SAEs were
generally fairly similar between the biologic DMARDs and the placebo groups.
l Subgroup analyses: the tocilizumab study reported data for subgroups but no statistical comparisons
between treatment groups were reported.
l OLE: all four studies included an OLE phase. There were differences in eligibility criteria between studies
and in how data were presented. Only results for ACR Pedi, AEs and growth are included in this report.
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l OLE ACR Pedi:
¢ Abatacept: the proportion of patients achieving ACR Pedi-30, -50 and -70 scores were similar for
those with continuous abatacept therapy and those who received placebo during the double-blind
phase, but were greater at achieving ACR Pedi-100 and inactive disease in abatacept-treated
patients (ACR Pedi-100 abatacept 39%, placebo 19%; inactive disease abatacept 43%,
placebo 23%).
¢ Adalimumab: there was no diminution of ACR Pedi responses, and 40% of patients had an ACR
Pedi-100 response after open-label treatment in the extension phase, but results included patients
not meeting the licensed indication.
¢ Etanercept: 26/58 (45%) patients who took part in the OLE entered the eighth year of follow-up.
ACR Pedi responses appear to have remained constant over the OLE.
¢ Tocilizumab: limited results were based on conference abstracts for 82 patients who received
continuous tocilizumab throughout the study. The proportion of patients achieving ACR Pedi-70
and -90 increased since the end of the double-blind phase, with 63% having inactive disease.
l OLE AEs:
¢ Abatacept: at 7-year follow-up, 19.6% of patients had SAEs, with similar incidence rates between
the OLE phase (5.6 per 100 patient-years) and the 6-month double-blind phase
(6.8 per 100 patient-years).
¢ Adalimumab: SAEs possibly related to study drug occurred in seven patients during the OLE, but
would appear to be in patients not in line with licensed indication (OLE phase ongoing, time period
unclear). Three patients discontinued treatment owing to AEs.
¢ Etanercept: there were a total of 39 SAEs based on 318 patient-years of etanercept exposure, with
26/69 patients entering their eighth year of etanercept treatment (0.12 events per patient-year).
Nine MIIs resulted in the need for intravenous antibiotic therapy or hospitalisation (0.03 events per
patient-year).
¢ Tocilizumab: AEs rates were 406.5 per 100 patient-years and the SAEs rate 11.1 per 100 patient-years
over around 2 years, with the most common AEs and SAEs related to infections (151.4 and 5.2 per
100 patient-years, respectively).
l Growth: limited data reported in abstracts at week 104 for adalimumab and tocilizumab appear to
support the positive effect of these drugs on growth, but the use of different outcome measures
prevents a comparison between the drugs.
l An exploratory adjusted indirect comparison found that there was a lack of statistically significant
differences between the four biologic DMARDs in terms of disease flare and ACR Pedi-50/-70 response,
with wide CIs and clinical heterogeneity between the trials.
Review of clinical effectiveness in company submissions to the
National Institute for Health and Care Excellence
Four companies made submissions in support of their drugs to NICE: BMS for abatacept, AbbVie for
adalimumab, Pfizer Ltd for etanercept and Roche for tocilizumab. A review of the information presented
about the economic evaluation of biologic DMARDs for treatment of JIA in the CSs can be found in
Chapter 5, Review of cost-effectiveness in company submissions to National Institute for Health and
Care Excellence.
Review of Bristol-Myers Squibb company evidence submission for abatacept
The company did not report a systematic review of clinical effectiveness of abatacept.85 There is no
indication that any databases were searched and no search strategies were supplied. Furthermore, there is
no search or report for any ongoing studies. The majority of the clinical effectiveness information in the CS
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comes from published papers with a few details that are commercial-in-confidence (CiC) which come from
the clinical study reports.
The CS includes one phase-III double-blind randomised withdrawal study, the AWAKEN trial. Although not
clearly summarised, the CS draws on two published papers,57,58 one conference presentation86 and the trial
clinical study reports. The published papers57,58 met the inclusion criteria of this assessment report. One
published paper59 relating to the AWAKEN trial that was identified in this assessment report was not
cited by the CS but the data in this appear to have been superseded by the more recent conference
presentation.86 However, the more recent efficacy data are not presented according to the randomised
groups in the double-blind period, whereas the safety summary data are.86 Furthermore, there is limited
detail regarding the length of follow-up, which is stated to be ≥ 56 months and up to 7 years of total
follow-up. No critical appraisal is reported for any of the studies cited in the CS.
A summary of the AWAKEN trial is provided in the CS which is broadly similar to the information
presented in the published papers.57,58,86 Information from the OLE phase drawn from the conference
presentation86 is more recent than the data from the published paper,59 which is included in the
assessment report. Furthermore, an analysis was conducted (using Fisher’s exact test) to compare SAEs
during the double-blind phases of trials of abatacept, adalimumab etanercept and tocilizumab
(CS section 3.4.6). The CS highlights the lack of statistical power attributable to the low numbers of
patients and event rates, which should be taken into account in the interpretation of their finding that the
incidence of SAEs was likely to be similar between the biologic DMARDs.
The CS focuses on abatacept, with very little information provided regarding the other biologic DMARDs
included in this MTA. However, information is presented in the CS on indirect pairwise comparisons for the
four biologic DMARDs for the outcome of disease flare. The comparisons for abatacept, adalimumab and
etanercept are taken from a published paper by Otten and colleagues79 and this is supplemented by new
indirect pairwise comparisons with tocilizumab, taking data from a RCT68 that has been published since the
Otten and colleagues study (the CHERISH trial.68) The results of the indirect comparisons reported in the CS
(tables 4 and 5) match those reported in the indirect comparisons conducted for this assessment report
[see Assessment of clinical effectiveness: biologic disease-modifying antirheumatic drugs versus each other
(with methotrexate where permitted)].
In summary, the CS has not conducted a systematic review of clinical effectiveness but has summarised
data from the AWAKEN trial,57 presented indirect pairwise comparisons of the four biologic DMARDs
included in this appraisal and conducted an analysis to compare SAEs during the double-blind phases of
trials of the four biologic DMARDs. No additional RCTs were included in the CS that would have met the
inclusion criteria of this assessment report.
Review of AbbVie company evidence submission for adalimumab
AbbVie submitted a report to NICE on adalimumab as a treatment for JIA.77 The clinical effectiveness
evidence has been briefly appraised.
The company did not conduct a formal systematic review of the clinical effectiveness evidence, but
provided what they describe as ‘an iterative literature review’ (CS page 15). The company asserts that all
RCTs of adalimumab in the treatment of JIA have been identified (CS page 15). It would appear that RCTs
were identified chronologically from an adalimumab trial programme, and there is no mention that any
databases were searched and no search strategies were provided. There is no search for or report of any
ongoing studies, but the CS does contain information about a trial in progress, the SYCAMORE RCT.87 This
trial is evaluating the clinical effectiveness, safety and cost-effectiveness of adalimumab in combination
with methotrexate for the treatment of JIA-associated uveitis (further information on this trial is given
Ongoing trials of this assessment report). Data from abstracts/conference proceedings are also presented in
the CS.
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The submission contains narrative summaries for the pivotal RCT by Lovell and colleagues,61 which formed
the basis of the original marketing authorisation in 2008; an ongoing RCT of adalimumab treatment in
patients with ERA by Burgos-Vargas and colleagues88–93 (see Ongoing trials of this assessment report for
details of this study); two open-label single-arm studies94,95 and supporting data from an ongoing registry
(STRIVE) funded by AbbVie. The multinational STRIVE registry is assessing the long-term safety and
effectiveness of adalimumab in patients with moderate to severe polyarticular JIA. Some data from this
registry are given in the CS, for efficacy outcomes up to 1 year, and safety outcomes for longer (mean
duration of drug exposure was 643 days for methotrexate patients and 653 days for adalimumab and
methotrexate patients). The registry does not appear to include patients from the UK. Other evidence such
as case series, open-label trials, a systematic review96 and data from an Italian registry were included to
provide evidence for the effectiveness of adalimumab in JIA-associated uveitis (see JIA-associated uveitis of
this assessment report for details of these).
Based on the Lovell and colleagues RCT,61 the key outcomes of disease flares and ACR Pedi responses are
the same in the CS and the assessment report.
The CS notes several methodological concerns that prevented the presentation of a network meta-analysis
comparing the four biologic DMARDs. An indirect comparison was therefore not presented.
In summary, the CS has not conducted a systematic review of clinical effectiveness but has summarised data
separately for RCTs and other non-randomised studies, as well as data from a registry. No indirect
comparison of the biologic DMARDs was conducted by the company. No additional RCTs were included in
the CS that met the inclusion criteria for systematic review in this assessment report; however, some of the
non-randomised study evidence in the CS is presented in this assessment report for patient subgroups where
randomised evidence is lacking (i.e. ERA and JIA-associated uveitis) (see Additional supporting evidence).
Review of Pfizer Ltd company evidence submission for etanercept
The company report a systematic review of clinical effectiveness of etanercept (in addition they report a
systematic review of observational evidence on etanercept-associated innovation, caregiver burden and
treatment adherence, plus a systematic review of HRQoL associated with etanercept).97 Details of the
literature search strategy are provided and the search appears to be comprehensive, up to date and
reproducible. A search for ongoing studies was also conducted. A systematic process was followed to
screen studies for inclusion, with titles, abstracts and full texts screened independently by two reviewers.
The inclusion criteria are in keeping with the scope of the appraisal, with the exception that only studies of
etanercept were included, not the other biologic DMARDs. A broad range of study designs were eligible,
with the exception of case reports. The majority of the data are in the public domain, although some
information is either academic-in-confidence (AiC) or CiC.
The review included 11 publications relating to five primary interventional studies and three extension
studies (see CS table 7, CS page 44). It also included 41 observational studies (including registry studies)
plus 2 unpublished studies (see CS table 18, CS page 81). Of the five included primary interventional
studies, only one meets the inclusion criteria for the systematic review in this current report – Lovell and
colleagues.42 Of the remaining four studies, three were not relevant, as they were single-arm studies, and a
fourth was a RCT reported in a conference abstract98 with only limited detail available. However, one of
the single-arm studies – the CLIPPER study99 – is noteworthy as it focuses specifically on the JIA subtypes
that were absent from the pivotal Lovell and colleagues trial,42 namely EO JIA, ERA and PA. Details are
presented in Additional supporting evidence.
Of the three extension studies, only one was relevant to the inclusion criteria of this assessment report,
namely the long-term follow-up publications65–67 of the Lovell and colleagues RCT,42 all of which have been
included in the data extraction for this study (see Appendix 5). The other two extension studies included a
Japanese open-label single-arm multicentre study followed by a double-blind, randomised dose-down
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extension study (two doses of etanercept – no comparator), and an open-label multicentre Phase-IIIb
long-term safety and efficacy study of the CLIPPER study (reported in Additional supporting evidence).99
A critical appraisal of the interventional studies is provided in CS section 4.7. The company’s appraisal of
the Lovell and colleagues RCT42 is provided in CS table 13 (CS page 62). Our critical appraisal differs
slightly from the company’s (see Quantity and quality of research available). Specifically, we did not
consider that adequate details had been provided of the study’s randomisation method or concealment of
allocation. We also note that there was a large imbalance in drop-outs between the randomised groups
(see Table 12 and Appendix 5).
A narrative synthesis of the interventional and observational studies is provided in the CS, with detailed
tabulation of study characteristics and results. A meta-analysis was not considered feasible or appropriate
by the company, and an indirect comparison was not conducted as it was not considered feasible to
conduct one owing to differences in respective marketing authorisations across biologic treatments,
paucity of data and heterogeneity.
Of note, some of the observational studies of etanercept included in the CS reported (limited) data for
outcomes relevant to the scope of the appraisal that were not included in the RCT by Lovell and
colleagues,42 namely corticosteroid reduction, growth and disease activity according to the JADAS
(see CS section 4.12.5).
In summary, the systematic review of clinical effectiveness reported in the CS appears to be of a good
standard and no additional RCTs were included in the CS that met the inclusion criteria for the systematic
review in this assessment report.
Review of Roche company evidence submission for tocilizumab
The company did not conduct a formal systematic review of the clinical effectiveness evidence, but
provided ‘most relevant literature’ on the use of tocilizumab in patients with polyarticular JIA and EO
(CS page 7). There is no evidence that searches were conducted and no search strategies were reported.
The CS does state that a systematic literature review was completed for the indirect comparison presented
in the submission but provides no further detail. The CS did not report searching conference proceedings
or details of any ongoing trials, but data from abstracts/conference proceedings are included in the
submission. CiC data are limited to the economic model.
The submission contains narrative summaries of two studies. One of the studies is a RCT comparing
tocilizumab with placebo (CHERISH)68 linked to six additional conference publications/abstracts.69,71–73,76,100
The CHERISH RCT68 met the inclusion criteria of this assessment report and was reported above in Results.
Of the six conference publications/abstracts linked to the CHERISH RCT, only two were related to the
randomised phase of the trial72,73 and the remaining four were related to the OLE phase. One of these four
conference abstracts was not identified by searches for this assessment report, but if it had been, it would
not have met the inclusion criteria as none of the outcomes reported was relevant.100
The other study was a single-arm open-label study of efficacy, pharmacokinetics and safety of adalimumab
in Japanese patients with polyarticular JIA.95
The CS presents all the evidence separately for each study in the form of a narrative summary. Individual
tables of baseline patient characteristics, as well as details of methods and design are reported for both the
CHERISH trial68 and the open-label Japanese study.95 No quality assessment of the studies is presented. The
CS reports growth data from the OLE phase of the CHERISH trial at week 104, which have been included
in this assessment report. The assessment report contains additional data for ACR Pedi-90 responses
relative to baseline at week 40 and inactive disease from the CHERISH trial, both of which are not reported
in the CS.
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The CS includes a hierarchical Bayesian indirect treatment comparison of adalimumab and tocilizumab,
conducted in WinBUGS version 1.4 software (Medical Research Council Biostatistics Unit, Cambridge, UK)
and using methods described by Dias and colleagues.101 Limited detail is provided on the specific methods
used to conduct the indirect comparison (e.g. which adalimumab trial was used to compare against
tocilizumab; this is likely to be Lovell and colleagues61 but is not explicitly stated). An indirect comparison
with abatacept was not considered possible owing to the difference in trial design, the fact that it is not
approved (appraised) by NICE, and also because of slight differences in licences (i.e. lower age for which
treatment is indicated). We note the heterogeneity between the RCTs that increases uncertainties in any
indirect comparison, although the fact that abatacept has not been appraised by NICE is not an adequate
justification for not performing the comparison. The CS provides an additional analysis which assumes a
class effect across antiTNF drugs (based on the indirect comparison with adalimumab which showed
‘overlapping ACR response rates’), permitting a comparison between tocilizumab with etanercept (CS
section 5.17). The exploratory pairwise indirect comparisons of all four biologic DMARDS presented in this
assessment report showed no statistically significant differences between the drugs [see Assessment of
clinical effectiveness: biologic disease-modifying antirheumatic drugs versus each other (with methotrexate
where permitted)].
Most of the AE and safety data are presented for the CHERISH RCT.68 The AE data reported at week 40
(end of the randomised phase of the RCT) in the CS do not include any data for the placebo group, which
is presented in this assessment report.
In summary, the CS has not conducted a systematic review of clinical effectiveness but has summarised
data from the CHERISH trial and an open-label Japanese study, presented an indirect pairwise comparisons
of two of the biologic DMARDs included in this appraisal (tocilizumab and adalimumab), as well as
exploratory analysis comparing tocilizumab with etanercept. No additional RCTs were included in the CS
that met the inclusion criteria of the assessment report.
Ongoing trials
As stated above (Quantity and quality of research available), citations relating to four ongoing RCTs were
identified from the electronic bibliographic database literature search (see Figure 1) and a separate search
specifically for ongoing studies identified a further three ongoing RCTs. Three trials are investigating
adalimumab and four etanercept. Each trial is described, in turn, below, with preliminary results presented
where possible. It should be noted that online clinical trial registers generally provide less information
(and no outcome data) in comparison with published conference abstracts.
Adalimumab ongoing trial 1
This is a Phase-III, multicentre, randomised, double-blind study (NCT01166282) described by six conference
abstracts (Burgos-Vargas and colleagues88–93) in children aged ≥ 6 to < 18 years with ERA based on ILAR
criteria, with active disease not responsive to ≥ 1 NSAID and ≥ 1 DMARD. No full paper appears to have
been published so far, and the six abstracts provide limited information, hence preventing a full assessment
of the methodology and trial quality and risk of bias. In addition, baseline characteristics were reported
only for the overall trial population and not separately for each randomised group. The estimated study
completion date was December 2015; however, the study was published in full after the submission date
of this report in July 2015.102
Forty-six patients were randomised in a 2 : 1 ratio (adalimumab n= 31; placebo n= 15) to receive blinded
adalimumab (24mg/m2 body surface area up to 40mg every other week) or placebo for 12 weeks
followed by open-label adalimumab every other week for up to 144 weeks. It is unclear whether or not
patients also received methotrexate. A table in one of the abstracts93 shows that 11/15 placebo patients
and 21/31 adalimumab patients received DMARDs at baseline.
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The primary endpoint of this study was per cent change from baseline in the number of active joints with
arthritis (active joint count) at week 12 and secondary variables assessed included enthesitis count, tender
and swollen joint counts, and ACR Pedi-30/-50/-70 responses. Active disease was defined as ≥ 3 active
joints (swelling or loss of motion and pain/tenderness) and enthesitis in ≥ 1 location (past or present).
Safety was assessed in terms of AEs, laboratory values and vital sign measurements. Some interim data
were reported for 52 weeks including discontinuation of concomitant medication (at the discretion of the
treating physician).
Authors state that no children discontinued the double-blind period, while at the same time reporting that
seven children ‘escaped early’ to open-label adalimumab.
Results
At baseline, children had a mean age of 12.9 years, with 2.6 mean years of ERA symptoms, and a mean
enthesitis count and active joint count of 8.1 and 7.8, respectively (Table 28). It is unclear if baseline
characteristics between the treatment groups were balanced.
Only the primary outcome per cent change from baseline in the number of active joints with arthritis showed
a statistically significantly greater improvement (p= 0.039) in the adalimumab treatment group (–62.6) than in
the placebo group (–11.6) (Table 29). Secondary outcomes were reported to be mostly numerically greater in
the adalimumab group, but none of the improvements was statistically significant.
TABLE 29 Results week 12
Primary outcomea ADA (n= 31) PBO (n= 15) p-value
AJC, % change from baseline at
week 12
–62.6 (SD 59.5)
(median % change –88.9%)
–11.6 (SD 100.5)
(median % change –50.0%)
0.039
Secondary outcomes, change from baseline, mean (SD)b
Number of enthesitis sites (0–35) –4.4 (6.2) –2.7 (5.0) NS
Tender joint count (0–72) –7.9 (8.3) –4.5 (9.0) NS
Swollen joint count (0–8) –3.5 (5.6) –2.4 (4.7) NS
ACR Pedi response, n (%)c
ACR Pedi-30 responder 21 (67.7) 10 (66.7) NS
ACR Pedi-50 responder 20 (64.5) 7 (46.7) NS
ACR Pedi-70 responder 16 (51.6) 4 (26.7) NS
ADA, adalimumab; AJC, active joint count; PBO, placebo; NS, not significant.
a Presumed mean and SD, but not specifically stated.
b Last observation carried forward.
c Analysed with non-responder imputation.
TABLE 28 Baseline characteristics
Parameter, mean (SD)a All children
Age, years 12.9 (2.9)
ERA symptoms, years 2.6 (2.3)
AJC 7.8 (6.6)
EC 8.1 (8.4)
AJC, active joint count; EC, enthesitis count.
a Not specially stated, but presumed to be standard deviation.
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Adverse events
Only one patient (in the adalimumab group) experienced a SAE (abdominal pain and headache). Around
two-thirds of the children in the adalimumab treatment group and just over half in the placebo group
experienced an AE, whereas nearly one-third of children in the adalimumab treatment group but only
one-fifth in the placebo group experienced infectious AEs (Table 30).
Open-label week-52 results
The authors state that treatment response was maintained with continued adalimumab therapy up to
52 weeks [% change from baseline at week 52 in active joint court: –88.7 (SD 26.1)]. In those receiving at
least one dose of adalimumab through to week 52, > 91% of children experienced an AE and > 76%
experienced infectious AEs (Table 31). SAEs were reported in approximately 11% of children, with no
reported deaths, tuberculosis or malignancies. Eight (19%) of the 43 participants who remained in the
study at week 52 had completely discontinued concomitant ERA medication.
Adalimumab ongoing trial 2
The second adalimumab RCT (SYCAMORE, ISRCTN10065623)87 is funded by the NIHR HTA programme
and Arthritis Research UK. The study is assessing adalimumab combined with methotrexate compared
with placebo combined with methotrexate for JIA-associated uveitis in participants aged between 2 and
18 years. All participants will receive 18 months of treatment with a 3-year follow-up. The study will also
include an assessment of cost-effectiveness. Originally expected to report findings in 2020, it has recently
been announced that the trial has closed for recruitment early following interim analysis showing a
favourable effect for adalimumab. Analysis of the primary outcome is under way and key findings will
therefore be available earlier than expected. Collection and analysis of health economic data will continue
as planned.
TABLE 31 Adverse events in children receiving > 1 dose of adalimumab to week 52
AEs ADA, %a
Any AEs 91.3
SAEs 10.9
Infectious AEs 76.1
ADA, adalimumab.
a Number of patients receiving ADA treatment during open label not reported.
TABLE 30 Adverse events week 12
AEs ADA (n= 31), % PBO (n= 15), %
Any AE 67.7 53.3
SAE 3.21 (1 patient) 0
Infectious AE 29.0 20.0
ADA, adalimumab; PBO, placebo.
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Adalimumab ongoing trial 3
This third adalimumab RCT [Effect of Adalimumab for the Treatment of Uveitis in Juvenile Idiopathic
Arthritis (ADJUVITE); NCT01385826] is also currently in progress and is not expected to report findings
until June 2016. The study is set in France (seven hospital ophthalmology departments) and assesses the
efficacy of 2-month adalimumab treatment versus placebo treatment on reduction of ocular inflammation
quantified by laser flare photometry in patients aged ≥ 4 years, with JIA-associated uveitis that is resistant
to steroid therapy. The investigators plan to include 40 patients, follow-up appears to be 12 months and
the final data collection date for the primary outcome measure is November 2015. The primary endpoint
of this study is improvement of uveitis.
Etanercept ongoing trial 1
This is a RCT evaluating the efficacy of etanercept in 124 Chinese JIA patients (no clinical trial registration
number has been found for this study).98 No full paper appears to have been published so far and only one
conference abstract was identified, which includes very limited information. The abstract states that a
‘randomised principle was applied’ to divide the JIA patients into a control and a treatment group.
Although no baseline characteristics were reported, the authors of the abstract state that there were no
significant differences of clinical classification and basic treatment between the groups.
Sixty-two patients in the treatment group (oligoarticular JIA n= 17, polyarticular JIA n= 15 and systemic
JIA n= 30) received 0.8mg/kg per week of subcutaneous etanercept for 6 months. No details for the
control group are reported.
American College of Rheumatology Pedi-30, -50 and -70 responses were used to assess the clinical
efficacy (primary outcome not stated) and adverse reactions were recorded.
Results
The authors state that the remission rates ‘of different cases’ (this is presumed to mean different types
of JIA) in the treatment group differed at each time point (3- and 6-month time points are mentioned),
with no obvious difference in ACR Pedi-30, -50 and -70 remissions for patients with oligoarticular and
polyarticular JIA. Eighty per cent of these patients had ACR Pedi-50 remission after 6 months of treatment
and > 50% had ACR Pedi-70 remission. The remission rate of systemic JIA cases was lower than the two
other types (data not extracted). Although the differences between the randomised groups are said to be
significant, no data were reported.
Adverse events
There were no reported AEs for patients with oligoarticular or polyarticular JIA. Details of AEs for the
systemic JIA subgroup are reported (not extracted).
Etanercept ongoing trial 2
The second placebo-controlled etanercept RCT [Remission Induction by Etanercept in Enthesitis related
Arthritis JIA-Patients (REMINDER) Study, EudraCT Number: 2010–020423–51] was identified from the
search of ongoing clinical trials registers. The trial is set in Germany and has a start date of February 2016.
This study has a withdrawal RCT design, with a 12-week open-label treatment phase prior to the
controlled randomised double-blind phase The study will assess the safety and effectiveness of etanercept
in patients diagnosed with ERA-JIA age ≥ 6 years and < 18 years having met all criteria for eligibility for
treatment with etanercept according to SPC and local guidelines, with expectation of the requirement
of a minimum of five affected joints. The online record does not provide the treatment time for the
double-blind phase or report any follow-up period. The primary endpoint of the study will be inactive
disease of ERA-JIA.
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Etanercept ongoing trial 3
The third multicentre etanercept RCT was identified from a conference abstract103 which does not provide
a clinical trial registration number. This trial appears to be set in Germany, has enrolled patients with ERA
and has a withdrawal design, with a 24-week open-label etanercept treatment phase prior to the 24-week
placebo-controlled double-blind withdrawal phase. Patients had to achieve at least an ACR Pedi-30
response in order to be randomised to the double-blind phase (terminated in case of a disease flare or at
week 48, whichever occurs earlier). No details of the study’s inclusion or exclusion criteria are reported in
the abstract.
Results
Forty-one patients entered the open-label phase, of whom two patients discontinued prematurely (one
owing to intolerance and one owing to protocol deviation). Thirty-eight patients (93%) achieved at least
an ACR Pedi-30 response and were randomised to the double-blind phase. As can be seen in Table 32,
during the double-blind phase the majority of flares occurred in the placebo group, with 10 (56%)
placebo-treated patients compared with 18 (90%) etanercept-treated patients reaching week 48 without a
flare [odds ratio 7.2 placebo vs. etanercept (1.3 to 40.7; although not stated, this is presumed to be a
95% CI); p= 0.016].
The authors state that in patients continuously treated with etanercept at week 48 (n= 20), JADAS 10
decreased to a mean of 3.4 (17.4 to 1.9 at week 24), with 12 (60%) patients reaching JADAS-minimal
disease activity and 11 (55%) JADAS remission. The equivalent data for the placebo group are
not reported.
Adverse events
There were 166 AEs in 39 patients and three SAEs. All were said to be considered unrelated and resolved
without sequelae. It is unclear if these data are for the combined open-label and double-blind phases, but
considering the number of patients reported (n= 39) this may indeed be the case.
Etanercept ongoing trial 4
The fourth multicentre etanercept RCT (set in the Netherlands) assessed when and in whom to stop etanercept
after successful treatment of JIA (NCT01287715) and was identified from the search of ongoing clinical trials
registers. Estimated enrolment was 50, the study completed in September 2013 and final data collection for
the primary outcome measure is reported as September 2012 in the online record. No publication of data has
been identified. Patients aged 4–17 years and in remission were selected from the National Arthritis and
Biologicals in Children (ABC) register, an observational study including all Dutch JIA patients on etanercept
therapy. The inclusion criteria states no or low dose of methotrexate and it is therefore unclear if patients were
intolerant or had a previous inadequate response to methotrexate. All JIA subtypes were included in the study.
Patients were randomised to a stop arm (discontinuation of etanercept – half of the dose for 3 months and
discontinuation thereafter) or a control arm (etanercept continued for another 9 months and, if still meeting
the eligibility criteria, discontinued thereafter). The primary outcome of the study was flare rate.
TABLE 32 Flares: 24-week double-blind phase
Time ETA (n= 20) PBO (n= 18)
Week 28 2 2
Week 32 0 4
Week 48 0 2
ETA, etanercept; PBO, placebo.
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Additional supporting non-randomised evidence
This section includes additional non-randomised study evidence relating to aspects of JIA where adequate
RCT data in the systematic review of clinical effectiveness were lacking. This evidence has been identified
from the systematic review search itself, and from relevant studies included in the CSs to NICE (see Review
of clinical effectiveness in company submissions to the National Institute for Health and Care Excellence).
Evidence relating to two aspects is presented: JIA ERA and PA subtypes, and JIA-associated uveitis.
Enthesitis-related arthritis and psoriatic arthritis
The most informative study available for these subtypes is the CLIPPER study.99
This is a single-arm, Phase-IIIb open-label, multicentre interventional study funded by Wyeth (subsequently
acquired by Pfizer Inc.). The study was designed to assess the safety and efficacy of etanercept in children
and adolescents with three JIA subtypes classified using the ILAR criteria: EO, ERA and PA. There are two
parts to the study. Part 1 (which has been published99) has investigated the efficacy and safety of
etanercept in the three JIA subtypes over an initial 12-week period with a primary endpoint of the
percentage of patients achieving ACR Pedi-30 criteria at week 12. Part 2 of the study is a 96-week OLE,
assessing the long-term safety and efficacy of etanercept in JIA subtypes, which is currently published in
poster format only.104 This study formed part of the evidence base supporting the licence extension for
etanercept across the JIA subtypes in 2012. The assessment group has extracted 12-week data from the
published paper99 on ACR Pedi response rates and inactive disease, change in CHAQ score, PGA of pain,
number of active joints, number of joints with LOM and JIA category-specific assessments (data at week 12
compared with historical placebo data, historical active control data and data from a meta-analysis have
not been data extracted). Data from the conference poster104 on ACR Pedi response rates and inactive
disease have also been extracted and this summary is supplemented with some data presented in the
Pfizer CS.
The study included 127 patients with the JIA subtypes of ERA (n= 38, age 12–17 years), EO (n= 60,
age 2–17 years) and PA (n= 29, age 12–17 years) who received 0.8 mg/kg of etanercept once weekly
(maximum dose 50mg/week). Key inclusion criteria were ≥ 2 active joints (swollen or LOM accompanied
by either pain or tenderness); history of intolerance or unsatisfactory response to at least a 3-month course
of ≥ 1 DMARD or, for ERA only, unsatisfactory response to at least a 1-month course of ≥ 1 NSAID (i.e. for
ERA, prior methotrexate treatment was not required). A stable dose of concomitant medication (only one
DMARD, one oral corticosteroid and one NSAID) was permitted. The inclusion criteria extended below
the threshold number of active joints for the classification of polyarticular disease. Key exclusion criteria
included other rheumatic diseases, active uveitis within 6 months of baseline and any prior receipt of
biologic DMARDs. A total of five patients failed to complete part 1 of the study (completed part 1:
EO 97%, ERA 95% and PA 97%) and 13 patients part 2 (completed part 2: EO 90%, ERA 79% and
PA 86%).
Key baseline characteristics can be seen in Table 33 (additional baseline characteristics are available in the
published paper99).
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Patients with EO and PA had a higher number of active joints and number of joints with LOM
[EO: mean 7.6 (SD 5.1) and 6.3 (SD 4.4), respectively; PA: mean 7.0 (SD 4.3) and 5.6 (SD 4.1), respectively]
at baseline than ERA patients [mean 5.2 (SD 3.6) and 4.8 (SD 4.0), respectively]. The number of painful
joints was highest in PA patients [mean 7.8 (SD 7.0)] compared with the other two subgroups, and the
number of swollen joints was the lowest in ERA patients [mean 3.8 (SD 2.8)] (Table 34). Mean CHAQ
subgroup scores ranged between 0.7 and 0.9, and the parent global assessment of pain VAS ranged
between 4.6 and 5.8. Also reported are JIA category-specific assessments [ERA: tender entheseal score,
back pain (VAS) and modified Schober’s test; PA: body surface area and PGA of psoriasis] at baseline.
Limitations of the study noted by the authors were the difference in concomitant medication use at
baseline which may have affected efficacy responses and the lower age limit of 12 years set for inclusion
of EO patients (the licensed indication is from 2 years of age).
TABLE 33 Key baseline characteristics
Parameter [mean (SD) unless
stated otherwise] All patients (n= 127) EO (n= 60) ERA (n= 38) PA (n= 29)
Age, years 11.7 (4.5) 8.6 (4.6) 14.5 (1.6) 14.5 (2.0)
Female, % 56.7 68.3 21.1 79.3
JIA duration 26.8 (26.4) 31.6 (31.7) 23.0 (19.8) 21.8 (20.2)
Age at onset, months 9.5 (4.8) 6.1 (4.5) 12.5 (2.1) 12.6 (2.7)
Concomitant medication use, n (%)
Any DMARD 109 (85.8) 54 (90.0) 32 (84.2) 23 (79.3)
Oral corticosteroid 16 (12.6) 7 (11.7) 8 (21.1) 1 (3.5)
Oral NSAID 74 (58.3) 32 (53.3) 26 (68.4) 16 (55.2)
Number of active joints 6.7 (4.6) 7.6 (5.1) 5.2 (3.6) 7.0 (4.3)
Number of joints with LOM 5.7 (4.2) 6.3 (4.4) 4.8 (4.0) 5.6 (4.1)
Number of painful joints 6.4 (5.2) 5.5 (4.1) 6.7 (4.9) 7.8 (7.0)
Number of swollen joints 5.5 (4.2) 6.5 (4.8) 3.8 (2.8) 5.6 (3.7)
CHAQ scorea 0.8 (0.6) 0.9 (0.7) 0.7 (0.5) 0.7 (0.6)
Parent global assessment pain (VAS) 5.1 (2.5) 4.8 (2.6) 5.8 (25) 4.6 (2.3)
JIA category-specific characteristics
Tender entheseal score 5.9 (9.4)
Overall back pain VAS, mm 25.9 (28.0)
Nocturnal back pain VAS, mm 16.4 (27.8)
Modified Schober’s test, cm 15.0 (1.9)
Psoriasis BSA, % 10.4 (13.4)
Parent global assessment of psoriasis 1.8 (1.4)
BSA, body surface area.
a CHAQ: 0–3 scale, no disability-severe disability; VAS: parent global assessment pain 0–10, overall and nocturnal back
pain 0–100.
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Results
At week 12, the overall ACR Pedi-30 response rate for patients was almost 89%, with response for the
separate JIA disease type subgroups varying from around 83% to 93% (see Table 34). The overall ACR
Pedi-90 response rate for patients was just under 30%, and 12% of patients had inactive disease. JIA
disease subgroups varied in ACR Pedi-90 response rates between (CiC information has been removed). At
week 12, 12%, 17% and 7% of EO, ERA and PA patients, respectively, had inactive disease, as can be
seen in Table 34.
By week 96, around 99% of all patients achieved a ACR Pedi-30 response and > 65% an ACR Pedi-90
response. Thirty-four per cent of all patients had inactive disease. Overall, patients in the ERA subgroup
appeared to have received the greatest benefit from etanercept therapy at 12 weeks, but by 96 weeks the
subgroups achieved similar levels of ACR Pedi-90 (62% to 72%) and ACR Pedi-100 (51% to 60%)
responses. Inactive disease at 96 weeks varied between 29% (ERA and PA) and 37% (EO). (CiC information
has been removed.)
At week 12 mean change from baseline for CHAQ scores were similar for the subgroups (improvement of
51% to 58%), but there were differences in the parent global assessment of pain VAS. The lowest mean
change in pain VAS occurred in patients with ERA and PA (decreases of 45% and 47%, respectively)
compared with patients with EO (59% decrease). The mean decreases from baseline for the number of
active joints ranged between 70% and 78% and between 64% and 72% for the number of joints with
LOM (Table 35). It is unclear why details about changes from baseline for the number of painful and the
number of swollen joints are not reported.
TABLE 35 Mean change from baseline week effectiveness measures at week 12 (observed cases)
Parameter
Overall (n= 123),
mean (95% CI)
[% change]
EO (n= 58),
mean (95% CI)
[% change]
ERA (n=36),
mean (95% CI)
[% change]
PA (n=29),
mean (95% CI)
[% change]
CHAQ −0.5 (−0.6 to −0.4)
[−53.6]
−0.5 (−0.7 to −0.4)
[−52.2]
−0.5 (−0.7 to −0.3)
[−57.8]
−0.4 (−0.6 to −0.2)
[−51.3]
Parent global assessment of
child’s pain VAS
−3.0 (−3.5 to −2.6)
[−51.9]
−3.2 (−3.8 to −2.5)
[−58.9]
−3.2 (−4.2 to −2.2)
[−44.9]
−2.6 (−3.4 to −1.8)
[−46.6]
Number of active joints −5.1 (−5.8 to −4.3)
[−73.0]
−5.5 (−6.7 to −4.2)
[−69.8]
−4.3 (−5.4 to −3.1)
[−77.7]
−5.2 (−6.8 to −3.6)
[−73.8]
Number of joints with LOM −4.1 (−4.8 to −3.4)
[−66.9]
−4.5 (−5.6 to −3.3)
[−64.1]
−3.4 (−4.1 to −2.6)
[−67.4]
−4.3 (−5.7 to −2.9)
[−71.7]
JIA category-specific assessments
Tender entheseal score −4.4 (−6.3 to −2.4)
[−57.8]
Overall back pain VAS, mm −12.5 (−21.3 to −3.7)
[−21.2]
Nocturnal back pain VAS, mm −8.9 (−16.7 to −1.2)
[−6.8]
Modified Schober’s test, cm 0.35a (−0.02 to 0.72)
[9.7] (n= 35)
Psoriasis BSA, % −6.7 (−10.6 to −2.9)
[−48.2]
PGA of psoriasis −1.0 (−1.4 to −0.6)
[−39.6] (n= 28)
BSA, body surface area.
a Change from baseline calculated after subtracting 10 from the baseline and week 12 scores.
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The greatest improvements in JIA category-specific assessments was a 58% improvement from baseline in
tender entheseal score at 12 weeks in patients with ERA, and for patients with PA a 48% improvement in
body surface area of psoriasis and a 40% improvement in PGA of psoriasis (see Table 35).
Adverse events
The highest number of treatment-emergent AEs per patient-year of etanercept exposure occurred in the ERA
subgroup (1.827; EO: 1.313; PA: 1.036), which also had the lowest number of treatment-emergent
infections per patient-year of etanercept treatment (0.979; EO subgroup: 2.114; PA: 1.514). As Table 36
illustrates, patients with ERA appear to experience more treatment-related injection-site reactions than
patients with either EO or PAA.
Treatment-emergent AEs leading to patient withdrawal occurred only in the ERA subgroup (events 3,
etanercept exposure 7.9), and there were two events of treatment emergent infections causing
withdrawal (one each in the EO and PA groups). The rate of serious treatment-emergent AEs and serious
treatment-emergent infections appears to be low in all three subgroups (see Table 36), as does the rate
of treatment-emergent autoimmune disorder events. Of the two cases of uveitis (EO n= 1, PA n= 1), one
was reported in a patient with EO after 7.8 months of etanercept plus methotrexate. This resolved and
the patient completed the 96-week study. There were a total of three cases of Crohn’s disease in patients
with ERA, of which two cases were considered to be unrelated to etanercept therapy.
TABLE 36 Adverse events at week 96
All values are reported as number
of events (events per patient-year
of exposure to etanercept) unless
otherwise stated
Overall (n= 127)
EXP= 215.086
EO (n= 60)
EXP= 103.603
ERA (n= 38)
EXP= 61.298
PA (n= 29)
EXP= 50.185
Treatment-emergent AEsa 300 (1.395) 136 (1.313) 112 (1.827) 52 (1.036)
Treatment-emergent infections 355 (1.651) 219 (2.114) 60 (0.979) 76 (1.514)
Treatment-emergent ISRs 63 (0.293) 22 (0.212) 29 (0.473) 12 (0.239)
Treatment-emergent AEs causing
withdrawal, n (%)a
3 (2.4) 0 3 (7.9) 0
Treatment-emergent infections
causing withdrawal, n (%)
2 (1.6) 1 (1.7) 0 1 (3.4)
Serious treatment-emergent AEsa 16 (0.074) 2 (0.019) 11 (0.179) 3 (0.060)
Serious treatment-emergent infections 10 (0.046) 4 (0.039) 3 (0.049) 3 (0.060)
Opportunistic infectionsb 1 (0.005) 0 1 (0.016) 0
Infections considered preventable by
vaccination in patients not previously
vaccinated
7 (0.033) 5 (0.048) 1 (0.016) 1 (0.020)
Infections considered preventable by
vaccination in patients previously
vaccinated
1 (0.005) 1 (0.010)c 0 0
Treatment-emergent autoimmune
disordersd
4 (0.019) 1 (0.010) 2 (0.033) 1 (0.020)
EXP, etanercept exposure; ISR, injection-site reaction.
a Excluding infections and ISRs.
b One case of herpes zoster affecting two dermatomes was considered an opportunistic infection and one case of latent
tuberculosis (purified protein derivative conversion) was not considered an opportunistic infection.
c One case of rubella.
d Two cases of uveitis (EO and PA subtypes), one case of iridocyclitis (a subtype of uveitis; ERA subtype) and one case of
Crohn’s disease (ERA subtype) were treatment emergent. One case of Crohn’s disease (ERA subtype) was not considered
treatment emergent based on missing last-dose data.
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Juvenile idiopathic arthritis-associated uveitis
As stated earlier, the effects of biologic DMARD on extra-articular manifestations such as uveitis were not
assessed by the included RCTs. However, evidence from non-randomised studies is available, as
summarised by systematic reviews.
A recently published systematic review by Simonini and colleagues96 assessed the effectiveness of
antiTNF drugs for childhood uveitis. To be included, studies had to include patients with autoimmune
uveitis refractory to topical and/or systemic steroids and at least one immunosuppressive therapy
(e.g. methotrexate). The antiTNFα drugs of relevance to the review were etanercept, infliximab and
adalimumab (infliximab is not within the scope of this NICE appraisal). The primary outcome was
improvement in intraocular inflammation, with additional outcomes including tapering/stopping systemic
steroid administration, improvement in visual acuity and treatment discontinuation among others. A
number of bibliographic databases were searched from January 2000 to October 2012.
The review included 23 studies, mainly retrospective chart reviews with very small patient numbers.
Of these 23 studies, only 7 were conducted exclusively in JIA uveitis patients (one RCT of etanercept;
two retrospective studies of etanercept; two retrospective studies of infliximab; and two retrospective
studies of adalimumab). Eleven studies comprised mixed study populations with uveitis associated with a
range of conditions, including JIA. The remaining five studies included populations that did not include any
children with JIA. It was not possible to analyse results separately by uveitis-associated condition. However,
of the 229 children included across all the studies, 152 had chronic uveitis associated with JIA. The results
can therefore be interpreted as being generally relevant to JIA uveitis.
A pooled analysis of the observational studies found that adalimumab and infliximab were more
efficacious at improving intraocular inflammation than etanercept. The proportion of children with
improved intraocular inflammation (responders) was 87% (95% CI 75% to 98%) for adalimumab,
72% (95% CI 64% to 79%) for infliximab, and 33% (95% CI 19% to 47%) for etanercept. There was no
statistically significant difference in the proportion of responders between adalimumab and infliximab
(p= 0.08), but there was a significant difference for both compared with etanercept (p= 0.001 for
both comparisons).
Simonini and colleagues96 did not pool the results of the single RCT identified in the systematic review with
the observational studies.56 This was a small RCT (n= 12 children) of treatment with etanercept. The
authors state that this study did not report substantial benefits for the biologic treatment. (Owing to
limitations in reporting, this RCT was judged to be unclear for inclusion in our systematic review of clinical
effectiveness, as it was not clear whether or not the etanercept was given within its licensed indication).
Caution is advised in the interpretation of the findings of the Simonini and colleagues96 systematic review
given the weaknesses of the study designs included.
The assessment group are aware of only one other recent systematic review of biologic DMARD treatment
of children with uveitis, by Cordero-Coma and colleagues.105 The most recent search date for literature was
October 2011. This review had a broader inclusion criteria than that of Simonini and colleagues96 and a
total of 61 studies was included. Again, much of the included evidence was from observational studies.
A total of 14 studies assessed adalimumab, 11 assessed etanercept and 50 studies assessed infliximab
[studies assessing certolizumab and golimumab were also included]. Of the 1093 patients included across
the studies, 316 (30%) were classed as having JIA uveitis. The review does not provide any formal
synthesis and quantification of the effectiveness of treatment, but provides a narrative conclusion for each
biologic DMARD and a level of evidence. Adalimumab and infliximab were considered by the authors to be
effective in autoimmune uveitis, both based on level-2b evidence (individual cohort study or low-quality
RCT). Etanercept was judged ineffective, based on level-1b evidence (individual RCTs with narrow CIs).
CLINICAL EFFECTIVENESS
NIHR Journals Library www.journalslibrary.nihr.ac.uk
60
The Abbvie CS to NICE77 provides narrative summaries of five selected studies published since the Simonini
and colleagues96 systematic review. All of them were observational in design (three case series;106–108
one Italian registry-based study;109 one comparative cohort study110), and all assessed treatment with
adalimumab (with one also assessing infliximab110 in uveitis patient populations with varying proportions of
JIA uveitis. We have not performed an independent critical appraisal of these studies in this assessment
report. From the summaries given it appears that adalimumab is associated with improvements in
intraocular inflammation and visual acuity, and a decrease in use of corticosteroids. AEs appeared to be
minor. The other CSs to NICE did not present much detail of studies of treatment of JIA uveitis with other
biologic DMARDs.
In summary, the evidence from observational studies suggests that biologic DMARDs can improve uveitis
symptoms in children with JIA, such as intraocular inflammation. Adalimumab and infliximab appear to be
more effective than etanercept in improving uveitis. The effects of the treatments in terms of arthritis
outcomes in JIA uveitis patients have not been reported. As noted above (see Ongoing trials), the
UK-based SYCAMORE RCT87 has investigated adalimumab in the treatment of JIA uveitis patients, and
the results of the trial (which will be available sooner than expected, although an exact date has not been
specified) will provide more rigorous evidence for effectiveness than that currently available.
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Chapter 5 Economic analysis
Introduction
The aim of the economic evaluation is to assess the cost-effectiveness of abatacept, adalimumab,
etanercept and tocilizumab for people with JIA compared with alternative treatments. The economic
evaluation comprises:
l a systematic review of the cost-effectiveness of biologic DMARDs for people with JIA
l a systematic review of studies of the HRQoL of people with JIA
l a critical appraisal of the submissions from the relevant drug companies received as part of the NICE
appraisal process
l a de novo economic model and cost-effectiveness evaluation developed by Southampton Health
Technology Assessments Centre (SHTAC) to inform the NICE appraisal.
Systematic review of cost-effectiveness evidence
Methods for the systematic review
A systematic literature search was undertaken to identify economic evaluations of the biologic DMARDs,
within the NICE scope for this appraisal. Studies were included if they were full economic evaluations
(cost-effectiveness, cost–utility, cost–consequence or cost–benefit analyses) conducted in children and
young people with JIA that compared one or more biologics with a DMARD, such as methotrexate. Studies
that were not reported in the English language or that did not provide sufficient information on the model
structure, data and results were excluded. This systematic review aimed to summarise the currently
available evidence and inform the construction of a de novo model.
Results of the systematic review
Searches for economic evaluations identified 387 potentially relevant references, and a further study was
identified through ad hoc searching. The full texts for 17 papers were retrieved for further screening. A
summary of the selection process and the reasons for exclusion are presented in Figure 6 and a list of
excluded studies can be found in Appendix 6. Although seven studies reported as abstracts appeared to
meet the a priori inclusion criteria, they did not contain sufficient information on the methods used and
the results to permit formal data extraction or critical appraisal.111–117 Five studies were found not to be
economic evaluations.118–122 Four studies were included, described in a total of five publications.123–127 The
characteristics of the four included economic evaluations are shown in Table 37. Data extraction forms for
the studies can be found in Appendix 7.
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Total identified from searching
(after deduplication)
(n = 388)a
Titles and abstracts inspected
(n = 388)
Studies included (n = 4)
(in 5 publications)
Excluded
(n = 371)
Excluded
(n = 12)
• Abstracts, n = 7b
• Not economic evaluations, n = 5
References for retrieval 
and screening
(n = 17)
FIGURE 6 Flow chart of identification of studies for inclusion in the review of cost-effectiveness. a, including one
study found through hand searching; b, the abstracts provided insufficient details of methods and results to allow
inclusion in the systematic review.
TABLE 37 Characteristics of economic evaluations
Characteristic
Cummins et al.
(2002)123 Prince et al. (2011)124
Simpson et al.
(2012)125
Costa et al. (2010)126 and
Ungar et al. (2011)127
Country UK Netherlands Russia Canada
Funding source UK HTA programme Dutch Board of Health
Insurance and Wyeth
International
Not stated Ontario Ministry of Health
and Long-term Care Drug
Innovation Fund
Analysis type Cost–utility analysis Cost–consequence
analysis
Cost–utility analysis Cost-effectiveness analysis
Perspective Health-care system Health-care system Health-care system
and societal
Societal
Study
population
Children with
polyarticular juvenile
rheumatoid arthritis
Dutch JIA patients
younger than 18 years
eligible for treatment
with etanercept;
various types of JIA
Patients from
adalimumab trial:61
children aged
4–17 years with JIA
Patients with JIA with a
prior inadequate response
to, or intolerance of,
DMARDs
Intervention(s) Etanercept Etanercept Adalimumab Etanercept, adalimumab,
abatacept and infliximab
vs. methotrexate
Intervention
effect
Effect size measured in
terms of CHAQ and
mortality. Cost per
HAQ point
Six response variables
measured, including
overall assessment of
well-being, CHAQ
score and number of
active joints. HUI3 also
measured
CHAQ scores and
active joint counts
Proportion of patients
who had a reduction in
symptoms at 1 year
according to the ACR
Pedi-30 criteria
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Critical appraisal of the studies
The cost-effectiveness studies were assessed using a critical appraisal checklist (Table 38). The checklist
assessed study quality and generalisability to the UK. The checklist was adapted by the review authors
from checklists by Philips and colleagues,128 Drummond and colleagues129 and methodological
requirements stated in the NICE reference case.130
The Cummins and colleagues study was conducted in the UK,123 whereas the generalisability of the other
studies to the NHS is unclear. The other studies were conducted in the Netherlands,124 Russia125 and
Canada;127 used appropriate modelling methodology; and included relevant costs.
In terms of the analytical and modelling methodology used, the studies were generally considered
appropriate, except for the model reported in Cummins and colleagues,123 which was based upon a
number of questionable assumptions as a result of limitations in the data available at the time.
The data inputs for the model were clearly described and justified by two studies,123,127 but the description
of some of the data inputs are missing from Simpson and colleagues.125 Prince and colleagues124
conducted a cost–consequence analysis based on a prospective observational study that collected cost and
utility data. The study did not measure quality-adjusted life-years (QALYs).
Two of the studies, Cummins and colleagues123 and Simpson and colleagues,125 used appropriate time
horizons, measured the health outcomes in QALYs and discounted costs and outcomes. The model by
Ungar and colleagues127 did not use QALYs in the model and used a 1-year time horizon, eliminating the
need for discounting.
All three modelling studies analysed results incrementally and assessed uncertainty through
sensitivity analyses.123,125,127
In summary, the cost-effectiveness studies have certain limitations with regard to methodology, reporting
of results or generalisability to the UK NHS (see Table 38).
TABLE 37 Characteristics of economic evaluations (continued )
Characteristic
Cummins et al.
(2002)123 Prince et al. (2011)124
Simpson et al.
(2012)125
Costa et al. (2010)126 and
Ungar et al. (2011)127
Currency base UK pounds (GBP, £) Euros (EUR, €) Russian roubles
(RUB)
Canadian dollars (CAD, $)
Model type,
health states
Not clear None Markov model Decision-analysis model
Time horizon Life course 27 months 7 years/lifetime 1 year
Base-case
results
Incremental cost
£28,022; incremental
effectiveness in terms
of QALY 1.7; ICER
£16,082
Sensitivity analysis ICER
varied from £3900 to
£34,000
HUI3 score increases
from 0.53 to 0.78 after
28 months; total
direct medical costs
were €12,478 per
patient-year after
start of etanercept
compared with €3720
before start
For a lifetime horizon,
the incremental
cost–utility ratio for
adalimumab vs.
conventional
non-biologic therapy
was 1,571,500
RUB/QALY
Costs per ACR Pedi-30
responder were $26,061,
$46,711, $16,204 and
$31,209 for etanercept,
adalimumab, abatacept
and infliximab,
respectively, compared
with methotrexate
HAQ, Health Assessment Questionnaire; HUI3, Health Utilities Index-3; ICER, incremental cost-effectiveness ratio;
QALY, quality-adjusted life-year.
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Cummins and colleagues123
Approach
The Cummins and colleagues123 study consisted of a HTA conducted as part of the NICE appraisal of
etanercept for JIA (NICE TA35).131 The HTA includes a systematic review of clinical effectiveness and a
critical appraisal of a CS to NICE from Wyeth Laboratories (manufacturer of etanercept). The HTA does not
provide an independent economic model owing to considerable uncertainties in the available evidence for
JIA at that time. The CS contained a cost–utility analysis of etanercept in patients with JIA, compared with
other treatment options. The cost–utility model was based upon a model developed for rheumatoid
arthritis in adults. The model used the results from the etanercept RCT by Lovell and colleagues.42 The
model assumed a positive linear relationship between the Health Assessment Questionnaire (HAQ) score
and costs, modelling responders, non-responders and deaths at each time point.
The model used European Quality of Life-5 Dimensions (EQ-5D™) values derived from mapping HAQ
values in adult rheumatoid arthritis patients. Mortality was related to HAQ values, with a 38% increase in
mortality per unit change in HAQ. The model assumed a RR of mortality in JIA.
TABLE 38 Critical appraisal checklist for economic evaluations
Item
Cummins et al.
(2002)123
Prince et al.
(2011)124
Simpson et al.
(2012)125
Costa et al. (2010)126
and Ungar et al. (2011)127
1. Is the decision problem (including
interventions compared and patient
group) relevant to the UK?
Yes Yes Yes Yes
2. Is the setting comparable to the UK? Yes Unclear Unclear No
3. Is the analytical and modelling
methodology appropriate?
No Yesa Yes Yes
4. Are all the relevant costs and
consequences for each alternative
identified?
No Yes Yes Yes
5. Are the data inputs for the model
described and justified?
Yes N/A No Yes
6. Are health outcomes measured in
QALYs?
Yes No Yes No
7. Is the time horizon considered
appropriate?
Yes No Yes No
8. Are costs and outcomes
discounted?
Yes No Yes No
9. Is an incremental analysis
performed?
Yes Uncleara Yes Yes
10. Is uncertainty assessed? Yes Noa Yes Yes
N/A, not applicable; QALY, quality-adjusted life-year.
a The methodology is appropriate for a cohort-based evaluation; however, a full incremental cost–utility analysis has not
been performed.
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Estimation of effectiveness
The HAQ progression rate was 0 for responders for 0–4 years, 0.034 for responders after 4 years and
0.0669 for non-responders. No definition was given for response.
Cummins and colleagues123 reported the evidence limitations attributable to limited or non-existent
long-term data on efficacy and lifelong impacts of the disease and treatment. The Juvenile Rheumatoid
Arthritis-30 efficacy measure was assumed to be equivalent to ACR Pedi-20, HAQ and CHAQ were
assumed equivalent, and utility and mortality were derived from an adult rheumatic arthritis trial. Owing
to limited evidence on potential adverse effects, disease progression and long-term prognosis for
treatment-resistant JIA, assumptions were made in the economic evaluation that are insufficiently
supported. The authors of the review expressed concerns about the validity of the economic model and
the assumptions made to extrapolate beyond the limited evidence base.
Estimation of quality-adjusted life-years
Utility values were derived from EQ-5D estimates for adults with rheumatoid arthritis, as there was limited
evidence on HRQoL in JIA. The model assumed that the HAQ was equivalent to CHAQ and that adult
values were therefore appropriate for children. The HAQ score for the placebo arm was 1.3 at baseline
and 1.2 after 7 months, and the HAQ score for the etanercept arm was 1.6 at baseline and 0.8 at
7 months (lower scores indicate better health). In the base case, the model reported a 1.7 incremental
QALY gain in favour of etanercept. However, this result was questioned by Cummins and colleagues123
owing to the limitations in the evidence for HRQoL.
Estimation of costs
Resource use was considered similar to that for the adult rheumatoid arthritis population. Information
regarding resource use was not available from the JIA etanercept trial.42 Costs were discounted at 6% per
annum and benefits at 1% per annum. The cost offset per HAQ point was £860.
Results
The incremental QALYs were 1.74 for the patients on etanercept compared with placebo. The incremental
cost-effectiveness ratio (ICER) was £16,082 per QALY gained in the base-case analysis, and in the
sensitivity analyses ICERs ranged between £3900 (cost-offsets assumption changed to exclude nursing
home and home help costs but to include indirect costs) and £34,000 (Short Form questionnaire-36 items
regression used). Probabilistic results were not reported.
Key issues
l There were concerns about the validity of the results owing to a lack of suitable evidence for model
input parameters, particularly with regard to HRQoL.
Prince and colleagues124
Approach
Prince and colleagues124 reported a cost–consequence analysis of etanercept therapy in patients with JIA in
the Netherlands, who had an insufficient response to the maximum dose of methotrexate. Forty-nine JIA
patients were evaluated at start of treatment and after 3, 15 and 27 months of therapy from the National
ABC register. For all included patients, data were collected on the use of etanercept, disease activity and
HRQoL. Most of the patients had polyarticular JIA (45%), followed by EO (22%) and systemic JIA (22%).
The remainder had ERA (4%) or juvenile arthritis psoriatica (6%). The median age of patients at the start
of etanercept treatment was 11.6 years and median disease duration was 3.6 years.
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Estimation of effectiveness
The outcome measure used to assess disease activity consisted of six response variables: (1) overall
assessment of disease activity by the physician by means of the VAS; (2) CHAQ by the patient or parent;
(3) overall assessment of well-being by the patient or parent through the VAS; (4) number of active joints
(joints with swelling and/or limited motion with pain or tenderness); (5) number of joints with limited
motion; and (6) a laboratory marker of inflammation, ESR.
After 3 months’ use of etanercept, the mean number of active joints decreased from 16.7 to 3.99 per
person and the CHAQ score decreased from 1.70 to 1.00. These outcomes further improved at 27 months
to 2.45 active joints per person and a CHAQ score of 0.50 (lower score indicates better outcome).
Estimation of quality-adjusted life-years
Health-related quality-of-life data were collected for patients in the study using the Health Utilities Index
(HUI)-3. The questionnaire consists of eight health domains: vision, hearing, speech, ambulation, dexterity,
emotion, cognition and pain, each with five or six levels representing the range of functioning. HRQoL was
collected by proxy by the parents of the study participants because children were considered unable to
value health states. The HRQoL data are reported in more detail in the systematic review of HRQoL studies
(see Systematic review of health-related quality-of-life studies).
Estimation of costs
Costs were collected for direct medical costs (i.e. medication, diagnostic and hospitalisation costs). The
base year was 2008 for all costs, with costs retrieved from other years converted to 2008 euros using the
general Dutch price index rate. Unit costs for medication were retrieved from the Pharmacotherapeutic
Compass provided by the Dutch Board of Health Insurances, and treatment costs were calculated with
the exact dose of medication and administration period as reported in the patients’ files. Prices for all
hospital-related costs were based on real prices from the co-ordinating centre (Erasmus MC Sophia
Children’s Hospital Rotterdam, the Netherlands). The etanercept unit cost was estimated at €10,478 per year.
Results
Mean total direct medical costs after the start of etanercept were, on average, €12,478 per patient-year
compared with €3720 before the start of etanercept treatment. The utility for patients was 0.53 before
start of etanercept treatment and increased to 0.78 over 27 months of etanercept treatment.
Key issues
l The study does not report cost-effectiveness.
l The study was based in the Netherlands, so unclear how generalisable results are to the NHS.
Simpson and colleagues125
Approach
Simpson and colleagues125 reported results from a Markov model developed to assess the cost-
effectiveness of adalimumab relative to methotrexate for the treatment of JIA. Cost-effectiveness analyses
were performed from the perspective of the Russian health-care system (base model) and society as a
whole (secondary model). The base-case model reported outcomes for a cohort of 100 children with a
mean age of 11 years. Sensitivity analyses assessed the variation in the age of children at treatment
initiation. The model has two parts. The first part followed children from 11 to 18 years of age with
4-month long cycles. This part of the model used data derived from the adalimumab RCT (Lovell and
colleagues61). Additional analyses followed patients aged 7 years at treatment initiation for a period of
11 years. The second part of the model was derived from the literature on adult rheumatoid arthritis and
modelled the remaining lifetime of the patients (age > 18 years). The adalimumab RCT61 compared
adalimumab plus methotrexate with placebo plus methotrexate for the treatment of JIA in children aged
4–17 years (further detail of this trial can be found in Chapter 4).
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Disease activity was defined as mild, moderate or severe using the CHAQ scores and active joint counts
from the adalimumab RCT.61 Health states from the childhood model were used to capture the effects of
joint damage and the need for hip replacement for the treatment of JIA in adulthood (> 18 years). The
base model included five health states (remission no disease, remission disease, activity mild, activity
moderate and activity severe). The remission disease group was introduced to capture the effect of joint
damage and the need for joint replacement.
Estimation of effectiveness
Effectiveness estimates were based on observed changes from the adalimumab trial,61 assessed using the
CHAQ. These effects within the model were translated to HUI2 utility values, using a mapping algorithm
developed by the authors.132
Estimation of quality-adjusted life-years
For the first part of the model (< 18 years), CHAQ items were transformed to HUI2 utility values, using the
mapping algorithm. QALY estimates were based on these utility values. Utility values for the second part of
the model were derived from the literature and were based on adult patients with rheumatoid arthritis.
Mean predicted utility values varied from 0.56 to 0.98 (range 0.18 to 1.00).
Estimation of costs
Health-care costs were derived from a study by Yagudina and colleagues133 reporting the cost of JIA during
a 15-month period in Russia. The costs were for the year 2011. Given that this study reported the cost of
1-month inpatient and 14-month outpatient treatments, the cost attributable to each health state was
adjusted using this as starting point. Base-case costs were discounted at a rate of 3%, whereas additional
sensitivity analysis used a discounting rate of 5%.
Results
Relative to conventional non-biologic therapy, adalimumab was assessed to be cost-effective when used to
treat JIA patients whose disease severity was comparable to that of participants in the adalimumab RCT.61
Adalimumab plus methotrexate was reported to be more effective and more costly than methotrexate with
an incremental cost per QALY ratio of approximately 1,437,480 roubles (£16,974 at current exchange rate)
for the base case (7 years) and 119,496 roubles (£1411) adopting a lifetime horizon.
Key issues
l There was uncertainty relating to the predicted utility values used to estimate QALYs; a recent study
indicated how using different algorithms to convert HAQ to utility values affects the cost-effectiveness
and HTA results.134
l The lifelong model uses utility estimates derived from adult patients with rheumatoid arthritis. JIA that
persists into adulthood has a different disease process to rheumatoid arthritis, and, therefore,
assumptions of similarity between the two conditions are not valid.
l Cost estimates may not be applicable to the UK.
l Mortality rates are assumed to be equal to published rates for Russia; it is not clear if this refers to the
general population or to JIA- and age-specific mortality rates.
Ungar and colleagues127
Approach
Ungar and colleagues127 developed a decision-analysis model for etanercept, infliximab, adalimumab and
abatacept for polyarticular-course JIA patients in Canada, who had had an inadequate response or
intolerance to DMARDs. The model had a 1-year time horizon and consisted of two consecutive 6-month
cycles, with no discounting. The model incorporated the probabilities that patients would, based on their
response at 6 months, either continue with the same treatment or switch to an alternative treatment.
Patients switched as a result of lack of response, intolerance to therapy or AEs. Where data on switching
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biologic DMARDs were not available in paediatric studies, the RR of switching from biologic DMARDs
owing to non-response or AEs was extrapolated from studies of rheumatoid arthritis in adults. Patients
who switched from methotrexate were assumed to receive a biologic DMARD for the next 6 months,
where the cost of the biologic was represented by the average cost of all the biologic DMARDs.
Estimation of effectiveness
The model compared each of the biologic DMARDs with methotrexate, but did not compare them with
each other, given that head-to-head trials were not available and that the study populations differed by JIA
onset type. The effectiveness measure was the proportion of patients who had a reduction in symptoms at
1 year in accordance with the ACR Pedi-30 criteria. To derive 6-month response rates for each biologic
DMARD, data from the key RCTs (Lovell and colleagues42,61 and Ruperto and colleagues57,135) were
combined with data from registry and observational studies in a meta-analysis. For the base-case analysis,
the proportion of patients achieving ACR Pedi-30 at 6 months varied between 79% and 82% for the
biologic DMARDs, with the assumption that 30% of patients treated with methotrexate would achieve
ACR Pedi-30. Probabilities for switching owing to non-response and AEs were estimated from the RCTs
and observational studies.
Estimation of quality-adjusted life-years
Health-related quality of life was not included in the analysis.
Estimation of costs
The model included the costs of medication, monitoring costs and costs associated with treating serious
infections. Costs were in Canadian dollars and the price year was 2008. In the base-case analysis a 40-kg
patient was assumed, based upon the mean weight of patients in the two paediatric trials that reported
weight. The direct medical costs included drug acquisition costs for biologic DMARDs and methotrexate,
concomitant drug costs, drug administration materials, nursing time, dispensing fees, physician
assessments and laboratory tests. Unit prices of health resources were obtained from public sources,
including the Quebec and Ontario provincial drug plan formularies for medications, and the Ontario
Ministry of Health and Long-Term Care fee schedules (laboratory tests and physician fees).
Results
The model reports results as additional cost per additional ACR Pedi-30 responder at 1 year of $26,061,
$46,711, $16,204 and $31,209 for etanercept, adalimumab, abatacept and infliximab versus
methotrexate, respectively. Probabilistic sensitivity analyses were conducted for each treatment versus
methotrexate, and cost-effectiveness acceptability curves were calculated. If a decision-maker was willing
to pay no more than $30,000 per additional responder, then the probability that etanercept would
demonstrate a net economic benefit would be 95%. The willingness-to-pay points at which the biologic
DMARDs had a 50% probability of cost-effectiveness were $45,000, $17,000 and $27,500 for
adalimumab, abatacept and infliximab, respectively.
Key issues
l The time horizon was inadequate to model treatment of a long-term condition (only 1 year).
l This was not a cost–utility study as no HRQoL data were included.
Summary of published economic evaluations
l A systematic review of economic evaluations of biologic treatments included four studies, two of which
were cost–utility analyses, one of which was a cost-effectiveness study and one of which was a
cost–consequence study.
l The evaluations were published between 2002 and 2012 in the UK,123 the Netherlands,124 Russia125
and Canada.127
l The studies varied in design and structure. The time horizons varied between 1 year127 and lifetime.123
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l The comparators differed between studies. One study compared etanercept with methotrexate,123 one
compared adalimumab with methotrexate,125 one compared etanercept, adalimumab, abatacept and
infliximab with methotrexate127 and the remaining study compared a cohort before and after
receiving etanercept.124
l There were limitations in the methodological quality in all the studies identified, including limited
reporting of model parameters and assumptions. The UK study123 is now considered out of date, and it
is unclear how generalisable the results from the other studies are given the methodological limitations.
Systematic review of health-related quality-of-life studies
Methods for the systematic review
A systematic literature review was undertaken to assess the HRQoL of people with JIA treated with biologic
DMARDs. The aim of the review was to provide data to populate the de novo economic model in this
report with health-state utility values to calculate QALYs. The description of the search strategy is shown in
Appendix 1. The inclusion criteria included primary studies that investigated HRQoL in people with JIA.
To be eligible, the study should report health utility values using any generic preference-based HRQoL
measure [e.g. EQ-5D, Short Form questionnaire-6 Dimensions (SF-6D)] or choice-based valuation methods
(e.g. time trade-off, standard gamble). Studies that were not reported in English or did not provide
sufficient information were excluded. The methodology used for searching and data extraction is outlined
in Chapter 3 of this assessment report.
Results of the systematic review
The database searches identified 2249 references, with one further study retrieved by hand searching,
making the total number of references identified 2250. Full-text papers for 28 references were retrieved,
meeting the a priori inclusion criteria. Figure 7 presents a flow chart of the selection process and the
excluded studies, with reasons for exclusion listed in Appendix 8. A total of 6 references were considered
to have insufficient information on the study methods, population and results, 9 included an inappropriate
population and 10 did not report a relevant outcome measure. Two studies, described in three
Total identified from searching
(after deduplication)
(n = 2250)
Titles and abstracts inspected
(n = 2250)
Studies included 
(n = 2)
(in 3 papers)
Excluded
(n = 2222)
Excluded
(n = 25)
• Insufficient detail, n = 6
• Inappropriate population, n = 9
• Outcome, n = 10
References for retrieval 
and screening
(n = 28)
FIGURE 7 Flow chart of identification of studies for inclusion in the review of QoL studies.
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publications, met the inclusion criteria and the characteristics of these studies are presented in Table 39.
Data extraction forms for the included studies can be found in Appendix 9.
The two HRQoL studies are each now described in more detail.
Hendry and colleagues136
Hendry and colleagues136 conducted an exploratory RCT to assess the effectiveness of a multidisciplinary
foot care programme in children with JIA, and to investigate the methodological considerations of such
a trial.
Children and adolescents with a definitive diagnosis of JIA and inflammatory joint disease affecting
the foot/ankle were recruited at a single hospital (the Royal Hospital for Sick Children, Glasgow, UK).
Participants were included if they satisfied at least one of the following criteria: (1) previously documented
foot arthritis including small joints derived from medical case notes; (2) previously documented foot
arthritis in one or more large joints derived from medical case notes; or (3) current widespread polyarthritis
involving large and small foot joints derived from clinical examination by a consultant paediatric
rheumatologist. Patients with an unconfirmed diagnosis of JIA, and/or only upper limb, jaw or neck
involvement were excluded. Therefore, a subgroup of the JIA patient population of relevance to this
assessment report (i.e. those whose disease had not affected the foot/ankle) was excluded from the
study (Table 40).
Enrolled participants (n= 44) were randomly allocated to the intervention group receiving multidisciplinary
foot care (individualised care packages including foot orthoses and targeted home exercise programmes)
or to the control group treated with standard care (normal outpatient medical care from their consultant
paediatric rheumatologists). Treatment groups were similar in terms of pharmacological treatment and
TABLE 39 Characteristics of included quality-of-life studies
Characteristic Hendry et al. (2013)136 Prince et al. (2011);124 Prince et al. (2010)137
Country UK Netherlands
Study type RCT Prospective observational study
Study population Children/adolescents with JIA and
inflammatory joint disease affecting the
foot/ankle (n= 44)
Children and adolescents with refractory JIA
from the National ABC register (n= 49)
Study population age
(mean)
10 years old 11.6 years old
Intervention(s) Multidisciplinary foot care intervention
informed by musculoskeletal ultrasound
Etanercept therapy
Comparator population Standard care No treatment
QoL instrument used EQ-5D HUI3
Time period where HRQoL
instruments administered
At baseline and 12 months Baseline, 3 months, 15 months and 27 months
Methodology of collecting
HRQoL data
EQ-5D was completed by patient
(using EQ-5D-Y) and by proxy (using
EQ-5D-3L)
The parents of the JIA patients completed
the HUI3
Results EQ-5D was 0.57 and 0.69 for the
intervention group at baseline for the
self-reported and proxy groups. Results
were similar at 12 months and in the
control group
Utility was 0.53 at baseline and increased to
0.78 after 27 months
EQ-5D-3L, European Quality of Life-5 Dimensions 3-level questionnaire; EQ-5D-Y, European Quality of Life-5
Dimensions (Youth).
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TABLE 40 Characteristics of included HRQoL study by Hendry and colleagues136
Characteristics Multidisciplinary foot care Standard care
Participants, n 21 23
Age (years), mean (SD) 10.1 (4.22) 10.0 (3.39)
Sex, n
Male 7 6
Female 14 17
Disease subtypes, n (%)
Persistent oligoarthritis 7 (33) 4 (17)
EO 4 (19) 5 (22)
Polyarthritis RF–ve 6 (29) 10 (43)
Polyarthritis RF+ve 0 (0) 2 (9)
PA 2 (10) 1 (4)
ERA 2 (10) 0 (0)
Undifferentiated 0 (0) 1 (4)
Pharmacological management, n (%)
Analgesics 2 (9) 3 (13)
NSAIDs 2 (9) 3 (13)
Methotrexate 18 (86) 16 (70)
Etanercept 7 (33) 5 (22)
Methotrexate and etanercept 5 (24) 5 (22)
Sulphasalazine 1 (5) 0 (0)
Rituximab 0 (0) 1 (4)
EQ-5D utility index at baseline
Self, mean (SD) 0.57 (0.31) 0.58 (0.35)
Self, median (IQR) 0.62 (0.52–0.76) 0.66 (0.52–0.75)
Proxy, mean (SD) 0.69 (0.29) 0.60 (0.33)
Proxy, median (IQR) 0.69 (0.58–1) 0.62 (0.55–0.82)
Change in EQ-5D utility index at 12 months, median (IQR)
Self 0 (–0.1 to 0.01) 0 (–0.04 to 0.04)
Proxy 0 (0 to 0.11) 0 (0 to 0.1)
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both had a proportion of patients receiving etanercept. There were small differences in proportions of
JIA disease subtypes, but there were no statistically significant differences in baseline characteristics
(see Table 40).
Patients’ HRQoL was collected at baseline and 12 months using the EQ-5D (Youth) (patients) and EQ-5D
3-Levels (parents/guardians). There were no significant differences in HRQoL between treatment groups at
12 months, and both self- and proxy-reported outcomes were similar (see Table 40).
Prince and colleagues124,137
Prince and colleagues124,137 evaluated changes in HRQoL in patients with refractory JIA who were being
treated with etanercept, following an insufficient response to the maximum tolerated dose of
methotrexate (This study was also discussed above; see Systematic review of existing cost-effectiveness
evidence). Data were collected from Dutch patients registered at the National ABC) register, supplemented
by prospectively collected additional data from patients who started etanercept treatment from 2003 until
2006. Three HRQoL questionnaires were used, one of which was the HUI3 preference-based HRQoL
instrument. HRQoL questionnaires were completed at the start and after 3, 15 and 27 months
of treatment.
Prince and colleagues124,137 report the results in two publications, and the results differ slightly between the
publications. In the publication including costs,124 four fewer patients are included, as these patients did
not continue treatment with etanercept for at least 27 months, whereas the publication reporting QoL
only reports the results for all 53 patients. For the purposes of this assessment report, the smaller dataset is
of more relevance,124 but results from both datasets are shown in Table 41.
The results from the study indicated a statistically significant improvement in the HUI3 utility score from
0.53 at baseline to 0.78 at 27 months’ follow-up. Mean utility values were 0.69 at 3 months and 0.74 at
15 months’ follow-up. For the cohort with more patients, there was a mean utility improvement of 0.25
during the 27 months of treatment.137 The baseline mean utility value was 0.51, and significant changes
were observed in the domains of pain, ambulatory and dexterity.
TABLE 41 Characteristics of patients included in Prince and colleagues124,137
Characteristic Prince et al. (2010)137 Prince et al. (2011)124
Participants, n 53 49
Age, median (IQR) 11.9 (8.1–14.9) 11.6 (7.9–14.6)
Sex, %
Male 38 41
Female 62 59
Proportion of sample with systemic JIA, % 26 (14/53) 22 (11/49)
Proportion of sample receiving methotrexate, % 80 79
HUI utility value (SD) baseline 0.51 (0.04) 0.53 (0.04)
HUI utility value (SD) follow-up (27 months) 0.77 (0.08) 0.78 (0.07)
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Summary and conclusions of the health-related quality-of-life review
The included studies assessed the HRQoL of children and adolescents with JIA, applying EQ-5D and HUI3
preference-based utility measures. Although both studies reported utility values, they are not directly
comparable. The study by Hendry and colleagues136 assessed the effectiveness of a foot care programme in
a RCT, whereas Prince and colleagues124,137 conducted an observational study reporting HRQoL and costs
from patients in the Dutch ABC registry to assess the effect of treating patients with etanercept. The mean
utility values reported for baseline by Hendry and colleagues136 for the intervention and control group
(0.57 and 0.58, respectively) are relatively similar to the baseline values reported by the Prince and
colleagues study (0.51 and 0.53, respectively).124,137 The HRQoL values may be higher for Hendry and
colleagues136 owing to 23% of patients receiving etanercept, whereas no patients received etanercept at
baseline in the Prince and colleagues study.124,137 The sample size of both cohorts is considered relatively
small, but it is reasonable given the population group. The cohort used in the Prince and colleagues
study124,137 included patients with systemic JIA, who are outside the scope of the current review; however,
the proportion of patients within the group with systemic JIA is relatively small (< 30%). Neither of the
studies can be considered fully informative for the de novo economic evaluation in this assessment report.
However, estimates provided by Prince and colleagues124,137 are considered reasonably appropriate for use
in the economic evaluation, despite not being considered directly generalisable to the UK population.
Review of cost-effectiveness in company submissions to the
National Institute for Health and Care Excellence
All four pharmaceutical companies submitted evidence to be considered for the NICE appraisal. Two of
these submissions [by BMS (abatacept) and Roche (tocilizumab)]78,85 consisted of a written report and
an electronic economic model, and the other two submissions [by AbbVie (adalimumab) and Pfizer
(etanercept)]77,97 comprised only a written report.
A structured data extraction form was used by the assessment group to assess the CSs (see Appendix 10).
A description and critique of each of the submissions in turn is provided in the following subsections.
Greater description is provided for the Roche and BMS submissions as these conducted economic models.
(a description and critique of the companies’ clinical effectiveness evidence is given in Chapter 4, Review of
clinical effectiveness in company submissions to the National Institute for Health and Care Excellence).
Review of Bristol-Myers Squibb’s submission to the National Institute for
Health and Care Excellence (abatacept)
The company submitted a de novo economic model that included all comparators specified in the NICE
scope except for methotrexate monotherapy (i.e. abatacept, etanercept, adalimumab and tocilizumab).85
The company states that methotrexate monotherapy was not included owing to inconsistency with the
clinical effectiveness data (i.e. all patients in the RCTs either did not have sufficient response with
methotrexate or were refractory to methotrexate). The scope reflects the licensed indication of abatacept,
namely polyarticular JIA patients aged ≥ 6 years who have received at least one TNFα inhibitor (etanercept
or adalimumab). All included drugs were assumed to be administered with subcutaneous methotrexate.
Modelling approach
The model presented in the CS is a cohort-based cost-minimisation model, in which all drugs were
assumed to have identical efficacy. The base-case model presents a cohort of 12-year-old polyarticular JIA
patients and follows them until aged 18 years in 4-week cycles. The model is essentially a one-state model.
Patients gain weight and height as they age, but their disease does not change; only the costs associated
with treating the disease increase owing to weight- and body surface area-based dosing among the drugs.
The drug acquisition cost values within the model were appropriately derived from Monthly Index of
Medical Specialties data.138
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Assumptions
The model contained a number of assumptions that appear reasonable: a 52-week year, a dosing regimen
for methotrexate consistent between < 16-year-olds and > 16-year-olds, a constant weight after the age of
20 years, methotrexate dosing based on an algorithm for lowest cost when > 30mg of methotrexate is
necessary, a normal distribution for height and weight, a truncation of the model starting age in the
probabilistic sensitivity analysis (PSA) to represent only between age 6 and 16 years as starting ages,
assumptions for standard errors where they were unavailable and no vial sharing of drugs.
Critical appraisal of model
Although the comparators and population within the model were generally consistent with the NICE
scope, the model does not adequately represent all the available evidence for the treatment pathway or
natural history of the disease.
The model time horizon and structure are inadequate to capture long-term treatment effects or the
treatment pathway of the disease, as many JIA patients continue to receive treatment into adulthood. The
model does not allow for drug discontinuation or treatment switching, which is known to happen in
clinical practice. The CS indicates that the model was validated by an internal reviewer but full details were
not reported of this validation.
Estimation of effectiveness
The model did not include clinical effectiveness data to represent clinical outcomes or to represent events
that incur costs such as disease flare, vision loss or joint surgery. The effectiveness of the biologic DMARDs
was assumed to be equivalent as a justification for the use of cost-minimisation methods. The CS cites
the systematic review and indirect comparison by Otten and colleagues79 for evidence of equivalent
effectiveness (as discussed in Chapter 4).
Estimation of quality-adjusted life-years
Health-related quality of life was not assessed in the model and the CS indicates that this was due to
uncertainty in the QoL values for JIA in the literature.
Estimation of costs
Intervention dosages and prices were derived from Monthly Index of Medical Specialties data,138 whereas
costs for subcutaneous injection and infusion drug delivery methods were derived from a previously
published HTA of biologic DMARDs in rheumatoid arthritis.139 A confidential patient access scheme (PAS)
was incorporated for abatacept. Sensitivity analyses were run for the price of tocilizumab using various
assumed percentage price discounts, as a confidential PAS has been agreed for tocilizumab.
The costs were derived from appropriate sources and are clearly reported, but it is assumed that the drugs
had identical AE costs, discontinuation rates and clinical effectiveness. The details for drug costs and
dosages used in the BMS company model are shown in Table 42.
Results
The model was a cost minimisation and analysed only costs, assuming equivalent clinical effectiveness for
all biologic DMARDs. The results of the base-case analysis are shown in Table 43. The model results
presented by the manufacturer include a PAS discount of (CiC information has been removed)
for abatacept.
In the base case, the company found that abatacept was the least costly biologic DMARD. The CS states
that abatacept has similar efficacy and safety to the other biologic DMARDs. Deterministic sensitivity
analyses and PSA were conducted for a variety of scenarios. The findings were found to be robust to a
wide range of scenarios.
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TABLE 42 Unit costs and dosages used in the BMS company model (list prices)
Drug Cost, £ Dose, mg
Abatacept 302.40 250
Etanercept 35.75 10
89.38 25
178.75 50
Adalimumab 352.14 40
Tocilizumab 102.40 80
256.00 200
512.00 400
Methotrexate 14.85 7.5
15.29 10
16.50 12.5
16.57 15
17.50 17.5
17.84 20
Administration method
Infusion 154.00
Subcutaneous injection 3.05
TABLE 43 Results of the BMS model base case (CS table 13) (CiC information has been removed)a
Costs Abatacept Adalimumab Etanercept Tocilizumab
Drug costs CiC information has
been removed
CiC information has
been removed
CiC information has
been removed
CiC information has
been removed
Administration
costs, £
11,797 871 871 11,646
Total costs CiC information has
been removed
CiC information has
been removed
CiC information has
been removed
CiC information has
been removed
Cost savings with abatacept CiC information has
been removed
CiC information has
been removed
CiC information has
been removed
a 12-year-olds, 6-year time horizon, from Excel 2010 (Microsoft Corporation, Redmond, WA, USA) model.
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The company undertook a number of deterministic and scenario sensitivity analyses:
l A sensitivity analysis was undertaken wherein the infusion costs for tocilizumab were increased owing
to the longer infusion time.
l The starting age of patients in the model was varied between 6 and 16 years. In the biologic DMARD
trials the mean age was 11 years at baseline, but the drug licences were for much younger ages.
l The time horizon of the model was varied between 6 months and 20 years. Longer time horizons were
meant to represent that one-third of children with JIA will have it into adulthood.
l PAS discount for tocilizumab was tested for a range of percentages of list price reductions and
calculated to show the tocilizumab discount with identical drug costs to abatacept.
l Methotrexate was excluded from the etanercept arm.
There were no analyses that varied more than one parameter at a time. None of the one-way sensitivity
analyses was accompanied by a probabilistic analysis that reassessed the probability that abatacept was the
least costly biologic for second-line biologic DMARD therapy of polyarticular JIA. Given that the model was
simple and that the number of simulations for the PSA was only 1000, these analyses would have been simple
and quick to perform. It would have been especially informative to do this for the tocilizumab cost-sensitivity
analyses. No analyses looked at subgroups of patients, and there was no discussion of potential subgroups.
The PSA results using 1000 simulations were within 5% of the base-case analysis results. Abatacept was
the least costly option in 67% of simulations, whereas etanercept was the least costly option in the
remaining 33% of simulations. Not all distributions used in the sensitivity analysis were appropriate. For
the infusion costs and subcutaneous administration costs, a normal distribution was used for the cost data,
which could lead to simulations with negative cost values; a gamma or log-normal distribution would be
more appropriate. The drug cost data do not appear to have been subjected to uncertainty. Given that
there is a PAS for tocilizumab, using a lower than average cost value for tocilizumab and subjecting it to
PSA could have been an alternative approach to conducting only a deterministic analysis for tocilizumab.
This would have given a more realistic estimates of the cost uncertainty between treatments.
Critique of the company’s submission
The company constructed a cost-minimisation model, assuming that there were no differences between
the biologic DMARDs in clinical effectiveness, AEs and discontinuation rates. Patients do not discontinue or
switch treatments, which does not reflect current clinical practice or the available evidence.
Overall, the model is limited for decision-making owing to factors such as inadequate time horizon and
structural limitations. However, the methods for integrating variable dosing over time used within the
model may be useful for building a more comprehensive model.
Review of the Roche submission to the National Institute for Health and
Care Excellence (tocilizumab)
The CS includes an economic model and reports the total costs, the QALYs gained and cost-effectiveness
of tocilizumab in the treatment of polyarticular JIA.78 The model evaluates the lifetime costs and benefits
for tocilizumab compared with adalimumab. The perspective of the analysis is that of the NHS and
Personal Social Services (PSS).
Modelling approach
A de novo Markov state-transition decision model was developed in Microsoft Excel® (Microsoft
Corporation, Redmond, WA, USA) with three health states (uncontrolled disease/off treatment, on
treatment and dead). The model has 6-month cycles and a time horizon of 25 years. Costs and benefits
are discounted at 3.5%. Patients entering the model have active JIA and have previously experienced an
inadequate response to, or were intolerant of, methotrexate. Patients in the model have a mean age of
11 years and are based on those in the CHERISH RCT.68
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Patients start with uncontrolled disease at cycle 0 then move to first-line biologic treatment. Once all lines
of treatment are exhausted, patients move into the uncontrolled disease health state. Mortality is included
in the model and assumes a 1% 6-month mortality rate across all years. The model includes the
occurrence of SAEs. The mortality rate used in the model is about 100 times higher than the annual
mortality rate for the general paediatric population of 0.02%. We consider that a lower mortality rate
should be used in the model.
Assumptions
The CS states that, owing to differences in terms of trial design, patients, methods of imputation and
quality, only adalimumab and tocilizumab could be compared. The CS states that an indirect comparison
of safety was not possible and so the risk of SAEs was assumed to be the same for both biologic DMARDs.
The model assumes that patients discontinue at a rate proportional to their ACR response [i.e. no response
(ACR Pedi < 30), moderate response (ACR Pedi-30–ACR Pedi-70) and good response (ACR Pedi ≥ 70)].
Critical appraisal of model
The submission meets all of the requirements for methodological quality and generalisability, except that it
did not fully explore uncertainty or provide any evidence that the economic model had been validated.
The evaluation provided a clear statement of the decision problem to be addressed, including the
population, which appeared to follow the scope for the appraisal issued by NICE. The comparators
included (adalimumab and tocilizumab) were appropriate, as these are being routinely used or considered
for use within the NHS in England and Wales. The model also included etanercept in an exploratory
analysis but did not include abatacept, and the CS states that this was not possible owing to differences in
trial design, patients, methods of imputation and quality. The 25-year time horizon reflects the chronic
nature of the disease and allows for all relevant costs and benefits to be included. The model structure was
clearly presented with a description and justification of the key assumptions and data inputs used. Benefits
for the model are measured in QALYs using the HUI3 for measuring utility. All benefits and costs are
discounted at 3.5% as required by NICE.130 The CS does not assess uncertainty in sensitivity analysis. It was
unclear if the model had been fully validated, as no details were provided.
Estimation of effectiveness
The company reported a systematic review of biologic DMARDs in the treatment of JIA. The CS states
that it was possible to compare adalimumab and tocilizumab only by indirect comparison, as these two
treatments had greater similarities in trial design, patients, methods of imputation and quality. Results from
each study were combined using a hierarchical Bayesian indirect treatment comparison, using an ordered
probit model in WinBUGS software to estimate the relative treatment effects and achieving different levels
of ACR response. The ACR response rates were estimated for the biologic DMARDs with and without
methotrexate and are shown in Table 44. The response is generally similar for adalimumab and tocilizumab
(both with methotrexate).
TABLE 44 American College of Rheumatology Pediatric response rates from Roche submission (CS table 21)
Response rates ACR Pedi-30, % ACR Pedi-50, % ACR Pedi-70, % ACR Pedi-90, %
Without methotrexate Placebo 31 28 25 12
Tocilizumab 62 59 54 35
Adalimumab 52 49 44 26
With methotrexate Methotrexate 52 51 41 25
Tocilizumab 72 70 61 44
Adalimumab 76 75 66 49
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The discontinuation rate used in the model was derived according to ACR response from the Dutch ABC
register.124 An exponential distribution was fitted to the data for no response (ACR Pedi response < 30),
moderate response (ACR Pedi response > 30 and < 70) and good response (ACR Pedi response ≥ 70).
The 6-month discontinuation rate was 0.126 for no response, 0.09 for moderate response and 0.042 for
good response.
Estimation of quality-adjusted life-years
The company conducted a literature review that identified one study reporting utility values suitable for
use in the model (Prince and colleagues124). This study reported utility scores obtained using the HUI3
questionnaire to JIA patients starting treatment with etanercept in the Dutch ABC register. Based on these
data, the company used values at time 0 for the patients who are off treatment (utility of 0.53), and used
values at time 1 year for patients on treatment (utility of 0.73).
The assessment group identified some errors in the Roche model with regard to estimation of QALYs.
First, utility values for patients have been applied as if patients were on treatment for some time after
finishing the first-line biologic treatment, when these patients should have been assigned the off-treatment
utility. Second, utility values have been incorrectly calculated as the utility value for 1 year has been
assigned to each cycle of 6 months. (For corrections to these errors, see Table 47.)
Estimation of costs
The costs associated with each health state was obtained from Prince and colleagues,124 who report costs
data from the Dutch ABC register for the year before and after starting etanercept. The total 6-month
health-state cost for patients on treatment is £912.33 and off treatment is £1591.43. Treatment unit costs
and doses were reported. Tocilizumab was provided with a confidential PAS discount (CiC information has
been removed). The model included costs for both intravenous infusion and for subcutaneous injection, as
required by the treatment. The administration cost of an infusion (for tocilizumab) was £152.24, using
inflated costs from Barton and colleagues.140 The cost of an administration of a subcutaneous injection was
£6.10 for children and £3.05 for a young person, assuming that a proportion of these patients would
require nurse assistance.
Cost-effectiveness results
Tables 45 and 46 show the cost-effectiveness results from the CS for tocilizumab compared with
adalimumab when used in combination with methotrexate or as a monotherapy. The CS states that the
results indicate that both treatments are of similar clinical effectiveness and cost-effectiveness, regardless of
TABLE 46 Roche base-case results: biologic DMARD monotherapy
Outcome Adalimumab Tocilizumab Incremental difference ICER (£ per QALY)
Total QALYs 18.65 18.7 0.0455
Total cost, £ 74,576 68,560 –6015 Dominant
TABLE 45 Roche base-case results: combination therapy
Outcome Adalimumab+methotrexate Tocilizumab+methotrexate
Incremental
difference ICER (£ per QALY)
Total QALYs 18.76 18.72 –0.0303
Total cost, £ 81,827 70,707 –11,120 South-west quadranta
a Adalimumab vs. tocilizumab has an ICER of £367,551.
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whether they are used in combination with methotrexate or as a monotherapy. The company urges
caution in the interpretation of the QALY estimates, but concludes that tocilizumab is less expensive and
therefore represents better value to the NHS.
The CS does not include any sensitivity analyses. It includes an exploratory analysis with etanercept. This
analysis assumed a class effect across antiTNFs in polyarticular JIA.
Critique of the company’s submission
There are some concerns over the reliability of the model results in the Roche submission owing to errors
found by the assessment group in the calculation of QALYs.
The assessment group has corrected the errors in the Roche model by applying the off-treatment utility
values when patients finished the first-line biologic treatment and assigning the 6-month utility value to
each cycle. In addition, the mortality rate has been reduced to 0.03% per cycle to reflect that of the
general population. The results for this analysis are shown in Table 47. The corrected results show reduced
QALYs and increased costs for adalimumab and tocilizumab in combination with methotrexate compared
with the base-case results. However, the incremental QALYs and costs between the tocilizumab and
adalimumab are similar in the corrected results to the base-case results.
Review of the AbbVie submission to the National Institute for Health and
Care Excellence (adalimumab)
The company did not provide a systematic review of cost-effectiveness studies or an economic evaluation.77
They discussed the interventions in the NICE scope: adalimumab, etanercept, abatacept, tocilizumab and
methotrexate. In sections 5.8–5.10 of the CS, the company provides justifications for not conducting an
economic evaluation. Other sections of the CS provide details on what the company would consider
important in conducting an economic evaluation in JIA, including an evaluation of the costs associated
with surgeries and vision loss.
The company states that an economic evaluation was not conducted owing to a lack of appropriate utility
data for HRQoL, heterogeneity in study methods and populations between the interventions that
complicated indirect comparisons, and a lack of long-term effectiveness data. The company identified one
HRQoL study (Prince and colleagues124), which collected HUI3 utilities in addition to other JIA clinical
variables, such as the CHAQ score. The data collected from Prince and colleagues124 were deemed
unsuitable to map the CHAQ to HUI3 owing to insufficient sample size, but were considered the most
suitable source of utility data by the company. The CS discusses the use of an algorithm by Khan and
colleagues141 that mapped the Pediatric Quality of Life Inventory instrument to EQ-5D in secondary school
pupils. The company notes the potential limitations in the use of this method in JIA, as Pediatric Quality of
Life data were not collected in any of the JIA biologic DMARD RCTs. The company considers that the
biologic DMARD trial populations and study methods were not sufficiently similar to allow indirect
comparison through network meta-analysis. The CS concluded that using current data and methods would
lead to ‘untenable’ uncertainty (CS page 90).
TABLE 47 Corrected Roche model results: combination therapy
Outcome Adalimumab+methotrexate Tocilizumab+methotrexate
Incremental
difference ICER (£ per QALY)
Total QALYs 10.10 10.05 –0.05
Total cost, £ 95,761 83,593 –12,168 South-west quadranta
a Adalimumab vs. tocilizumab has an ICER of £251,208.
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Review of the Pfizer submission to the National Institute for Health and
Care Excellence (etanercept)
Pfizer did not submit any cost-effectiveness evidence.97 The CS notes the limitations raised in the previous
submissions for NICE of etanercept TA3543 and tocilizumab TA238.44 These relate to the limitations in the
HRQoL data and the limited evidence on the long-term outcomes and the effectiveness of the treatments.
The CS states that any cost-effectiveness evidence would be associated with considerable and unresolvable
uncertainty. The company submitted a cost analysis that compared the annual costs for the first year of
treatment based on etanercept against adalimumab and tocilizumab in patients with polyarticular JIA. The
CS states that the cost analysis showed that etanercept is the biologic DMARD with the lowest acquisition
cost compared with list prices for tocilizumab and adalimumab.
Comparison of economic models in company submissions
The CSs differ in the approach to providing economic evidence for biologic DMARDs for JIA. Only one
company (Roche) constructed an economic model for tocilizumab that included both costs and outcomes.
Two companies (BMS for abatacept and Pfizer for etanercept) submitted cost analyses and assumed
that the biologic DMARDs were equivalent, whereas the remaining company (AbbVie for adalimumab)
considered there to be too many limitations with any potential analysis and, therefore, did not submit an
economic analysis.
Although AbbVie has raised valid concerns about uncertainty in the data available for conducting an
economic evaluation, we consider that concerns about uncertainty are an insufficient justification for not
building an economic model. A model provides a representation of current knowledge in a subject and
uncertainty is part of that current knowledge. A model, even an uncertain one, with limitations noted by
the company, gives a more transparent description of available knowledge and enables more informed
decision-making than simply presenting clinical trial data from trials that represent only a highly selected
subgroup of the drug licences. Modelling also allows the exposure of the most valuable areas for future
research enquiries.
Bristol-Myers Squibb and Pfizer consider that all of the treatments are equivalent. It is noted that the
available evidence base consists of small trials that lack the statistical power to justify this assumption, and
Otten and colleagues79 do not conclude that there is equivalent efficacy between the treatments, but that
the treatments are similar.
Briggs and O’Brien142 argue that a cost-minimisation analysis should be conducted only when equivalence
of comparators has been statistically demonstrated. Dakin and Wordsworth143 argue that the limitations of
a cost-minimisation analysis do not allow for an appropriate assessment of uncertainty or for the value of
future research and may lead to biased conclusions. It is also the case that equivalence of one clinical
outcome does not mean equivalence of all clinical outcomes. Patients may have the same QoL on
treatment but have different adherence and discontinuation or different AEs, for example. For these
reasons, a cost-minimisation analysis is generally forgone in favour of a cost-effectiveness analysis and/or a
cost–utility analysis.
Roche have provided a cost–utility analysis that compared two of the biologic DMARDs (adalimumab and
tocilizumab). The model appears to be a reasonable attempt at modelling JIA, albeit in only two of the
biologic DMARDs. However, we have noted errors in the calculation of QALYs in the model, which limit
the credibility of the results.
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Independent economic evaluation
The models described in our systematic review of economic evaluations (see Systematic review of
cost-effectiveness evidence) had certain methodological limitations and were not wholly generalisable to
the NHS. Furthermore, the economic evaluation used to inform the NICE appraisal of tocilizumab for
systemic JIA (NICE TA238) was subject to a number of concerns from the Appraisal Committee, in
particular with regard to the estimation of HRQoL.44 Given the limitations of existing available models,
we therefore constructed a de novo economic model to inform this current appraisal.
The model estimates the costs, benefits and cost-effectiveness of the four biologic DMARDs in patients
with JIA and inadequate responses to, or intolerance of, methotrexate. The model compares the biologic
DMARDs (in combination with methotrexate, where permitted) with a DMARD (e.g. methotrexate), as
specified in the NICE scope. The model does not compare the biologic DMARDs with best supportive care
(e.g. NSAIDS; corticosteroids) for patients who cannot tolerate a DMARD, as there are limited data
available to make this comparison. Furthermore, patients who are intolerant to a DMARD such as
methotrexate would be offered a biologic DMARD rather than best supportive care, particularly to avoid
any potential adverse effects of long-term corticosteroid use.144
The evidence used in the model was taken from data sources such as the RCTs of biologic DMARDS (in
which a number of JIA subtypes were represented, with polyarticular-course JIA being the predominant
subtype), and data sources such as registry studies comprising mixed JIA populations (primarily comprising
polyarticular and oligoarthritis JIA patients, but also small proportions of patients with ERA, PA and
systemic JIA). However, there was insufficient evidence available for all input parameters to permit a
cost-effectiveness subgroup analysis for each of the respective types of JIA within the scope of the
appraisal. Therefore, the modelled patient population is people with JIA, with the results of particular
relevance to people with polyarticular course JIA (EO, and RF +ve and RF –ve polyarthritis). The biologic
DMARDs are assessed in this report within their licensed indications (e.g. the cost-effectiveness estimates
for some of the biologic DMARDs cannot be applied to JIA subtypes for which they are not licensed, such
as abatacept and tocilizumab for the treatment of ERA and PA).
The model was populated with clinical effectiveness data from the included RCTs in our systematic review
of clinical effectiveness (see Chapter 4), HRQoL data from our systematic review of HRQoL studies (see
Systematic review of health-related quality-of-life studies) and cost data derived from published studies
(where available), as well as national and local NHS unit costs.
The economic evaluation was from the perspective of the NHS and Personal Social Services, with only
these direct costs included. The model estimates the long-term costs and benefits from each of the
treatments. The costs and benefits were discounted at 3.5%, as recommended by NICE.130 The base price
year for the costs was 2014. The intervention effect, in terms of reducing disease flare, was derived from
the systematic review of clinical effectiveness reported in Chapter 4. The outcome of the economic
evaluation is reported as incremental cost per QALY gained.
Methods for independent economic analysis
A Markov model was developed in Microsoft Excel to assess the cost-effectiveness of the biologic
DMARDs. The model contains health states for ‘on treatment’, ‘off treatment’, ‘remission off treatment’
and ‘death’. A diagram of the model is shown in Figure 8. The model uses 3-month cycles to be consistent
with the usual time between outpatient appointments for JIA patients. A time horizon of 30 years was
modelled as the base case, with shorter and longer horizons tested in sensitivity analyses. This time horizon
was considered sufficiently long to capture the costs and effects of biologic DMARDs for paediatric
patients, given the uncertainty around the long-term clinical outcomes for adults with JIA. The model
structure is based upon the clinical pathway of patients who participated in the withdrawal RCTs,
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described in Chapter 4, the natural history of JIA described in registry data and discussions with clinical
experts. The starting age of patients in the model is 11 years, based upon the mean age of patients in the
RCTs. Patients’ heights and weights are assumed to be similar to those in the general population.
Patients treated with a biologic DMARD continue on treatment unless they die or withdraw from
treatment owing to adverse effects, loss of efficacy or clinical remission off treatment. Patients with clinical
remission who have their treatment discontinued may relapse and resume treatment with a biologic
DMARD. Based on clinical advice, we assumed that clinicians would be reluctant to stop treatment with a
biologic DMARD as a result of remission because of the risk of relapse, and so, for the base-case analysis
we assume that no patients discontinue treatment owing to remission. We investigate discontinuation
attributable to remission in more detail in a scenario analyses. Therefore, for the base-case analysis, no
patients enter the ‘clinical remission off treatment’ health state and this is indicated in Figure 8 by dotted
lines for this health state.
In the base-case analysis, patients treated with adalimumab, etanercept and tocilizumab receive only one
line of biologic DMARD treatment. Patients treated with abatacept receive two lines of biologic DMARD
treatment, as abatacept is licensed for use only after a preceding antiTNF. Following withdrawal from
these biologic DMARDs, patients continue on a standard treatment regimen that does not contain a
biologic DMARD.
In a scenario analysis (scenario V), we investigate multiple lines of treatment with biologic DMARDs, which
reflects the range of strategies used in clinical practice. Patients continue on the subsequent treatments
until they die or withdraw from treatment as a result of AEs, loss of efficacy or clinical remission. Following
withdrawal from the final biologic DMARD, patients continue on a standard treatment regimen that does
not contain a biologic DMARD.
Patients treated with methotrexate only (i.e. those not receiving a biologic DMARD) are assumed to
continue on treatment unless they die or withdraw from treatment owing to AEs or loss of efficacy.
The model incorporates disease flares to estimate the clinical effectiveness of treatment. This was the
primary outcome measure in the RCTs of the biologic DMARDs. Patients who have a disease flare continue
in their current health state in the model but are allocated a HRQoL disutility and an additional health-care
cost during that cycle.
The costs in the model comprise drug treatment, consultation and monitoring costs and costs for treating
AEs. Costs used in the model are described in more detail in Data sources. HRQoL is estimated according
to each health state.
Switch
treatment
On treatment
Off treatment
Remission off
treatment
Death
FIGURE 8 Schematic of the SHTAC JIA model structure.
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In each cycle, the total costs and QALYs are calculated by multiplying the individual costs and HRQoL by
the number of people in the cohort still alive for each of the treatments. The total long-term costs and
QALYs are calculated by aggregating the costs and QALYs for all cycles. The total discounted QALY gain
and cost of treatments are calculated and compared to give the cost-effectiveness of the treatments.
Assumptions are applied to all treatment options unless explicitly stated otherwise. These assumptions
have been made owing to an absence of data and have been informed by discussion with our clinical
advisors. The model includes the following main assumptions:
l There are few studies for biologics, other than for etanercept, that report long-term discontinuation
owing to AEs and inefficacy. The discontinuation rate is assumed to be similar for each of the
biologic DMARDs.
l Our clinical effectiveness review concluded that there is no evidence of a difference in efficacy between
biologics and, therefore, we assumed that the QoL utility values are the same for all biologic DMARDs
(‘on treatment’).
l It is currently unclear whether or not the effectiveness of subsequent lines of biologic DMARDs would
be reduced or remain the same. The effectiveness of the biologic DMARDs is assumed to be similar
taken as a first- or subsequent-line biologic treatment. This applies to abatacept as a second-line
biologic DMARD in the base case, and to the scenario analysis that models three lines of biologic
DMARD treatment (scenario V).
Evaluation of uncertainty
The evaluation of the cost-effectiveness of JIA treatment is based on uncertain information about variables
such as clinical effect, HRQoL and resource use. This uncertainty was evaluated using deterministic and
PSA. One-way deterministic sensitivity analyses were conducted to evaluate the influence of individual
parameters on the model results and to test the robustness of the cost-effectiveness results to variations in
the structural assumptions and parameter inputs (see Results of the independent economic analysis).
Where possible, the parameters were varied according to the ranges of the CIs of these parameters based
on the published estimates. Where these data were not available an alternative range was chosen.
Multiparameter uncertainty in the model was addressed using PSA (Results of the independent economic
analysis).145 In the PSA, probability distributions are assigned to the parameter point estimates used in the
base-case analysis. The model is run for 1000 iterations, with a different set of parameter values for each
iteration by sampling parameter values at random from their probability distributions.
The uncertainty surrounding the cost-effectiveness of the treatment is represented on a cost-effectiveness
acceptability curve according to the probability that the intervention will be cost-effective at a particular
willingness-to-pay threshold. Appendix 11 reports the parameters included in the PSA, the form of
distribution used for sampling each parameter and the upper and lower limits assumed for each variable.
Model validation
The model was validated by checking the model structure, calculations and data inputs for technical
correctness by another researcher. The structure was reviewed by clinical experts from the advisory group
for its appropriateness for the disease and its treatment. A senior health economist from the advisory
group reviewed the methods and assumptions of the economic evaluation. The robustness of the model to
changes in input values was tested using sensitivity analyses to ensure that any changes to the input values
produced changes to the results of the expected direction and magnitude.
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Data sources
Effectiveness data
Disease flare
The risk of disease flare was included in the model as a RR compared with methotrexate (Table 48), as
derived from our systematic review of clinical effectiveness [Chapter 4, Assessment of clinical effectiveness:
biologic disease-modifying antirheumatic drugs versus placebo (with methotrexate where permitted)].
The baseline risk of flare for methotrexate was a weighted average of the risk of flare estimates from the
placebo arms of the abatacept, adalimumab and tocilizumab trials, converted to a 3-month cycle risk.
For each biologic DMARD, the risk of flare was derived using the RR for that treatment compared with
methotrexate from the relevant RCT, multiplied by the baseline risk.
Treatment discontinuation
Treatment discontinuation was assumed to be attributable to AEs, lack of efficacy or clinical remission.
Estimates for treatment discontinuation were identified through a literature search of trial and registry
data. The first model cycle has certain different treatment discontinuation parameters because it was
designed to represent the open-label lead-in phase of the RCTs.
The estimates for the first model cycle were taken from the RCTs of the biologic DMARDs42,57,61,68 for the
open-label lead-in period (Table 49). For the period after the treatment lead-in, the clinical trials of the
biologic DMARDs also include other categories of withdrawal (such as patient/guardian consent or
physician decision), but it is unclear whether these categories would also apply to clinical practice or were
particular to the trials. As a result, the discontinuation rate after the first model cycle was not taken from
these clinical trials but from Tynjala and colleagues146 who conducted a retrospective observational study
on JIA patients in Finland taking etanercept or infliximab with a 4-year follow-up.
There were few long-term data on treatment discontinuation identified except for etanercept and, hence,
we assumed that the discontinuation rate would remain constant over time and would be the same for all
biologic DMARDs (based on data for from Tynjala and colleagues146). The discontinuation rate was 7% for
AEs and 28% for inefficacy over 4 years. The discontinuation rate for inefficacy for methotrexate was
taken from a retrospective analysis of the German Methotrexate Registry,147 which collected data on the
TABLE 49 Discontinuations during the trials’ lead-in time (first cycle)
Parameter Abatacept57 Adalimumab61 Etanercept42 Tocilizumab68
AE, % 0.5 1.8 1.4 1.6
Loss of efficacy, % 9.5 3.5 2.9 8.0
Total discontinuation, % 10.0 5.3 4.3 9.6
TABLE 48 Risk of disease flare
Drug Risk of flare per cycle Source
Methotrexate 0.25 Ruperto et al. (2008),57 Lovell et al. (2008)61
Brunner et al. (2015)68
Abatacept 0.09 Ruperto et al. (2008)57
Adalimumab 0.14 Lovell et al. (2008)61
Etanercept 0.09 Lovell et al. (2000)42
Tocilizumab 0.14 Brunner et al. (2014)68
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efficacy and safety of methotrexate treatment since 2005. The discontinuation rate for inefficacy used
in the model was 0.4% per cycle. The STRIVE registry (see Review of cost-effectiveness in company
submissions to the National Institute for Health and Care Excellence) reported a methotrexate
discontinuation rate for AEs of 2.3% per year and this was converted to a 3-month rate and used in
the model.77
Mortality Patients are assumed to have the same mortality rate as for the general population. Mortality
was taken from age-related statistics from the Office for National Statistics.21
Health-related quality of life Our systematic review of HRQoL studies identified two potentially relevant
studies that reported generic preference-based HRQoL studies of people with JIA who received a biologic
DMARD.124,136 Furthermore, none of the clinical trials of the biologic DMARDs under review collected
HRQoL data that could be used as health-state utility values. We investigated methods for mapping HRQoL
to treatment response, for example from CHAQ or ACR Pedi to HUI3, but concluded that the data
available were insufficient to provide a reliable fit for modelling. Therefore, the utility values used in the
model were taken directly from the Dutch ABC Registry by Prince and colleagues,124 as this study was
considered to be of most relevance from the available literature. This study is described in more detail
above (see Systematic review of health-related quality-of-life studies). It consists of patients who have
polyarticular-course JIA and in whom the response to the maximum dose of methotrexate is insufficient.
The utility value for patients who had not yet received etanercept in that study is assumed to be
representative of those patients with uncontrolled disease not currently receiving a biologic DMARD
(i.e. those patients in the methotrexate-only arm and those patients who discontinue biologic DMARD
therapy). In the study by Prince and colleagues,124 most of the patients were still receiving methotrexate. In
the absence of any other utility data, we assumed that all biologic DMARDs would have the same utility
values as each other and that this would increase over time, as seen in the Prince and colleagues study.124
For simplicity, for the scenarios with additional lines of biologic treatments (scenario V), we assumed that
treatment with the biologic DMARD would have a constant utility value of 0.74 (i.e. the value after
15 months of treatment for second- and third-line biologic DMARD treatment). The annual health-state
utility values used are shown in Table 50.
Patients with a disease flare are assumed to have an associated disutility. We assumed that patients with
a disease flare would have a similar HRQoL to patients with uncontrolled disease, but with appropriate
treatment would recover from their disease flare within 3 months (one model cycle). Assuming that
patients recovered HRQoL at a constant rate over the model cycle, the average HRQoL for these patients
during that cycle would be 0.655, and converting this to an annual disutility would be equivalent to
0.03 per flare.
TABLE 50 Health-related quality-of-life utility values
HRQoL utility values Per year Source
No treatment 0.53 Prince et al. (2011)124
Treatment with first-line biologic, 0–3 months 0.53 Prince et al. (2011)124
Treatment with first-line biologic, 3–15 months 0.69 Prince et al. (2011)124
Treatment with first-line biologic, 15–27 months 0.74 Prince et al. (2011)124
Treatment with first-line biologic, 27+ months 0.78 Prince et al. (2011)124
Treatment with second- and third-line biologics 0.74 Prince et al. (2011)124
Disutility for disease flare 0.03 Assumption
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Caregiver disutility We conducted a literature search of studies reporting the quality-of-life impact on
caregivers of patients with JIA and did not identify any studies that reported HRQoL as utility values. The
precise quality-of-life impact on primary caregivers of patients with JIA, in terms of change in HRQoL
utility values, is unclear. A study by Bruns and colleagues148 examined the HRQoL and disease burden of
primary caregivers of 70 patients with JIA. They used the CHAQ, Short Form questionnaire-36 items and
the psychiatric screening questionnaire (the Self-Reporting Questionnaire-20 items). The burden of disease
on the caregivers was measured by the Caregiver Burden Scale. They concluded that there was a high
prevalence of psychoemotional disturbance in JIA caregivers and that the burden of disease on the
caregivers was primarily related to patients’ emotional status (rather than to their physical status).
In the absence of suitable HRQoL data for caregiver disutility, we assumed in the base-case analysis that
there was no utility benefit for parents of children and young people and varied this assumption in a
scenario analysis (scenario IV).
Estimation of costs
Drug costs
Drug unit costs and doses were based on the British National Formulary for Children 2015.149 A summary
of the dose and unit cost of treatment for each of the comparators is given in Table 51. The manufacturers
of abatacept and tocilizumab have provided a confidential PAS. Cost-effectiveness results for these
treatments presented in Results of the independent economic analysis are based on the drug list price,
whereas a CiC separate appendix to this report available only to the NICE Appraisal Committee presents
results with the confidential PAS discount applied. Patient height, weight and body surface area were
taken from the British National Formulary and reflect the increase in children’s heights and weights as they
TABLE 51 Drug acquisition costs and dosages (source: British National Formulary for Children149)
Parameter Methotrexate Abatacept Adalimumab Etanercept Tocilizumab
Drug dose 10–15mg/m2 10mg/kg 24mg/m2
(maximum 40mg)
aged 4–13 years
40mg (aged
13–18 years)
0.4mg/kg (up to a
maximum of 25mg
per dose)
10mg/kg for patients
< 30 kg; 8mg/kg for
patients > 30 kg
Method Subcutaneous
injection/oral
Intravenous
infusion
Subcutaneous
injection
Subcutaneous
injection
Intravenous infusion
Dosing
schedule
Once weekly Infusions given
at weeks 0, 2,
4, 8, 12, 16
Every other week Twice weekly Every 4 weeks
Unit cost Oral: 2.5mg 24-tab
pack= £2.22; 28-tab
pack= £2.60
Subcutaneous:
Metoject (Medac
GmbH, Wedel,
Germany) pre-filled
syringe. 50mg/ml:
0.15ml= £14.85;
0.2ml= £15.29;
0.3ml= £16.57;
0.4ml= £17.84;
0.5ml= £18.48;
0.6ml= £18.95
250-mg
vial= £302.40
40-mg prefilled
pen or prefilled
syringe= £352.14
10-mg vial= £35.75;
25-mg vial= £89.38;
25-mg prefilled
syringe= £89.38
3ml (80-mg vial)=
£102.40; 10ml
(200-mg vial= £256;
20ml (400-mg
vial)= £512.00
Administration
cost, £
0 154 0 0 154
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grow older.150 The administration costs for an intravenous infusion was £154 based on a HTA monograph
of disease-modifying drugs in the treatment of rheumatoid arthritis (Stevenson and colleagues139). We
assumed that for patients taking methotrexate, half would receive oral and half subcutaneous administration,
based upon clinical advice.
Patients taking biologic DMARDs also receive concomitant methotrexate treatment as shown in Table 52.
These values have been taken from the RCTs or registries for these treatments. Patients receiving
etanercept in the model do not also receive methotrexate, according to etanercept’s marketing
authorisation. It was assumed that 20% of patients in the methotrexate comparator arm would be
intolerant to methotrexate and therefore would not receive it.124
Resource use
We conducted a literature search for costing studies in patients with JIA and identified two relevant studies.
Thornton and colleagues153 examined the resources used and associated patient-based costs during the first
year after diagnosis for JIA patients in the UK. Prince and colleagues124 analysed the costs of treatment for
patients in the Dutch ABC Register before and after receiving etanercept. There are limitations to both
studies: the patients in the Thornton and colleagues153 study are likely to have different resources and costs
in the first year after diagnosis than the patients included in this assessment report; for example, they may
have had less severe disease. The resources used by patients in the Prince and colleagues study124 are not
reported and it is unclear how different Dutch health-care costs would be to the NHS. Our clinical experts
commented that the resources for monitoring patients costs were not substantially different between the
patients treated with methotrexate only or with a biologic DMARD, and were broadly similar to those in the
Thornton and colleagues153 study. We therefore used the resources described by Thornton and colleagues
in the base case and explored the costs used by Prince and colleagues124 in a scenario analysis (scenario II).
The assumed resources used by patients are shown in Table 53. Blood tests consisted of the combined cost
of full blood count, CRP, urea and electrolytes and a liver function test. Clinical imaging consisted of the
combined cost of magnetic resonance imaging scan, dual-energy X-ray absorptiometry scan, ultrasound and
radiography. The total health-care cost for patients on biological treatment and off biologic treatment using
the resources shown in Table 53 was £724 per cycle.
Patients who experienced a disease flare received one or more injections of intra-articular steroids and
were treated as paediatric rheumatology inpatient cases at a cost of £429.97.152
Adverse events
The database of studies from our systematic review was searched for studies reporting any AEs or
discontinuation. In addition, the CSs were consulted for any relevant data. Although the types and
frequencies of AEs were reported, no cost data were identified in any of the studies that reported SAEs or
discontinuation rates, or in observational studies reported in the CSs. In order to identify data, previous
NICE TAs were searched. Neither of the JIA technology appraisals, TA35 and TA238, contained data on
the cost of SAEs.43,44
TABLE 52 Concomitant biologic DMARD and methotrexate use
Drug use Methotrexate only Abatacept Adalimumab Etanercept Tocilizumab
Methotrexate use, % 80 80 69 0 82
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Owing to the paucity of data relating to JIA, TAs of rheumatoid arthritis were also assessed. Of the six
TA publications available on the NICE website,154–159 only one contained data for the cost of an AE, namely
TA195: Adalimumab, Etanercept, Infliximab, Rituximab and Abatacept for the Treatment of Rheumatoid
Arthritis after the Failure of a TNF Inhibitor.158 A Pfizer CS provided the only relevant cost data in TA195.
Pfizer assumed that a SAE involved two general practitioner visits, 7 days of hospitalisation and a utility
decrement of 0.05, with a total cost of £1181. No specific AEs were identified by Pfizer. Further details on
the types of SAE experienced by JIA patients are given in Chapter 4, Assessment of clinical effectiveness:
biologic disease-modifying antirheumatic drugs versus placebo (with methotrexate where permitted) and in
Appendix 2. The most common SAEs were serious infections and infestations, but SAEs also included
autoimmune diseases and malignancies. All independent analyses in rheumatoid arthritis conducted by
assessment groups to this point have been based on the Birmingham Rheumatoid Arthritis Model,140 which
assigns a cost to increases in HAQ scores. In JIA, it is not possible to model SAE costs in this way owing to
lack of HAQ in the RCTs.
In order to model the cost of SAEs, health-care resource group codes for intermediate and severe paediatric
infections were consulted. In addition, a study in etanercept patients by Otten and colleagues160 indicated
that the median length of hospitalisation for SAEs was 9 days (IQR 2–12). Given this, we estimated inpatient
costs by averaging all spells for intermediate and major paediatric infections (£1532.87).
A summary of the input parameters used in the model are shown in Table 54.
TABLE 53 Resource use and unit costs
Resource per year
Resource use per year
Unit cost, £ Reference
Off biologic
treatment
On biologic
treatment
General practitioner visit 10 10 46.00 PSSRU (2013)151
Hospital appointments
Rheumatology paediatric consultant 5.58 5.58 234.86 National reference costs 2013/14152
(OP code 262)
Ophthalmologist 2.69 2.69 114.73 National reference costs 2013/14152
(OP code 216)
Specialist nurse 7.00 7.00 40.00 PSSRU 2013151
Physiotherapist 4.00 4.00 16.50 PSSRU 2013151
Occupational therapist 0.65 0.65 16.50 PSSRU 2013151
Podiatry 0.61 0.61 43.59 National Reference Costs 2013/14152
(OP code 653)
Hospital tests
Blood tests 1 1 46.27 Thornton et al. (2008),153 updated
to 2013/14 values using PSSRU
HCHS IndexClinical imaging 1 1 386.42
Disease flare
Inpatient treatment per disease
flare
429.97 National Reference Costs 2013/14152
(non-elective short stay. Weighted
average codes HD23D–HD23JK)
HCHS, Hospital and Community Health Services; PSSRU, Personal Social Services Research Unit.
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TABLE 54 Summary of the input parameters used in the SHTAC economic model
Parameter Mean Higher value Lower value Source
Starting age, years 11 15 6 Assumption, based on RCTs
Time horizon, years 30 10 70 Assumption
Discount rate (costs), % 3.5 6 1.5 NICE reference case130
Discount rate (benefits), % 3.5 6 1.5 NICE reference case130
Utility values, per cycle
No treatment 0.13 0.15 0.11 Prince et al. (2011)124
Treatment after 3 months 0.17 0.20 0.15 Prince et al. (2011)124
Treatment after 15 months 0.19 0.21 0.16 Prince et al. (2011)124
Treatment after 27 months 0.20 0.23 0.16 Prince et al. (2011)124
Disease flare disutility 0.03 0.04 0.02 Assumption
Disease flare, per cycle
Placebo 0.25 0.34 0.16 Ruperto et al. (2008),57 Lovell et al.
(2008),61 Brunner et al. (2015)68
Abatacept 0.09 0.16 0.05 Ruperto et al. (2008)57
Adalimumab 0.14 0.23 0.09 Lovell et al. (2008)61
Etanercept 0.09 0.17 0.04 Lovell et al. (2000)42
Tocilizumab 0.14 0.20 0.09 Brunner et al. (2015)68
AEs, first cycle, %
Abatacept 0.53 1.51 0.00 Ruperto et al. (2008)57
Adalimumab 1.75 3.71 0.00 Lovell et al. (2008)61
Etanercept 1.45 4.19 0.00 Lovell et al. (2000)42
Tocilizumab 1.60 3.36 0.00 Brunner et al. (2015)68
Loss of efficacy, %
Abatacept 9.47 13.59 5.36 Ruperto et al. (2008)57
Adalimumab 3.51 6.25 0.76 Lovell et al. (2008)61
Etanercept 2.90 6.82 0.00 Lovell et al. (2000)42
Tocilizumab 7.98 11.90 4.06 Brunner et al. (2015)68
Further-line treatment, %
AEs, biologic DMARD 0.43 0.82 0.04 Tynjala et al. (2009)146
Loss of efficacy biologic DMARD 2.00 2.59 1.41 Tynjala et al. (2009)146
AEs, methotrexate 0.58 0.82 0.34 STRIVE (2015)77
Loss of efficacy methotrexate 0.42 0.79 0.05 Klein et al. (2012)147
Costs, £
On biologic DMARD cost 724 940.92 506.65 National Reference Costs 2013/14152
PSSRU 2013151
Off biologic DMARD cost 724 940.92 506.65
SAE cost 1533 1993 1073 National Reference Costs 2013/14152
Disease flare cost 430 301 559 National Reference Costs 2013/14152
PSSRU, Personal Social Services Research Unit.
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Results of the independent economic analysis
This section reports the cost-effectiveness results for a person with JIA who received treatment with a
biologic DMARD in combination with methotrexate (where permitted) compared with those who received
methotrexate only. Results for costs and QALYs are presented for each treatment, with costs and benefits
discounted at 3.5%. The results are presented for biologic DMARDs licensed for use as a first-line biologic
treatment (i.e. adalimumab, etanercept and tocilizumab) and are then presented for abatacept as a
second-line biologic treatment following previous treatment with an antiTNF. The results shown in this
section are for the drug list price, and the results with the confidential PAS discount for abatacept and
tocilizumab are presented in a separate CiC appendix to this report available only to the NICE
Appraisal Committee.
Licensed first-line biologics: adalimumab, etanercept and tocilizumab
The undiscounted summary results of the analyses for adalimumab, etanercept and tocilizumab compared
with methotrexate for the treatment effects are shown in Tables 55–57. In the base case, total
undiscounted QALYs vary between 14.98 for methotrexate and 17.99 for tocilizumab (see Table 55).
Patients on methotrexate have higher QALYs only in the off-biologic-DMARD health state than the patients
on biologics, as they spend more time in this health state. The summary results of the undiscounted drug
costs are shown in Table 56. The total undiscounted drug acquisition cost of the biologic DMARDs varied
between £103,497 and £128,071 for treatment first with etanercept and tocilizumab, respectively,
compared with a total undiscounted cost of £7029 for patients treated with methotrexate only. The total
patient costs varied between £107,299 and £225,797 for methotrexate only and tocilizumab, respectively.
As noted earlier, patients taking etanercept do not receive methotrexate, which partially explains the lower
costs for the etanercept regimen.
TABLE 56 Summary of the total undiscounted costs in each health state for treatment with first-line biologic
compared with methotrexate
Treatment
Total undiscounted costs, £
Medical Drug AEs Flare Total
Methotrexate only 86,938 7029 498 12,834 107,299
Adalimumab 86,938 114,701 248 10,805 212,693
Etanercept 86,938 103,497 254 9766 200,454
Tocilizumab 86,938 128,071 269 10,519 225,797
TABLE 55 Summary of the total undiscounted QALYs in each health state for treatment with first-line biologic
compared with methotrexate
Treatment
Health-state QALYs
On biologic DMARD Off biologic DMARD Disease flare Total
Methotrexate only N/A 15.9 –0.9 14.98
Adalimumab 8.6 9.9 –0.8 17.77
Etanercept 8.5 10.0 –0.7 17.81
Tocilizumab 9.2 9.5 –0.8 17.99
N/A, not applicable.
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The base-case discounted cost-effectiveness results are shown in Table 57. Each of the biologic DMARDs is
more expensive than methotrexate only, with the incremental cost ranging from £77,513 to £82,995 for
etanercept and tocilizumab, respectively. The ICER versus methotrexate only for adalimumab, etanercept
and tocilizumab is £38,127, £32,256 and £38,656 per QALY gained, respectively. The results are not
presented as an incremental analysis of the biologic DMARDs, as the costs and QALYs for each biologic
DMARD are generally similar and it has been previously discussed in Chapter 4 that the biologic DMARDs
may be regarded as similar in effectiveness.
Licensed second-line biologic: abatacept
Abatacept is licensed for use after at least one previous antiTNF biologic DMARD. The results are shown
for abatacept, adalimumab, etanercept and tocilizumab compared with methotrexate. For each biologic
comparator, patients are assumed to have been treated initially with etanercept as the first-line biologic.
The summary results of the non-discounted treatment effects are shown in Table 58. In the base case,
total undiscounted QALYs vary between 14.98 for methotrexate and 20.07 for abatacept. The summary
results of the undiscounted costs are shown in Table 59. The total undiscounted drug acquisition cost of
the DMARDs varied between £7029 for methotrexate only to £222,533 for abatacept. The total patient
costs varied between £107,299 and £317,097 for methotrexate only and abatacept.
The base-case discounted cost-effectiveness results are shown in Table 60. The costs and QALYs are
different from those for the first-line biologic cost-effectiveness analysis (see Table 57) because this analysis
includes the costs and QALYs of two lines of biologics. The cost-effectiveness of abatacept compared with
methotrexate is £39,536 per QALY. The results are not presented as an incremental analysis, as the costs
and QALYs for the biologic DMARDs are similar.
TABLE 57 Cost-effectiveness of first-line biologic DMARDs vs. methotrexate only
Treatmenta Costs, £ QALYs Incremental costs, £ Incremental QALYs
ICER (£ per QALY gained)
vs. methotrexateb
Methotrexate only 67,426 9.35
Adalimumab 145,047 11.40 77,513 2.0 38,127
Etanercept 134,868 11.44 67,334 2.1 32,526
Tocilizumab 150,530 11.52 82,995 2.1 38,656
a Abatacept was not included in this analysis as the marketing authorisation is not for first-line biologic DMARD.
b Results presented compared with methotrexate; no incremental analysis presented.
TABLE 58 Summary of the total undiscounted QALYs in each health state for treatment with second-line biologics
compared with methotrexate
Treatment
QALYs
On biologic DMARD Off biologic DMARD Disease flare Total
Methotrexate only N/A 15.9 –0.9 14.98
Abatacept 15.8 4.8 –0.5 20.07
Adalimumab 15.1 5.3 –0.6 19.80
Etanercept 15.0 5.4 –0.5 19.82
Tocilizumab 15.7 4.8 –0.6 20.00
N/A, not applicable.
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Sensitivity analysis
Deterministic sensitivity analysis
Tables 61–64 show the results of the deterministic sensitivity analyses for each of the biologic DMARDs
versus methotrexate for the most influential parameters. Other parameters, such as time horizon, cost and
frequency of disease flare, complete response rate and utility values were varied in the sensitivity analyses
but were found to have only a negligible effect on the results. For each of the treatments, the models are
most sensitive to the utility values chosen while on biologic DMARD treatment. They are also sensitive to
the discount rate and the health-state costs.
TABLE 59 Summary of the total undiscounted costs in each health state for treatment with second-line biologic
DMARDs compared with methotrexate
Treatment
Costs, £
Medical Drug AEs Flare Total
Methotrexate only 86,938 7029 498 12,834 107,299
Abatacept 86,938 222,533 502 7124 317,097
Adalimumab 86,938 184,594 433 8118 280,082
Etanercept 86,938 179,686 440 7311 274,374
Tocilizumab 86,938 205,174 457 7840 300,409
TABLE 61 Deterministic sensitivity analysis for adalimumab vs. methotrexate only
Adalimumab vs. methotrexate High 95% CI, £ Low 95% CI, £ Range, £
Base-case ICER: £38,127
Utility treatment, long terma 26,571 67,470 40,898
Utility no treatment 59,814 27,982 31,832
Discount rate benefits 45,936 32,123 13,813
Discount rate costs 31,919 45,016 13,097
On biologic DMARD cost 41,630 34,624 7006
Off biologic DMARD cost 34,624 41,630 7006
Disease flare methotrexate 35,871 40,598 4727
AE adalimumab 37,983 33,308 4675
a After treatment for > 27 months with biologic DMARD.
TABLE 60 Cost-effectiveness of second-line biologic DMARDs compared with methotrexate using list price
Treatment Costs, £ QALYs Incremental costs, £
Incremental
QALYs
ICER (£ per QALY gained)
vs. methotrexatea
Methotrexate only 67,534 9.37
Abatacept 203,276 12.80 135,742 3.4 39,536
Adalimumab 183,387 12.65 115,853 3.3 35,284
Etanercept 179,580 12.67 112,045 3.3 33,948
Tocilizumab 194,263 12.76 126,728 3.4 37,363
a Results presented compared with methotrexate; no incremental analysis presented.
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TABLE 63 Deterministic sensitivity analysis for tocilizumab vs. methotrexate only
Tocilizumab vs. methotrexate High 95% CI, £ Low 95% CI, £ Range, £
Base-case ICER: £38,656
Utility (treatment, long term)a 26,835 69,092 42,257
Utility (no treatment) 58,865 28,777 30,088
Discount rate costs 31,360 46,904 15,545
Discount rate benefits 47,140 32,196 14,943
Start age 42,589 32,993 9596
On biologic DMARD cost 42,130 35,182 6948
Off biologic DMARD cost 35,182 42,130 6948
Disease flare methotrexate 36,395 41,130 4735
a After treatment for > 27 months with biologic DMARD.
TABLE 62 Deterministic sensitivity analysis for etanercept vs. methotrexate only
Etanercept vs. methotrexate High 95% CI, £ Low 95% CI, £ Range, £
Base-case ICER: £32,526
Utility (treatment, long term)a 22,886 56,196 33,310
Utility (no treatment) 50,511 23,986 26,525
Discount rate (costs) 26,909 38,783 11,874
Discount rate (benefits) 39,075 27,478 11,598
Start age 35,045 26,173 8873
Off biologic DMARD cost 29,118 35,934 6817
On biologic DMARD cost 35,934 29,118 6817
Disease flare methotrexate 30,566 34,668 4102
a After treatment for > 27 months with biologic DMARD.
TABLE 64 Deterministic sensitivity analysis for tocilizumab vs. methotrexate only
Abatacept vs. methotrexate High 95% CI, £ Low 95% CI, £ Range, £
Base-case ICER: £39,536
Utility (treatment, long term)a 31,529 52,995 21,467
Discount rate costs 30,512 50,137 19,625
Utility treatment 15–27 months 32,110 51,430 19,319
Discount rate benefits 49,908 31,906 18,002
Utility no treatment 50,345 32,549 17,796
Start age 42,187 33,234 8952
On biologic DMARD cost 43,094 35,978 7117
Off biologic DMARD cost 35,978 43,094 7117
a After treatment for > 7 months with biologic DMARD.
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The deterministic sensitivity results for adalimumab versus methotrexate are shown in Table 61 and varied
between £26,571 and £67,470 per QALY gained.
The deterministic results for etanercept versus methotrexate only varied between £22,886 and £56,196 per
QALY gained (see Table 62).
The deterministic sensitivity results for tocilizumab versus methotrexate only varied between £26,835 and
£69,092 per QALY gained (see Table 63).
The deterministic sensitivity analysis results for abatacept versus methotrexate only varied between
£31,259 and £52,995 per QALY gained (see Table 64).
Scenario analysis
We conducted several scenario analyses to investigate uncertainty for specific aspects of the modelling.
The results of these analyses are presented for the first-line biologics.
Discontinuation of treatment owing to clinical remission (scenario I)
Patients with clinical remission off medication are at high risk of relapse. Baszis and colleagues161
conducted a retrospective chart review in a cohort of 171 patients with JIA (of a range of subtypes but
predominantly polyarticular course) in the USA treated with TNFα antagonists. They found that 12 months
after stopping treatment only 33% of patients still had clinical remission. Similarly, a retrospective chart
review of 437 JIA patients from centres in the USA and Italy by Wallace and colleagues162 estimated that
6% of patients who had discontinued methotrexate therapy with clinical remission had persistent
remission after 5 years off treatment.
The rate of discontinuation of biologic treatment varies between studies. In a retrospective observational
study by Tynjala and colleagues,146 patients receiving etanercept were followed up for 4 years and 10% of
patients had discontinued treatment owing to inactive disease. In the study by Baszis and colleagues,161
80% of patients discontinued TNFα antagonist treatment owing to inactive disease. We varied the
discontinuation rate between that seen by Tynjala and colleagues146 (used in the base case) and that seen
by Baszis and colleagues.161
We assumed a relapse rate from Baszis and colleagues161 of 67% for that analysis and a 40% relapse rate
as seen in Wallace and colleagues162 for the Tynjala and colleagues146 analysis. We assumed that no
patients on the methotrexate-only arm would discontinue, as fewer patients on methotrexate would be
in remission.
The results for the scenario with patients discontinuing treatment for clinical remission is shown in
Table 65 for first-line biologics compared with methotrexate only. In the scenario with the highest
discontinuation rate, the cost-effectiveness of the biologics improves from the base case by about
£4000 per QALY.
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Health-state costs from Prince and colleagues124 (scenario II)
The base-case analysis uses health-state costs estimated by a UK study by Thornton and colleagues153 of
patients during the first year after diagnosis. However, as stated earlier, this may not necessarily reflect the
patient group in this economic evaluation as patients in that study were newly diagnosed. The Roche CS
cost-effectiveness analysis uses health-state costs based on the Prince and colleagues study.124 Assuming
that hospital admissions would be for disease flare only, the health-state costs per cycle are £589.51 and
£408.91 for the off-treatment and on-treatment health states, respectively (compared with £724 in the
base case). In this analysis, the biologic DMARDs are slightly more cost-effective and the ICER decreases by
approximately £2900 per QALY compared with the base-case analysis (e.g. the ICER for adalimumab
decreases to £35,214 per QALY) (Table 66).
Discount rates used in the National Institute for Health and Care Excellence
appraisal of etanercept (scenario III)
The previous NICE appraisal of etanercept (NICE TA3543) used a discount rate of 6% for costs and 1% for
benefits123 (which were the recommended rates at the time). We ran the analysis for etanercept using
those discount rates. Table 67 shows ICERs that are much reduced compared with the base case in the
current assessment report, namely £21,718 per QALY. Using this discount rate, etanercept would be
cost-effective at a willingness-to-pay threshold of £20,000–30,000 per QALY.
TABLE 65 Cost-effectiveness for first-line biologics vs. methotrexate only with patient discontinuation of treatment
for clinical remission
Analysis
Remission off treatment
(per cycle), % Relapse rate, %
ICER (£/QALY) vs. methotrexate
Adalimumab Etanercept Tocilizumab
Base case 0 38,127 32,526 38,656
Baszis et al. (2011)161 7.8 67 33,744 28,580 34,214
Tynjala et al. (2009)146 0.66 40 37,512 31,970 38,028
TABLE 67 Cost-effectiveness for etanercept vs. methotrexate using a discount rate of 6% for costs and
1% for benefits
Treatment Costs, £ QALYs Incremental costs, £ Incremental QALYs ICER (£/QALY)
Methotrexate only 51,494 12.96
Etanercept 107,200 15.53 55,707 2.6 21,718
TABLE 66 Summary of the cost-effectiveness for adalimumab, etanercept and tocilizumab vs. methotrexate only
using health-state costs from Prince and colleagues124
Treatment Costs, £ QALYs Incremental costs, £ Incremental QALYs ICER (£/QALY)
Methotrexate only 57,306 9.37
Adalimumab 128,894 11.40 71,589 2.0 35,214
Etanercept 118,771 11.44 61,465 2.1 29,691
Tocilizumab 134,097 11.52 76,792 2.1 35,767
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Caregiver benefit (scenario IV)
We were unable to find HRQoL utility values associated with caring for a child or young person with JIA and
assumed in the base-case analysis no disutility benefit for parents and caregivers. A study by Kuhlthau and
colleagues163 compared the well-being of parents of children with and without activity limitations. This list of
conditions includes medical conditions that would commonly be considered disabling (e.g. paraplegia and
blindness) as well as typically less disabling but chronic conditions (e.g. attention deficit hyperactivity disorder
and asthma). They estimated the disutility for these parents to be 0.07 using the EQ-5D. Values from
caregivers’ disutility for patients with multiple sclerosis, from a study by Gani and colleagues,164 indicate that
the caregiver disutility is small (< 0.02) until patients reach a health state with significant mobility limitations.164
Patients receiving a biologic DMARD have a better HRQoL than those eligible for a biologic who have not yet
received one. It follows that this improvement in HRQoL may also improve the HRQoL of caregivers, although
the magnitude of any improvement is unclear. In this scenario, we assume that the disutility of caregivers is
half that for patients on a biologic DMARD compared with those on methotrexate only and vary the disutility
according to the values in the studies by Kuhlthau and colleagues163 and Gani and colleagues.164
The results for the scenario including a disutility for caregivers are shown in Table 68 for first-line
biologics compared with methotrexate only. In the scenario with the highest disutility for caregivers,
cost-effectiveness improves, with the ICER for etanercept reducing to £28,619 per QALY.
Three lines of biologic therapy (scenario V)
In the base-case analysis, patients treated with adalimumab, etanercept and tocilizumab received one line of
biologic DMARD treatment, and those treated with abatacept received two lines of biologic DMARDs to
account for the licensed indication for that drug. In this scenario, patients can receive three lines of biologic
DMARDs to allow for treatment switching as happens in clinical practice. We included a scenario in which
patients received etanercept as the first-line biologic, adalimumab as the second-line biologic and tocilizumab
as the third-line biologic. These were the most common first-line and second-line treatments in an analysis of
the UK Childhood Arthritis Prospective Study.23 We also presented an alternative analysis with a third-line
biologic of abatacept instead of tocilizumab.
The cost-effectiveness of the two scenarios varied between £36,982 and £38,152 per QALY (Table 69). The
cost-effectiveness of three-line biologic therapy is similar to that seen in the base-case analysis for one line
of biologic therapy (see Table 57).
TABLE 69 Cost-effectiveness for three lines of biologic therapy
Treatment Costs, £ QALYs Incremental costs, £ Incremental QALYs ICER (£/QALY)
Methotrexate only 67,534 9.37
Etanercept, adalimumab,
tocilizumab
207,565 13.16 140,031 3.8 36,982
Etanercept, adalimumab,
abatacept
212,562 13.17 145,028 3.8 38,152
TABLE 68 Cost-effectiveness for first-line biologics vs. methotrexate only with inclusion of disutility for caregivers
Scenario
Disutility for caregivers ICER (£/QALY)
On biologic Off biologic Adalimumab Etanercept Tocilizumab
Base case 0 0 38,127 32,256 38,656
Higher disutility163 –0.035 –0.07 33,436 28,619 33,933
Lower disutility164 –0.01 –0.02 36,658 31,305 37,178
ECONOMIC ANALYSIS
NIHR Journals Library www.journalslibrary.nihr.ac.uk
98
Younger biologic disease-modifying anti-rheumatic drug starting age
(scenario VI)
Adalimumab, etanercept and tocilizumab have a licensed indication from 2 years of age for patients with
polyarticular arthritis, and abatacept has a licensed indication from ≥ 6 years. In this scenario we
investigated the cost-effectiveness of the biologics with a starting age of 6 years old (in the base case the
starting age is 11 years). The results of the analysis for first-line biologics are shown in Table 70. These
indicate that there is minimal difference in the cost-effectiveness for adalimumab but a decrease of about
£6000 in the cost-effectiveness of etanercept and tocilizumab.
The results of the analysis for second-line biologics are shown in Table 71. These indicate a similar improvement
in the cost-effectiveness and there is a reduction in the cost-effectiveness of abatacept of £6302 per QALY.
Probabilistic sensitivity analyses
In the PSA, all parameters were sampled probabilistically from an appropriate distribution using similar ranges
as used in the deterministic sensitivity analyses. The parameters sampled were: treatment effectiveness,
discontinuation rate, health-state costs, disease flare parameters and HRQoL. The distribution assigned to
each variable included in the PSA and the parameters of the distributions are reported in Appendix 11.
First-line biologics
A total of 1000 simulations were run. The PSA results are presented in Table 72 for first-line biologics and
show similar results to the deterministic analyses (see Table 58). The cost-effectiveness for biologics versus
methotrexate only varied between £32,554 and £38,744 per QALY for tocilizumab.
TABLE 71 Cost-effectiveness of second-line biologics with a starting age of 6 years
Treatment Costs, £ QALYs Incremental costs, £ Incremental QALYs ICER (£/QALY)
Methotrexate only 67,492 9.39
Abatacept 181,776 12.83 114,285 3.4 33,234
Adalimumab 170,364 12.68 102,872 3.3 31,283
Etanercept 163,006 12.69 95,514 3.3 28,895
Tocilizumab 176,066 12.78 108,575 3.4 31,961
TABLE 70 Cost-effectiveness of first-line biologics with a starting age of 6 years
Treatment Costs, £ QALYs Incremental costs, £ Incremental QALYs ICER (£/QALY)
Methotrexate only 67,492 9.39
Adalimumab 145,089 11.42 77,597 2.0 38,124
Etanercept 121,737 11.46 54,245 2.1 26,173
Tocilizumab 138,421 11.54 70,929 2.1 32,993
TABLE 72 Summary of the probabilistic sensitivity results for first-line biologics vs. methotrexate only
Treatment Costs, £ QALYs Incremental costs, £ Incremental QALYs ICER (£/QALY)
Methotrexate only 67,531 9.38
Adalimumab 145,933 11.43 78,402 2.05 38,181
Etanercept 135,803 11.48 68,272 2.10 32,554
Tocilizumab 151,800 11.55 84,269 2.18 38,744
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The cost-effectiveness acceptability curve is shown in Figure 9 and indicates that at the £20,000 and
£30,000 willingness-to-pay thresholds methotrexate has the highest probability of being cost-effective,
at 0.98 and 0.62, respectively.
Second-line biologics
The PSA results are presented in Table 73 for second-line biologics and show similar results to the
deterministic analyses (see Table 61). The cost-effectiveness of abatacept in the PSA is £39,608 per QALY.
The cost-effectiveness acceptability curve is shown in Figure 10 and indicates that at the £20,000 and
£30,000 willingness-to-pay thresholds methotrexate has the highest probability of being cost-effective,
at 0.99 and 0.71, respectively.
1.0
0.9
0.8
0.7
0.6
0.5
Pr
o
b
ab
ili
ty
 c
o
st
 e
ff
ec
ti
ve
0.4
0.3
0.2
0.1
0
0 50 100
Willingness to pay (£000)
150
Methotrexate
Adalimumab
Etanercept
Tocilizumab
FIGURE 9 Cost-effectiveness acceptability curve from the PSA for first-line biological treatments compared
with methotrexate.
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FIGURE 10 Cost-effectiveness acceptability curve from the PSA for second-line biological treatments compared
with methotrexate.
TABLE 73 Summary of the probabilistic sensitivity results for second-line biologics vs. methotrexate only
Treatment Costs, £ QALYs Incremental costs, £ Incremental QALYs ICER (£/QALY)
Methotrexate only 67,168 9.35
Abatacept 203,396 12.81 136,041 3.43 39,608
Adalimumab 183,563 12.66 116,208 3.29 35,366
Etanercept 179,807 12.67 112,452 3.30 34,053
Tocilizumab 194,464 12.77 127,109 3.39 37,443
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Subgroups
There are a number of potential subgroups that were within the NICE scope, including the subtypes of JIA
(EO, polyarticular arthritis, ERA and PA) and patients with extra-articular manifestations such as uveitis. As
stated earlier, subgroup analyses by subtype of JIA was not possible owing to insufficient evidence for input
parameters to support modelling. The modelled patient population is therefore people with JIA, with the
results of particular relevance to those with polyarticular-course JIA (EO, and RF+ve and RF–ve polyarthritis).
In considering the potential for modelling the clinical effectiveness and cost-effectiveness of biologic
DMARDs in patients with JIA-associated uveitis, a draft NHS clinical commissioning policy on the use of
antiTNFα agents in paediatric patients with severe refractory uveitis was consulted.29 The policy discusses
the cost-effectiveness of treatment and the elements of an economic evaluation are given, although the
full results from such an economic evaluation have not been reported.
The report states that infliximab and adalimumab in combination with methotrexate are widely used
worldwide for the treatment of refractory uveitis, and that etanercept is not recommended for use in this
patient group. The report also cites evidence from a systematic review by Simonini and colleagues96
(see Chapter 4, Juvenile idiopathic arthritis-associated uveitis), which shows that, based on a pooled
analysis of observational studies, the proportion of children with improved intraocular inflammation
(responders) was 87% for adalimumab, 72% for infliximab and 33% for etanercept. Potential modelling
of the clinical effectiveness and cost-effectiveness in JIA-associated uveitis in this report would therefore
apply only to adalimumab, as this is the only one of the four biologic DMARDs within the scope of the
appraisal recommended for treating this patient subgroup.
With regard to QoL, the clinical commissioning policy assumes that loss of vision causes detrimental effects
on utility based on the results of a study of age-related macular degeneration by Reeves and colleagues.165
This study measured HRQoL changes associated with loss of vision using data from the SF-6D and best
corrected visual acuity. This population is quite different from JIA-associated uveitis, and the data do not
capture aspects of JIA related to arthritic joints.
In our model, we have used utility data derived using the HUI3 generic preference instrument from the
study by Prince and colleagues.124 This instrument is appropriate for conditions that involve vision
impairment, as it includes a domain for vision. HUI3 is not compatible with the SF-6D and the instruments
will produce different QoL estimates. Attempting to combine data from Reeves and colleagues165 and
Prince and colleagues124 would be inappropriate owing to the differences in the populations of the studies
and the incompatibility of SF-6D and HUI3. Moreover, if it is assumed that adding vision loss to the other
QoL decrements owing to advancing JIA even partially decreases patient QoL, then it follows that
adalimumab will be more cost-effective in JIA patients with uveitis and joint inflammation than it is in JIA
patients without uveitis.
Likewise, if most of the costs related to uveitis relate to the management of vision loss, as stated in the
clinical commissioning policy,29 then any reduction of these costs attributable to improving vision would
increase cost-effectiveness in the subgroup of JIA patients with uveitis. Any additional analysis of
cost-effectiveness in a JIA uveitis population that is refractory to methotrexate, as is indicated in the
licensing for adalimumab, is therefore likely to have predictable results.
As discussed Chapter 4, the SYCAMORE trial of adalimumab and methotrexate in JIA-associated uveitis
patients has recently closed early following an interim analysis that showed a favourable effect for
treatment.87 The trial also includes a cost-effectiveness analysis, the results of which would be likely to
concur with the logical implications discussed above.
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Comparison of the economic models
The cost-effectiveness of biologic DMARDs estimated in this report varies between £30,000 and £40,000
per QALY gained compared with methotrexate only. This is higher than estimated by the previous NICE
appraisal for etanercept in patients with JIA, which estimated an ICER of £16,082 per QALY gained.123
The NICE Appraisal Committee accepted that the ICER for etanercept was likely to be in the region of
£15,000–30,000 per QALY.43 The model used in that NICE appraisal is not fully described and so it difficult
to compare with the current model developed for this report. However, the discount rate for that appraisal
was 6% for costs and 1% for benefits. Using these discount rates in the independent model in this
assessment report gives cost-effectiveness estimates of between £20,000 and £30,000 per QALY gained.
A cost–consequence analysis conducted by Prince and colleagues124 in the Netherlands did not estimate
the cost-effectiveness of etanercept. We have estimated the cost-effectiveness of etanercept compared
with methotrexate from that study, by aggregating the costs and QALYs in each time period reported,
to be £32,590 (€43,300).
Comparing the results from the independent model in this assessment report with those submitted by the
companies was complicated by differences in structure between the models. Roche, who manufacture
tocilizumab, was the only company that submitted a full economic analysis to NICE, including costs and
QALYs and with a 25-year time horizon. BMS, who manufacturer abatacept, submitted a model with a
20-year time horizon with only drug and administration costs. In addition, in one company model, patients
receive oral methotrexate (Roche), and in another company model, patients receive subcutaneous
methotrexate (BMS). It was therefore only possible to compare drug costs between the three models with
a 20-year time horizon and with discounting applied to allow a level comparison between the models
independent of structural assumptions. Table 74 shows the comparison with the Roche model with
patients using oral methotrexate, whereas Table 75 shows the comparison with the BMS model with
patients using subcutaneous methotrexate.
It should be noted that the Roche analysis has not compared the biologic DMARDs against methotrexate
in its submission but has compared adalimumab with tocilizumab; however, this analysis was present in
the economic model.
As can be seen, there was variation in costs between the models. The Roche model has lower drug costs
and total costs than the assessment report model. This is because their model uses a higher discontinuation
rate so patients remain on the biologic for a shorter duration, and with lower health-state costs. The BMS
model does not include discontinuation for any cause, which explains why it has the highest drug costs of
TABLE 74 Comparison of the drug costs in the assessment report model with the Roche CS model (20-year
discounted, no PAS) (CiC information has been removed)
Treatment
Assessment report model
(using oral methotrexate) Roche model
Drug costs, £ Total costs, £ Drug costs, £ Total costs, £
Methotrexate 393 49,178 CiC information has been
removed
CiC information has been
removed
Adalimumab 71,992 119,269 CiC information has been
removed
CiC information has been
removed
Etanercept 65,396 111,941 CiC information has been
removed
CiC information has been
removed
Tocilizumab 74,578 121,725 CiC information has been
removed
CiC information has been
removed
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the above models. Overall, the differences between the model results may be explained by differences in
model structures and choices with regard to discontinuation, AEs and other costs.
Discussion
l A systematic search of the literature found four relevant economic evaluations of biologic DMARDs
for patients with JIA. Two of the studies were presented as cost–utility studies,123,125 one was a
cost-effectiveness study126 and the other was a cost–consequence study.124 The evaluations were
published between 2002 and 2012 in the UK, the Netherlands, Russia and Canada. One of the studies
was the previous NICE appraisal of etanercept.123 The studies varied in design and structure, time
horizons and the comparators included. The limitations in the methodological quality in all the studies
identified include limited reporting of model parameters and assumptions.
l A systematic search of the literature found two HRQoL studies in children and adolescents with JIA.
One study assessed the effectiveness of a foot care programme in a RCT setting,136 whereas the other
evaluated QoL in a cohort of patients from the Dutch ABC Registry before and after treatment
with etanercept.124,137
l Four pharmaceutical companies submitted evidence to NICE for consideration in this appraisal. Only
one company (Roche) constructed a cost–utility analysis that included both costs and outcomes.78 Two
companies (BMS85 and Pfizer97) submitted cost analyses and assume that the biologic DMARDs were
equivalent in effectiveness, whereas AbbVie77 did not submit an economic analysis owing to limitations
identified with any potential analysis. Roche submitted a Markov state-transition model with health
states for uncontrolled/off treatment, on treatment and dead. The model compared treatment with
adalimumab to tocilizumab. The base-case results from the submission conclude that tocilizumab is of
similar effectiveness and is less expensive than adalimumab.
l We developed an independent cost–utility model comparing the biologic DMARDs to methotrexate
alone. From this model, the incremental cost-effectiveness of adalimumab, etanercept and tocilizumab
versus methotrexate only is estimated at £38,127, £32,526 and £38,656 per QALY gained,
respectively. An analysis comparing second-line biologics with methotrexate only estimated a
cost-effectiveness ratio of £39,536 per QALY gained. The model results are most sensitive to changes
to the HRQoL utility values.
TABLE 75 Comparison of the drug costs in the assessment report model with the BMS CS model (20-year
discounted, no PAS) (CiC information has been removed)
Treatment
Assessment report model
(using subcutaneous
methotrexate) BMS model
Drug costs, £ Total costs, £ Drug costs, £ Total costs, £
Methotrexate 8012 56,798 CiC information has been
removed
CiC information has been
removed
Adalimumab 81,804 129,081 CiC information has been
removed
CiC information has been
removed
Etanercept 70,368 116,914 CiC information has been
removed
CiC information has been
removed
Tocilizumab 85,312 132,459 CiC information has been
removed
CiC information has been
removed
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Chapter 6 Assessment of factors relevant to the
NHS and other parties
E tanercept was recommended by NICE in 2002,131 and it is known that adalimumab, abatacept andtocilizumab are commonly used in practice (as well as infliximab – although not in the scope of this
NICE appraisal).144 It is unlikely that any positive NICE recommendations for the use of these biologic
DMARDs will significantly increase the number of patients requesting treatment and thus affect
budget impact.
Given that biologic DMARDs are currently used in the management of patients with JIA in the NHS, it is
unlikely that substantial modifications will be needed to services, such as infrastructure development or
increased staff training. However, a survey of services for children, young people and families living with JIA in
the UK by the National Rheumatoid Arthritis Society found that, among the 13 specialist (tertiary) centres
surveyed, there was a shortfall of staff to adequately cover the services required.166 These included paediatric
rheumatology consultants and clinical nurse specialists, clinical psychologists, occupational therapists and
physiotherapists. Further recruitment and training of professionals to make up the multidisciplinary teams
needed to provide effective treatment and care of JIA patients would seem to be necessary.
A long-term condition such as JIA can have a significant impact on children and young people’s education.
They may need to miss lessons to attend health-care appointments and may be absent for longer periods of
time while experiencing symptoms (including disease flares) or if joint or other surgery is required. This can
have a negative impact on educational attainment and, in turn, on their ability to gain employment in
adulthood. It may also affect their social and psychological health, through a reduced ability to participate in
social and leisure activities and sport, and the general burden of a serious health condition during the sensitive
period of adolescence. The effect of this may, therefore, widen socioeconomic and health inequalities in this
group. Only one of the RCTs included in the systematic review of clinical effectiveness reported the impact of
treatment (abatacept)58 on missed school days. This outcome was not formally included in our review, but it
was found that treated patients experienced a statistically significantly higher increase in school days (1.9 days)
than placebo patients (0.9 days). This indicates the potential for biologic DMARDs to improve education as well
as health outcomes, although further evidence is required, particularly in a UK context.
Schools and health services are required to liaise to ensure appropriate care for children and young people
with JIA. The National Rheumatoid Arthritis Society survey of 13 specialist centres found that all centres
liaise with schools by letter or telephone, but fewer than half were unable to visit schools or provided only
a limited service.166 However, there were some examples of greater involvement, such as in one centre
where the clinical nurse specialist will visit schools and give talks if required. Effective liaison between
health services and schools is important to ensure that the needs of children with JIA receiving biologic
DMARDs are adequately met.
The impact of JIA on parents and caregivers can also be significant. For example, they may have to pay for
child care, take time away from work, or even cease employment altogether to provide care. This will
negatively affect their income and may increase dependency on welfare benefits (where available). Again,
this is likely to increase socioeconomic inequalities. The inability of parents and caregivers to work may
have a negative impact on society and the economy, through reduced productivity, less income tax
collection and, in some professions, a shortage of skilled workforce capacity. The impact of treating JIA
on parents and caregivers was generally not assessed by the RCTs in the systematic review of clinical
effectiveness. However, one of the RCTs (abatacept)58 reported improvements in the number of days of
normal activity per month missed by parents, including work and non-work activities, compared with
placebo. The number of days on which paid care was required remained stable in both trial arms
(following an initial decline in the open-label lead-in phase with abatacept treatment). Further evidence
on the impact of biologic DMARD treatment on parents and carers would be useful to gauge the full
potential benefits of treatment beyond the patients themselves.
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Chapter 7 Discussion
Statement of principal findings
Clinical effectiveness
The systematic review of clinical effectiveness conducted for this report found that biologic DMARDs are
superior to placebo (with methotrexate where permitted) across a number of outcome measures in
children with JIA (predominantly polyarticular course) and an insufficient response to previous DMARD
treatment. With the exception of the etanercept trial, the majority of patients in the trials received
methotrexate in addition to the biologic DMARD/placebo. Biologic DMARD-treated patients had fewer
arthritis flares, a longer time to disease flare (applicable to abatacept, adalimumab and etanercept), were
more likely to achieve a treatment response as defined by the ACR Pedi criteria and were more likely to
have inactive disease (measured only in the abatacept and tocilizumab trials). This last outcome can be
considered to be the most clinically significant, as absence of disease activity (e.g. no joints with active
arthritis; PGA indicates no disease activity, etc.) is a key treatment goal. Treatment was associated with
reduced pain scores, although this was reported as statistically significant in only one study (tocilizumab).
HRQoL as measured by the CHAQ appeared to be higher for treated patients, although this was not
always statistically significant.
The percentage of patients achieving ACR Pedi-30 in the open-label lead-in phases of the RCTs ranged
from 65% to 94% across the trials. It should be acknowledged that owing to the withdrawal design of
the RCTs, in which only patients achieving an ACR Pedi-30 response during the open-label lead-in phase
are eligible for randomisation, the results of the double-blind randomised phase of the trials are therefore
applicable only to patients who have achieved an initial degree of treatment benefit. The effects seen
during the double-blind period in the placebo group may not necessarily be the same for a placebo group
who had not received a biologic DMARD prior to randomisation. However, expert clinical opinion suggests
that ACR Pedi-30 can be considered an inadequate or partial response threshold, and higher rates, such as
ACR Pedi-70 or above, are considered more clinically significant. In this respect, the patients responding
to ACR Pedi-30 in the open-label lead-in phase (and eligible to be randomised) may not necessarily be
considered atypical of patients eligible for treatment in clinical practice, as both would have active disease.
The clinical significance of the ACR Pedi-30 results of the randomised phases of the trials may also be
questioned. ACR Pedi-30 response rates varied from 63% to 80% across the trials and declined with
increasing response thresholds. Nonetheless, at ACR Pedi-70 (the highest threshold for which data were
available across all four RCTs), the response rate varied from 44% to 65% and remained higher in biologic
DMARD-treated patients than placebo patients in all trials. Research is under way to further develop the
JADAS tool as a clinically useful measurement tool,35–37 although clinical trials are continuing to use the
ACR Pedi criteria, albeit with effectiveness judged at thresholds higher than ACR Pedi-30.
In the longer term, treatment effectiveness, in terms of ACR Pedi response, appears to be sustained, as
reported in the observational OLE studies for all four included RCTs. The longest follow-up available is for
etanercept, where ACR Pedi responses were maintained up to 8 years after treatment.
The occurrence of AEs was generally similar between biologic DMARD- and placebo-treated patients,
based on reported non-statistically significant differences. A range of AEs were reported, including viral
and upper respiratory tract infections, injection-site reactions and nasopharyngitis. Serious AEs were
uncommon. Discontinuations attributable to AEs were also uncommon (< 3% patients). In the lead-in
phase of the RCTs, discontinuations attributable to AEs were low, ranging from 0.5% to 1.8%. The
incidence of AEs and SAEs during open-label long-term follow-up did not appear to be excessive. The
safety profile of the biologic DMARDs, therefore, appears to be relatively favourable.
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Subgroup analyses were reported in only one of the included RCTs (tocilizumab).68 Patients receiving
methotrexate background therapy had higher ACR Pedi response rates than those not receiving it, as did
patients receiving background glucocorticoids. Patients who had received previous treatment with a
biologic agent had lower ACR Pedi responses than those who were naive to biologic DMARDs. It is not
clear whether these subgroup analyses were pre-planned or post hoc, so caution is advised in
their interpretation.
Two recently published systematic reviews of the effectiveness of biologic DMARDs were identified during
the production of this report.167,168 Both of these included a range of biologic DMARDs, including the four
relevant to the scope of this assessment. However, none of these reviews identified any additional RCT
evidence to this assessment report. The only other relevant published systematic review of biologic DMARDs
that we are aware of is by Otten and colleagues,79 (most recent search date January 2012). As discussed
earlier in this report [see Chapter 4, Assessment of clinical effectiveness: biologic disease-modifying
antirheumatic drugs versus each other (with methotrexate where permitted)], Otten and colleagues79
conducted an adjusted indirect comparison of adalimumab, abatacept and etanercept, using the same RCTs
as included in this assessment report. We replicated the indirect comparison, extending it to include the
tocilizumab RCT,68 which was not published during the timescale of the Otten and colleagues79 review. Our
results and conclusions match those of Otten and colleagues,79 namely that the biologic DMARDs appear
similar in effectiveness in polyarticular-course JIA, in terms of ACR Pedi response and preventing disease
flares. Otten and colleagues79 also share some of the caveats made in this assessment report about the
limitations of the data included in the indirect comparison, namely, the small number of trials (and patient
numbers), and differences between the trials in key patient characteristics and in treatment duration.
The conclusion that biologic DMARDs may be similar in clinical effectiveness was supported by the expert
advisers to this assessment report. In their experience, there is similarity in effects between the drugs at a
population level. However, it is noted that interpatient variation in effects may occur, and comparative
effectiveness of the biologic DMARDs may potentially vary between JIA subtypes. Currently, there are a
lack of clinical trial data to confirm this. Experts suggested that future trials of biologic DMARDs should
stratify by disease phenotype to assess the differential effects of each treatment.
As noted earlier in this report, the RCTs of the biologic DMARDs included a mixture of JIA subtypes,
broadly under the classification of polyarticular-course JIA (including EO). The trials did not appear to
include patients with ERA or PA; thus, we reviewed available evidence from trials in progress (see Chapter 4,
Ongoing trials) and from non-randomised studies (see Chapter 4, Additional supporting evidence) to gauge
the effectiveness of biologic DMARD treatment in these groups. Much of the evidence is for etanercept
(licensed for ERA and PA) with some available for adalimumab (licensed for PA). A broad comparison of the
results of these studies with those of the RCTs included in this assessment report suggests that effectiveness
is generally similar between these JIA subtypes. For example, ACR Pedi-70 response rates for biologic
DMARDs were in the range of 44–65% across the RCTs (see Table 14), compared with around (CiC
information has been removed) across the JIA subtypes in the CLIPPER study of etanercept99 (see Table 34)
(notwithstanding differences in study variables such as length of follow-up). Evidence from trials in progress
will provide greater clarity regarding the efficacy and safety of biologic DMARDs in these JIA subtypes. At
present, there do not appear to be any studies of the comparative effectiveness of biologic DMARDs in
these subtypes (e.g. adalimumab vs. etanercept).
All of the RCTs were multinational, with only one specifying that it included patients from the UK. The
distribution of JIA subtypes within the trials, as far as reported (see Table 11), appears reasonably similar to
that seen in UK registry studies (see Table 2), although this comparison may be limited by different
reporting classifications used between studies. In addition, clinical practice in the RCTs (e.g. the oldest one
published in 200042) may not necessarily reflect current NHS care. The generalisability of the RCTs to the
NHS is considered uncertain.
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Cost-effectiveness
A systematic search of the literature found four economic evaluations of biologic DMARDs for patients
with JIA. Two of the studies were presented as cost–utility studies, one was a cost-effectiveness study and
the other was a cost–consequence study. The evaluations were published between 2002 and 2012 in the
UK, the Netherlands, Russia and Canada. One of the studies was the assessment report which informed
the previous NICE appraisal of etanercept (NICE TA35).123 The studies varied in design and structure, time
horizons and the comparators included. There were limitations in the methodological quality in all the
studies identified, and limited reporting of model parameters and assumptions.
A systematic search of the literature found two HRQoL studies in children and adolescents with JIA. One
study assessed the effectiveness of a foot care programme in a RCT setting, whereas the other evaluated
the QoL in a cohort of patients from the Dutch ABC Registry before and after treatment with etanercept.
Four drug companies submitted evidence to be considered as part of the NICE appraisal. Only one
company (Roche) constructed a cost–utility analysis that included both costs and outcomes. Two
companies (BMS and Pfizer) submitted cost analyses and assumed that the biologic DMARDs were
equivalent in effectiveness, whereas another company (AbbVie) did not submit an economic analysis owing
to suggested methodological limitations with any potential analysis. Roche submitted a Markov state-
transition model with health states for uncontrolled/off treatment, on treatment and dead. The model
compared treatment with adalimumab to that with tocilizumab. The base-case results from the submission
conclude that tocilizumab is of similar effectiveness and is less expensive than adalimumab.
We developed an independent cost–utility model comparing the biologic DMARDs to methotrexate only.
From the model, the incremental cost-effectiveness versus methotrexate only for adalimumab, etanercept
and tocilizumab is estimated at £38,127, £32,526 and £38,656 per QALY gained, respectively. The
incremental cost-effectiveness for abatacept as a second-line biologic was £39,536 per QALY gained.
The model results are most sensitive to changes to the HRQoL utility values.
The cost-effectiveness of biologic DMARDs estimated in this report is associated with some uncertainty
owing to the limitations of the evidence base. For this reason, assumptions have had to be made to
simplify the modelling. There was limited evidence on HRQoL, in particular with regard to disease
progression. The HRQoL utility values were taken from a small Dutch registry study of patients receiving
etanercept. The HRQoL values for patients treated with methotrexate were assumed to be constant over
time. Patients with JIA who do not receive a biologic will experience disease progression and, therefore,
their HRQoL will decline over time. In the model, we have assumed a constant HRQoL utility value for
patients receiving methotrexate only and so the biologic DMARDs would be more cost-effective than
estimated by the economic model.
The model has not considered the underlying disease progression in terms of joint damage for patients
with JIA. These patients may have sustained permanent damage to one or more joints, thereby affecting
their physical function and HRQoL into adulthood and potentially requiring joint surgery. The model has
not considered the cost of this surgery and this assumption implies that biologic DMARDs have no impact
on long-term disease progression in terms of joint damage. However, a prospective registry-based cohort
study by Minden and colleagues169 showed improved long-term prognosis for adult JIA patients who
received etanercept during childhood. Furthermore, the AbbVie CS suggests that the reduction in
orthopaedic surgery in JIA patients has been attributable to the increase in the use of immunomodulatory
agents among children in recent decades and so DMARDs and biologic agents may have successfully
prevented end-stage joint damage, based upon historical data that have shown a reduction. Therefore,
biologic DMARDs are likely to reduce long-term damage compared with treatment with methotrexate, and
they would potentially be more cost-effective than estimated by the independent economic model.
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The cost-effectiveness of biologic DMARD treatment of patients with JIA-associated uveitis has not been
formally estimated in this economic evaluation, owing to a lack of suitable input parameter data. The
current evidence base comprises mainly small retrospective observational studies and suggests that
adalimumab and infliximab are clinically effective in terms of improving intraocular inflammation and vision
impairment.96 A US cohort study of children with JIA compared those with JIA-associated uveitis with those
without JIA-associated uveitis.170 It reported that vision-related HRQoL was worse in uveitis patients, but
general HRQoL was similar to that of JIA patients without uveitis.170 It can be assumed that biologic
DMARD treatment in JIA-associated uveitis patients will result in bigger overall HRQoL improvement
(including vision-related HRQoL) and therefore would be more cost-effective in this group than in JIA
patients without uveitis.
It was also reported that significant predictors of uveitis were persistent oligoarthritis and younger age at
JIA diagnosis.170 As discussed in Chapter 1, persistent oligoarthritis accounts for up to 48% of JIA cases in
the UK and is regarded as a milder form of JIA. In contrast, EO accounts for between 6% and 17% of JIA
cases in the UK and results in more severe symptoms and disease progression. Only EO was explicitly
included in the NICE scope for this appraisal, and, therefore, it can be considered that uveitis is less likely
to affect the patient subtypes that are relevant to the appraisal.
The economic model does not include the wider societal costs associated with JIA, which are described in
more detail in Chapter 6. In the base-case analysis we have not included caregiver benefits associated with
biologic DMARD treatment. A scenario analysis showed an improvement in cost-effectiveness for the
biologic DMARDs when incorporating a utility disutility for patient caregivers.
The base-case analysis includes only one line of biologic DMARD treatment; however, in clinical practice
some patients may switch to second- or third-line DMARDs. A scenario analysis that included a sequence
of biologic treatments that most resembles current clinical practice was performed. The cost-effectiveness
of multiple lines of biologic therapy is similar to that seen in the base-case analysis for one line of biologic
therapy. There are many other possible treatment sequences but these have not been modelled, as they
were considered to be less likely to occur in clinical practice and the results for these sequences are similar
to those presented. In clinical practice, infliximab is often used but this has not been included as a
treatment in the economic model, as it is licensed for this indication.
The cost-effectiveness results in this report are consistent with those from an earlier NICE technology
appraisal for etanercept for patients with JIA (NICE TA3543). The previous appraisal used a discount rate of
6% for costs and 1% for benefits.123 We ran the analysis for etanercept using these discount rates and the
cost-effectiveness of etanercept improved to £21,718 per QALY. Using these discount rates, etanercept
would be cost-effective at a willingness-to-pay threshold of £30,000 per QALY.
Strengths and limitations of the assessment
The systematic reviews and economic evaluation in this report have been carried out independently of any
competing interest, and the results are presented in a consistent and transparent manner.
The systematic reviews of clinical effectiveness, cost-effectiveness and HRQoL have been undertaken
following an established methodology and principles for conducting a systematic review.52 The methods
used were reported in a research protocol, which defined the decision problem in line with the NICE scope
and set out the inclusion and quality assessment criteria, data extraction process and the other methods to
be employed during the evidence synthesis.
A multidisciplinary advisory group has informed the review from its initiation. The research protocol was
informed by comments received from the advisory group. The group also commented on a draft of the
final report.
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A de novo economic model has been developed following recognised guidelines. The model structure and
data inputs are clearly presented in this report. The economic model is based upon data identified from
systematic searches for clinical effectiveness, cost-effectiveness and QoL evidence, and other best
available data.
This report is subject to certain limitations. The lack of head-to-head trials meant performing an indirect
comparison of the biologic DMARDs, which is subject to a number of caveats due to heterogeneity
between the trials (e.g. patient characteristics, treatment duration).
Limited HRQoL data were available for children with JIA, with none of the RCTs of biologic DMARDs
reporting health utility data. The model results were based upon one Dutch registry study for patients
treated with etanercept. It was necessary to make assumptions about the QoL of patients treated with
other biologic DMARDs. Owing to the scarcity of the HRQoL data, it was not possible to link effectiveness
data from the RCTs, in terms of ACR Pedi or CHAQ score, to a HRQoL utility measure. Furthermore, no
HRQoL data were identified to inform the estimate of disutility of disease flare or the caregiver burden.
There were limited data available for the long-term discontinuation rates for patients for some of the
biologic DMARDs, and it was necessary to assume that the discontinuation rates for the biologic DMARDs
were the same as each other.
The economic analysis has compared biologic DMARDs against methotrexate only, for patients with an
insufficient response to previous methotrexate. The NICE scope also includes best supportive care (e.g.
NSAIDs, corticosteroids) as a comparator in patients who cannot tolerate a DMARD (e.g. methotrexate),
but this has not been included in the analysis owing to a lack of available data to make a comparison with
best supportive care. Such patients would be likely to be offered a biologic DMARD rather than receiving
best supportive care; therefore, this comparison is not necessarily clinically relevant.
The model consists of a simple structure that does not incorporate the natural history of the disease in
terms of long-term disease progression. JIA causes joint disease that requires joint operations and is
associated with other comorbidities. It is unclear from the current evidence how biologic DMARDs affect
the natural history of the disease and the occurrence of these outcomes.
Uncertainties
The RCTs included in our systematic review of clinical effectiveness did not report the impact of treatment
on extra-articular manifestations. Uveitis is the most common of these manifestations and, if not identified
and adequately controlled, can lead to permanent vision loss. Current guidance is to treat JIA patients with
uveitis who have not responded to steroids or methotrexate with either adalimumab or infliximab, both of
which are antiTNF drugs (of these, only adalimumab is within the scope of this assessment).29 The
guidance29 states that etanercept is not suitable for the treatment of JIA patients with uveitis.
Furthermore, no HRQoL utility values for the impact of uveitis on the HRQoL in children with JIA were
identified in our systematic review of QoL. The paucity of good-quality evidence for the effectiveness of
biologic DMARDs means that the clinical effectiveness and cost-effectiveness of treating JIA patients with
uveitis is currently uncertain. However, it could be assumed that if biologic DMARD treatment of uveitis is
effective in reducing sight impairment in addition to improving general JIA symptoms, then the cost-
effectiveness estimates generated in the independent economic evaluation in this assessment report would
be improved. The SYCAMORE RCT of adalimumab in combination with methotrexate for JIA-associated
uveitis (funded by the NIHR HTA programme and Arthritis Research UK) has recently completed
recruitment and will include an assessment of cost-effectiveness.87
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The lack of available, suitable, published cost–utility models necessitated building a new model which
aimed to resemble clinical practice but also to utilise the effectiveness data from the RCTs. The design of
the RCTs does not necessarily represent clinical practice (e.g. there would not be a lead-in phase with a
biologic DMARD).
The model has not incorporated the impact of biologic DMARD treatment on disease progression and
assumes that the HRQoL of patients treated with methotrexate is constant over time. The results may,
therefore, underestimate the cost-effectiveness of treatment.
The model has assumed that treatment is equally effective for subsequent lines of biologic DMARD
treatment as for the first line of treatment. If effectiveness is seen to be reduced in subsequent lines of
therapy for particular switching regimens, then cost effectiveness may be reduced compared with the
results presented in this report (relating to abatacept as a second-line treatment, and the scenario analysis
of three lines of treatment).
The model has been modelled with a 30-year time horizon in the base-case analysis. There are a lack of
long-term outcome data for JIA patients. In addition, there are often differences in the management of JIA
patients as adults, which may affect patient outcomes. However, there are few empirical data available on
the management of adult patients with JIA.
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Chapter 8 Conclusions
Implications for service provision
Given that biologic DMARDs are currently used in the treatment of JIA, any recommendation supporting
their use is unlikely to have significant implications for service provision (e.g. in terms of changes to
infrastructure and staff training). However, further recruitment and training of staff is required to address
workforce capacity shortages in some specialist centres.
Suggested research priorities
Randomised head-to-head comparisons of biologic DMARDs are necessary to establish comparative
effectiveness. Currently, they are assumed to be equivalent based on indirect comparisons of a small
number of trials with relatively small patient numbers. Trials should be sufficiently powered, with long-term
follow-up of safety and efficacy, and should include an economic evaluation to assess cost-effectiveness.
Treatment response should be assessed at a threshold that is considered clinically significant (e.g. ACR
Pedi-70 or higher) and should also include measures of disease inactivity. Additional instruments to the
ACR Pedi criteria should be used, such as the JADAS instrument.35–37 Future trials of biologic DMARDs
should stratify by disease phenotype to assess the differential effects of each treatment. Where possible,
trials should measure the impact of treatment on children’s educational and social outcomes, such as time
away from school/college when experiencing symptoms and for health-care management, and the ability
to participate in leisure and social activities.
Randomised controlled trials are also required for subtypes of JIA for which evidence is currently lacking,
including ERA and PA. As mentioned, the SYCAMORE trial of adalimumab in patients with JIA-associated
uveitis87 has recently closed for recruitment early, following interim analysis showing that adalimumab is
favourable in the treatment of JIA-associated uveitis.
Further research is needed to establish the HRQoL benefits associated with biological treatment in
children with JIA and their caregivers. Validated child-appropriate instruments should be used to
assess HRQoL, including generic preference-based tools to enable utilities to be estimated to inform
cost-effectiveness analyses.
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The Assessment Group has presented the results of its economic modelling using the drug list prices for
abatacept, adalimumab, etanercept and tocilizumab in this report. A separate confidential appendix
reporting the results incorporating the confidential PASs for abatacept and tocilizumab has been prepared
by the Assessment Group for NICE. The confidential appendix will not be released publicly. The economic
model associated with this document is protected by intellectual property rights, which are owned by the
University of Southampton. Anyone wishing to modify, adapt, translate, reverse engineer, decompile,
dismantle or create derivative work based on the economic model must first seek the agreement of the
property owners.
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Appendix 1 Search dates and example MEDLINE
search strategies for clinical effectiveness,
cost-effectiveness and health-related quality of life
Databases searched for the systematic reviews of clinical effectiveness, cost-effectiveness and HRQoL arepresented below. Clinical effectiveness searches were updated on 5 May 2015 and cost-effectiveness
and HRQoL searches were updated on 6 May 2015.
Database searched (host) Clinical effectiveness searches
Cost-effectiveness searches
HRQoL searches
BIOSIS Previews (Web of Science) Searched to 29 October 2014 1956–11 November 2014
1956–2 December 2014
Cochrane Central, CDSR, Cochrane DARE,
Cochrane HTA and Cochrane Methods
(The Cochrane Library)
Searched to 4 November 2014
Cochrane Central, Cochrane DARE, Cochrane
Economic Evaluations and Cochrane Methods
(The Cochrane Library)
HRQoL: searched to 9 December
2014
Centre for Reviews and Dissemination databases:
DARE, HTA and NHS EED (CRD)
Searched to 4 November 2014 All available years to 11 November
2014
All available years to 9 December
2014
CPCI-S (Web of Science) 1990–29 October 2014 1970–11 November 2014
1970–2 December 2014
DELPHI Costs: searched to 10 November
2014
EMBASE (Ovid) All available years to 29 October
2014
Searched to 10 November 2014
1974–1 December 2014
MEDLINE (Ovid) Searched to 29 October 2014 1946 to October week 5 2014
1946 to November week 2 2014
MEDLINE In-Process & Other Non-Indexed
Citations (Ovid)
Searched to 29 October 2014 Searched to 10 November 2014
Searched to 25 November 2014
PsycINFO (EBSCOhost) HRQoL: 1954–9 December 2014
Science Citation Index Expanded (SCI-EXPANDED)
(Web of Science)
1970–29 October 2014 1970–11 November 2014
1970–2 December 2014
Zetoc (Mimas) Searched to 4 November 2014
CDSR, Cochrane Database of Systematic Reviews; CPCI–S, Conference Proceedings Citation Index – Science;
DARE, Database of Abstracts of Reviews of Effects; NHS EED, NHS Economic Evaluation Database.
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Searched for ongoing trials (all searched on 13 May 2015)
National Institute for Health Research Clinical Research Network (NIHR CRN Portfolio, formally the UKCRN website).
Clinical trials.gov.
World Health Organization’ ICTRP.
ISRCTN.
MEDLINE search strategies for clinical effectiveness, cost-effectiveness and HRQoL are shown here.
These were adapted for other databases and are available on request.
Clinical effectiveness MEDLINE search strategy
1. Arthritis, Juvenile/
2. JIA.tw.
3. exp Arthritis/
4. (arthriti* or oligoarthriti* or polyarthriti* or polyarticula*).tw.
5. Rheumatoid Factor/
6. “rheumatoid factor“.tw.
7. or/3-6
8. (juvenile* or child* or teen* or adolescen* or youth* or “young person” or “young people” or
pediatric* or paediatric*).tw.
9. exp Child/ or Adolescent/
10. 7 and (8 or 9)
11. 1 or 2 or 10
12. (etanercept or enbrel).mp.
13. (abatacept or orencia).mp.
14. (adalimumab or humira).mp.
15. (tocilizumab or toclizumab or RoActemra).mp.
16. or/12-15
17. 11 and 16
18. limit 17 to English language
19. limit 18 to humans
20. (letter or editorial or comment).pt.
21. 19 not 20
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Cost-effectiveness MEDLINE search strategy
1. Arthritis, Juvenile/
2. JIA.tw.
3. exp Arthritis/
4. (arthriti* or oligoarthriti* or polyarthriti* or polyarticula*).tw.
5. Rheumatoid Factor/
6. “rheumatoid factor”.tw.
7. or/3-6
8. (juvenile* or child* or teen* or adolescen* or youth* or “young person” or “young people” or
pediatric* or paediatric*).tw.
9. exp Child/ or Adolescent/
10. 7 and (8 or 9)
11. 1 or 2 or 10
12. (etanercept or enbrel).mp.
13. (abatacept or orencia).mp.
14. (adalimumab or humira).mp.
15. (tocilizumab or toclizumab or RoActemra).mp.
16. or/12-15
17. 11 and 16
18. limit 17 to English language
19. limit 18 to humans
20. (letter or editorial or comment).pt.
21. 19 not 20
22. exp economics/
23. exp economics hospital/
24. exp economics pharmaceutical/
25. exp economics nursing/
26. exp economics medical/
27. exp “Costs and Cost Analysis”/
28. Cost Benefit Analysis/
29. exp models economic/
30. exp fees/ and charges/
31. exp budgets/
32. (economic* or cost or costs or costly or costing or price or prices or pricing
or pharmacoeconomic*).tw.
33. (value adj1 money).tw.
34. budget$.tw.
35. or/22-34
36. ((energy or oxygen) adj cost).tw.
37. (metabolic adj cost).tw.
38. ((energy or oxygen) adj expenditure).tw.
39. or/36-38
40. 35 not 39
41. (letter or editorial or comment or historical article).pt.
42. 40 not 41
43. 21 and 42
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Health-related quality-of-life MEDLINE search strategy
1. Arthritis, Juvenile/
2. JIA.tw.
3. exp Arthritis/
4. (arthriti* or oligoarthriti* or polyarthriti* or polyarticula*).tw.
5. Rheumatoid Factor/
6. “rheumatoid factor”.tw.
7. or/3-6
8. (juvenile* or child* or teen* or adolescen* or youth* or “young person” or “young people” or
pediatric* or paediatric*).tw.
9. exp Child/ or Adolescent/
10. 7 and (8 or 9)
11. 1 or 2 or 10
12. CHAQ.tw.
13. childhood health assessment questionnaire.tw.
14. child health questionnaire.tw.
15. CHQ.tw.
16. CHU 9D.tw.
17. PedsQL.tw.
18. “Paediatric Quality of Life Inventory”.tw.
19. “Pediatric Quality of Life Inventory”.tw.
20. “juvenile arthritis disease activity score”.tw.
21. JADAS*.tw.
22. value of life/
23. quality adjusted life year/
24. quality adjusted life.ti,ab.
25. (qaly* or qald* or qale* or qtime*).tw.
26. disability adjusted life.ti,ab.
27. daly*.ti,ab.
28. health status indicators/
29. eq 5d 3l.tw.
30. (euroqol or euro qol or eq5d or eq 5d).tw.
31. (hql or hqol or “h qol” or hrqol or “hr qol”).tw.
32. (hye or hyes).tw.
33. health* year* equivalen*.ti,ab.
34. health utilit*.ab.
35. (hui or hui1 or hui2 or hui3).ti,ab.
36. disutil*.ti,ab.
37. rosser.ti,ab.
38. “quality of well being”.tw.
39. “quality of wellbeing”.tw.
40. qwb.tw.
41. “willingness to pay”.tw.
42. “standard gamble*”.tw.
43. “time trade off”.tw.
44. “time tradeoff”.tw.
45. tto.tw.
46. (index adj2 “well being”).mp.
47. (quality adj2 “well being”).mp.
48. (health adj3 utilit*).mp.
49. ((multiattribute* or “multi attribute*”) adj3 (“health ind*” or theor* or “health state*” or utilit*
or analys*)).mp.
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50. “quality adjusted life year*”.mp.
51. (15D or “15 dimension*”).mp.
52. (12D or “12 dimension*”).mp.
53. “rating scale*”.mp.
54. “linear scal*”.mp.
55. “linear analog”.mp.
56. “visual analog*”.mp.
57. (categor* adj2 scal*).mp.
58. or/12-57
59. 11 and 58
60. (comment or editorial or letter).pt.
61. 59 not 60
62. limit 61 to English language
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Appendix 2 Screening phase 1: titles and
abstracts for systematic review of
clinical effectiveness
TABLE 76 Titles and abstracts for systematic review of clinical effectiveness
Language
Non-English language Exclude
Intervention
l Abatacept (Orencia) (with or without methotrexate)
l Adalimumab (Humira) (with or without methotrexate)
l Etanercept (Enbrel)
l Tocilizumab (RoActemra) (with or without methotrexate)
Can be either with or without methotrexate (will check
usage is as per licensed indication at full-paper screen)
Participants
JIA
l EO
l Polyarthritis (onset or course)
l Enthesitis related
l Psoriatic
l Undifferentiated
For mixed populations (e.g. including systemic or
oligoarthritis), include only if the proportion of the
unwanted type(s) is < 33% (i.e. two-thirds of the population
should meet the inclusion criteria)
Exclude systemic arthritis (unless NO active systemic symptoms
in the previous 6 months); exclude persistent oligoarthritis
Comparators
l DMARDs (e.g. methotrexate, azathioprine, cyclosporin,
penicillamine, sulphasalazine and gold preparations)
l Best supportive care if DMARDs not tolerated
(e.g. NSAIDs, corticosteroids)
l Interventions compared with each other
Outcomes
One or more of:
l disease activity
l disease flares
l physical function
l joint damage
l pain
l corticosteroid-reducing regimens
l extra-articular manifestations (e.g. uveitis)
l body weight and height
l mortality
l AEs of treatment
l HRQoL
Do not exclude at title and abstract screening stage on
outcome. Get full paper to check
Design
RCT If NO but data may not be available from RCTs (e.g. long-term
AEs, height and growth)
Systematic review If YES (or possibly Yes) and cannot exclude on P, I or C,
RETRIEVE for full-paper screen and possible reference list
check if meets criteria
Abstracts/conference presentations
Published 2011 or earlier Exclude
Published 2012 or later: are sufficient details presented to
allow appraisal of methodology and assessment of results?
If cannot definitely exclude on P, I, C or D RETRIEVE (for full-text
screen and possible tie up with full papers or ongoing studies)
C, comparator; I, intervention; P, population.
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Appendix 3 Screening phase 2: full papers for
systematic review of clinical effectiveness
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Appendix 4 Table of excluded and unclear
studies from systematic review of
clinical effectiveness
TABLE 77 Excluded and unclear studies from systematic review of clinical effectiveness
Excluded study
Primary reason for
exclusion (comments)
Amarilyo G, Tarp S, Foeldvari I, Cohen N, Pope TD, Woo JMP, et al. Efficacy and safety of
biologic agents in patients with poly-articular juvenile idiopathic arthritis: network meta-analysis
of randomized controlled withdrawal trials. Arthritis Rheum 2013;65:S922–3
Design (NMA)
Anink J, Otten MH, Spronk S, van Suijlekom-Smit LW. Efficacy of biologic agents in juvenile
idiopathic arthritis: a systematic review using indirect comparisons. Arthritis Rheum 2012;64:S490
Design (SR and indirect
comparison)
Canadian Agency for Drugs and Technologies in Health. Common Drug Review: Clinical Review
Report for Tocilizumab (Actemra, intravenous) for the Treatment of Signs and Symptoms of
Active Polyarticular Juvenile Idiopathic Arthritis. 2014. URL: www.cadth.ca/media/cdr/clinical/
SR0343_Actemra%20pJIA_CL_Report_e.pdf (accessed May 2015)
Design (SR)
Cummins C, Connock M, Fry-Smith A, Burls A. A systematic review of effectiveness and
economic evaluation of new drug treatments for juvenile idiopathic arthritis: etanercept.
Health Technol Assess 2002;6(17)
Design (SR and
economic evaluation)
Decelle K, Horton ER. Tocilizumab for the treatment of juvenile idiopathic arthritis. Ann
Pharmacother 2012;46:822–9
Design (SR)
Foster CS, Tufail F, Waheed NK, Chu D, Miserocchi E, Baltatzis S, et al. Efficacy of etanercept in
preventing relapse of uveitis controlled by methotrexate. Arch Ophthalmol 2003;121:437–40
Population (adults)
Gartlehner G, Hansen RA, Jonas BL, Thieda P, Lohr KN. Biologics for the treatment of juvenile
idiopathic arthritis: a systematic review and critical analysis of the evidence. Clin Rheumatol
2008;27:67–76
Design (SR)
Kemper AR, Van Mater HA, Coeytaux RR, Williams JW Jr, Sanders GD. Systematic review of
disease-modifying antirheumatic drugs for juvenile idiopathic arthritis. BMC Pediatr 2012;12:29
Design (SR)
Kingsbury D, Quartier P, Arora V, Kalabic J, Kupper H, Mozaffarian N. Safety and effectiveness
of adalimumab in children with polyarticular juvenile idiopathic arthritis aged 2 to < 4 years
or >= 4 years weighing < 15 kg. Ann Rheum Dis 2013;72:A729
Design
Kingsbury D, Quartier P, Arora V, Kalabic J, Kupper H, Mozaffarian N. PReS-FINAL-2161: Safety
and effectiveness of adalimumab in children with polyarticular juvenile idiopathic arthritis aged
2 to < 4 years or >= 4 years weighing < 15 kg. Pediatr Rheumatol 2013;11:P173
Design
Kingsbury DJ, Quartier P, Arora V, Kalabic J, Kupper H, Mozaffarian N. Safety and effectiveness
of adalimumab in children with polyarticular juvenile idiopathic arthritis aged 2 to < 4 years
or >= 4 years weighing < 15 kg. Arthritis Rheum 2013;65:S117
Design
Maneiro JR, Salgado E, Gomez-Reino JJ. Immunogenicity of monoclonal antibodies against
tumor necrosis factor used in chronic immune-mediated Inflammatory conditions: systematic
review and meta-analysis. JAMA Intern Med 2013;173:1416–28
Design (SR and MA)
Martini A. Etanercept improves active polyarticular juvenile rheumatoid arthritis. Clin Exp
Rheumatol 2001;19:122–4
Design (commentary)
Mease P, Genovese MC, Gladstein G, Kivitz AJ, Ritchlin C, Tak PP, et al. Abatacept in the
treatment of patients with psoriatic arthritis: results of a six-month, multicenter, randomized,
double-blind, placebo-controlled, phase II trial. Arthritis Rheum 2011;63:939–48
Population (adults)
Mori M, Takei S, Imagawa T, Imanaka H, Nerome Y, Kurosawa R, et al. Etanercept in the treatment
of disease-modifying anti-rheumatic drug (DMARD)-refractory polyarticular course juvenile idiopathic
arthritis: experience from Japanese clinical trials.Mod Rheumatol 2011;21:572–8
No comparator
continued
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TABLE 77 Excluded and unclear studies from systematic review of clinical effectiveness (continued )
Excluded study
Primary reason for
exclusion (comments)
Mori M, Takei S, Imagawa T, Imanaka H, Nerome Y, Higuchi R, et al. Safety and efficacy of
long-term etanercept in the treatment of methotrexate-refractory polyarticular-course juvenile
idiopathic arthritis in Japan. Mod Rheumatol 2012;22:720–6
Design (open-label part)
Otten MH, Anink J, Spronk S, van Suijlekom-Smit LWA. Efficacy of biological agents in juvenile
idiopathic arthritis: a systematic review using indirect comparisons. Ann Rheum Dis
2013;72:1806–12
Design (review)
Pato E, Munoz-Fernandez S, Francisco F, Abad MA, Maese J, Ortiz A, et al. Systematic review
on the effectiveness of immunosuppressants and biological therapies in the treatment of
autoimmune posterior uveitis. Semin Arthritis Rheum 2011;40:314–23
Design (review)
Sawyer L, Diamantopoulos A, Brunner HI, Benedetti F, Ruperto N, Dejonckheere F, et al.
PReS-FINAL-2070: efficacy of biologic treatments in juvenile idiopathic arthritis with a
polyarticular course: an indirect comparison. Pediatr Rheumatol 2013;11:P82
Design (indirect
comparison)
Sawyer L, Diamantopoulos A, Brunner H, De Benedetti F, Ruperto N, Dejonckheere F, et al.
Efficacy of biologic treatments in juvenile idiopathic arthritis with a polyarticular course:
an indirect comparison. Ann Rheum Dis 2013;72:740–1
Design (indirect
comparison)
Sawyer L, Diamantopoulos A, Brunner HI, De Benedetti F, Ruperto N, Dejonckheere F, et al.
Efficacy of biologic treatments in juvenile idiopathic arthritis with a polyarticular course:
an indirect comparison. Arthritis Rheum 2013;65:S119
Design (indirect
comparison)
Simonini G, Druce K, Cimaz R, Macfarlane GJ, Jones GT. Current evidence of anti-tumor
necrosis factor alpha treatment efficacy in childhood chronic uveitis: a systematic review and
meta-analysis approach of individual drugs. Arthritis Care Res 2014;66:1073–84
Design (review)
Simonini G, Katie D, Cimaz R, Macfarlane GJ, Jones GT. Does switching anti-TNFalpha biologic
agents represent an effective option in childhood chronic uveitis: the evidence from a systematic
review and meta-analysis approach. Semin Arthritis Rheum 2014;44:39–46
Design (review)
Ungar WJ, Costa V, Burnett HF, Feldman BM, Laxer RM. The use of biologic response modifiers
in polyarticular-course juvenile idiopathic arthritis: a systematic review. Semin Arthritis Rheum
2013;42:597–618
Design (review)
Wallace CA, Giannini EH, Spalding SJ, Hashkes PJ, O’Neil KM, Zeft AS, et al. The effects of early
aggressive therapy in JIA: results of the TREAT study. Pediatr Rheumatol 2012;10:32
Abstract (methods)
Wallace CA, Giannini EH, Spalding SJ, Hashkes PJ, O’Neil KM, Zeft AS, et al. Trial of early
aggressive therapy in polyarticular juvenile idiopathic arthritis. Arthritis Rheum 2012;64:2012–21
Unclear population
Wallace CA, Giannini EH, Spalding SJ, Hashkes PJ, O’Neil KM, Zeft AS, et al. Predictors and
sustainability of clinical inactive disease in polyarticular juvenile idiopathic arthritis given
aggressive therapy very early in the disease course. Arthritis Rheum 2013;65:S334–5
Abstract (methods)
Wallace CA, Giannini EH, Spalding SJ, Hashkes PJ, O’Neil KM, Zeft AS, et al. Clinically inactive
disease in a cohort of children with new-onset polyarticular juvenile idiopathic arthritis treated
with early aggressive therapy: time to achievement, total duration, and predictors. J Rheumatol
2014;41:1163–70
Unclear population
Wallace CA, Bonsack J, Spalding SJ, Brunner H, O’Neil KM, Milojevic D, et al. Results of a
24 month extension study in patients who participated in the trial of early aggressive therapy in
polyarticular juvenile idiopathic arthritis. Arthritis Rheum 2013;65:S116
Abstract (methods)
MA, meta-analysis; NMA, network meta-analysis; SR, systematic review.
Unclear studies
Smith JA, Thompson DJ, Whitcup SM, Suhler E, Clarke G, Smith S, et al. A randomized, placebo-controlled, double-masked
clinical trial of etanercept for the treatment of uveitis associated with juvenile idiopathic arthritis. Arthritis Rheum
2005;53:18–23
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Appendix 5 Clinical effectiveness data
extraction tables
Data extraction: abatacept
Reference and design
Intervention and
comparator Participants Outcome measures
Study identifier:
Ruperto et al. (2008),57
Ruperto et al. (2010),58
Ruperto et al. (2010),59
Lovell et al. (2012)60
Study acronym: AWAKEN
Study design: withdrawal
RCT (4-month open-label
lead-in phase, 6-month
double-blind randomised
phase, OLE phase)
Country or countries:
Europe (none from the UK),
Latin America, USA
Number of centres: 45
Recruitment dates:
February 2004 to June
2006 (date of last
treatment, recruitment
likely to be finished before
then)
Funding: BMS
Intervention: 4-month
open-label lead-in phase
(days 1–113) ABA
(10mg/kg according to
weight; maximum dose
1000mg) on days 1, 15,
29, 57 and 85
Double-blind phase: ABA
given at doses of 10mg/kg
at randomisation and at
about 28-day intervals
thereafter for 6 months
(days 114–283) or until a
flare of arthritis
Comparator: matching
placebo
Other interventions
used: all DMARDs except
MTX (stable dose)
withdrawn and prohibited
during the trial (wash-out
period of at least 4 weeks
for any DMARD other than
MTX, before the first dose
of study medication).
Oral corticosteroids were
stabilised 4 weeks before
enrolment
NSAIDs or analgesics
permitted for pain control
Folinic acid or folic acid
permitted. 140/190 (74%)
received MTX concomitantly
OL lead-in phase, number
enrolled: n= 190. Those
achieving ACR Pedi-30
response randomised in
double-blind phase (limited
data extracted for this
phase)
Double-blind withdrawal
phase
Number of randomised
participants:
ABA: n= 60
Placebo: n= 62
OLE study [up to day 1681
(year 5.5) efficacy, and up to
7 years safety]59,60
Non-responders to ABA
during OL phase: n= 36
ABA treated patients in
double-blind phase: n= 58
Placebo treated patients in
double-blind phase: n= 59
Total in OLE: n= 153
Inclusion criteria: JIA
(EO, polyarticular positive
or negative for RF, or
systemic without systemic
manifestations)
Aged 6–17 years
At least five active joints
(those with swelling or, in
the absence of swelling,
limited range of motion,
accompanied by either pain
or tenderness) and active
disease (at least two active
joints and two joints with a
limited range of motion);
inadequate response to, or
intolerance to, at least one
DMARD including biologic
agents (e.g. etanercept,
Primary outcome(s): time
to disease flare
Secondary outcomes:
proportion of patients at the
end of 6-month double-
blind phase who had disease
flare; changes from baseline
in each of the six ACR core
variables; pain; assessment
of safety and tolerability;
HRQoL (sleep and missed
school days reported but not
extracted here)
Method of assessing
outcomes: disease flare
defined as worsening of
30% or more in at least
three of the six ACR
core-response variables for
JIA, and at least 30%
improvement in no more
than one variable during the
double-blind period. If a
global assessment by either
physician or parent was
used, flare was defined as a
worsening of 20mm or
more on the 100-mm VAS.
If the number of active joints
or joints with limited range
of motion was used for
assessment, it was defined
as worsening in two or more
joints
Improvement defined as an
improvement of 30% or
more in at least three of six
ACR core-response variables
and at least 30% worsening
in not more than one
variable. Improvements were
also defined by 50%, 70%
and 90% improvements in
the ACR paediatric criteria
CHAQ used to assess
physical, emotional and
social aspects of HRQOL.
Higher scores indicate better
HRQoL, 0–100 scale. CHAQ
disability index is scored 0–3,
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Reference and design
Intervention and
comparator Participants Outcome measures
infliximab and adalimumab).
(Previous anti-TNF therapy
reported in 57/190 patients
during OL lead in.)
Exclusion criteria: active
uveitis, major concurrent
medical conditions, pregnant
or lactating
with a higher score
indicating greater disability.
CHQ used to assess pain on
100-mm VAS. Higher score
indicates more severe pain
Length of follow-up: end
of double-blind period
(day 169), plus assessments
made for OLE at ≥21 months
(day 589) (efficacy and safety),
and at day 1681 (study year
5.5 – efficacy and safety, and
study year 7 (safety). It is
presumed that these time
points are in relation to the
start of the OL lead-in
Baseline characteristics
(double-blind period) ABA (n= 60) Placebo (n= 62) Comments
Age (mean), years (SD) 12.6 (3) 12.0 (3)
Sex female, n (%) 43 (72) 45 (73)
Ethnic origin, n (%)
White
Black
Other
46 (77)
5 (8)
9 (15)
49 (79)
4 (7)
9 (15)
Type of JIA
Persistent oligoarthritis
EO
Polyarthritis (RF+ve)
Polyarthritis (RF–ve)
Systemic
0
9 (15)
14 (23)
26 (43)
11 (18)
2 (3)
7 (11)
12 (19)
28 (45)
12 (19)
RF+ve, n (%)
RF–ve, n (%)
19 (32)
41 (68)
12 (19)
50 (81)
Duration of JIA (mean),
years (SD)
3.8 (3.7) 3.9 (3.5)
Previous anti-TNF therapy
discontinued, n (%)
Lack of efficacy
For financial reasons
8 (13)
7 (12)
1 (2)
13 (21)
11 (18)
2 (3)
Results (for double-blind period,57 unless otherwise stated)
Primary outcome ABA (n= 60) Placebo (n= 62) p-value
Time to flare (median,
months)
Not reached 6 0.0002
Comments: Kaplan–Meier survival curves are presented, but the survival probabilities can be read-off only from the curves
and have not been extracted here. IQR could not be calculated for the placebo group as there were too few events
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Secondary outcomes ABA (n= 60) Placebo (n= 62) p-value
Disease activity, n (%)a
ACR Pedi-30
ACR Pedi-50
ACR Pedi-70
ACR Pedi-90
Inactive diseaseb
49 (82)
46 (77)
32 (53)
24 (40)
18 (30)
43 (69)
32 (52)
19 (31)
10 (16)
7 (11)
0.1712
0.0071
0.0185
0.0062
0.0195
Disease flares, n (%) 12 (20) 33 (53) 0.0003
Disease flares, hazard ratio 0.31 (95% CI 0.16 to 0.59) NR
Core-response variables,
mean (SD)
PGA (VAS: 100mm) 14.7 (18.9) 23.2 (21.8) 0.0004
Parent’s global
assessment (VAS:
100mm)
17.9 (22.2) 23.9 (21.6) 0.6992
Physical function (CHAQ
disability index: 0–3)
0.8 (0.9) 0.8 (0.7) 0.0388
Number of active joints 4.4 (7.0) 6.0 (5.8) 0.0245
Number of joints with
limited range of motion
8.8 (12.8) 8.6 (12.0) 0.0128
ERS (mm per hour) 25.1 (26.4) 30.7 (30.1) 0.9562
CRT (mg/l) 0.16 (0.25) 0.29 (0.54) 0.0255
Pain (mean parent global
assessment of pain, CHAQ
100-mm VAS)
15c 21c 0.105
Corticosteroid-reducing
regimens
NR
Extra-articular
manifestations
NR
Body weight and height NR
Mortality NR
HRQoL
CHQ physical summary
score
CHQ psychosocial
summary score
43.6
51.7
41d
47d
0.666
0.056
AEs (for double-blind period, unless otherwise stated)
Total SAEs, n (%) 0 2 (3) 0.50
Total SAEs, OLE, n (%)e 23 (15)
Total AEs, n (%)f 37 (62) 34 (55) 0.47
Infections and infestations,
n (%)
27 (45) 27 (44) 1.00
Gastrointestinal disorders,
n (%)
10 (17) 9 (15) 0.81
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Secondary outcomes ABA (n= 60) Placebo (n= 62) p-value
General disorders and
administration site
conditions, n (%)
4 (7) 9 (15) 0.24
Nervous system disorders,
n (%)
3 (5) 2 (3) 0.68
Respiratory, thoracic and
mediastinal disorders,
n (%)
6 (10) 3 (5) 0.32
p-values for the core-response variables were based on the difference in the adjusted mean percentage change from
day 113 to day 282.
a After 6 months of double-blind treatment or at the time of flare for patients who did not complete this period. In
addition to the ACR Pedi overall response, data for the respective six ACR Pedi core response variables are reported at
the start and end of the double-blind period. Only the number of active joints, number of joints with limited range of
motion and the CHAQ disability index (physical function) are data extracted here.
b Defined as no joints with active arthritis, a PGA of ≤ 10 on a 100-mm VAS, and a normal ESR.
c Read-off from graph by reviewer. Number of patients in the trial arms not clear. Abatacept-treated patients (n= 52)
had improved scores for 14 of the 15 subscales and placebo-treated patients (n= 34) for 6 of the 15 subscales
(p> 0.05 for abatacept vs. placebo for all subscales; details not data extracted).
d Abatacept-treated patients (n= 52) had improved scores for 14 of the 15 subscales of the CHQ from start to end of
double-blind period (p> 0.05 for abatacept vs. placebo for all subscales). Placebo-treated patients (n= 34) had improved
scores for 6 of the 15 subscales.
e SAEs during the OLE (by day 589) occurred in 23/153 patients including an arthritis flare (n= 6), arthralgia (n= 2), foot
deformity (n= 2), pyrexia (n= 2) and vomiting (n= 2). At 7-year follow-up, 30/153 (19.6%) patients had SAEs. Most
were unrelated and were primarily musculoskeletal or infectious events. The incidence rate (per 100 patient-years) of
SAEs in the OLE (5.6/100 patient-years) did not increase vs. the 6-month double-blind rate (6.8/100 patient-years).
f AEs that occurred in at least 5% of patients in the open-label and double-blind phases.
Results OLE
Original group sizes in double-blind phase ABA (n= 60) Placebo (n= 62)
ACR Pedi outcomes OLE at day 58959
Received ABA in double-blind
phase (n= 51)
Received placebo in double-blind
phase (n= 47)
ACR Pedi-30 46/51 (90%) 41/47 (87%)
ACR Pedi-50 45/51 (88%) 39/47 (83%)
ACR Pedi-70 38/51 (75%) 35/47 (75%)
ACR Pedi-90 29/51 (57%) 19/47 (40%)
ACR Pedi-100 20/51 (39%) 9/47 (19%)
Inactive disease
g
22/51 (43%) 11/47 (23%)
Comments: Patients treated with abatacept during the double-blind phase had in total (lead-in, double-blind and OLE
phases) received continuous abatacept therapy for a minimum of 31 months (those recruited to the study earliest had been
treated longer, the maximum was 52 months at the time of database lock), whereas those who received placebo during
the double-blind phase usually received abatacept for a shorter period (length not stated).
An analysis according to prior exposure to biologic agents, ACR Pedi data for those in the OLE who had not taken part in
the double-blind phase and information on anti-abatacept and anti-CTLA-4 antibody production is presented but has not
been extracted.
g Inactive disease was defined as having no joint with active disease, a PGA of disease severity score < 10mm, and an ESR
≤ 20mm/hour.
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Methodological comments:
Allocation to treatment groups: patients randomly assigned (1 : 1) to receive either abatacept or placebo. The sequential
number for each patient was allocated according to a computer-generated randomisation schedule
Blinding: the main phase of the trial was described as double-blind. Responder and flare status were determined by
independent blinded evaluators at the co-ordinating centres
Comparability of treatment groups: appear similar on most variables, although placebo group had a greater proportion of
RF–ve patients than ABA group (81% vs. 68%)
Method of data analysis: Kaplan–Meier survival curves used to estimate the distribution of time to disease flare for each
group in the 6-month double-blind phase. Log-rank test used to compare the time to disease flare between groups. A Cox
proportional hazards model, with treatment as the only covariate, was used to compare the hazard ratio and 95% CIs for
flare of arthritis between the two groups. Missing values in the double-blind phase imputed with the LOCF method in the
analysis of the individual components of the six ACR paediatric response variables, the ACR responses and inactive disease
status. HRQoL analysis (CHQ) based on available data at each time point
Sample size/power calculation: estimated 200 patients needed in the open-label phase to have a sufficient sample size to
compare the time to flare over 6 months between the abatacept and placebo groups (with two-sided log-rank tests at 5%
significance). Assuming that 64% of patients would respond to treatment (based on experience with rheumatoid arthritis in
adults), a sample size of 128 patients would yield 95% power to detect a difference of 35%, assuming a flare rate of 65%
in placebo controls and a dropout rate of 10% for the double-blind phase. (The actual flare rate for placebo was 53% and
the drop-out rate was 34%, with a difference of 33% between abatacept and placebo in percentage of patients
experiencing a flare.)
Attrition/drop-out: 42 (34%) patients discontinued during the double-blind period, 31 (50%) in the placebo group and
11 (18%) in the abatacept group); all but one (abatacept-treated patient) did so because the treatment was not effective.
8 patients (2 ABA, 6 placebo) did not receive treatment in accordance with protocol during the double-blind phase but
were included in end-point analysis
General comments:
Generalisability: results applicable to patients aged 6–17 years with JIA (EO, polyarthritis or systemic without systemic
manifestations) with an inadequate response to, or intolerance to, at least one DMARD (including biologic agents),
receiving background MTX
Outcome measures: appear appropriate
Intercentre variability: not reported, but to minimise variability in joint assessments each centre had at least two certified
joint assessors who underwent specific and standardised joint assessment training
Conflict of interests: the first two authors have received funding for research activity from a variety of pharmaceutical
companies including BMS, although they have not received funding from companies as personal contribution for assistance
during the trial. Three other authors are employees of BMS
ABA, abatacept; MTX, methotrexate; NR, not reported; OL, open label.
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Quality criteria (Cochrane Risk of Bias tool) randomised controlled trials171
Criteria Judgementa Support for judgement
Random sequence generation (selection
bias)
Yes Computer-generated randomisation sequence
Allocation concealment (selection bias) Yes Centres were informed of the random allocation of patients
by an interactive voice-randomisation system run by the
central drug management group
Blinding of participants and personnel
(performance bias)
Yes Double-blind phase of the study (after open-label lead in)
Blinding of outcome assessment
(detection bias)
Yes Responder and flare status determined by independent
blinded evaluators at the co-ordinating centres
Incomplete outcome data addressed
(attrition bias)
Larger proportion of patients dropped out of the placebo
group in the double-blind phase than the ABA group
(50% vs. 18%). Main reason for drop-out was lack of efficacy
ACR responses, inactive disease status Yes Missing values imputed with LOCF method
HRQoL58 No Analyses based on available data (observed analysis)
Selective reporting (reporting bias) Yes All outcomes reported on
Other sources of bias Unclear Intercentre variability not discussed
ABA, abatacept.
a Yes, low risk of bias; no, high risk of bias; unclear, uncertain risk of bias.
Data extraction: adalimumab
Reference and design
Intervention and
comparator Participants Outcome measures
Study identifier:
Lovell et al. (2008),61
Lovell et al. (2012),62
Ruperto et al. (2013),63
Ruperto et al. (2014)64
Study acronym: none
Study design: medication-
withdrawal RCT (16-week
randomised open-label,
32-week double-blind
randomised withdrawal
phase, OLE phase)
Country or countries: not
specifically stated but
appear to be Belgium,
Czech Republic, France,
Germany, Italy, Spain,
Slovak Republic and the
USA
Number of centres: 31
(not specified by country)
Recruitment dates:
19 September 2002 to
13 January 2005
16-week open-label phase:
24mg ADA per square
metre (maximum of 40mg)
subcutaneously EOW
Licence indication:
polyarticular onset JIA:
presumed to be the same
as polyarticular-course JIA
Double-blind phase:
ADA: as per open-label
phase for 32 weeks
Comparator: placebo
Other interventions
used: MTX: ≥ 10mg/m2
per week for 3-month prior
screening, same dosage
during open-label lead-in
and double-blind phases
No MTX: have never
received MTX or had
discontinued it ≥ 2 weeks
prior to study drug
First randomisation,
open-label lead-in phase,
number randomised:
n= 171
MTX: n= 85
No-MTX: n= 86)
(Limited data extracted for
this phase.)
Second randomisation,
double-blind withdrawal
phase:
Number randomised:
n= 133
MTX/placebo: n= 37
MTX/ADA: n= 38
No data for ADA (n= 30)
and placebo (n= 28) group
not receiving MTX extracted
Loss to follow-up: n= 4
(5.3%)
Primary outcome(s):
percentage of patients not
receiving MTX with disease
flares (week 16–48)
Secondary outcomes: AEs
Method of assessing
outcomes: every 12 weeks
Disease flare (ACR Pedi
responses): worsening of
≥ 30% in more than three
of the six core criteria for JIA
and an improvement of
≥ 30% in one or fewer
criteria. If the number of
joints with active arthritis
was used as a criterion of
flare, an increase in the
number of active joints to
two or more was required if
there were no initial active
joints or only one active
joint. The same approach
was used if the number of
joints with loss of motion
was used as a criterion of
flare. If either of the global
assessments was used as a
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Reference and design
Intervention and
comparator Participants Outcome measures
Funding: research grant
from Abbott Laboratories
Stable dosages of NSAIDs
and low-dose
corticosteroids (≤ 0.2mg of
prednisone or prednisone
equivalent per kilogram of
body weight per day to a
maximum of 10mg per
day) were permitted. Pain
medications were allowed
except for the 12 hours
preceding assessment of
the joints
ADA: n= 3 (7.9%)
Placebo: n= 1 (2.7%)
Inclusion criteria:
Aged 4–17 years
Polyarticular-course JIA
(with any type of onset) with
active disease (≥ 5 swollen
joints and ≥ 3 joints with
LOM) and without adequate
response to NSAIDs
Either no previous treatment
with MTX or previous
treatment with MTX and
AEs or an inadequate
response
Had to have an ACR
Pedi-30 response at week
16 to enter double-blind
phase
Exclusion criteria:
Clinically significant
deviations in clinically
hematologic, hepatic or
renal indicators
Ongoing infection or recent
major infection requiring
hospitalisation or
intravenous antibiotics
Recent live or attenuated
vaccines
Previously treated with other
biologic agents at any time
or recent treatment with
intravenous immune
globulin, cytotoxic agents,
investigational agents,
DMARDs other than MTX, or
corticosteroids administered
by the intra-articular,
intramuscular or intravenous
route
criterion of flare, any
increase of > 30% in the
VAS of 0 to 100 was
sufficient and no minimum
clinically important increase
was required (e.g. an
increase of 2–4 would
qualify for use of that
criterion in the
determination of flare)
ACR Pedi criteria:
physician’s and patient’s/
parent’s global assessment
of overall well-being (both
measured with a 100-mm
VAS: 0= no disease activity
or ‘very well’ for overall
well-being, 100=most
disease activity or ‘very poor’
for overall well-being) the
number of joints with active
arthritis (defined as joints
with swelling not caused by
deformity or joints, in the
absence of swelling, with
limitation of passive motion
accompanied by pain
tenderness, or both), the
number of joints with
limitation of passive motion,
physical function measured
by the CHAQ-DI, and a
laboratory assessment of
inflammation (CRP
concentrations)
ACR Pedi-50, -70, -90 and
-100 levels of response were
evaluated, defined as
improvements of 50% or
more, 70% or more, 90%
or more and 100%,
respectively, in three or more
of the six core criteria for
JIA, with worsening of 30%
or more in only one criterion
Safety: physical
examinations, laboratory
results, vital signs and AEs
Post hoc analysis:
Clinical outcomes: 27-joint
JADAS27 based on C-creative
protein; functional outcome:
CHAQ-DI. MDA defined as
JADAS-27 <3.8 and normal
function defined as CHAQ-DI
<0.5. Higher scores indicate
higher disease activity
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Reference and design
Intervention and
comparator Participants Outcome measures
Length of follow-up:
70 days after last dose for
AEs for all patients who
discontinued study
medication. Those enrolled
in the double-blind phase
were eligible to receive
open-label treatment with
ADA in an extension phase
of the study (duration not
specified)
Baseline characteristics ADA (n= 38) Placebo (n= 37) Comments
Age, mean years (SD) 11.7 (3.3) 10.8 (3.4)
Age group, n (%)
4–8 years
9–12 years
13–17 years
6 (16)
17 (45)
15 (40)
12 (32)
10 (27)
15 (41)
Sex: female, n (%) 30 (79) 30 (81)
Ethnicity, n (%)
White
Black
Other
36 (95)
0
2 (5)
36 (97)
0
1 (3)
Determined
by the patient
or parent
Body weight (mean), kg (SD) 42.1 (17.9) 44.3 (18.9)
Type of JIA Reported as
poly-articular-
course JIA
RF–ve, n/N (%) 27/37 (73) 30/36 (83)
Duration of JIA (mean), years (SD) 4.3 (4.1) 4.0 (3.5)
Previous medication use, n (%)
MTX
Other DMARDs
Methylprednisolone
38 (100)
1 (3)
2 (5)
37 (100)
7 (19)
2 (5)
Results (double-blind phase, weeks 16–48)
Primary outcome ADA (n= 38) Placebo (n= 37) p-value
Disease flares, n/N (%) 14/38 (37) 24/37 (65) p= 0.02
Comments:
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Secondary outcomes ADA (n= 38) Placebo (n= 37) p-value
Disease activity
ACR Pedi response week 48 (%)a
30
50
70
90
63
63
63
42
38
38
27
27
p= 0.03
p= 0.03
p= 0.002
p= 0.17
Physical function NR NR
Joint damage NR NR
Pain NR NR
Corticosteroid reducing regimens NR NR
Extra-articular manifestations (such as uveitis) NR NR
Body weight and height NR NR
Mortality See comments AEs
HRQoL NR NR
a A patient who had a flare according to the protocol definition was classified as having no response (ACR Pedi < 30) from
that point forward, regardless of the patient’s ACR Pedi response at that time.
AEs, number of events (number of events
per patient-year)
ADA (n= 38)
(18.3 patient-years)
Placebo (n= 37)
(15 patient-years) p-value
Any AE 234 (12.8) 155 (10.3)
Most frequently reported AEs
Related to injection-site reaction 73 (4.0) 57 (3.8)
Contusion 12 (0.7) 7 (0.5)
Nasopharyngitis 5 (0.3) 6 (0.4)
Upper respiratory tract infection 6 (0.3) 5 (0.3)
Viral infection 7 (0.4) 3 (0.2)
Vomiting 4 (0.2) 2 (0.1)
Excoriation 10 (0.6) 1 (0.1)
Serious AEs, possibly related to study drugb 0 1 (0.1) –
gastroduodenitis
AEs leading to the discontinuation of the drug 0 0
Comments:
No occurrence of deaths, opportunistic infections, malignant conditions, demyelinating diseases or lupus-like reactions.
27/171 (16%) patients had at least one positive test for anti-ADA antibody during the open-label and double-blind phases
[MTX: 5/85 (6%), no MTX: 22/86 (26%)], but development of anti-ADA antibody did not lead to a greater rate of
discontinuation of the study drug, nor did it increase the incidence of serious AEs.
b SAEs were death or any event that was life-threatening, required hospitalisation or prolongation of existing
hospitalisation, resulted in persistent or significant disability, congenital anomaly or spontaneous or elective abortion,
or required medical or surgical intervention to prevent another serious outcome.
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First 104 weeks of OLE phase61
ACR Pedi at 104 weeks of OLE, % OLE phase (n= 128)c
30 89%d
50 86%d
70 77%d
90 59%d
100 40%
c Only 71/128 (55%) of this group received MTX during the open-label and double-blind phases of the study and meet
the licensed indication for adalimumab (i.e. the 128 includes participants not receiving MTX in the two study arms that
do not meet the licensed indication).
d Data extracted from figure using Engauge digitizer software (version 4.1, © Mark Mitchell). Data available for earlier
time points in OLE (weeks 8, 16, 24, 56, 104) but not data extracted. For missing values, the last observation was
carried forward.
Post hoc analysis: OLE,64 n (%) ADA Placebo p-valuee
week 48 week 88 week 48 week 88
Minimal disease activityf 19 (76) 26 (83.9) 15 (62.5) 14.0 (50.0)
Minimal disease activityf with normal function
g
17 (68.0) 24 (77.4) 15 (62.5) 14 (50.0)
e Statistical comparison between ADA with or without MTX vs. placebo with or without MTX only. Post hoc analysis on
growth in patients with JIA62,63 reported per MTX or non-MTX group only (not data extracted).
f JADAS27 < 3.8.
g CHAQ-DI < 0.5.
The OLE61 was ongoing at the time the key effectiveness paper was published and the time period for which events were
reported is not clear. SAEs considered possibly related to study drug occurred in seven patients during the OLE (a table
in the published paper61 suggests none was receiving MTX, in which case they were not receiving ADA treatment in
accordance with the licensed indication). Three patients discontinued treatment owing to AEs during the OLE.
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Methodological comments:
Allocation to treatment groups: randomisation at a 1 : 1 ratio within patients’ previous respective strata (stratified according
to MTX use), no further details reported
Blinding: double-blind (investigators, study co-ordinators, assessors, patients and parents were unaware of the treatment
assignment during the double-blind phase of the study)
Comparability of treatment groups: states no significant differences in baseline characteristics between the placebo and the
ADA group within either stratum (MTX or no MTX) – no statistical comparison between the ADA–MTX and placebo–MTX
group reported. There were some baseline differences between the later treatment groups: the ADA group had a higher
percentage of children in the 9- to 12-year age group than the placebo group; conversely, mean body weight was slightly
lower. Mean negative for RF was 10% lower in this group compared with placebo, duration of JIA was slightly lower and
previous medication use for other DMARDs was 16% lower than the placebo group
Method of data analysis: efficacy analyses ITT; however, this was defined as all patients who received a ≥ 1 dose of the
study drug during the phase of the study for which the analysis was being conducted. For the primary efficacy end point
and for all secondary analyses of disease flare, missing values were treated as disease flares. For secondary analyses of ACR
Pedi-30, -50, -70 and -90 responses during the open-label lead-in and double-blind phases, missing values were imputed as
non-responses. In addition, patients in whom a flare occurred according to the protocol definition during the double-blind
phase were classified as having no response (ACR Pedi < 30) at week 48, regardless of their actual ACR Pedi responses
Sample size/power calculation: assumption of a 70% response rate to ADA reported, requiring 42 patients in the open-
label lead-in phase to yield the 29 patients needed for each group in the double-blind phase. This estimate was based on a
40% difference in the rate of flare between the placebo and the ADA groups and provided a power of 80% at an alpha
level of 0.05. However, it is stated that the study was not statistically powered to detect differences between patients
receiving and those not receiving MTX
Attrition/drop-out: Double-blind: n= 4 (5.3%); ADA, n= 3 (withdrew for other reasons, no further details); placebo, n= 1
(withdrew consent). [Loss to follow-up, total: n= 43 (25%); open-label, all: n= 38 (22%); double-blind all n= 5 (3.8%)]
General comments:
Generalisability: limited to polyarticular-course JIA patients aged 4 to 17 years, who have previously received 16 weeks’
ADA treatment and treated with MTX, and had an ACR Pedi-30 response at week 16
Outcome measures: appear to be appropriate
Intercentre variability: not discussed
Conflict of interests: authors received various financial support and/or unrestricted continued medical education grants from
various pharmaceutical companies including the drug manufacturer. States ‘no other potential conflict of interests relevant
to this article was reported’. Individuals at JK Associates and Abbott Laboratories provided editorial support, and individuals
at Abbott Laboratories helped with data management and statistical analysis
ADA, adalimumab; CHAQ-DI, Disability Index of the Childhood Health Assessment Questionnaire; ITT, intention to treat;
MTX, methotrexate; NR, not reported.
Quality criteria (Cochrane Risk of Bias tool) randomised
controlled trials171
Criteria Judgementa Support for judgement
Random sequence generation (selection bias) Unclear No details reported
Allocation concealment (selection bias) Unclear No details reported
Blinding of participants and personnel (performance bias) Yes Double-blind, details reported
Blinding of outcome assessment (detection bias) Yes Double-blind, details reported
Incomplete outcome data addressed (attrition bias) Yes Details reported
Selective reporting (reporting bias) Yes All outcomes stated were reported
Other sources of bias Unclear Intercentre variability not discussed
a Yes, low risk of bias; no, high risk of bias; unclear, uncertain risk of bias.
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Data extraction: etanercept
Reference and design
Intervention and
comparator Participants Outcome measures
Study identifier:
Lovell et al.(2000),42
Lovell et al. (2003),65
Lovell et al. (2006)66 and
Lovell et al. (2008)67
Study acronym: none
Study design: medication-
withdrawal RCT (3 months
open-label lead-in phase,
4-month double-blind
randomised withdrawal
phase, OLE phase)
Country or countries:
Canada and the USA
Number of centres: not
specifically stated, but
appears to be 965
Recruitment dates: not
reported
Funding: Immunex
Corporation171
Intervention: 0.4mg of
etanercept per kilogram
subcutaneously twice
weekly until disease flare
occurred or 4 months
elapsed
(includes 33% of patients
with systemic onset JIA)
Comparator: placebo
Other interventions
used: stable doses of
NSAIDs, low doses of
corticosteroids (≤ 0.2mg of
prednisone per kilogram
per day, with a maximum
of 10mg per day) or both.
Pain medications were
allowed except during the
12 hours before a joint
assessment MTX
discontinued 14 days and
other DMARDs 28 days
before receipt of
etanercept
OLE: 0.4mg/kg etanercept
twice weekly (maximum
dose 25mg per injection)
or 0.8mg/kg once weekly
(maximum dose of 50mg/
week) subcutaneously
(3 months open- label (OL)
lead-in phase: n= 69)
(limited data extracted for
this phase)
Double-blind withdrawal
phase
Number of randomised
participants: n= 51
Etanercept: n= 25
Placebo: n= 26
OLE: n= 58
Loss to follow-up: [Part 1:
n= 5 (7%)]
Part 2-RCT:
Etanercept: n= 6 (24%);
Placebo: n= 19 (73%)
Part 3: OLE: n= 38 (66%)
Inclusion criteria: children
aged 4–17 years with JIA,
with active disease (five or
more swollen joints and
three or more joints with
LOM and pain, tenderness,
or both) despite treatment
with NSAIDs and with MTX
at doses of at least 10mg/m2
of body-surface area per
week
Exclusion criteria:
No intra-articular and
soft-tissue corticosteroid
injections for 1 month before
the trial; patients with major
concurrent medical
conditions; Pregnant and
lactating patients
Primary outcome(s):
number of patients with
disease flare
Secondary outcomes: not
specifically stated
Method of assessing
outcomes for Part 2:
physical examinations,
measures of disease activity
and laboratory tests
(hematologic analysis, serum
chemical analysis, and
urinalysis) on day 1 (before
etanercept or placebo) and
day 15 and at the end of
each month. Final safety
assessments 30 days after
discontinuation of study
drug for withdrawals or at
next scheduled visit if
withdrawal is attributable to
disease flare. Serum at the
end of 7 months for testing
for autoantibodies
(antinuclear antibodies,
antibodies to double-
stranded DNA, IgG and IgM
anticardiolipin antibodies
and antibodies to extractable
nuclear antigens), and on
day 1 before the
administration of the study
drug and at the end of
months 7 for testing for
antibodies to etanercept
Physician’s global
assessment of disease
severity 0–10 (best-worst);
patient’s or parent’s global
assess of overall well-being:
0–10 (best-worst); CHAQ:
0–3 (best–worst); ESR:
normal ranges 1–30mm
per hour for females and
1–13mm per hour for
males; articular severity
score: 0 (best) to 962
(worst); pain: VAS 0 cm
(best) to 10 cm (worst);
CRP: normal range is
0–0.79mg per decilitre.
Other: 73 joints were
evaluated for the total
active-joint count; 71 for
LOM with pain, tenderness
or both; 66 for swollen
joints; and 71 for LOM
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Reference and design
Intervention and
comparator Participants Outcome measures
Definition of disease
flare: change in the core set
of response variables from
the beginning of the double-
blind study: worsening of
≥ 30% in three of six
response variables and a
minimum of two active
joints. Could also have
improvement of ≥ 30% in
no more than one of six
response variables. Global
assessments, if used to
define flare, had to change
by at least 2 units on a scale
from 0 to 10
Definition of improvement
of disease response was
based on changes from
baseline values at
enrolment, whereas flare
was measured from
beginning of the double-
blind study. For example, 28
active joints at baseline, but
only 2 active joints at the
time of randomisation – a
change to 3 active joints
would be considered a flare
(at least 30% worse than
the condition at the time of
randomisation) but would
also still be considered
improvement (at least 30%
improved from baseline)
Length of follow-up:
4 months (double-blind only);
OLE: 8 years67
Baseline characteristics: double-blind study Etanercept (n= 25) Placebo (n= 26) Comments
Mean age, year 8.9 12.2
Age group, n (%)
4–8 years
9–12 years
13–17 years
13 (52)
5 (20)
7 (28)
5 (19)
4 (15)
17 (65)
p< 0.02
Sex, n (%)
Female
Male
19 (76)
6 (24)
15 (58)
11 (42)
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Baseline characteristics: double-blind study Etanercept (n= 25) Placebo (n= 26) Comments
Ethnicity, n (%)
White
Black
Hispanic
Other
14 (56)
3 (12)
6 (24)
2 (8)
23 (88)
1 (4)
2 (8)
0
p< 0.02
Type of JIA, n (%)
Pauciarticular
Polyarticular
Systemic
2 (8)
14 (56)
9 (36)
1 (4)
17 (65)
8 (31)
RF+ve, n (%) 4 (16) 8 (31)
Mean duration of JIA, year 5.3 6.4
Previous medication, n (%)
MTX 25 (100) 26 (100)
DMARDs at washout, n (%)
MTX
Hydroxychloroquine
16 (64)
16 (64)
2 (8)
19 (73)
18 (69)
7 (27)
Concomitant therapy at washout, n (%)
Corticosteroids
NSAIDs
6 (24)
25 (100)
13 (50)
24 (92)
Mean dose of corticosteroids, mg/day 6.5 5.5
Results: double-blind study
Primary outcome Etanercept (n= 25) Placebo (n= 26) p-value
Disease flare, n (%)
Corticosteroid use at baselineb
Yes
No
7 (28)
3/6 (50)
4/19 (21)
21 (81)
12/13 (92)
9/13 (69)
p= 0.003a
p= 0.05
Time to flare, median days > 116 28 p< 0.001
a p< 0.001 after adjustment for baseline characteristics in logistic regression model.
b Authors state that, with the exception of corticosteroid use at baseline (p= 0.05), none of the baseline characteristics
was significant predictors of flare rates (p> 0.15).
Because 13/25 patients were still receiving etanercept at the end of the study (day 116) without disease flare, the median
time to flare was greater than 116 days.
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Secondary outcomes at 7 months, median Etanercept (n= 25) Placebo (n= 26) p-value
30% improvement, n (%)
50% improvement, n (%)
70% improvement, n (%)
20 (80)
18 (72)
11 (44)
9 (35)
6 (23)
5 (19)
p< 0.01
JIA core set criteria, median
Total number of active joints (out of 73 joints) 7.0 13.0
Number of joints with LOM and with pain, tenderness, or
both (out of 71 joints)
1.0 4.5
PGA of disease severity 2 5
Patient/parent’s global assess. of overall well-being 3 5
Score on CHAQ (disability domain) 0.8 1.2
ESR 18 30
Articular severity score, median 38 66
Duration of stiffness (minimum), median 5 38
Pain (on a VAS), median 1.5 3.5
CRP, median 0.4 3.0
Number of swollen joints, median 4.0 11.0
Number of joints with LOM, median 9 22
Corticosteroid reducing regimens NR NR
Extra-articular manifestations (such as uveitis) NR NR
Body weight and height NR NR
Mortality See AEs
Authors state that in the double-blind study, as compared with the end of the open-label study, a significant proportion of
patients who received placebo had shifts from normal levels of CRP and ESR to above-normal values (p≤ 0.003 for each
variable). LOCF approach for missing data and visits and for early termination.
AEs Etanercept (n= 25) Placebo (n= 26) p-value
Death, n 0 0
Urticaria, n 1c 0
Hospitalisation for serious AEs, n
Depression and personality disorder
Gastroenteritis-flu syndrome
1
1
0
0
Injection-site reactions, n 1 1
Tested positive for non-neutralising antibody to etanercept, n 2 N/A
c After first dose of etanercept (responded to oral antihistamines). Other AEs were reported to be of mild-to-moderate
intensity, with no significant difference in the frequency of AEs between the treatment groups. There were no laboratory
abnormalities requiring urgent treatment in the etanercept group. No patient had persistent elevations in autoantibodies
or had signs or symptoms of another autoimmune disease.
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Baseline characteristics: OPE, 8-year follow-up67 OLE (n= 58) Eighth year of OLE (n= 26)
Age, mean years (SD) 10.4 (3.8) 10.8 (3.9)
JRA onset type, n (%)
Pauciarticular
Polyarticular
Systemic
5 (9)
34 (58)
19 (33)
2 (8)
19 (73)
5 (19)
Duration of JRA, mean years (SD) 5.9 (3.2) 6.4 (3.4)
RF+ve, n (%) 13 (23) (n= 56) 6 (24) (n= 25)
Concomitant therapy at enrolment, n (%)
NSAIDs
Corticosteroids
Corticosteroid dosage, mg/day mean (SD)
56 (97)
22 (38)
5.7 (3.2)
25 (96)
8 (31)
4.1 (2.3)
After 1 year of the OLE, the dosages and the use of other medications for JRA (including corticosteroids, intra-articular
injections of steroids and NSAIDs) could be adjusted or added at the discretion of the treating physician, without restriction.
MTX could be added to the regimen (dosage limited to 10–20mg/m2/week).
Results: OLE year 8, mean (SEM)d Completed year 8 (n= 16)
Total number of joints with active arthritis (n= 11) 2.2 (0.9)
Total number of joints with LOM and tenderness and/or pain on motion (n= 11) 0
Total number of joints with LOM (n= 11) 11.8 (4.4)
PGA 1.6 (0.3)
Patient’s/parent’s global assessment 2.0 (0.6)
Pain score 1.8 (0.5)
CHAQ score (n= 11) 0.6 (0.2)
CRPe 1.1 (0.5)
d 74 joints were assessed for tenderness and/or pain on motion, 71 for LOM and 66 for swelling.
e New high-sensitivity method of analysing CRP levels for year 8 (old method: normal range 0–0.79mg/dl; new method:
normal range 0–0.287mg/dl).
ACR Pedi response, 8 years (LOCF), % (n/N)
ACR Pedi-30 83 (40/48)
ACR Pedi-50 77 (36/47)
ACR Pedi-70 61 (28/46)
ACR Pedi-90 41 (19/46)
ACR Pedi-100 18 (8/45)
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Year of etanercept treatment from RCT
(excluding gaps between RCT and OLE)
SAEf MIIg
Number
of events
Number of events/
patient-year
Number
of events
Number of events/
patient-year
1 (n= 69; 57 patient-years of drug exposure) 5 0.09 2 0.04
9 (n= 14; 4 patient-years of drug exposure) 0 0 0 0
Total for all years (n= 69; 318 patient-years
of drug exposure)
39 0.12 9 0.03
SAEs defined as events that were fatal or life-threatening, required hospitalisation or prolonged an existing hospitalisation,
resulted in a persistent or significant disability or incapacity, or resulted in a congenital anomaly or birth defect.
f SAEs occurring during the study or within 30 days of the last dose of etanercept.
g Defined as MIIs resulting in the need for intravenous antibiotic therapy or hospitalisation. Only one MII reported by
patients since report at 4 years (pyelonephritis). The most common new SAEs reported beyond 4 years of drug exposure
were a flare or worsening of disease [6/9 SAEs (67%)].
Methodological comments:
Allocation to treatment groups: a blocked randomisation scheme with stratification according to study centre and number
of active joints (≤ 2 vs. > 2) at the end of month 3 (in the open-label study) was used to assign patients to their treatment
group
Blinding: double-blind (no further details)
Comparability of treatment groups: authors state that the groups were well balanced in the double-blind study, except for age
group and ethnicity (p<0.02) and corticosteroid use at baseline (p=0.05) and that the unequal randomisation did not affect the
study results. The etanercept group had a significantly higher number of younger patients than the placebo group (4- to 8-year
olds: etanercept 52% vs. 19% placebo) and a greater ethnic mix (white: etanercept 56% vs. 88% placebo), whereas the placebo
group had a significantly larger use of corticosteroid use at washout (placebo 50% vs. 24% E)
Method of data analysis: statistical methods employed were reported. All tests were two-sided, with a significance level of 0.05.
Patients who withdrew early without disease flare were counted in the analysis with those who continued to have a response; a
LOCF approach was used for missing data and visits and for early termination. To evaluate any bias introduced by the withdrawal
assumption in the primary analysis, an analysis of time to flare (by the log-rank test) was undertaken in which data on patients
who withdrew without flare were censored at the time of withdrawal. The effect of baseline characteristics on flare rates was
assessed by main-effects logistic regression
OLE: data from patients who reached the age of 18 and discontinued the study and who therefore no longer had valid
childhood efficacy measures were not included in efficacy analysis (summary of the last visit using the LOCF method). Adult-
specific measures of disease for patients ≥18 years of age were not included in analyses (n=5 each at years 7 and 8)
Sample size/power calculation: none reported
Attrition/drop-out: part 1 OL: 64/69 (93%) urticaria with the first dose of etanercept n=1; refusal of treatment n=2; lack of
response n=2. Part 2 – RCT: etanercept 6/25 (24%): disease flare n=6; placebo: 19/26 (73%): parental refusal to allow
continuation n=1, disease flare n=18
Part 3 OLE: 38/58 (66%): lack of efficacy n=7 (12%); AEs n=4 (7%); physician decision n=5 (9%); protocol issue n=3 (5%);
lost to follow-up n=3 (5%); patient/guardian refusal n=5 (9%); other n=8 (14%). 36% patients (n=21) discontinued during
the first 4 years
General comments:
Generalisability: limited to pauciarticular, polyarticular and systemic onset JIA patients aged 4 to 17 years, who did not
tolerate or had an inadequate response to MTX and had received 3 months of etanercept treatment
Outcome measures: appear to be appropriate
Intercentre variability: not discussed
Conflict of interests: two authors had served as ad hoc consultants to Immunex
IgM, immunoglobulin M; MTX, methotrexate; N/A, not applicable; NR, not reported; OL, open label; SEM, standard error of
the mean.
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Quality criteria (Cochrane Risk of Bias tool) randomised controlled trials171
Criteria Judgementa Support for judgement
Random sequence generation
(selection bias)
Unclear Blocked randomisation scheme with stratification, no details about how
randomisation was performed
Allocation concealment
(selection bias)
Unclear No details reported
Blinding of participants and
personnel (performance bias)
Yes Double-blind phase of study (after open-label lead in)
Blinding of outcome assessment
(detection bias)
Yes Paper states that study site-staff who were not involved in patient
assessments constituted the contents of the vials (etanercept or
placebo)
Incomplete outcome data
addressed (attrition bias)
Yes Details reported, but drop-outs are nearly three times higher in the
placebo group. Incomplete data appears to have been address with the
LOCF method (used for missing data/visits and early terminations)
Selective reporting (reporting bias) Yes All outcomes reported on
Other sources of bias Unclear Intercentre variability not discussed
a Yes, low risk of bias; No, high risk of bias; Unclear, uncertain risk of bias.
Data extraction: tocilizumab
Reference and design
Intervention and
Comparator Participants Outcome measures
Study identifier:
Brunner et al. (2015),68
Brunner et al. (2014),69
Baildam et al. (2014),70
Brunner et al. (2013),71
De Benedetti et al. (2013),72
Baildam et al. (2013),73
De Benedetti et al. (2013),74
and Brunner et al. (2012)75
Study acronym: CHERISH
Study design: medication-
withdrawal RCT (16-week
randomised open-label,
24-week double-blind
randomised withdrawal
phase, OLE phase)
Country or countries:
Australia, Canada, Europe,
Latin America, Russia and
the USA
Number of centres: 58
Recruitment dates:
14 October 2009 to
31 January 2011
Funding: funding for
manuscript preparation by
F. Hoffmann-La Roche Ltd
Intervention: intravenous
TCZ at 8mg/kg (8mg/kg
for < 30 kg group) or
10mg/kg (10mg/kg for
< 30 kg group) every
4 weeks (based on
pharmacokinetic modelling
and simulation, doses of
10mg/kg for patients
weighing < 30 kg achieved
TCZ exposure comparable
to that of 8mg/kg for
patients weighing ≥ 30 kg)
Comparator: placebo
Other interventions
used: stable doses of
NSAIDs and low-dose
glucocorticoids
(≤ 0.2mg/kg/day
prednisone; daily maximum
10mg) and MTX
(10–20mg/m2 body surface
area/week)
Randomised, OL lead-in
phase: TCZ every 4 weeks
until week 16, n= 188 –
patients randomised to
< 30 kg TCZ (n= 69) or
≥ 30 kg TCZ (n= 119)
(Limited data extracted for
this phase.)
Double-blind withdrawal
phase
Number of randomised
participants: n= 166
TCZ: n= 82:
10mg/kg < 30 kg body
weight: n= 16
8mg/kg < 30 kg body
weight: n= 11
8mg/kg ≥ 30 kg body
weight: n= 55
Placebo: n= 84:
10mg/kg < 30 kg body
weight: n= 15
8mg/kg < 30 kg body
weight: n= 13
Primary outcome(s): proportion
of patients in whom a JIA-flare
occurred during part 2 (up to
and including week 40)
compared with week 16
Secondary outcomes week 40:
JIA–ACR 30/50/70/90 responses,
change from baseline in JIA-
CRVs and clinically inactive
disease
Method of assessing
outcomes: 4-weekly
assessments
JIA–ACR-30 response: defined as
≥ 30% improvement of three or
more of six JIA core response
variables (JIA–CRVs) without
> 30% worsening in one or
more of the remaining JIA-CRVs
compared with baseline
(part 1: patients who had at least
one JIA–ACR-30 response
entered part 2)
Active joints: defined as the
presence of swollen joints (or, in
the absence of swelling, joints
with LOM plus pain on motion
and/or tenderness with palpation)
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Reference and design
Intervention and
Comparator Participants Outcome measures
8mg/kg ≥ 30 kg body
weight: n= 56
Loss to follow-up:
OL: n= 22/188 (11.7%)
RCT: TCZ n= 3/82 (3.7%)
Placebo: 3/84 (3.6%).
OLE: n= 5/160 (3.1%)
Inclusion criteria:
2- to 17-year olds;
Diagnoses of RF+ve or
RF–ve
Polyarticular-course JIA or
EO JIA
Disease duration
≥ 6months;
Inadequate responses to
or intolerant of MTX
Five or more active joints,
with LOM present in three
or more of the active joints
No MTX ≥ 4 weeks before
and including baseline
visit or had been taking
MTX ≥ 12 weeks
immediately before and
including baseline visit
and on stable dose of
10–20mg/m2 for
≥ 8 weeks before and
including baseline visit
together with either folic
acid or folinic acid
No oral glucocorticoids at
baseline visit or had been
taking oral glucocorticoids
at a stable dose for
≥ 4 weeks before and
including baseline visit
(n≤ 10mg/day or
0.2mg/kg/day)
No NSAIDs at baseline or
more than one type of
NSAID at a stable dose
(less than or equal to the
recommended daily dose)
≥ 2 weeks before and
including the baseline visit
Clinically inactive disease was
defined as PGA indicating no
disease activity plus absence of
all the following: joints with
active arthritis, uveitis and
ESR >20mm/h
Serious infections were defined
in accordance with the definition
of SAEs in the International
Conference on Harmonisation
guidelines (reference provided)
PGA of disease activity: VAS
0–100 (0= inactive disease);
assessment of patient overall
well-being: VAS 0–100 (0= very
poor); physical function
measured by the CHAQ-DI: 0–3
(0= no disability)
Patients continued RCT until
week 40 unless JIA-flare
(> 30% worsening in three of six
JIA–CRVs without > 30%
improvement in one or more of
the remaining JIA–CRVs)
compared with week 16. They
then entered the OLE study
Length of follow-up: OL
16 weeks; RCT 24 weeks; total
40 weeks. OLE 64 weeks
(total 104 weeks)
DOI: 10.3310/hta20340 HEALTH TECHNOLOGY ASSESSMENT 2016 VOL. 20 NO. 34
© Queen’s Printer and Controller of HMSO 2016. This work was produced by Shepherd et al. under the terms of a commissioning contract issued by the Secretary of State for
Health. This issue may be freely reproduced for the purposes of private research and study and extracts (or indeed, the full report) may be included in professional journals
provided that suitable acknowledgement is made and the reproduction is not associated with any form of advertising. Applications for commercial reproduction should be
addressed to: NIHR Journals Library, National Institute for Health Research, Evaluation, Trials and Studies Coordinating Centre, Alpha House, University of Southampton Science
Park, Southampton SO16 7NS, UK.
161
Reference and design
Intervention and
Comparator Participants Outcome measures
Never been treated with
biologics or had been
previously treated with
biologics and discontinued
them for at least the
following periods:
anakinra: 1 week;
etanercept: 2 weeks;
rilonacept: 5 weeks;
infliximab or adalimumab:
8 weeks; abatacept:
12 weeks; canakinumab:,
20 weeks, before and
including the baseline visit
Exclusion criteria: none
in addition to the above
Baseline characteristicsa
TCZ 8mg/kg
< 30 kg
(n= 34)
TCZ 10mg/kg
< 30 kg
(n= 35)
TCZ 10mg/kg
30 kg
(n= 119)
Age, years 7.6 (2.71) 6.9 (3.02) 13.1 (2.78)
Sex, females n (%) 24 (71) 30 (86) 90 (76)
Ethnicity NR
Type of JIA NR
Weight (kg) 22.4 (5.3) 20.7 (5.7) 50.0 (12.6)
RF+ve, n (%) 2 (6) 4 (11) 48 (40)
Duration of JIA, years 3.5 (2.57) 3.4 (2.39) 4.7 (4.16)
Previous medication, n (%)
DMARD
Biologic agentb
26 (76)
6 (18)
21 (60)
8 (23)
87 (73)
47 (39)
Joints with active arthritis, n 21.2 (13.6) 23.9 (18.3) 18.9 (13.0)
Joints with LOM, n 17.3 (13.3) 23.1 (19.2) 16.0 (12.7)
Assessment of patient overall well-being, VAS 59.1 (26.2) 51.5 (26.9) 51.6 (24.1)
PGA of JIA activity, VAS 64.7 (18.5) 64.7 (20.5) 59.4 (21.3)
CRP (mg/l) (standard reference range 0–10mg/l) 26.6 (33.6) 21.8 (32.3) 22.8 (38.8)
CHAQ-DI score 1.8 (0.68) 1.7 (0.71) 1.2 (0.69)
ESR (mm/h) (standard reference range 0–18mm/h) 36.6 (23.0) 35.1 (24.1) 34.2 (26.7)
Concurrent MTX use, n (%)
Dose (mg/m2/week)
30 (88)
13.8 (2.9)
29 (83)
16.5 (11.1)
89 (75)
11.6 (2.7)
Concurrent glucocorticoid use, n (%)c
Dose (mg/kg/day)c
18 (53)
0.15 (0.038)
15 (43)
0.15 (0.033)
54 (45)
0.12 (0.052)
a All patients randomised in part 1. 15/188 (7.9%) did not achieve JIA-ACR30 response and were not randomised in part 2.
b 9% of patients previously received three or more biologic agents. TNF inhibitors: n= 56; anakinra n= 5; abatacept n= 5;
canakinumab (Ilaris®, Novartis) n= 1.
c Measured in prednisone equivalents.
Baseline characteristic not given the TCZ vs. placebo groups in Part 2.
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Results, week 40 double-blind study68,73,75
Primary outcome TCZd (n= 82) Placebo (n= 81)
Differenced TCZ vs. placebo
(95% CI); p-value
Proportion with JIA-ACR30 flare
(compared with week 16), n (%)
21 (25.6%) 39 (48.1) –0.21 (–0.35 to –0.08); 0.0024
Secondary outcomes TCZd (n= 82) Placebo (n= 81)
Differenced TCZ vs. placebo
(95% CI); p-value
Proportion of patients with JIA–ACR-30
improvement relative to baseline, n (%)
61 (74.4) 44 (54.3) 0.09 (0.05 to 0.33); 0.0084
Proportion of patients with JIA–ACR-50
improvement relative to baseline, n (%)
60 (73.2) 42 (51.9) 0.20 (0.06 to 0.34); 0.0050
Proportion of patients with JIA–ACR-70
improvement relative to baseline, n (%)
53 (64.6) 34 (42.0) 0.22 (0.07 to 0.37); 0.0032
Change from baseline in number of active
joints, adjusted mean
−14.3 −11.4 –2.9 (–5.7 to –0.1); 0.0435
Change from baseline in PGA (VAS),
adjusted mean
−45.2 −35.2 –9.9 (–16.5 to –3.4); 0.0031
Change from baseline in the pain (VAS),
adjusted mean
−32.4 −22.3 –10.2 (–17.6 to –2.7); 0.0076
Change from baseline in number of joints
with LOM, adjusted mean
−9.5 −7.7 –1.8 (–4.1 to 0.5); 0.1229
Change from baseline in ESR (mm/h),
adjusted mean
−26.3 −12.0 –14.3 (–19.6 to –9.0)e
CHAQ-disability score −0.8 −0.6 –0.2 (–0.4 to 0.0)e
Proportion with JIA-ACR90 improvement,
n (%)
37 (45.1) 19 (23.5) 0.21 (0.07 to 0.35)e
Proportion with inactive disease, n (%) 30 (36.6) 14 (17.3) 0.18 (0.05 to 0.32)e
Corticosteroid reducing regimens NR
Extra-articular manifestations
(such as uveitis)
NR
Body weight and height NR
Mortality 0 0
Change from baseline in patient global
assessment of well-being adjusted mean
−32.1 −24.7 –7.4 (–14.8 to 0.0)e
d Adjusted for baseline stratification factors (background use of MTX and oral glucocorticoids).
e p-values were not provided because they fell below a non-significant parameter in the hierarchical chain to
address multiplicity.
Time to JIA–ACR-30 flare reported in a Kaplan–Meier curve, but not presented here.
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Proportion of patients in the ITT population with JIA–ACR-70 and JIA–ACR-90 response at week 40 by
background MTX, glucocorticoid and previous biologic agent use at baselinef
Concomitant therapies and
previous exposure to biologic
agent, n/N (% N) Response level
TCZ (n= 82) Placebo (n= 81)
Yes No Yes No
Background MTX JIA-ACR70
JIA-ACR90
45/67 (67.2)
32/67 (47.8)
8/15 (53.3)
5/15 (33.3)
30/64 (46.9)
18/64 (28.1)
4/17 (23.5)
1/17 (5.9)
Background glucocorticoid JIA-ACR70
JIA-ACR90
23/33 (69.7)
16/33 (48.5)
30/49 (61.2)
21/49 (42.9)
4/38 (36.8)
5/38 (13.2)
20/43 (46.5)
14/43 (32.6)
Previous biologic agent JIA-ACR70
JIA-ACR90
13/27 (48.1)
5/27 (18.5)
40/55 (72.7)
32/55 (58.2)
2/23 (8.7)
2/23 (8.7)
32/58 (55.2)
17/58 (29.3)
f Patients who withdrew or escaped to OL TCZ or for whom the end point could not be determined were classified as
non-responders.
Authors report an ad hoc analysis of patients who received TCZ continuously in parts 1 and 2 (not data extracted).
AEs and SAEs
SAEs and AEs occurring ≥ 5% of patients, n (%) TCZg (n= 82) Placebog (n= 81) p-value
Duration in study (years) 32.33 27.41
Patients with ≥ 1 AE 58 (70.7) 60 (74.1)
Total number of AEsh 147 141
Rate of AEs per 100 patient-years 454.7 514.4
Most frequent AEs
Nasopharyngitis 14 (17.1) 9 (11.1)
Headache 3 (3.7) 0
Upper respiratory infection 4 (4.9) 2 (2.5)
Cough 2 (2.4) 1 (1.2)
Pharyngitis 3 (3.7) 3 (3.7)
Nausea 2 (2.4) 2 (2.5)
Diarrhoea 2 (2.4) 3 (3.7)
Rhinitis 2 (2.4) 1 (1.2)
Vomiting 3 (3.7) 1 (1.2)
Abdominal pain 2 (2.4) 2 (2.5)
Oropharyngeal pain 1 (1.2) 5 (6.2)
Rash 4 (4.9) 1 (1.2)
SAEs
Patients with ≥ 1 SAE 3 (3.7) 3 (3.7)
Rate of SAEs per 100 patient-years 9.3 10.9
Patients with ≥ 1 infectious SAE 1 (1.2) 0
Rates of infectious SAEs per 100 patient-years 3.1 0
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SAEs and AEs occurring ≥ 5% of patients, n (%) TCZg (n= 82) Placebog (n= 81) p-value
Pneumonia 1 (1.2) 0
Upper limb fracture 1 (1.2) 0
Uveitis 0 1 (1.2)
Psychosomatic disease 1 (1.2) 0
Enterocolitis 0 1 (1.2)
Complicated migraine 0 1 (1.2)
AEs leading to study drug discontinuation
Increased blood bilirubin leveli 1 (1.2)
Gastroenteritis 1 (1.2)j
g AE data on open-label TCZ escape therapy were excluded.
h Multiple occurrences of the same AE in one individual were counted.
i Highest total bilirubin reading, 50 µmol/l (normal range, 3–24 µmol/l); two consecutive readings > 51mmol/l mandated
withdrawal per protocol. The event resolved without sequelae.
j Occurred 46 days after the last of five doses of placebo.
Exposure to TCZ varied for individual patients, depending on the period from the first dose of TCZ to the date of data cut
or withdrawal (maximum exposure 1.8 years). The safety population consisted of all patients who received ≥ dose of study
medication. Safety data included full exposure data for each patient.
Results for OLE, 104 weeks
kEfficacy endpoints and percentage change
from baseline in JIA ACR components
(continuous TCZ, n= 82)69,71,74 Baseline Week 40
Week 104
(n= 160)
Change from
baseline to week
104, %
JIA ACR-70 responders, n (%)l 65 (79.3) 71 (86.6)
JIA ACR-90 responders, n (%)l 41 (50.0) 58 (70.7)
Active joints (0–71), mean (SD) 19.7 (14.0) 4.7 (9.1) 3.3 (9.1) –87.7 (27.1)
Joints with LOM (0–67), mean (SD) 16.5 (13.8) 5.6 (10.1) 3.6 (7.3) –81.3 (31.7)
Patient global (VAS 0–100mm), mean (SD)m 45.5 (23.1) 12.2 (19.0) 9.1 (18.4) –75.4 (43.8)
PGA (VAS 0–100mm), mean (SD) 57.8 (20.3) 8.8 (10.9) 5.0 (10.5) –89.7 (23.7)
CHAQ-DI (0–3), mean (SD) 1.2 (0.7) 0.4 (0.5) 0.2 (0.4) –76.7 (34.7)
ESR (mm/h), mean (SD) 31.7 (22.9) 5.4 (6.3) 5.1 (5.6) –76.2 (27.3)
Inactive disease, n (%)n 33 (40.2) 52 (63.4)
Remission, n (%)o 5 (6.1) 31 (37.8)
Minimal disease activity (JADAS-71 < 3.8), n (%) 0 (0) 49 (59.8) 60 (73.2)
Inactive disease (JADAS-71 < 1), n (%) 0 (0) 24 (29.3) 48 (58.5)
k Patients who withdrew because of non-safety reasons are non-responders. Patients who withdrew because of safety are
included using LOCF.
l Two abstracts69,74 contain a table with a footnote to indicate patients who withdrew were excluded, however in the third
abstract71 the table footnote states that patients who withdrew owing to non-safety reasons are non-responders
whereas patients who withdrew owing to safety are included using LOCF.
m Parent rated.
n No active joints, no active uveitis, ESR < 20mm/h and PGA VAS ≤ 10.
o Met criteria for inactive disease at each visit for 6 preceding months.
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AEs and SAEs69–71,74 Safety population= 188 with 307 patient-years
AEs, rates/100 patient-years 406.5
SAEs, rates/100 patient-years 11.1
Most common AE: infections 151.4
Infections: SAE 5.2
ALT elevations ≥ 3× upper limit of normal, % 6.4
AST elevations ≥ 3× upper limit of normal, % 2.7
Grade 3 lowest neutrophil count, % 5.9
Grade 2/3/4 thrombocytopenia, % 1.6
Low-density lipoprotein cholesterol ≥ 110mg/dl, % 16.2
Methodological comments:
Allocation to treatment groups: randomly assigned 1 : 1, stratified by background use of MTX and oral glucocorticoid use.
OL (Part 1): patients weighing < 30 kg were randomly assigned 1 : 1 to receive intravenous TCZ 8mg/kg or 10mg/kg,
whereas patients weighing ≥ 30 kg received 8mg/kg. Double-blind RCT (Part 2): each of the three previous groups was
randomised to receive either the existing dose of TCZ or placebo, equating to six groups in total. No further details about
randomisation procedure were reported
Blinding: double-blind, no further details of procedure reported. States that JIA ACR response rates and clinically inactive
disease status were performed in real time by independent masked evaluators at the co-ordinating centres of the Pediatric
Rheumatology International Trials Organisation and Pediatric Rheumatology Collaborative Study Group, according to
validated criteria
Comparability of treatment groups: no baseline characteristics for Part 2 (RCT) reported. States that disease characteristics
at baseline for the OL (Part 1) were generally similar across the 3 groups with the exception of body weight based dosing
regime, but no details are reported for the six groups in the RCT Part 2
Method of data analysis: ITT, however 3/166 patients from the placebo group were excluded as they discontinued without
receiving the study drug therefore modified ITT. To control for the type-1 error rate, secondary endpoints were tested in a
hierarchical fixed-sequence approach provided the primary endpoint was found to be statistically significant. The robustness
of the results of the statistical procedure used for the primary endpoint analysis was assessed by logistic regression analysis
of the proportion of patients with JIA–flare in the ITT during Part 2, showed a statistically significant treatment difference in
favour of TCZ and was consistent with the primary analysis
Primary endpoint analysis was conducted with the Cochran–Mantel–Haenszel test (also used for secondary endpoints),
adjusted for stratification factors; patients who withdrew or for whom the endpoint could not be determined were
considered to have experienced JIA flare. Patients who escaped or withdrew or for whom the end point could not be
determined were considered non-responders. Continuous variables were evaluated using analysis of variance, adjusted for
baseline differences between groups and stratification variables
Ad hoc analysis was conducted in patients continuously treated with TCZ up to week 40, including those who escaped
from blinded to OL TCZ, using an ITT approach
Sample size/power calculation: sample size estimation was reported. States that recruitment was planned to ensure that a
sufficient number of patients were available for randomisation in Part 2, needing 60 patients in each group to achieve 80%
power to detect a significant difference in assumed JIA flare rates (35% TCZ, 65% placebo) between groups using a
two-sided significance test with α= 0.05. For the results, the three TCZ groups were combined and so were the three
placebo groups, giving each combined group sufficient power
Attrition/drop-out: Part 1 lead in – states 10.6% discontinued (n= 20), but flow chart shows n= 22 (11.7%): lack of JIA
ACR-30 response n= 15, withdrew consent, n= 3, AEs n= 3, failure to return n= 1
Part 2 RCT: TCZ 3/82 [3.7% (10mg/kg < 30 kg body weight group: n= 1; 8mg/kg ≥ 30 kg body weight: n= 2) – AEs n= 1,
insufficient therapeutic response n= 1, withdrew consent n= 1. Placebo n= 3/84 (3.6%) – AEs n= 2, insufficient
therapeutic response n= 1]
OLE: 5/160 (3.1%) – reasons not reported69
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General comments:
Generalisability: to patients aged 2 to 17 years, with diagnoses of RF+ve or RF–ve polyarticular-course JIA or EO JIA, with a
minimum disease duration of at least 6 months and had inadequate responses to or were intolerant of MTX, and
experienced at least one (JIA ACR-30) response to TCZ
Outcome measures: appear to be appropriate
Intercentre variability: not discussed
Conflict of interests: various authors received funding/support from a variety of pharmaceutical companies
ALT, alanine aminotransferase; AST, aspartate aminotransferase; CHAQ-DI, Disability Index of the Childhood Health
Assessment Questionnaire; ITT, intention to treat; MTX, methotrexate; NR, not reported; OL, open label; TCZ, tocilizumab.
Quality criteria (Cochrane Risk of Bias tool) randomised controlled trials171
Criteria Judgementa Support for judgement
Random sequence generation
(selection bias)
Unclear Insufficient information
Allocation concealment
(selection bias)
Unclear Insufficient information
Blinding of participants and
personnel (performance bias)
Yes Double-blind
Blinding of outcome assessment
(detection bias)
Yes JIA-ACR response rates and clinically inactive disease status were
performed in real time by independent masked evaluators at two
co-ordinating centres according to validated criteria
Incomplete outcome data
addressed (attrition bias)
Yes Details reported and similar between groups
Selective reporting (reporting
bias)
Yes All outcomes reported on
Other sources of bias Unclear Intercentre variability not discussed
a Yes, low risk of bias; no, high risk of bias; unclear, uncertain risk of bias.
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Appendix 6 Table of excluded studies for
systematic review of cost-effectiveness
TABLE 78 Excluded studies for systematic review of cost-effectiveness
Excluded study
Primary reason for
exclusion
Haapasaari JE, Kauppi M, Hakala MS, Kautiainen H. Economic evaluation of etanercept
therapy in the treatment of re-fractory JIA. Arthritis Rheum 2002;46:S480
Abstract
Brodszky V, Pentek M, Majer I, Karpati K, Gulacsi L. [Etanercept in patients with juvenile
idiopathic arthritis: systematic review and economic evaluation.] Budapest: Unit of Health
Economics and Technology Assessment in Health Care; 2006
Abstract
Prince FHM, de Bekker-Grob EW, Twilt M, Van Rossum MAJ, Hoppenreijs EPAH, ten Cate R,
et al. An analysis of the costs and treatment success of etanercept in juvenile idiopathic
arthritis. Clin Exp Rheumatol 2011;29:443
Abstract
Simpson K, Hubert MM, On PV, Cifaldi M, Shaw J. Long-term cost-effectiveness of
adalimumab therapy in juvenile idiopathic arthritis: from a Canadian perspective. J Rheumatol
2012;39:1712
Abstract
Luca N, Burnett H, Ungar W, Beukelman T, Feldman BM, Schwartz G, et al. Cost-effectiveness
analysis of early biologic treatment in polyarticular juvenile idiopathic arthritis. Arthritis Rheum
2012;64:S501
Abstract
Luca N, Burnett H, Ungar W, Beukelman T, Feldman B, Schwartz G, et al. Cost-effectiveness
analysis of early biologic treatment in polyarticular juvenile idiopathic arthritis. J Rheumatol
2013;40:988
Abstract
Chang S, Sawyer L, Dejonckheere F, van Suijlekom-Smit LW, Anink J, Diamantopoulos A.
Tocilizumab in polyarticular juvenile idiopathic arthritis – a cost–utility model for the United
Kingdom. Value Health 2013;16:A564
Abstract
All Wales Medicines Strategy Group. Adalimumab (Humira®). 2013. URL: www.awmsg.org/ Not economic evaluation
All Wales Medicines Strategy Group. Etanercept (Enbrel®). 2013. URL: www.awmsg.org/ Not economic evaluation
All Wales Medicines Strategy Group. Abatacept (Orencia®). 2014. URL: www.awmsg.org/ Not economic evaluation
All Wales Medicines Strategy Group. Tocilizumab (RoActemra®). 2014. URL: www.awmsg.org/ Not economic evaluation
Canadian Agency for Drugs and Technologies in Health. Tocilizumab (Actemra – Hoffmann-La
Roche Limited) New Indication: Polyarticular Juvenile Idiopathic Arthritis. 2014
Not economic evaluation
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Appendix 7 Cost-effectiveness studies: data
extraction forms
1 Study Cummins et al. (2002)123
2 Research question To provide background info and systematic review of JIA, including economic evidence of
etanercept compared with other treatment options
3 Country/setting Not stated
4 Funding source Not stated
5 Analysis type Cost–utility analysis
6 Study type Industry submission cost–utility model using results from one JIA trial (Lovell et al.42).
The model assumes response related to health assessment (HAQ) and mortality
7 Perspective Health-care system
8 Time horizon Model cycle length: 3months, 6months and 1 year, then yearly intervals over the
life-course
9 Model assumptions It is an adaptation of a rheumatoid arthritis model for adults using strong and
questionable assumptions, related to health assessment, utility, mortality and costs
10 Discounting (rate) Yes, costs 6% per annum and benefits 1%
11 Costing year, currency 2001, £
12 Population Etanercept in children with polyarticular juvenile rheumatoid arthritis
Definition of condition: JIA, heterogeneous group of painful conditions involving
persistent swelling of the joints with variable presentation and course
13 Intervention(s),
comparator(s)
Etanercept vs. placebo (placebo effect assumed to last 3months)
14 Intervention effect Effect size measured in terms of CHAQ and mortality
Cost offset per HAQ point £860
38% increase in mortality per point change in HAQ
Relative risk of mortality in JIA was 2.98
Placebo and etanercept HAQ progression: responders 0–4 years 0, responders > 4 years
0.034, non-responders 0.0669
Annual withdrawal from responders to non-responders: placebo 50%, etanercept 13%
15 Health-state utilities EQ-5D adults
16 Intervention cost Adult cost
17 Indirect costs N/A
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18 Results
Discounted/undiscounted Intervention Comparator Incremental ICER, £
Costs, £ 40,624 12,602 28,022
QALY 15.0 13.3 1.7 16,082
19 Sensitivity analysis
Sensitivity analysis varied from £3900 to £34,000 (SF-36 regression used)
20 Author’s conclusions Insufficient data to construct a model for JIA, and little is known about HRQoL in JIA.
The ICER should be viewed with caution
21 Reviewer’s comments Limited relevance in cost/utilities; adult rheumatoid arthritis cannot be assumed to be
the same for JIA in children
N/A, not applicable.
Critical appraisal checklist for economic evaluations (based on
Drummond et al.)129
Item Y/N?
1. Is the decision problem (including interventions compared and patient group) relevant to the UK? Y
2. Is the setting comparable to the UK? Y
3. Is the analytical and modelling methodology appropriate? N
4. Are all the relevant costs and consequences for each alternative identified? N
5. Are the data inputs for the model described and justified? Y
6. Are health outcomes measured in QALYs? Y
7. Is the time horizon considered appropriate? Y
8. Are costs and outcomes discounted? Y
9. Is an incremental analysis performed? Y
10. Is uncertainty assessed? Y
Comments Out of date, not children-specific, relying on very strong assumptions due to lack of evidence.
Informative in general terms but not relevant
?, unclear; N, no; Y, yes.
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1 Study Prince et al. (2011)124
2 Research question To analyse and report the costs and effects of etanercept therapy in patients with JIA
3 Country/setting Netherlands/national ABC register
4 Funding source The Dutch Board of Health Insurances and Wyeth International
5 Analysis type Cost–consequence analysis
6 Study type Trial-based: prospective etanercept effectiveness and safety add-on study with JIA
patients in 7 of 9 Dutch paediatric rheumatology centres
7 Perspective Health-care system
8 Time horizon 27 months
9 Model assumptions N/A
10 Discounting (rate) No
11 Costing year, currency 2008, €
12 Population Dutch JIA patients younger than 18 years of age are eligible for treatment with
etanercept if the disease has a polyarticular course and the response to the maximum
(tolerated) dose of MTX) is not sufficient
Onset subtype JIA (n= 49):
l Systemic (22%)
l Polyarticular RF+ve (8%)
l Polyarticular RF–ve (37%)
l EO (22%)
l ERA (4%)
l Juvenile arthritis psoriatica (6%)
Concomitant drug use at start of etanercept:
l NSAID (92%)
l Glucocorticoids systemic (47%)
l MTX (80%)
l Other DMARD (10%)
13 Intervention(s),
comparator(s)
Intervention: etanercept (add-on to conventional treatment)
Comparator: conventional treatment with synthetic DMARDs, mostly MTX, if required
accompanied by anti-inflammatories or systemic glucocorticoids
14 Intervention effect Effect size measured in the study in terms of change in disease activity response variables
of the JIA core set and HUI3
15 Health-state utilities HUI3: preference-based HRQoL measure completed by the parents of study participants
(eight domains in 15-item parent questionnaire)
Valuation using value scores obtained by Feeny et al.172 from the Canadian general
population
16 Intervention cost Unit costs for medication were retrieved from the Pharmacotherapeutic Compass
provided by the Dutch Board of Health Insurances, and treatment costs were calculated
with the exact dose of medication and administration period as reported in the patients’
files
Etanercept unit cost ≈€10,478/year
17 Indirect costs N/A
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18 Results:
Undiscounted Intervention Comparator Incremental
Costs (€) (27 months) 28,075 8370 19,705
Utility 0.78 (27 months) 0.53 (0 months) 0.25
19 Sensitivity analysis: N/A
20 Author’s conclusions ‘Although etanercept is expensive, the major utility gain justifies the costs’
21 Reviewer’s comments Sound trial-based evaluation of costs and consequences (including disease activity
improvement and utility) associated to adding etanercept to conventional care
Full incremental cost-effectiveness/utility analysis not performed and there is no indication
of the variation from the mean estimates reported nor assessment of uncertainty
MTX, methotrexate; N/A, not applicable.
Critical appraisal checklist for economic evaluations (based on
Drummond et al.)129
Item Y/N?
1. Is the decision problem (including interventions compared and patient group) relevant to the UK? Y
2. Is the setting comparable to the UK? ?
3. Is the analytical and modelling methodology appropriate? Ya
4. Are all the relevant costs and consequences for each alternative identified? Y
5. Are the data inputs for the model described and justified? N/A
6. Are health outcomes measured in QALYs? N
7. Is the time horizon considered appropriate? N
8. Are costs and outcomes discounted? N
9. Is an incremental analysis performed? ?a
10. Is uncertainty assessed? N
?, unclear; N, no; N/A, not applicable; Y, yes.
a The methodology is appropriate for a cohort-based evaluation; however, a full incremental cost–utility analysis has not
been performed.
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1 Study Simpson et al. (2012)125
2 Research question To evaluate the cost-effectiveness of adalimumab vs. non-biologic therapy for the
treatment of JIA in Russian children and adolescents
3 Country/setting Russia/health-care system
4 Funding source Not stated
5 Analysis type Cost–utility analysis
6 Study type Markov model; mutually exclusive health states:
l Base model (children under 18 years): (1) mild disease activity; (2) moderate disease
activity; (3) severe disease activity; (4) remission without movement limitations;
(5) remission with movement limitations
Second part of the model (adults from 18 years to death): (6) remission; (7) active mild
disability; (8) active moderate disability; and (9) active severe disability; (10) death (not clear
if children mortality is included)
7 Perspective Health-care system and society
8 Time horizon Lifetime. Model cycle length: 4 months
9 Model assumptions l Adult patients with moderate to severe disability are assumed to have hip and knee
prosthetic surgery at the frequency observed in patients173
l Patients who do not achieve remission after 1 year of treatment had a median time on
treatment of 3 years (as observed in DE038)
l Mean age of 11 years at start of therapy
10 Discounting (rate) Yes (3% per annum, costs and outcomes)
11 Costing year,
currency
2011, Russian roubles
12 Population Trial name: randomised double-blinded placebo-controlled trial DE038
(adalimumab+methotrexate vs. placebo+methotrexate)
Children aged 4–17 years with JIA
13 Intervention(s),
comparator(s)
Intervention: adalimumab+methotrexate
Comparator: placebo+methotrexate
14 Intervention effect Intervention effect was incorporated in terms of HRQoL and the estimated number of
person-years spent in each health state. The HRQoL associated to each health state was
obtained from the CHAQ responses in trial DE038
15 Health-state utilities For the base model, HUI2 utilities for each health state were mapped from CHAQ
responses from parents of children participating in DE038. HUI2 valuation was derived
from survey to the UK general population
For the second part of the model, utilities were derived from the literature on adult
patients with rheumatoid arthritis174
16 Intervention cost Cost of treatment with adalimumab was derived from its expected cost in the List of Vital
and Essential Medicinal Products (58,100 roubles for two 40-mg syringes after adjustment
for VAT and 10% trade mark-up)
17 Indirect costs A secondary analysis included value of time lost from work to provide care for a sick child.
Value and source not reported
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18 Results for base-case lifetime time horizon NHS perspective
Discounted Intervention Comparator Incremental ICER
Costs (roubles) 4,116,231 2,753,954 1,362,277 –
QALY 24.80 20.04 4.76 286,267
19 Sensitivity analysis: Deterministic univariate lifetime time horizon
Parameter/scenario Value ICER, £
Age of treatment initiation 7 years of age 229,744
Discounting rate 0% 119,496
5% 428,236
Note: results for 11-year time horizon and societal perspective also reported
20 Author’s conclusions Adalimumab seems to be cost-effective relative to conventional non-biologic therapy.
ICERs estimated in the base-case lifetime analyses did not exceed the per-capita gross
domestic product for Russia (≈380,000 roubles)
21 Reviewer’s comments Transition probabilities not reported; poor reporting of sources for the estimates used
and their derivation; limited sensitivity analysis without indication of most influential
parameters
Critical appraisal checklist for economic evaluations (based on
Drummond et al.)129
Item Y/N?
1. Is the decision problem (including interventions compared and patient group) relevant to the UK? Y
2. Is the setting comparable to the UK? ?
3. Is the analytical and modelling methodology appropriate? Y
4. Are all the relevant costs and consequences for each alternative identified? Y
5. Are the data inputs for the model described and justified? N
6. Are health outcomes measured in QALYs? Y
7. Is the time horizon considered appropriate? Y
8. Are costs and outcomes discounted? Y
9. Is an incremental analysis performed? Y
10. Is uncertainty assessed? Y
Comments: Limited assessment of uncertainty
?, unclear; N, no; Y, yes.
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1 Study Ungar et al. (2011)127
2 Research question To determine the incremental costs of biologics per additional responder compared with
conventional treatment (methotrexate)
3 Country/setting Canada, secondary care
4 Funding source Ontario Ministry of Health and Long-term Care Drug Innovation Fund
5 Analysis type CEA
6 Study type Decision-analysis model
7 Perspective Societal
8 Time horizon 1-year time horizon with two consecutive 6-month cycles
9 Model assumptions Model incorporated probabilities that patients would, based on their response at
6 months, either continue with the same treatment or switch
10 Discounting (rate) Not included
11 Costing year, currency 2008 Canadian dollars
12 Population In the base case, a 40-kg patient was assumed, similar to the mean weight in two
paediatric RCTs. Patients had JIA with a prior inadequate response or intolerance to
DMARDs
13 Intervention(s),
comparator(s)
Etanercept, adalimumab, abatacept and infliximab vs. MTX
14 Intervention effect The effectiveness measure was the proportion of patients who had a reduction in
symptoms at 1 year according to the ACR Pedi-30 criteria
Effect size were taken from RCTs: etanercept (Lovell et al., 200042), adalimumab
(Lovell et al., 200861), infliximab (Ruperto et al., 2007135) and abatacept (Ruperto et al.,
200857)
For the base case, patients achieving ACR Pedi-30, %
Time Etanercept Adalimumab Abatacept Infliximab DTX
6 months 79 80 82 80 30
12 months 79 63 82 79 30
15 Health-state utilities No utility values included
16 Intervention cost Total annual costs for treatment were: abatacept ($14,733), infliximab ($17,259),
etanercept ($18,966), adalimumab ($18,654), methotrexate ($952). Treatment costs
included medication costs, preparation and administration costs and concomitant
medications
17 Indirect costs The costs for abatacept and infliximab included parental time losses of $1875 and
$1071. There were no indirect costs for the other treatments
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18 Results
Intervention vs. MTX
Undiscounted Etanercept Adalimumab Abatacept Infliximab
Incremental costs, $ 11,090 13,107 7,873 12,167
Incremental effectiveness, % 47.6 29.4 49.4 43.2
ICER, £ 26,061 46,711 16,204 31,209
19 Sensitivity analysis
Deterministic analysis was performed for extreme efficacy with biologic high efficacy and MTX low efficacy and vice
versa
Probabilistic sensitivity analyses were conducted for each treatment vs. MTX and cost-effectiveness acceptability
curves were calculated. If a decision-maker was willing to pay no more than $30,000 to gain a responder, then the
probability that etanercept would demonstrate a net economic benefit would be 95%. The willingness to pay points
at which the biologic had a 50% probability of cost-effectiveness were $45,000, $17,000 and $27,500 for
adalimumab, abatacept and infliximab respectively
20 Author’s conclusions JIA patients with a prior suboptimal response or intolerance to MTX may benefit from
treatment with biologic for at least 1 year
21 Reviewer’s comments Results not present in QALYs, which makes results difficult to interpret. Short time
horizon used (1 year). Unclear how ICERs are calculated
Critical appraisal checklist for economic evaluations (based on
Drummond et al.129)
Item Y/N?
1. Is the decision problem (including interventions compared and patient group) relevant to the UK? Y
2. Is the setting comparable to the UK? N
3. Is the analytical and modelling methodology appropriate? Y
4. Are all the relevant costs and consequences for each alternative identified? Y
5. Are the data inputs for the model described and justified? Y
6. Are health outcomes measured in QALYs? N
7. Is the time horizon considered appropriate? N
8. Are costs and outcomes discounted? N
9. Is an incremental analysis performed? Y
10. Is uncertainty assessed? Y
?, unclear; N, no; Y, yes.
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Appendix 8 Table of excluded studies for
systematic review of health-related quality of life
TABLE 79 Excluded studies for systematic review of HRQoL
Identified studies from titles/abstracts and full papers Reason for exclusion
Anink J, Prince FHM, Dijkstra M, Otten H, Twilt M, Ten CR, et al. Long term functional outcome
and quality of life of patients with refractory juvenile idiopathic arthritis treated with etanercept:
results of the Dutch arthritis and biologicals in children register. Pediatr Rheumatol
2014;12(Suppl. 1):P28
Abstract
Duarte-Salazar C, Guzman-Vazquez S, Soto-Molina H, Chaidez-Rosales P, Ilizaliturri-Sanchez V,
Nieves-Silva J, et al. Disability impact on quality of life in Mexican adults with juvenile idiopathic
arthritis and juvenile ankylosing spondylitis. Clin Exp Rheumatol 2007;25:922–7
No utilities reported
Hendry GJ, Gardner-Medwin J, Turner DE, Woodburn J, Lorgelly PK. Self-vs Proxy-Reported
Health-Related Quality of Life of Patients with Juvenile Idiopathic Arthritis: Implications
for a Cost-Utility Analysis of Multidisciplinary Foot Care. 2011. URL: http://rheumatology.
oxfordjournals.org/content/50/suppl_1/i2.full.pdf+html (accessed March 2015)
Abstract
Hendry GJ, Gardner-Medwin J, Steultjens MPM, Woodburn J, Sturrock RD, Turner DE. Frequent
discordance between clinical and musculoskeletal ultrasound examinations of foot disease in
juvenile idiopathic arthritis. Arthritis Care Res 2012;64:441–7
No utilities reported
Janse AJ, Uiterwaal CS, Gemke RJ, Kimpen JL, Sinnema G. A difference in perception of quality
of life in chronically ill children was found between parents and pediatricians. J Clin Epidemiol
2005;58:495–502
Irrelevant population
Janse AJ, Sinnema G, Uiterwaal CS, Kimpen JL, Gemke RJ. Quality of life in chronic illness:
perceptions of parents and paediatricians. Arch Dis Child 2005;90:486–91
Irrelevant population
Janse A, Sinnema G, Uiterwaal C, Kimpen J, Gemke R. Quality of life in chronic illness: children,
parents and paediatricians have different, but stable perceptions. Acta Paediatr
2008;97:1118–24
Irrelevant population
Angeles-Han ST, Griffin KW, Lehman TJA, Rutledge JR, Lyman S, Nguyen JT, et al. The
importance of visual function in the quality of life of children with uveitis. J Am Assoc Pediatr
Opthalmol Strabismus; 2010;14:163–8
Irrelevant population
Cespedes-Cruz A, Gutierrez-Suarez R, Pistorio A, Ravelli A, Loy A, Murray KJ, et al. Methotrexate
improves the health-related quality of life of children with juvenile idiopathic arthritis.
Ann Rheum Dis 2008;67:309–14
No utilities reported
Feinstein AB, Forman EM, Masuda A, Cohen LL, Herbert JD, Moorthy LN, et al. Pain intensity,
psychological inflexibility, and acceptance of pain as predictors of functioning in adolescents
with juvenile idiopathic arthritis: a preliminary investigation. J Clin Psychol Med Settings
2011;18:291–8
No utilities reported
Maetzel A, Strand V, Tugwell P, Wells G, Bombardier C. Economic comparison of leflunomide
and methotrexate in patients with rheumatoid arthritis: an evaluation based on a 1-year
randomised controlled trial. Pharmacoeconomics 2002;20:61–70
Irrelevant population
Matza LS, Boye KS, Feeny DH, Johnston JA, Bowman L, Jordan JB. Impact of caregiver and
parenting status on time trade-off and standard gamble utility scores for health state
descriptions. Health Qual Life Outcomes 2014;12:48
Irrelevant population
McTaggart-Cowan HM, Brazier JE, Tsuchiya A. Clustering Rasch results: a novel method for
developing rheumatoid arthritis states for use in valuation studies. Value Health 2010;13:787–95
Irrelevant population
Medrare L, Ngeuleu A, Rkain M, Bouaddi I, Znat F, El KS, et al. Is there any relationship between
the children health assessment questionnaire (CHAQ) and the european quality of life
(EUROQOL) in children suffering from chronic haemophilic arthropathy? Ann Rheum Dis
2014;73:1099
Irrelevant population
continued
DOI: 10.3310/hta20340 HEALTH TECHNOLOGY ASSESSMENT 2016 VOL. 20 NO. 34
© Queen’s Printer and Controller of HMSO 2016. This work was produced by Shepherd et al. under the terms of a commissioning contract issued by the Secretary of State for
Health. This issue may be freely reproduced for the purposes of private research and study and extracts (or indeed, the full report) may be included in professional journals
provided that suitable acknowledgement is made and the reproduction is not associated with any form of advertising. Applications for commercial reproduction should be
addressed to: NIHR Journals Library, National Institute for Health Research, Evaluation, Trials and Studies Coordinating Centre, Alpha House, University of Southampton Science
Park, Southampton SO16 7NS, UK.
179
TABLE 79 Excluded studies for systematic review of HRQoL (continued )
Identified studies from titles/abstracts and full papers Reason for exclusion
Mo F, Choi BC, Li FC, Merrick J. Using Health Utility Index (HUI) for measuring the impact on
health-related quality of life (HRQL) among individuals with chronic diseases. Scientific World J
2004;4:746–57
Irrelevant population
Nordvag B-Y, Bernklev T, Slevolden E, Myhr K-M, Stensland E. Norwegian quality registry for
biological drugs: The NOKBIL project. Scand J Rheumatol 2012;41(Suppl. 126):50
Abstract
Osnes-Ringen H, Kvien TK, Henriksen JE, Mowinckel P, Dagfinrud H. Orthopaedic surgery in
255 patients with inflammatory arthropathies: longitudinal effects on pain, physical function
and health-related quality of life. Ann Rheum Dis 2009;68:1596–601
Irrelevant population
Osnes-Ringen H, Kvien TK, Henriksen JE, Dagfinrud H. Patients with inflammatory arthropathies
undergo feet surgery later in the disease course than hand surgery. Clin Exp Rheumatol
2010;28:702–7
Irrelevant population
Osnes-Ringen H, Kvamme MK, Kristiansen IS, Thingstad M, Henriksen JE, Kvien TK, et al.
Cost-effectiveness analyses of elective orthopaedic surgical procedures in patients with
inflammatory arthropathies. Scand J Rheumatol 2011;40:108–15
Irrelevant population
Shelepina TA, Stepanenko NY, Fedorov ES. Comparative characteristic of quality of life with
patients suffering from juvenile idiopathic arthritis (JIA), attending school and taught at home.
Pediatr Rheumatol 2011;9:106
Abstract
Simpson K, Hubert MM, On PV, Cifaldi M, Shaw J. Long-term cost-effectiveness of adalimumab
therapy in juvenile idiopathic arthritis: from a Canadian perspective. J Rheumatol 2012;39:1712
Abstract
Solari N, Viola S, Pistorio A, Magni-Manzoni S, Vitale R, Ruperto N, et al. Assessing current
outcomes of juvenile idiopathic arthritis: a cross-sectional study in a tertiary center sample.
Arthritis Rheum 2008;59:1571–9
No utilities reported
Sparsa L, Job DC, Quartier P, Kahan A, Wipff J. Quality of life of juvenile idiopathic arthritis
cohort at adulthood in a transition program. Ann Rheum Dis 2013;71(Suppl. 3):432
Abstract
Wade AG, Crawford GM, Pumford N, Koscielny V, Maycock S, McConnachie A. Baseline
characteristics and patient reported outcome data of patients prescribed etanercept: web-based
and telephone evaluation. BMC Med Res Methodol 2011;11:91
No utilities reported
Wang H-M, Beyer M, Gensichen J, Gerlach FM. Health-related quality of life among general
practice patients with differing chronic diseases in Germany: cross sectional survey. BMC Public
Health 2008;8:246
Irrelevant population
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Appendix 9 Health-related quality-of-life
systematic review: data extraction forms
Reference
Hendry et al. (2013)136
Study characteristics
Research question
What are the stated objectives of the study?
To evaluate the effectiveness of multidisciplinary foot-care, and to evaluate the methodological considerations
of a trial of multidisciplinary care in JIA.
Describe the type of study and study design.
Exploratory randomised controlled trial
Was the sample from (1) the general population; (2) patients with the disease of interest; (3) individuals
with knowledge of the disease; (4) other?
Are inclusion/exclusion criteria clearly described? Do these exclude any individuals that may be relevant
(e.g. > 80 years)?
The sample was drawn from patients with the disease of interest (i.e. children and adolescents with a definitive
diagnosis of JIA and inflammatory joint disease affecting the foot/ankle).
The inclusion/exclusion criteria were clearly stated; however, might exclude a proportion of individuals with the
disease of interest but whose disease has not affected the foot/ankle.
Patients were included if they satisfied at least one of the following: (1) previously documented arthritis in the
foot including small joints derived from medical case notes; (2) previously documented foot arthritis in one
or more large joints derived from medical case notes; or (3) current widespread polyarthritis involving large
and small foot joints derived from clinical examination by a consultant paediatric rheumatologist. Patients
with an unconfirmed diagnosis of JIA, and/or only upper limb, jaw, or neck involvement were excluded.
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What are the characteristics of the baseline cohort for the evaluation?
Age, years, mean (SD)
Intervention arm 10.1(4.22)
Control arm 10.0(3.39)
Male/female, n
Intervention arm 7/14
Control arm 6/17
Race (if appropriate) NR
Disease subtypes, n (%)
Intervention arm
Persistent oligoarthritis 7 (33)
EO 4 (19)
Polyarthritis RF–ve 6 (29)
Polyarthritis RF+ve 0 (0)
Psoriatic arthritis 2 (10)
ERA 2 (10)
Undifferentiated 0 (0)
Control arm
Persistent oligoarthritis 4 (17)
EO 5 (22)
Polyarthritis RF–ve 10 (43)
Polyarthritis RF+ve 2 (9)
Psoriatic arthritis 1 (4)
ERA 0 (0)
Undifferentiated 1 (4)
Sample size, n
Intervention arm 21
Control arm 23
Pharmacological management, n (%)
Intervention arm
Analgesics 2 (9)
NSAIDs 18 (86)
Methotrexate 7 (33)
Etanercept 1 (5)
Sulphasalazine 0 (0)
Rituximab 5 (24)
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Control arm
Analgesics 3 (13)
NSAIDs 16 (70)
Methotrexate 5 (22)
Etanercept 0 (0)
Sulphasalazine 1 (4)
Rituximab 5 (22)
Combination methotrexate
and etanercept
–
QoL instrument EQ-5D-Y (patients) and EQ-5D-3L (parents/guardians) questionnaires
Utility values (Y/N) Y
Treatment effect, if reported Both the treatment groups appeared to improve by one point on the JAFI impairment
scale between baseline and 12 months follow up, however, the differences between
groups for change scores did not reach statistical significance
Country/setting
What is the country and setting for the evaluation?
Royal Hospital for Sick Children, Glasgow, UK.
Data sources
Effectiveness
Were the QoL data derived from: a single (observational) study, a review/synthesis or combination of
previous studies, expert opinion?
This single exploratory RCT.
DOI: 10.3310/hta20340 HEALTH TECHNOLOGY ASSESSMENT 2016 VOL. 20 NO. 34
© Queen’s Printer and Controller of HMSO 2016. This work was produced by Shepherd et al. under the terms of a commissioning contract issued by the Secretary of State for
Health. This issue may be freely reproduced for the purposes of private research and study and extracts (or indeed, the full report) may be included in professional journals
provided that suitable acknowledgement is made and the reproduction is not associated with any form of advertising. Applications for commercial reproduction should be
addressed to: NIHR Journals Library, National Institute for Health Research, Evaluation, Trials and Studies Coordinating Centre, Alpha House, University of Southampton Science
Park, Southampton SO16 7NS, UK.
183
Results
Summarise the results.
There were no significant differences between treatment groups for secondary outcomes at final
follow-up.
Intervention arm Control arm
Baseline
Self EQ-5D utility index, mean (SD) 0.57 (0.31) 0.58 (0.35)
Self EQ-5D utility index, median (IQR) 0.62 (0.52–0.76) 0.66 (0.52–0.75)
Proxy EQ-5D utility index, mean (SD) 0.69 (0.29) 0.60 (0.33)
Proxy EQ-5D utility index, median (IQR) 0.69 (0.58–1) 0.62 (0.55–0.82)
Change at 12 months
Self EQ-5D utility index, median (IQR) 0 (–0.1 to 0.01) 0 (–0.04 to 0.04)
Proxy EQ-5D utility index, median (IQR) 0 (0–0.11) 0 (0–0.1)
Were the methods for deriving these data adequately described (give sources if using data from other
published studies)? (Was a valid preference based instrument used to describe health states, such as
EQ-5D? Was the valuation of health states from the UK general population?)
A valid preference-based instrument was used: EQ-5D-Y and EQ-5D-3L.
Are the levels of missing data reported? How are they dealt with?
For missing data identified at the end of the study, a sensitivity analysis was performed in order to identify the
most appropriate method to address this problem (LOCF, mean value imputation, maximum value imputation,
minimum value imputation and random value imputation). LOCF was found to be the most conservative
method while being less labour intensive; therefore, it was subsequently used to impute all missing data at final
follow-up.
Mapping
If a model was used, describe the type of model (e.g. regression) or other conversion algorithm.
Not applicable.
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Conclusions/implications
Give a brief summary of the author’s conclusions from their analysis.
Integrated multidisciplinary foot care did not result in a significant reduction in disease-related foot impairments
and disability.
What are the implications of the study for the model?
In both arms, a proportion of participants received etanercept, so the utility values reported cannot be used in
the model for baseline HRQoL with standard of care.
Reference
Prince et al. (2011),124 Prince et al. (2010)137
Study characteristics
Research question
What are the stated objectives of the study?
To evaluate changes in HRQoL in patients with refractory JIA who are being treated with etanercept.
Describe the type of study and study design.
Prospective study.
Was the sample from: (1) the general population; (2) patients with the disease of interest; (3) individuals
with knowledge of the disease; (4) other?
Are inclusion/exclusion criteria clearly described? Do these exclude any individuals that may be relevant
(e.g. > 80 years)?
JIA patients younger than 18 years treated with etanercept.
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What are the characteristics of the baseline cohort for the evaluation?
Study Prince et al. (2010)137 Prince et al. (2011)124
Age 11.9 years (IQR 8.1–14.9) 11.6 years (IQR 7.9–14.9)
Sex, n (%)
Male
Female
20 (38)
33 (62)
20 (41)
33 (59)
Ethnicity (if appropriate)
Indication/disease, n (%) Systemic 14 (26)
Polyarticular RF+ve 5 (9)
Polyarticular RF–ve 18 (34)
EO 11 (21)
ERA 2 (4)
Juvenile PA 3 (6)
Systemic 11 (22)
Polyarticular RF+ve 4 (8)
Polyarticular RF–ve 18 (37)
EO 11 (22)
ERA 2 (4)
Juvenile PA 3 (6)
Other characteristics (sample size) Sample size 53
Median disease duration JIA (years)
at start of etanercept 3.0
Sample size 49
Median disease duration JIA (years)
at start of etanercept 3.6
Quality-of-life instrument HUI3 HUI3
Utility values (Y/N) Yes Yes
Treatment effect, if reported Significant improvements were shown
after 3 months and these continued at
least up to 27 months
Significant improvements were shown
after 3 months and these continued at
least up to 27 months
Country/setting
What is the country and setting for the evaluation?
The Netherlands.
Data sources
Effectiveness
Were the QoL data derived from: a single (observational) study, a review/synthesis or combination of
previous studies, expert opinion?
Single prospective study.
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Results
Summarise the results.
Prince et al. (2010)137 Baseline 3 months 15 months 27 months
HUI3 mean (SE) 0.53 (0.04) 0.69 (0.05) 0.74 (0.06) 0.78 (0.07)
Were the methods for deriving these data adequately described (give sources if using data from other
published studies)? (Was a valid preference based instrument used to describe health states, such as
EQ-5D? Was the valuation of health states from the UK general population?)
Yes.
Are the levels of missing data reported? How are they dealt with?
Not reported.
Mapping
If a model was used, describe the type of model (e.g. regression) or other conversion algorithm.
Mapping was not used.
Conclusions/implications
Give a brief summary of the author’s conclusions from their analysis.
This study shows that the HRQoL of patients with refractory JIA can be substantially improved by the use
of etanercept.
What are the implications of the study for the model?
This is a potential source of HRQoL for the SHTAC economic model.
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Appendix 10 Cost-effectiveness data extraction
forms for the company submissions
Company submission from Abbvie
Reference
AbbVie (2015)77
Health technology
Adalimumab
Interventions and comparators
What interventions/strategies were included?
No economic evaluation was conducted; however, reasons for not conducting an economic evaluation were
discussed and included the following interventions: adalimumab, etanercept, abatacept, tocilizumab
and methotrexate.
Was a no treatment/supportive care strategy included?
No.
Describe interventions/strategies
p. 13 CS: ‘The aim of drug therapy in JIA patients is to induce and maintain remission of symptoms, and thus
allow a child to achieve normal growth, development, and allow full participation in school, career, sport and
all other aspects of normal life. The initial aim is induction of complete disease remission using corticosteroids –
either intravenously (IV) or intra-articular. Oral corticosteroids are avoided where possible to avoid side effects
(can affect growth or increase risk of osteoporosis) but may be needed for short time periods.’
p. 14 EMA licence: ‘Adalimumab in combination with methotrexate is indicated for the treatment of active
polyarticular juvenile idiopathic arthritis, in patients from the age of 2 years who have had an inadequate
response to one or more disease-modifying anti-rheumatic drugs (DMARDs). Adalimumab can be given as
monotherapy in case of intolerance to methotrexate or when continued treatment with methotrexate is
inappropriate. Adalimumab has not been studied in patients aged less than 2 years.’
Adalimumab is delivered as 24mg/m2 body surface area (with varying maximum doses dependent on weight
and study protocol) subcutaneous injection with concomitant methotrexate for 24 weeks or more. Patients
were allowed to take NSAIDs and prednisone or equivalents to prednisone.
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Research question
What are the stated objectives of the evaluation?
No economic evaluation was conducted.
Study type: cost-effectiveness/cost–utility/cost–benefit analysis?
No economic evaluation was conducted.
Study population
What definition was used for [condition]? What are the characteristics of the baseline cohort for
the evaluation?
From pp. 9–10 of the CS: ‘Juvenile Idiopathic Arthritis (JIA) is the most common rheumatic disease of childhood
and describes a group of conditions that involve joint inflammation which lasts for more than 6 weeks in
people under 16 years of age. . . . JIA is an “umbrella” term which covers a number of different subtypes listed
below that were proposed by the International League of Associations for Rheumatology (ILAR) in 1995 for the
classification of JIA:
l Oligoarticular JIA – Oligoarthritis is the most common type of JIA, accounting for up to 50% of new
diagnoses in Europe each year. It is diagnosed when four or fewer joints are affected in the first 6 months
of disease.
l Extended Oligoarticular JIA – If oligoarthritis progresses and affects more than four joints during the first
6 months, it is called extended oligoarthritis.
l Poly-Articular JIA (RF –ve or RF +ve) – Polyarticular JIA is diagnosed when five or more joints are affected at
presentation, and can be further divided into rheumatoid factor positive arthritis and rheumatoid factor
negative disease.
l Systemic-Onset JIA – Systemic JIA accounts for 5–10% of new diagnoses and is diagnosed when arthritis
is part of a general illness involving features such as fever, lymphadenopathy, hepatosplenomegaly and
serositis. This patient group was not included in the NICE Scope for this project.
l Psoriatic JIA – Psoriatic arthritis accounts for 2–15% of new diagnoses and is diagnosed when there is joint
swelling associated with psoriasis, or a family history of psoriasis.
l Enthesitis-Related Arthritis (ERA) – ERA accounts for 2–10% of new diagnoses and is diagnosed in the
presence of arthritis or inflammation of tendon attachments to the bones (entheses), in association with
two or more other features of spondyloarthropathy.’
l No economic evaluation was conducted, so there is no relevant baseline cohort.
Institutional setting: where is/are the intervention(s) being evaluated
usually provided?
Paediatric secondary care.
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Country/currency
Has a country setting been provided for the evaluation? What currency are costs expressed in and does the
publication give the base year to which those costs relate?
No economic evaluation was conducted.
Funding source
AbbVie.
Analytical perspective
What is the perspective adopted for the evaluation (health service, health and personal social services, third
party payer, societal (i.e. including costs borne by individuals and lost productivity)?
No economic evaluation was conducted.
Effectiveness
Were the effectiveness data derived from: a single study, a review/synthesis of previous studies or expert
opinion? Give the definition of treatment effect used in the evaluation. Give the size of the treatment
effect used in the evaluation.
No economic evaluation was conducted.
Intervention costs
Were the cost data derived from: a single (observational) study, a review/synthesis of previous studies expert
opinion? Were the methods for deriving these data adequately described (give sources if using data from
other published studies)? List the direct intervention costs and other direct costs used in the evaluation:
include resource estimates (and sources for these estimates, if appropriate) as well as sources for unit
costs used.
No economic evaluation was conducted.
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Indirect costs (costs attributable to lost productivity, unpaid inputs
to patient care)
Were indirect costs included?
No economic evaluation was conducted.
Health-state valuations/utilities (if study uses quality-of-life adjustments
to outcomes)
Were the utility data derived from: a single (observational) study, a review/synthesis of previous studies
expert opinion. Were the methods for deriving these data adequately described (give sources if using data
from other published studies)?
No economic evaluation was conducted.
List the utility values used in the evaluation
No economic evaluation was conducted.
Modelling
If a model was used, describe the type of model used (e.g. Markov state transition model, discrete event
simulation). Was this a newly developed model or was it adapted from a previously reported model? If an
adaptation, give the source of the original. What was the purpose of the model (i.e. why was a model
required in this evaluation)? What are the main components of the model (e.g. health states within a
Markov model)? Are sources for assumptions over model structure (e.g. allowable transitions) reported:
list them if reported.
No modelling was undertaken.
Extract transition probabilities for (natural history/disease progression) model
and show sources (or refer to table in text)
No modelling was undertaken.
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What is the model time horizon?
No modelling was undertaken.
What, if any, discount rates have been applied in the model? Same rate for
costs and outcomes?
No modelling was undertaken.
If no economic evaluation was conducted, state the manufacturer’s reasons
for this
No economic evaluation was conducted owing to heterogeneity in study methods and populations between
the interventions that complicated indirect comparisons, a lack of appropriate utility data for HRQoL and lack of
long-term data.
Results/analysis
What measure(s) of benefit were reported in the evaluation?
No economic evaluation was undertaken.
Provide a summary of the clinical outcome/benefits estimated for each
intervention/strategy assessed in the evaluation
No economic evaluation was undertaken.
Provide a summary of the costs estimated for each intervention/strategy
assessed in the evaluation
No economic evaluation was undertaken.
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Synthesis of costs and benefits: are the costs and outcomes reported
together (e.g. as cost-effectiveness ratios)? If so, provide a summary
of the results
No economic evaluation was undertaken.
Give results of any statistical analysis of the results of the evaluation
No economic evaluation was undertaken.
Was any sensitivity analysis performed: if yes, what type(s)
[i.e. deterministic (one-way, two-way, etc.) or probabilistic]?
No economic evaluation was undertaken.
What scenarios were tested in the sensitivity analysis? How do these relate to
structural uncertainty (testing assumptions over model structure such as
relationships between health states), methodological uncertainty (such as
choices of discount rate or inclusion of indirect costs) or parameter
uncertainty (assumptions over values of parameters in the model, such as
costs, quality of life or disease progression rates)?
No economic evaluation was undertaken.
Give a summary of the results of the sensitivity analysis: did they differ
substantially from the base-case analysis. If so, what were the
suggested causes?
No economic evaluation was undertaken.
Conclusions/implications
Give a brief summary of the author’s conclusions from their analysis.
No economic evaluation was undertaken.
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What are the implications of the evaluation for practice?
No economic evaluation was undertaken.
Southampton Health Technology Assessments Centre commentary
Selection of comparators
Although no economic evaluation was conducted, the comparators listed by the manufacturer were
appropriate and in accordance with the NICE scope.
Validity of estimate of measure of benefit
No economic evaluation was undertaken.
Validity of estimate of costs
No economic evaluation was undertaken.
Company submission from BMS
Reference
BMS (2015)85
Health technology
Abatacept.
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Interventions and comparators
What interventions/strategies were included?
Abatacept, adalimumab, etanercept and tocilizumab.
Was a no treatment/supportive care strategy included?
No.
Describe interventions/strategies
Abatacept is a biologic DMARD that prevents T-cell activation, thus down-regulating the immune response of
inflammatory disease. (p. 9). Abatacept is administered intravenously.
p. 9 CS: ‘The recommended dose of abatacept for polyarticular JIA patients aged 6 to 17 years (who weigh
less than 75 kg) is 10mg/kg, calculated based on the patient’s body weight at each administration. Paediatric
patients weighing 75 kg or more should follow the abatacept adult dosing regimen and should not exceed a
maximum dose of 1,000mg. Abatacept should be administered as a 30-minute intravenous infusion. Following
the initial administration, abatacept should be given at 2 and 4 weeks after the first infusion, and every
4 weeks thereafter.’
Etanercept is a biologic DMARD that inhibits TNF activation. It is administered subcutaneously. For patients
aged 2–18 400 µg/kg (maximum 25mg twice a week) or 800 µg/kg (maximum 50mg once a week) was
administered. For patients over 18 years of age the dose was 50mg.
Adalimumab is a biologic DMARD that inhibits TNF activation. It is administered subcutaneously. For patients
aged 4–13 24mg/m2 (maximum 40mg) was administered EOW. For patients aged 13 and above the dose
was 40mg.
Tocilizumab is a biologic DMARD. It is a humanised monoclonal antibody that inhibits the cytokine IL-6. It is
administered by intravenous infusion. Tocilizumab dose was based on weight. For patients weighing < 30 kg
the dose was 10mg/kg. For patients 30 kg and above the dose was 8mg/kg (maximum 800mg). Doses were
administered every 4 weeks. All tocilizumab patients were older than 2 years of age.
All drugs were administered with subcutaneous methotrexate. BMS indicated that methotrexate was given
every 4 weeks at a dosage of 13.5mg/m2.
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Research question
What are the stated objectives of the evaluation?
From CS model: ‘The model evaluates the cost-effectiveness of abatacept against other biological disease
modifying anti rheumatic drugs (bDMARDs) in moderate-to-severe active polyarthritis in paediatric patients
from the age of 6 years and who have shown insufficient response to other DMARDs, including at least one
anti-TNF.’
BMS reports that this is not in perfect agreement with the NICE Scope, but is in accord with the drug licence.
The NICE Scope is broader with no specifications for patient age, or insufficient response on other DMARDs
(including failure of at least one TNF inhibitor). The NICE Scope also includes ERA.
Study type: cost-effectiveness/cost–utility/cost–benefit analysis?
BMS has conducted a cost-minimisation analysis with an assumption that there is no difference between the
biologic DMARDs in effectiveness. BMS indicated that effectiveness evidence was not considered because it
‘would lead to uncertainty within the model’.
Study population
What definition was used for [condition]? What are the characteristics of the baseline cohort for
the evaluation?
‘JIA encompasses all forms of arthritis of unknown aetiology that persist for at least 6 weeks and begin in
patients younger than 16 years.1 JIA comprises several heterogeneous subtypes (oligoarthritis, polyarthritis,
systemic, psoriatic, enthesitis-related and undifferentiated), all presenting with different clinical signs and
symptoms.1,3,14 Overall, JIA is characterised by persistent joint swelling, pain and limitation of movement
and has an estimated incidence in the UK of 1 per 10,000 children and a prevalence in the order of 1 per
1,000 children.2 Polyarticular JIA (classifiable as polyarthritis [rheumatoid factor-positive or -negative]) is
characterised by arthritis affecting five or more joints during the first 6 months of the disease,1,3,14,15 and it
affects 13%–37% of patients with JIA.3
JIA causes functional impairment due to joint and back pain, heel pain, swelling of joints and morning
stiffness, contractures, pain and anterior uveitis leading to blindness.16 This leads to suboptimal
health-related quality of life (HRQL) in patients and parents or carers alike.17,18 Moreover, as JIA patients
reach adulthood, they face possible continuing disease activity, medication-associated morbidity, life-long
disability and the risk of emotional and social dysfunction.16’
CS p. 8. Reference citations have been reproduced from the CS as supplied
The baseline cohort population was defined as 12-year old ‘moderate-to-severe active polyarticular JIA
[patients] who have had an insufficient response to other DMARD, including at least one TNF inhibitor’ in the
decision problem stated by BMS.
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Institutional setting: where is/are the intervention(s) being evaluated
usually provided?
The institutional setting appears to be paediatric secondary care, but this is not entirely clear. The delivery
environment is not specifically referenced.
Country/currency
Has a country setting been provided for the evaluation? What currency are costs expressed in and does the
publication give the base year to which those costs relate?
The country setting given is the UK. Costs are expressed in pounds sterling (£). Costs were derived from the
MIMS database (accessed November 2014). The price year was not explicitly stated.
Funding source
BMS.
Analytical perspective
What is the perspective adopted for the evaluation [health service, health and personal social services, third
party payer, societal (i.e. including costs borne by individuals and lost productivity)]?
The model reports that it adopts an NHS and PSS perspective; however, it appears that only drug and
administration costs have been included in the model. The NHS and PSS perspective generally includes costs
associated with the disease. This would routinely include hospitalisation costs, costs for physician visits and
nurse time, as well as costs for managing AEs. This could also include reductions in costs attributable to
temporary dose reductions and interruptions. The NHS and PSS perspectives presented by BMS are much more
limited than those commonly presented in NHS economic evaluations.
Effectiveness
Were the effectiveness data derived from: a single study, a review/synthesis of previous studies or expert
opinion? Give the definition of treatment effect used in the evaluation. Give the size of the treatment
effect used in the evaluation.
No effectiveness data were used.
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Intervention costs
Were the cost data derived from: a single (observational) study, a review/synthesis of previous studies
expert opinion? Were the methods for deriving these data adequately described (give sources if using data
from other published studies)? List the direct intervention costs and other direct costs used in the
evaluation – include resource estimates (and sources for these estimates, if appropriate) as well as sources
for unit costs used.
Intervention costs were derived from MIMS. A PAS was incorporated for abatacept (CiC information has been
removed). Sensitivity analyses were run for the price of tocilizumab using various percentage price discounts as
a CiC PAS has been agreed for tocilizumab.
Drug Cost, £ Dose PAS discount PAS cost
Abatacept 302.40 250mg (CiC information has been
removed)
(CiC information has been
removed)
Etanercept 35.75 10mg
89.38 25mg
178.75 50mg
Adalimumab 352.14 40mg
Tocilizumab 102.40 80mg
256.00 200mg
512.00 400mg
Methotrexate 14.85 7.5mg
15.29 10mg
16.50 12.5mg
16.57 15mg
17.50 17.5mg
17.84 20mg
Administration method Costs, £
Infusion 154.00
Subcutaneous injection 3.05
Indirect costs (costs attributable to lost productivity, unpaid inputs
to patient care)
Were indirect costs included:
No.
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Health-state valuations/utilities (if study uses quality-of-life adjustments
to outcomes)
Were the utility data derived from: a single (observational) study, a review/synthesis of previous studies
expert opinion. Were the methods for deriving these data adequately described (give sources if using data
from other published studies)?
No health valuations were undertaken.
List the utility values used in the evaluation
No health valuations were undertaken.
Modelling
If a model was used, describe the type of model used (e.g. Markov state transition model, discrete event
simulation). Was this a newly developed model or was it adapted from a previously reported model? If an
adaptation, give the source of the original. What was the purpose of the model (i.e. why was a model
required in this evaluation)? What are the main components of the model (e.g. health states within a
Markov model)? Are sources for assumptions over model structure (e.g. allowable transitions) reported?
List them if reported.
The model is essentially a one-state model where child height and weight change as they age which affects
only the cost of drug doses. There are no health states.
Extract transition probabilities for (natural history/disease progression) model
and show sources (or refer to table in text)
There was no natural history modelling.
What is the model time horizon?
The base-case model has a 6-year time-horizon. The time-horizon is user adjustable within the model by setting
different exit ages.
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What, if any, discount rates have been applied in the model? Same rate for
costs and outcomes?
A discount rate of 3.5% annually has been applied to costs, in accordance with the NICE Reference Case.
If no economic evaluation was conducted, state the manufacturer’s reasons
for this
A cost-minimisation analysis was conducted.
Results/analysis
What measure(s) of benefit were reported in the evaluation?
No benefit measure was evaluated.
Provide a summary of the clinical outcome/benefits estimated for each
intervention/strategy assessed in the evaluation
No clinical outcomes nor benefit measures were evaluated.
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Provide a summary of the costs estimated for each intervention/strategy
assessed in the evaluation
Discounted results for the base case (table 13 in CS)
Results for the base-case model (12 year olds, 6-year time horizon, from Excel model)
Abatacept Adalimumab Etanercept Tocilizumab
Drug costs (CiC information has
been removed)
(CiC information has
been removed)
(CiC information has
been removed)
(CiC information has
been removed)
Administration
costs, £
11,797 871 871 11,646
Total costs (CiC information has
been removed)
(CiC information has
been removed)
(CiC information has
been removed)
(CiC information has
been removed)
Cost savings with abatacept (CiC information has
been removed)
(CiC information has
been removed)
(CiC information has
been removed)
Undiscounted results for the base case (table 12 in CS)
Results for the base-case model (12 year olds, 6-year time horizon, from Excel model)
Abatacept Adalimumab Etanercept Tocilizumab
Drug costs (CiC information has
been removed)
(CiC information has
been removed)
(CiC information has
been removed)
(CiC information has
been removed)
Administration
costs, £
13,040 964 964 12,889
Total costs (CiC information has
been removed)
(CiC information has
been removed)
(CiC information has
been removed)
(CiC information has
been removed)
Cost savings with abatacept (CiC information has
been removed)
(CiC information has
been removed)
(CiC information has
been removed)
Synthesis of costs and benefits: are the costs and outcomes reported
together (e.g. as cost-effectiveness ratios)? If so, provide a summary
of the results
A cost minimisation analysis was undertaken, so there was no synthesis of costs and benefits.
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Give results of any statistical analysis of the results of the evaluation
There were no statistical analyses of the results of the evaluation.
Was any sensitivity analysis performed – if yes, what type(s)
[i.e. deterministic (one-way, two-way, etc.) or probabilistic]
A PSA was undertaken and scenario analyses were undertaken.
What scenarios were tested in the sensitivity analysis? How do these relate to
structural uncertainty (testing assumptions over model structure such as
relationships between health states), methodological uncertainty (such as
choices of discount rate or inclusion of indirect costs) or parameter
uncertainty (assumptions over values of parameters in the model, such as
costs, quality of life or disease progression rates)?
A sensitivity analysis was undertaken wherein the infusion costs for tocilizumab were increased owing to the
longer infusion time. This evaluates parameter uncertainty.
The starting age of patients in the model was varied between 6 and 16 years. This related to the structural
assumption of starting age. In the biologic DMARD trials, the mean age was 11 years at baseline, but the drug
licences were for much younger ages.
The time horizon of the model was varied between 6 months and 20 years. Longer time horizons were meant
to represent that one-third of children with JIA will have it continue into adulthood. It was unclear why shorter
time horizons were tested.
PAS discount for tocilizumab. This represents parameter uncertainty in the cost of tocilizumab.
Exclude methotrexate from the etanercept arm. This scenario dabbles across all the types of uncertainty. NICE
specifies that etanercept probably benefits from methotrexate being given concurrently, but the licence is not for
etanercept plus methotrexate, so there is some uncertainty in the appropriateness of methodology recommended
by NICE. Changing a comparator is a structural modification and requires new parameter estimates.
Give a summary of the results of the sensitivity analysis: did they differ
substantially from the base-case analysis. If so, what were the
suggested causes?
Adjusting the starting age of patients downwards favoured etanercept with a starting age of 10 or under
resulting in etanercept being cost saving compared with abatacept. Applying a PAS discount of (CiC
information has been removed) to tocilizumab makes the costs for the two drugs identical. Excluding
methotrexate costs from the etanercept arm made etanercept cost-saving compared with abatacept. There
were no suggested causes for any of the analyses, only a statement of the analysis results.
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Conclusions/implications
Give a brief summary of the author’s conclusions from their analysis.
In the base case, abatacept is the least costly bDMARD and has similar efficacy and safety to other bDMARDs.
These results remain stable for a wide range of scenarios.
What are the implications of the evaluation for practice?
There are no implications, because the economic evaluation did not evaluate practice, it only evaluated drug
pricing. The model assumes that the drugs will have identical discontinuation rates, AEs and onset of
effectiveness and duration of effectiveness. These assumptions are unlikely to be true. Even in an analysis that
assumes there is no difference in effectiveness, differences in how the drugs behave in practice should be
reflected in the costs.
Southampton Health Technology Assessments Centre commentary
Selection of comparators:
The comparators were consistent with the NICE Scope.
Validity of estimate of measure of benefit:
The assumption of equivalent efficacy was of unclear validity. Although BMS provided justification for assuming
equivalence, the nature of the data available may not justify this approach. The trials were small, but generally
share many characteristics, and indirect comparisons were referenced by BMS and conducted by BMS. A full
evaluation of AEs using data beyond the clinical trials was not undertaken, and no comparisons of
discontinuation rates were undertaken. The data from the trials were of insufficient quantity to make
equivalency assumptions on event rates over time.
Given that there is a large amount of uncertainty in the effectiveness data, it may have been more appropriate
to conduct a full economic evaluation with that uncertainty incorporated.
Validity of estimate of costs:
The costs were derived from appropriate sources, but BMS has assumed that the drugs will have identical AE
costs and discontinuation rates (and identical everything else), both of which would lead to costs that have not
been captured here. The strong assumption that there are no differences in the behaviour of the drugs in spite
of different licences and mechanisms of action lacks face validity.
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Critical appraisal checklist of economic evaluation (questions in this checklist based on Philips et al.128 and
Drummond et al.129)
Item MS 1
1 Is there a clear statement of the decision problem? Yes
2 Is the comparator routinely used in UK NHS? Yes
3 Is the patient group in the study similar to those of interest in UK NHS? Yes
4 Is the health-care system comparable to UK? Yes
5 Is the setting comparable to the UK? Yes
6 Is the perspective of the model clearly stated? Yes
7 Is the study type appropriate? No
8 Is the modelling methodology appropriate? No
9 Is the model structure described and does it reflect the disease process? ?a
10 Are assumptions about model structure listed and justified? Yes
11 Are the data inputs for the model described and justified? Yes
12 Is the effectiveness of the intervention established based on a systematic review? N/A
13 Are health benefits measured in QALYs? N/A
14 Are health benefits measured using a standardised and validated generic instrument? N/A
15 Are the resource costs described and justified? Yes
16 Have the costs and outcomes been discounted? Nob
17 Has uncertainty been assessed? Yes
18 Has the model been validated? Yes
N/A, not applicable.
a The model is a single-state cost model with a time horizon from age 12–18 years that includes neither costs nor benefits
of disease progression or complications. The model represents only the disease process by having patients take higher
doses of drugs as they age.
b The model was a cost model with no measure of benefits; therefore, only costs were discounted.
Company submission from Pfizer
Reference
Pfizer (2015)97
Health technology
Etanercept.
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Interventions and comparators
What interventions/strategies were included?
No economic evaluations were conducted; however, a cost analysis comparing etanercept, adalimumab and
tocilizumab was conducted.
Was a no treatment/supportive care strategy included?
No.
Describe interventions/strategies
No economic evaluation was conducted. The cost analysis included etanercept, adalimumab and tocilizumab.
Etanercept is administered by subcutaneous injection at a recommended dose of 0.4mg/kg (up to a maximum
of 25mg per dose), given twice weekly as a subcutaneous injection with an interval of 3–4 days between doses
or 0.8mg/kg (up to a maximum of 50mg per dose) given once weekly.
Research question
What are the stated objectives of the evaluation?
No economic evaluation was conducted.
Study type: cost-effectiveness/cost–utility/cost–benefit analysis?
No economic evaluation was conducted, however a cost analysis was conducted.
Study population
What definition was used for (condition)? What are the characteristics of the baseline cohort for
the evaluation?
The cost analysis was undertaken for a cohort with polyarticular JIA.
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Institutional setting: where is/are the intervention(s) being evaluated
usually provided?
NHS outpatient setting.
Country/currency
Has a country setting been provided for the evaluation? What currency are costs expressed in and does the
publication give the base year to which those costs relate?
No economic evaluation. The cost analysis was conducted in pounds sterling (£) but does not state the
price year.
Funding source
Pfizer.
Analytical perspective
What is the perspective adopted for the evaluation (health service, health and personal social services, third
party payer, societal (i.e. including costs borne by individuals and lost productivity)?
No economic evaluation was conducted.
Effectiveness
Were the effectiveness data derived from: a single study, a review/synthesis of previous studies or expert
opinion? Give the definition of treatment effect used in the evaluation. Give the size of the treatment
effect used in the evaluation.
No economic evaluation was conducted.
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Intervention costs
Were the cost data derived from: a single (observational) study, a review/synthesis of previous studies expert
opinion? Were the methods for deriving these data adequately described (give sources if using data from other
published studies)? List the direct intervention costs and other direct costs used in the evaluation – include
resource estimates (and sources for these estimates, if appropriate) as well as sources for unit costs used.
No economic evaluation was conducted. The cost analysis used drug costs and administration costs for first
year of treatment for different patient ages and weights. Cost sources are not given.
Indirect costs (costs attributable to lost productivity, unpaid inputs
to patient care)
Were indirect costs included:
No economic evaluation was conducted.
Health-state valuations/utilities (if study uses quality-of-life adjustments
to outcomes)
Were the utility data derived from: a single (observational) study, a review/synthesis of previous studies
expert opinion. Were the methods for deriving these data adequately described (give sources if using data
from other published studies)?
No economic evaluation was conducted.
List the utility values used in the evaluation
No economic evaluation was conducted.
Modelling
If a model was used, describe the type of model used (e.g. Markov state transition model, discrete event
simulation). Was this a newly developed model or was it adapted from a previously reported model? If an
adaptation, give the source of the original. What was the purpose of the model (i.e. why was a model
required in this evaluation)? What are the main components of the model (e.g. health states within a
Markov model)? Are sources for assumptions over model structure (e.g. allowable transitions)
reported – list them if reported.
No economic evaluation was conducted.
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Extract transition probabilities for (natural history/disease progression) model
and show sources (or refer to table in text)
No economic evaluation was conducted.
What is the model time horizon?
No economic evaluation was conducted.
What, if any, discount rates have been applied in the model? Same rate for
costs and outcomes?
No economic evaluation was conducted.
If no economic evaluation was conducted, state the manufacturer’s reasons
for this
The CS notes the limitation raised in previous NICE submission TA35 and TA238. These relate to the limitations
in the HRQoL data and the limited evidence on the long term outcomes and the effectiveness of the
treatments. The company states that any cost-effectiveness evidence would be associated with considerable
and unresolvable uncertainty and have therefore not submitted a cost-effectiveness model for this appraisal.
Results/analysis
What measure(s) of benefit were reported in the evaluation?
No economic evaluation was conducted.
Provide a summary of the clinical outcome/benefits estimated for each
intervention/strategy assessed in the evaluation
No economic evaluation was conducted.
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Provide a summary of the costs estimated for each intervention/strategy
assessed in the evaluation
No economic evaluation was conducted; the cost analysis shows the costs were similar between
etanercept, adalimumab and tocilizumab.
Etanercepta Adalimumab Tocilizumabb
2 years £1,859.00 £9,155.64 £5,000.19
3 years £3,718.00 £9,155.64 £5,000.19
4 years £3,718.00 £9,155.64 £5,665.79
5 years £3,718.00 £9,155.64 £5,665.79
6 years £3,718.00 £9,155.64 £6,331.39
7 years £3,718.00 £9,155.64 £6,331.39
8 years £3,718.00 £9,155.64 £6,996.99
9 years £4,647.76 £9,155.64 £6,996.99
10 years £4,647.76 £9,155.64 £6,996.99
11 years £9,295.00 £9,155.64 £6,996.99
12 years £9,295.00 £9,155.64 £8,328.19
13 years £9,295.00 £9,155.64 £8,993.79
14 years £9,295.00 £9,155.64 £8,993.79
15 years £9,295.00 £9,155.64 £8,993.79
16 years £9,295.00 £9,155.64 £10,324.99
17 years £9,295.00 £9,155.64 £10,324.99
a Where relevant, the cheapest dosage regimen was assumed to be used in selecting between once-weekly and
twice-weekly options.
b Includes cost of administration in hospitals.
To reflect clinical practice and avoidance of drug wastage, doses were rounded down to the nearest
available combination of vial strengths to a maximum of 10% variation from estimated dose.
Synthesis of costs and benefits: are the costs and outcomes reported
together (e.g. as cost-effectiveness ratios)? If so, provide a summary of
the results
No economic evaluation was conducted.
Give results of any statistical analysis of the results of the evaluation
No economic evaluation was conducted.
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Was any sensitivity analysis performed: if yes, what type(s) (i.e. deterministic
(one-way, two-way, etc.) or probabilistic)
No economic evaluation was conducted.
What scenarios were tested in the sensitivity analysis? How do these relate to
structural uncertainty (testing assumptions over model structure such as
relationships between health states), methodological uncertainty (such as
choices of discount rate or inclusion of indirect costs) or parameter
uncertainty (assumptions over values of parameters in the model, such as
costs, quality of life or disease progression rates)?
No economic evaluation was conducted.
Give a summary of the results of the sensitivity analysis: did they differ
substantially from the base-case analysis. If so, what were the
suggested causes?
No economic evaluation was conducted.
Conclusions/implications
Give a brief summary of the author’s conclusions from their analysis.
No economic evaluation was conducted.
What are the implications of the evaluation for practice?
No economic evaluation was conducted.
Southampton Health Technology Assessments Centre commentary
Selection of comparators:
No economic evaluation was conducted, the cost analysis did not include abatacept.
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Validity of estimate of measure of benefit:
No economic evaluation was conducted.
Validity of estimate of costs:
No economic evaluation was conducted. Costs used in the cost analysis appear reasonable.
Company submission from Roche
Reference
Roche (2015)78
Health technology
Tocilizumab.
Interventions and comparators
What interventions/strategies were included?
Tocilizumab vs. adalimumab.
Was a no treatment/supportive care strategy included?
No.
Describe interventions/strategies
Tocilizumab+MTX vs. adalimumab+MTX.
Tocilizumab only vs. adalimumab only.
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Research question
What are the stated objectives of the evaluation?
To demonstrate the cost-effectiveness of tocilizumab when used in patients with pJIA who had an inadequate
response to DMARDs.
Study type: cost-effectiveness/cost–utility/cost–benefit analysis?
Cost utility.
Study population
What definition was used for (condition)? What are the characteristics of the baseline cohort for
the evaluation?
Patients entering the model have active JIA and have previously experienced an inadequate response to,
or were intolerant of methotrexate. The modelled population is in line with the CHERISH trial population.
Institutional setting: where is/are the intervention(s) being evaluated
usually provided?
NHS outpatient care.
Country/currency
Has a country setting been provided for the evaluation? What currency are costs expressed in and does the
publication give the base year to which those costs relate?
UK. Costs have been taken from sources from year 2011–15 with some costs taken from the Netherlands.
Costs have not been inflated to a common base year.
Funding source
Roche.
Analytical perspective
What is the perspective adopted for the evaluation (health service, health and personal social services, third
party payer, societal (i.e. including costs borne by individuals and lost productivity)?
UK NHS and PSS.
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Effectiveness
Were the effectiveness data derived from: a single study, a review/synthesis of previous studies or expert
opinion? Give the definition of treatment effect used in the evaluation. Give the size of the treatment
effect used in the evaluation.
The company completed a systematic review of biologics in the treatment of JIA. The effectiveness data were
derived from a WinBUGS indirect comparison with an order probit model. The results were in terms of level
of ACR response.
JIA ACR-30 JIA ACR-50 JIA ACR-70 JIA ACR-90
Without MTX Placebo 31% 28% 25% 12%
Tocilizumab 62% 59% 54% 35%
Adalimumab 52% 49% 44% 26%
With MTX MTX 52% 51% 41% 25%
Tocilizumab 72% 70% 61% 44%
Adalimumab 76% 75% 66% 49%
MTX, methotrexate.
Intervention costs
Were the cost data derived from: a single (observational) study, a review/synthesis of previous studies
expert opinion? Were the methods for deriving these data adequately described (give sources if using data
from other published studies)? List the direct intervention costs and other direct costs used in the
evaluation – include resource estimates (and sources for these estimates, if appropriate) as well as sources
for unit costs used.
The costs associated with each health state was obtained from Prince et al.,124 who report costs data from the
Dutch ABC register for the year before and after starting etanercept. The total 6-month health-state cost for
patients on treatment is £912.33 and off treatment is £1591.43.
The source of the treatment acquisition costs was not stated (assumed to be BNF).
Treatment Dose 1 Frequency Unit cost (list price), £
Adalimumab (40mg) 40mg (assume wastage and
all children receive 40-mg vial)
Every 2 weeks 352.14
Etanercept (10mg) 0.4mg/kg (maximum 25mg) Twice a week 35.75
Etanercept (25mg) 89.38
Methotrexate (10mg, oral) 10mg Every week 0.56
Tocilizumab (80mg) 10mg/kg for patients < 30 kg;
8mg/kg for patients ≥ 30 kg
Every 4 weeks 102.40
Tocilizumab (200mg) 256.00
Tocilizumab (400mg) 512.00
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Indirect costs (costs attributable to lost productivity, unpaid inputs
to patient care)
Were indirect costs included:
Indirect costs are not included.
Health-state valuations/utilities (if study uses quality-of-life adjustments
to outcomes)
Were the utility data derived from: a single (observational) study, a review/synthesis of previous studies
expert opinion. Were the methods for deriving these data adequately described (give sources if using data
from other published studies)?
The company conducted a literature review that identified one study that reported utility values suitable for use
in the model (Prince et al.124) This study reported utility scores obtained using the HUI3 questionnaire to JIA
patients starting treatment with etanercept in the Dutch ABC register.
Based on these data, the company used values at time 0 for the patients who are off treatment, and used
values at time 1 year for patients on treatment.
List the utility values used in the evaluation
On treatment: 0.7275.
Off treatment: 0.53.
Dead: 0.
Modelling
If a model was used, describe the type of model used (e.g. Markov state transition model, discrete event
simulation). Was this a newly developed model or was it adapted from a previously reported model? If an
adaptation, give the source of the original. What was the purpose of the model (i.e. why was a model required
in this evaluation)? What are the main components of the model (e.g. health states within a Markov model)?
Are sources for assumptions over model structure (e.g. allowable transitions) reported – list them if reported.
A de novo Markov state transition model with three health states (uncontrolled disease/off treatment,
on treatment and dead) was developed. The model has 6-month cycles. Patients start with uncontrolled disease
at cycle 0 then move to first-line treatment. Patients discontinue from treatment at a rate proportional to their
response. Once all lines of treatment are exhausted, patients move into uncontrolled disease health state.
The model uses a 1% 6-month mortality rate.
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Extract transition probabilities for (natural history/disease progression) model
and show sources (or refer to table in text)
The 6-month discontinuation rate is 0.126 for no response, 0.09 for moderate response and 0.042 for good response.
What is the model time horizon?
25-year time frame. The company states that this reflects the chronic nature of the disease and allows for all
relevant costs and benefits to be included in the analysis.
What, if any, discount rates have been applied in the model? Same rate for
costs and outcomes?
3.5% for costs and benefits.
If no economic evaluation was conducted, state the manufacturer’s reasons
for this
Not applicable.
Results/analysis
What measure(s) of benefit were reported in the evaluation?
Cost per QALY gained.
Provide a summary of the clinical outcome/benefits estimated for each
intervention/strategy assessed in the evaluation
Combination therapy
Adalimumab + MTX Tocilizumab + MTX
Total QALYs 18.76 18.72
Monotherapy
Adalimumab + MTX Tocilizumab + MTX
Total QALYs 18.65 18.7
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Provide a summary of the costs estimated for each intervention/strategy
assessed in the evaluation
Combination therapy
Adalimumab + MTX Tocilizumab + MTX
Total cost, £ 81,827 70,707
Monotherapy
Adalimumab + MTX Tocilizumab + MTX
Total cost, £ 74,576 68,560
Synthesis of costs and benefits: are the costs and outcomes reported together
(e.g. as cost-effectiveness ratios)? If so, provide a summary of the results
Combination therapy Monotherapy
Incremental QALYs 0.03 0.0455
Incremental cost, £ 11,120 6015
Incremental ICER, £ 280,370 Tocilizumab dominant
Give results of any statistical analysis of the results of the evaluation
None reported.
Was any sensitivity analysis performed. If yes, what type(s)
[i.e. deterministic (one-way, two-way, etc.) or probabilistic]
None reported.
What scenarios were tested in the sensitivity analysis? How do these relate to
structural uncertainty (testing assumptions over model structure such
as relationships between health states), methodological uncertainty
(such as choices of discount rate or inclusion of indirect costs) or parameter
uncertainty (assumptions over values of parameters in the model, such as
costs, quality of life or disease progression rates)?
An exploratory analysis has been performed for tocilizumab versus etanercept. The analysis assumes a class
effect across TNFs in pJIA. The analysis found that tocilizumab was a cost-effective alternative to etanercept.
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Give a summary of the results of the sensitivity analysis: did they differ
substantially from the base-case analysis. If so, what were the
suggested causes?
None reported.
Conclusions/implications
Give a brief summary of the author’s conclusions from their analysis.
Adalimumab and tocilizumab have similar outcomes for patients with JIA, however tocilizumab is a less
expensive alternative to adalimumab.
What are the implications of the evaluation for practice?
None.
Southampton Health Technology Assessments Centre commentary
Selection of comparators:
Results not presented for tocilizumab compared with methotrexate only.
Validity of estimate of measure of benefit:
Based on only utility estimates available for this population.
Validity of estimate of costs:
Based on relevant dataset of costs for patients on etanercept in the Netherlands. May be differences in costs
between countries.
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Critical appraisal checklist of economic evaluation (questions in this checklist based on Philips et al.128 and
Drummond et al.129).
Item Roche
1 Is there a clear statement of the decision problem? Yes
2 Is the comparator routinely used in UK NHS? Yes
3 Is the patient group in the study similar to those of interest in UK NHS? Yes
4 Is the health-care system comparable to UK? ?a
5 Is the setting comparable to the UK? Yes
6 Is the perspective of the model clearly stated? Yes
7 Is the study type appropriate? Yes
8 Is the modelling methodology appropriate? Yes
9 Is the model structure described and does it reflect the disease process? Yes
10 Are assumptions about model structure listed and justified? Yes
11 Are the data inputs for the model described and justified? Yes
12 Is the effectiveness of the intervention established based on a systematic review? Yes
13 Are health benefits measured in QALYs? Yes
14 Are health benefits measured using a standardised and validated generic instrument? Yes
15 Are the resource costs described and justified? Yes
16 Have the costs and outcomes been discounted? Yes
17 Has uncertainty been assessed? Nob
18 Has the model been validated? No
a Costs and utilities have been taken from a Dutch registry study.
b An exploratory analysis was conducted against etanercept.
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Appendix 11 Parameters used in the independent
model probabilistic sensitivity analysis
TABLE 80 Parameters used in the independent model PSA
Parameter Mean Higher CI Lower CI Standard error Distribution
Utility values
No treatment 0.13 0.15 0.11 0.010 Beta
Treatment 3 months 0.17 0.20 0.15 0.013 Beta
Treatment 15-month phase 0.19 0.21 0.16 0.015 Beta
Treatment long term 27+ months 0.20 0.23 0.16 0.018 Beta
Disease flare disutility 0.03 0.04 0.02 0.006 Beta
Disease flare
Placebo 0.25 0.34 0.16 0.046 Beta
Abatacept 0.09 0.16 0.05 0.021 Beta
Adalimumab 0.14 0.23 0.09 0.028 Beta
Etanercept 0.09 0.17 0.04 0.021 Beta
Tocilizumab 0.14 0.20 0.09 0.025 Beta
AEs first cycle, %
Abatacept 0.53 1.51 0.00 0.005 Beta
Adalimumab 1.75 3.71 0.00 0.010 Beta
Etanercept 1.45 4.19 0.00 0.014 Beta
Tocilizumab 1.60 3.36 0.00 0.009 Beta
Loss of efficacy, %
Abatacept 9.47 13.59 5.36 0.021 Beta
Adalimumab 3.51 6.25 0.76 0.014 Beta
Etanercept 2.90 6.82 0.00 0.020 Beta
Tocilizumab 7.98 11.90 4.06 0.020 Beta
Further-line treatment, %
AEs biologic DMARD 0.43 0.82 0.04 0.002 Beta
Loss of efficacy biologic DMARD 2.00 2.59 1.41 0.003 Beta
AEs MTX 0.58 0.82 0.34 0.001 Beta
Loss of efficacy MTX 0.42 0.79 0.05 0.002 Beta
Costs, £
On biologic DMARD cost 724 724 941 507 Gamma
Off biologic DMARD cost 724 724 941 507 Gamma
SAE cost 1,533 1,533 1,993 1,073 Gamma
Disease flare cost 430 430 559 301 Gamma
MTX, methotrexate.
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